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Abstract 
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease causing inflammation of the 
synovium resulting in severe pain, joint disfigurement and disability as well as malaise, fatigue and a 
depressed immune system. Treatment consists of three broad phases; firstly, following diagnosis 
treatment is focussed on rapid reduction of pain and inflammation. Secondly, maintenance of 
quiescence is sought through medication. Finally, if disease activity remains high despite medication, 
escalation to anti-TNF α therapy is required to prevent permanent joint damage and disability. The 
primary course of treatment is prescription of disease modifying anti-rheumatic drugs (DMARDs) 
within 3 months of onset of symptoms. However, DMARDs can take 8-12 weeks to exhibit a 
noticeable benefit whereas unpleasant side effects can occur shortly after initiation. Also, DMARDs 
do not alleviate pain; therefore it is difficult for patients to attribute recovery to this medication. For 
these reasons, although it is imperative for future health and functioning to take DMARDs as 
prescribed, non-adherence is common at 30-50%. 
Non-adherence to treatment can be intentional, where a decision is made not to conform to the 
prescription, or unintentional which is often due to forgetting. To measure intentional non-
adherence, a validated measure of adherence for rheumatoid arthritis was reduced through 
exploratory factor analysis from 19 items to 5 items by removing items that did not add to the 
explained variance of adherence. The CQR5 explained 53% of the variance in adherence and was 
shown to have a good fit to the data through confirmatory factor analysis. A discriminant function 
equation was generated that correctly identifies 88.5% of patients as high or low adherers and has 
high clinical utility due to the brevity for patients and unidimensionality for easy interpretation. The 
CQR5 was used throughout the programme of research to measure intentional non-adherence along 
with a separate measure of unintentional non-adherence.  
Four commonly used social cognition models of illness were measured in 227 RA patients to 
determine which had the best utility for predicting non-adherence to DMARDs. Patients were 
recruited to represent the three stages of illness including newly diagnosed, established on DMARD 
therapy and established with concurrent anti-TNF α therapy. Logistic regression analysis showed that 
the Self Regulatory Model best predicted intentional non-adherence as patients with perceptions of 
worse consequences of RA and longer disease duration were more likely to be highly adherent to 
DMARDs in cross-sectional analysis. In contrast, the Theory of Planned Behaviour better predicted 
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patients who self-reported forgetting their DMARDs with patients with more confidence in being 
able to take their medications (Perceived Behavioural Control) being less likely to forget.  
171 patients were successfully followed-up six months after baseline recruitment. The longitudinal 
results showed that the social cognition models differed for patients at different stages of the illness 
suggesting that their experience of living with rheumatoid arthritis influenced perceptions of their 
illness and medications. Newly diagnosed patients scored lower on factors measuring perceptions of 
disease chronicity and seriousness whereas patients that had escalated to anti-TNF α therapy scored 
higher on these factors. The newly diagnosed patients also showed more variability in the social 
cognition scores whereas the more established patients demonstrated stable models of illness. This 
supports Leventhal’s (1992) theory that illness representations will be regulated through integration 
of knowledge and experience of an illness. 
Structural equation modelling was used to establish the best predictors of intentional non-adherence 
at six month follow-up. In support of research in other chronic illnesses (Horne & Weinman, 2002; 
Niklas, Dunbar & Wild, 2010), the effect of perceptions of the consequences and chronicity of the 
illness on adherence are mediated by perceptions of the necessity of the medication. In addition, the 
impact of the emotional reaction to the illness on adherence to DMARDs is mediated by concerns 
about the medication. In addition, this study incorporated factors from the Theory of Planned 
Behaviour to explain medication adherence and found that the influence of friends and family 
impacts on the patient’s confidence to follow the prescription accurately which in turn as an effect 
on adherence to DMARDs. This large longitudinal study found that by combining factors from a 
number of social cognition models, it is possible to explain and predict intentional non-adherence 
and provides some evidence for best ways to intervene to improve adherence and prognosis.        
To provide a more comprehensive and clinically useful picture of non-adherence, a Cost of Illness 
study was carried which found that patients self-reporting low adherence to DMARDs also had 
significantly higher costs for this medication. This was caused by an increased incidence of 
Leflunamide prescribing for patients who often forget their medication and was maintained 
longitudinally. This association has not been previously reported in the literature and provides some 
evidence that non-adherence to DMARDs is having a concrete effect on the clinical management of 
patients.  
Finally, an SMS text message based reminder service designed to remind patients who self-report 
forgetting their medications was tested through a simulation study for the cost and likely benefit in 
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health related quality of life using the health economic analysis of the longitudinal study and the 
results of a survey establishing the feasibility of implementing such a service in the rheumatology 
clinic. A sensitivity analysis testing the number of messages sent and the cost per message found 
that a reminder service for the sample of patients in this programme of research would cost 
between £1387.00 and £142.27 per year. This would equate to a cost per Quality Adjusted Life Year 
(QALY) gain of between £2889.58 and £296.40 by enabling patients to adhere more rigorously to 
their DMARD regimen.  
This programme of research is the first to test four commonly used social cognition models to predict 
adherence to DMARDs in a large, multi-centre longitudinal study of rheumatoid arthritis patients. 
Perceptions of the likely duration and consequences of the illness, as measured by the Illness 
Perceptions Questionnaire and the necessity of medications (measured by the Beliefs about 
Medications Questionnaire) along with self-efficacy (measured by the Theory of Planned Behaviour) 
explained 24% of the variance in intentional adherence over six months. The results show the 
importance of considering intentional and unintentional non-adherence separately as they appear to 
have different underlying mechanisms as well as patients in different phases of the illness as their 
experience influences their social cognition models of illness. A simple SMS based reminder service 
could act as a cue to action to reduce unintentional non-adherence whereas addressing issues 
surrounding maladaptive perceptions about the illness and the treatment could improve intentional 
non-adherence which has the potential to improve the prognosis and quality of life for patients as 
well as safe costs for the NHS.  
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Chapter 1 
Introduction to Rheumatoid Arthritis 
1.1: What is Rheumatoid Arthritis? 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease which results in inflammation in the 
synovial membrane of the joints caused by white blood cells which release cytokines resulting in 
pain, swelling and stiffness. Continued inflammation leads to irreversible damage to the joints 
through erosion of the cartilage and bone (Neidel, Schulze & Lindschau, 1995). The disease 
commonly affects the small joints of hands and feet symmetrically (Hameed & Akil, 2010). The 
National Institute for Health and Clinical Excellence (NICE, 2009) report the incidence rate as 12,000 
people per year being diagnosed in the UK, however, as RA is chronic, the cumulative effect results in 
approximately 400,000 people currently living with the condition in the UK. The average age of onset 
is 55-64 years (Symmons, 2005) although it can occur at any age and approximately three times as 
many women as men are affected (Lawrence et al., 1989).  
 
 
 
 
 
 
 
The pain and stiffness of joints can lead to loss of mobility; however other symptoms include fatigue, 
malaise and other extra-articular problems such as skin ulcers, dry eyes and anaemia. Combined, 
these symptoms can lead to severe disability which generally worsens as the disease progresses. 
Approximately 70% of patients experience unpredictable “flares” characterised by intense active 
disease followed by periods of quiescence (Weinblatt & Maier, 1989) with 10-15% of patients 
displaying progressively disabling disease despite therapy (Young, 1992). As RA is incurable, 
 
Figure 1.1: Physical and radiological effects of joint erosion in rheumatoid arthritis 
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treatment is focused upon prevention of joint damage and function loss as well as pain 
management.  
1.2: Aetiology of Rheumatoid Arthritis 
The cause of RA is not yet established, however the mechanism behind the inflammation is well 
known. The key effecter cell appears to be the T-cell which orchestrates the immune response 
through a host of cytokines. The key cytokines implicated in RA are Tumour Necrosis Factor-alpha 
and Interleukin 1 (Hameed & Akil, 2010).  
There has been recent research indicating that there is a genetic component to RA. Historically, this 
has been demonstrated through incidence, family and twin studies. For example, there is a much 
higher incidence of RA in Native American populations at 5.3% for Pima Indians (del Puente, 
Knowler, Pettit & Bennett, 1989) and 6.8% for Chippewa Indians (Harvey, Lotze, Stevens, Lambert & 
Jacobson, 1981) compared to Caucasian populations at 0.8-1% (Symmons, 2005). There is also a 
much lower incidence in Africa (Brighton, de la Harpe, van Staden, Badenhorst & Myers, 1988; 
Silman et al., 1993) and South East Asia (Dans, Tankeh Torres, Amanter & Penserga, 1997; 
Shichikawa et al., 1999). Although some of this difference may be due to environmental factors, 
differences in prevalence have been observed in non-indigenous racial groups that have immigrated 
to Europe and North America supporting the view that there is some genetic component (Silman & 
Pearson, 2002). 
Few studies have looked at the familial risk of RA; however the Norfolk Arthritis Register in England 
found that there is evidence of a small familial risk of developing RA (Jones, Silman, Whiting, Barrett 
& Symmons, 1996). Twin studies have consistently shown a fourfold increased concordance in 
monozygotic twins compared with same-sexed dizygotic twins (MacGregor et al., 2000). Again, the 
effect of environmental factors is difficult to determine in twin studies, however MacGregor et al. 
suggest that 50-60% of the occurrence of RA in the twins is explained by shared genetic effects.  
A review by Silman & Pearson (2002) suggests that there is some evidence that infectious agents 
may trigger RA, as the occurrence of RA has reduced in the past 30 years during which time many 
infectious agents have been eradicated whereas genetic populations have remained stable. 
However, there are difficulties studying this because RA could be the final pathway from a number of 
infectious agents which are often also found in the non-RA population. The likelihood is that an 
individual has a genetic predisposition for RA and a triggering agent (either infectious or not) causes 
onset of symptoms (Hameed & Akil, 2010). 
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1.3: Diagnosis of Rheumatoid Arthritis 
Traditionally, diagnosis of rheumatoid arthritis can only reliably be made following clinical 
examination which incorporates serological and radiographic results as there is not yet a set of 
diagnostic tests that are sensitive or specific enough to definitively classify RA (Hameed & Akil, 2010). 
NICE (2009) referral guidelines stipulate that any person with suspected persistent synovitis of 
undetermined cause should be referred to a specialist and that this should be urgent if more than 
one joint is affected and/or there has been more than 3 months delay from onset of symptoms to 
seeking medical advice. The emphasis on emergency referral within 3 months of symptom onset 
reflects evidence that persistent joint damage can occur during the first few months which is 
irreversible (Brook & Corbett, 1977; Conoghan et al., 2010).  
The American College of Rheumatology (ACR; formally the American Rheumatism Association) 
proposed a set of classification criteria for RA in 1956 (Bennett, Cobb, Jacox, Jessar & Ropes, 1956), 
however these were heavily criticised for a lack of sensitivity and specificity, particularly for early 
presentation of rheumatoid arthritis. In response to this, the ACR and the European League Against 
Rheumatism (EULAR) jointly proposed revised criteria with the aim of improving diagnosis of early 
RA (Aletaha et al., 2010). The criteria are reproduced in Table 1.1 and should be used for patients 
who have at least one joint with synovitis (swelling) which is unexplained by another disease.   
Once a diagnosis of rheumatoid arthritis has been made, treatment should focus primarily on 
reduction of the swelling and associated pain and stiffness and long-term control of the autoimmune 
process to prevent further joint damage. Self-management and psychological adaptation strategies 
can then be addressed.  
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Table 1.1: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (adapted from Aletaha et al., 
2010) 
Category  Score 
A – Joint involvements 1 large joint 0 
 2-10 large joints 1 
 1-3 small joints (with or without involvement of large joints) 2 
 4-10 small joints (with or without involvement of large joints) 3 
 >10 joints (at least 1 small joint) 
 
5 
B – Serology (at least 1 test result 
is needed for classification) 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high positive ACPA 
 
3 
C – Acute phase reactants (at least 
1 test result is needed for 
classification) 
 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D – Duration of symptoms <6 weeks 0 
 ≥6 weeks 1 
Classification criteria for RA (score based algorithm: add score of categories A-D; a score of ≥6/10 is needed for 
classification of a patient as having definite RA) 
 
1.4: Assessment of disease severity 
In order to effectively treat and manage rheumatoid arthritis, NICE (2009) guidelines recommend 
regular measurement of blood inflammatory markers as well as disease activity using a composite 
score such as the Disease Activity Score 28 (DAS28; see section 1.4.2 for more details). This is 
essential to inform the decision to increase treatment to control the disease as well as monitoring 
the effects of decreasing treatment once remission has been established.  Regular monitoring of 
DAS28 score is also a necessary component of escalation of treatment (see section 1.6.4). 
1.4.1: Inflammatory blood markers 
There are two commonly used inflammatory blood markers which assess levels of inflammation in 
rheumatoid arthritis patients and therefore are used as a proxy for disease activity: 
Erythrocyte Sedimentation Rate (ESR) is a non-specific test of chronic or acute inflammation which 
can be associated with infections, cancers and autoimmune diseases. As it is non-specific, it must be 
used in conjunction with other clinical indicators for diagnosis of rheumatoid arthritis; however it can 
be a useful way of monitoring disease activity as it is inexpensive and can be carried out alongside 
other blood monitoring tests. Slightly elevated results can occur for benign reasons such as; older 
age, menstruation, pregnancy and some medications. The test measures the rate at which 
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erythrocytes (red blood cells) sediment in the laboratory which is measured in millimetres per hour 
(mm/hr). Normal results for men aged over 50 are <20mm/hr and for women aged over 50; 
<30mm/hr, however as ESR rates are expected to be elevated in autoimmune disease such as RA, it 
is useful to track changes within an individual to monitor periods of flare and quiescence.  
C-Reactive Protein (CRP) is another non-specific measure of inflammation that can be used to assess 
infection, and more chronic inflammation seen in RA. It is often used to monitor patients’ response 
to therapy and assess disease activity. CRP is more reactive than ESR with changes occurring more 
quickly at the beginning and end of the inflammatory process and so can be more useful when 
assessing the effects of fast-acting anti-inflammatory drugs such as corticosteroids (see section 1.6 
for more information on RA medication). CRP is produced by the liver in response to general 
inflammation and the laboratory test assesses the levels of this protein in the blood. Normally, levels 
of C-reactive protein are not detectable in the blood, although they can be slightly elevated in the 
latter half of pregnancy or as a response to oral contraceptive. It is possible for patients with 
rheumatoid arthritis to have undetectable levels of CRP, despite active disease although generally 
levels above 10mg/dL are considered to be very high and indicative of active disease. As with ESR, 
CRP is most useful to assess changes of inflammation within individuals to be used as a proxy for 
disease activity.  
1.4.2: Disease activity (DAS28) 
The Disease Activity Score (DAS28) is a combined index that incorporates subjective assessments of 
global health and tender joints with objective measurements of inflammation (via ESR or CRP) and 
physician assessments of swollen joints. During assessment, a trained clinician will evaluate whether 
28 specific joints are swollen or tender. These joints include the knee, shoulder, elbow, wrist, 
Proximal Interphalangeal and Metacarpophalangeal (finger joints) on both sides of the patient’s 
body. Patients are also required to self report their global health on a 100mm visual analogue scale 
(VAS) and will have some input into the clinician’s judgment of which of the 28 joints are tender to 
touch. The DAS28 is a validated composite score based on a formula with standardized weights to 
combine the swollen joint count, tender joint count, ESR or CRP and the patient’s global assessment 
of health (Prevoo et al., 1996).  
 The DAS28 has been extensively validated for use in clinical trials (Van Riel & Schumacher, 2001) and 
correspond well with EULAR response criteria for Disease Modifying Anti-Rheumatic therapy (van 
Gestel, Haagsma & van Riel, 1998).  Scores can range from 0 to 9.4 and usually have a Gaussian 
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distribution in RA populations. Cut off values have been identified to be used in relation with the 
British Society for Rheumatology’s (BSR) recommendations  (Ding et al., 2010) with remission set at 
<2.6, low activity; 2.6-3.2, moderate activity; 3.2-5.1 and high disease activity at >5.1 (Fransen & van 
Riel, 2005). A change of 1.2 points (twice the measurement error) within an individual patient is 
considered to be significant (van Gestel et al., 1998). 
1.4.3: Functional disability (HAQ) 
The Health Assessment Questionnaire (HAQ; Fries, Spitz, Kraines & Holman, 1980) is the most 
commonly used measure to assess functional disability in arthritis patients. It has been cited over 
400 times and is usually used as an outcome measure for clinical trials in rheumatoid arthritis (Felson 
et al., 1993). Patients are asked to self report their ability to perform eight functions over the past 
week including; dressing, arising, eating, walking, hygiene, reach, grip, and common activities (Bruce 
& Fries, 2003; Fries, Spitz & Young, 1982) with response options of (without ANY difficulty-with SOME 
difficulty-with MUCH difficulty-UNABLE to do). The total score (max=24) is divided by the number of 
items completed (max=8) resulting in scores ranging between 0 and 3 with higher values indicating 
greater disability. Patients are also asked to indicate if they need either an aid to perform an activity 
(e.g. a walking stick) or help from someone else for each of the eight functions. Scores are weighted 
more heavily if a patient requires help or an aid.  
The HAQ has been shown to have good reliability and validity across many applications and in 
different patient populations and has been significantly correlated with a wide variety of health 
status measures, including self-report measures, biochemical and clinical studies, assessment of 
morbidity, evaluation of health care resource utilization and cost estimations  (Ramey, Fries & Singh, 
1996). A review by Bruce & Fries (2003) demonstrated that the HAQ is a useful and well accepted 
measure with excellent clinical utility that has the ability to sensitively detect changes in functional 
disability in rheumatoid arthritis patients.  
1.5: Prognosis 
As rheumatoid arthritis is incurable, patients are faced with progressive disability (Young, 1992) as 
well as an increased risk of co-morbidity and mortality. It has been shown that life expectancy can be 
shortened by up to seven years for men and three years for women with RA (Chan, Wilson & 
Cronstein, 2010). One reason for this is the increased incidence of cardiovascular disease, 
particularly for women as those with seropositive inflammatory polyarthritis have been shown to 
have a twofold increased risk in death due to cardiovascular disease (Goodson et al., 2002). This 
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could be due to high levels of C-Reactive Protein which have been linked to increased risk of 
cardiovascular death in RA when compared to controls with osteoarthritis who were matched for 
potential risk factors (Kitas, Banks & Bacon, 2001; Kitas & Erb, 2003). However, there are other areas 
of concern as Symmons, Jones, Scott & Prior (1998) found an increased mortality ratio of 2.7 
(2.4:3.0) with an increased number of deaths from respiratory causes and cancers in addition to 
cardiovascular disease. Although the increased risk of mortality in RA has been known for some time, 
the exact mechanisms are not fully understood as yet and therefore as well as the need to control 
inflammation to reduce the burden of the RA itself, it is important for treatment to also consider 
other co-morbidities that may result from the pathology itself or the treating medications.  
1.6: Treatment for Rheumatoid Arthritis  
For the majority of patients, treatment will be commenced following diagnosis by a rheumatologist 
in secondary care (Lard, Huizinga, Hazes & Vliet Vlieland, 2001) which will likely be as a result of 
active disease and the accompanying symptoms (Watkins, Shifren, Park & Morrell, 1999). Therefore, 
treatment forms two strategies; firstly, reduction of symptoms to improve quality of life for patients 
and secondly, to prevent further joint damage and preserve function. A number of different 
treatments are given to relieve symptoms (Matteson, 2000) which are described in more detail 
below.  
1.6.1: Corticosteroids  
Corticosteroids (e.g. Prednisolone) are useful to stimulate quick remission (NICE, 2009) and can be 
given orally, intra-muscularly or intravenously. They are frequently prescribed during a flare of 
disease to quickly reduce pain and swelling and can be used in the longer term to reduce disease 
progression. However long-term use is not advised as they can cause serious side effects such as 
osteoporosis, hypertension, diabetes, cataracts and weight gain (Erb et al., 2002) and can suppress 
the hypothalamus-pituitary-adrenal axis (NICE, 2009). 
1.6.2: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have, in the past, been used prolifically to relieve 
pain in rheumatoid arthritis (Brooks & Day, 1991). They have a rapid onset of action and are usually 
at least in part effective at reducing inflammation (Young, 2008). However, more recent guidelines 
by NICE (2009) recommend that oral NSAIDs should be used at the lowest effective dose and for the 
shortest possible period of time. This is due to their potential for toxicity and contraindications with 
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co-morbidity because of interactions with other drugs such as diuretics and ACE-inhibitors (Young, 
2008). 
1.6.3: Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
Rheumatoid arthritis responds well to traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs; 
Park et al., 1999; Young, 2008), such as Methotrexate, which are considered to be the foundation of 
RA treatment to prevent accelerated disease progression and to maintain function (ten Wolde et al., 
1996). There is increasing evidence that the early use of DMARDs produces better outcomes, 
particularly in the short term (van der Heide et al., 1996) and therefore, NICE (2009) guidelines 
stipulate that DMARDs should be offered to all patients newly diagnosed with RA ideally within three 
months of the onset of symptoms. It is therefore important that these medications are taken as 
directed by a medical professional for a sustained period of time in order to maintain disease 
suppression (Nikiphorou & Young, 2010). However, DMARDs can take months to start to exhibit 
noticeable benefits and often have undesirable side effects such as skin rash, ulcers, and 
gastrointestinal problems including nausea, vomiting and diarrhoea (Young, 2008). Although 
DMARDs are the mainstay of RA treatment, the lack of immediate benefit and the presence of side 
effects and inconveniences such as blood monitoring can lead to non-adherence by patients 
reducing the efficacy of these medications. The most commonly prescribed DMARDs are described in 
more detail below.  
Methotrexate (MTX) is the anchor DMARD and the gold standard against which new therapies are 
compared. It is administered weekly either orally or subcutaneously on the same day every week. 
Common side effects include bone marrow suppression and gastrointestinal problems (eg nausea, 
vomiting). Folic acid is frequently prescribed alongside MTX to combat nausea. Although MTX is the 
most commonly prescribed DMARD in the UK, it can be contraindicated for a number of reasons 
including; pregnancy, high alcohol intake and impaired liver function. Monitoring blood tests are 
required every 6-8 weeks to check for abnormal renal and hepatic function and MTX should not be 
used if regular monitoring is not achieved.  
Sulfasalazine (SSZ) was the first drug developed specifically for RA. It is taken orally, typically twice 
daily. Common side effects include; headache, skin rash, nausea and diarrhoea. There is also the 
potential for serious side effects such as toxicity, drug-induced hepatitis and cytopenia. As with 
Methotrexate, regular blood monitoring tests are needed to check for hepatic and haemotological 
problems.  
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Hydroxychloroquine (HCQ) is an anti-malaria drug with proven efficacy in early and mild rheumatoid 
arthritis. It is taken daily by tablet. Side effects are less common and severe than other DMARDs, 
however, evidence of radiological joint protection is minimal and so it is often used as combination 
therapy with other DMARDs.  Following initial blood tests checking for normal renal and hepatic 
function, regular blood monitoring is not required for HCQ per se, however as it is usually used in 
combination with MTX or SSZ, regular checks will still be needed. Hydroxychloroquine can damage 
the retina and so yearly ophthalmological tests are recommended.  
Leflunamide (LFM) is the newest DMARD and has been shown to be as efficacious as MTX, although 
it is more expensive. It may be useful in patients who have not responded to MTX, although it can be 
used in conjunction. LFM is taken orally once daily. Similar side effects to other DMARDs are possible 
including nausea, skin rash, hair loss and more seriously, a lowered blood count and life-threatening 
liver disease. For this reason, regular blood monitoring is required. Leflunamide also has a long wash 
out period of 2 years required before conception and so is not recommended for men or women 
who are planning to have children.   
1.6.4: Anti-TNF α agents (biologics) 
It has been shown that Tumour Necrosis Factor alpha (TNF α) is a cytokine released in excessive 
amounts in RA and is a major contributor to the synovial inflammation and cartilage destruction. For 
this reason, agents that specifically target this inflammatory process have been developed and these 
so called Anti-TNF α agents have been demonstrated to be efficacious in the treatment of RA on 
clinical, radiological and lab measures, particularly when used in combination with Methotrexate 
(Chan et al., 2010). Despite the fact that 70-80% of patients will see a positive effect of biologic 
therapy, they are very expensive and therefore NICE (2010) recommends the use of Anti-TNF α 
agents only when patients have active disease (defined as a DAS28 score of greater than 5.1) on two 
occasions, one month apart and have previously failed to respond to two traditional DMARDs, one of 
which must be Methotrexate (unless contraindicated). Anti-TNF α therapy should be used in 
conjunction with Methotrexate, unless the use of MTX is contraindicated as clinical trials have 
suggested that this is the most efficacious administration (Soliman et al., 2011). However, some 
agents can be given as monotherapy. Due to the cost of administration, NICE (2009) recommend 
regular monitoring of disease activity as biologic therapy should only be continued if an adequate 
response has been identified within six months of initial administration and is maintained (an 
adequate response is defined as an improvement in DAS28 score of at least 1.2 points).  
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There are three commonly prescribed Anti-TNF α agents; 1) Adalimumab is administered 
subcutaneously fortnightly by the patient, 2) Etanercept is also administered subcutaneously by the 
patient once or twice per week and 3) Infliximab is administered intravenously in an outpatient 
setting every eight weeks. As these drugs block the inflammatory process, they also interfere with 
the body’s normal process of fighting infection and so can have serious side effects such as increased 
risk of infection and a reaction at the administration site. Due to a lack of evidence, these agents are 
also not suitable for use during pregnancy. However, as well as reducing joint swelling and 
radiological erosions biologics have also been reported to greatly improve malaise and fatigue in RA 
patients (Maini, 2001). 
1.7: Treatment phases of Rheumatoid Arthritis 
There are detailed guidelines available for the treatment of rheumatoid arthritis (NICE, 2009; 
Luqmani et al., 2009; Combe et al., 2007; Smolen et al., 2010) and the treatment trajectory is well 
established. The main aim is to promote and maintain remission by reducing inflammation which in 
turn will preserve joint function. There is strong evidence by Tsakonas, Fitzgerald, Fitzcharles et al. 
(2000) and Fries, Williams, Morfeld, Singh & Sibley (1996) that people with RA who are treated early 
and continue therapy have better functional outcomes than those who are treated intermittently. 
For that reason, the treatment course of RA can be conceptualised in a way presented in Figure 1.2. 
 
Figure 1.2: Typical treatment phases for rheumatoid arthritis 
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The treatment strategies described in Figure 1.2 demonstrate distinct phases of treatment for RA; 1) 
newly diagnosed when treatment is focussed on rapid reduction in inflammation and choosing an 
efficacious and well-tolerated DMARD for long term therapy; 2) established disease that can be 
controlled with DMARD therapy and 3) serious disease which requires Anti-TNF α therapy to 
maintain remission and functioning. Some patients may react well to traditional DMARDs and remain 
on this therapy for life. However, some patients may suffer serious, progressive disease which 
requires more aggressive treatment and result in more serious consequences.  
1.8: Impact of Rheumatoid Arthritis  
1.8.1: Impact on the patient  
As the joints become damaged, more patients require help, aids and adaptations to the home for 
everyday functioning (Eberhardt & Fex, 1995; Young et al., 2000). Despite these adaptations the 
disease often leads to many patients being unable to work with some studies reporting up to 85% 
work disability for RA patients (Barrett, Scott, Wiles & Symmons, 2000; Wolfe & Hawley, 1998; Young 
et al., 2000) resulting in many RA patients having a reduced income (Albers et al., 1999). This will 
differ between patients as education and socioeconomic status is shown to be protective of work 
disability, most likely because of more flexible and less physical working conditions (Barrett et al., 
2000; Wolfe, 1996). However, as being in employment has been shown to improve psychological 
wellbeing (Albers et al., 1999), this level of work disability can have a profound effect on RA patients. 
The unpredictable and progressive nature of the disease can lead to a feeling of loss of control and 
helplessness by the patient which can have an impact on mental health. Depression and anxiety are 
more prevalent in people with RA (Brown, 1990; Pincus, Griffiths, Pearce & Isenberg, 1996) with 
estimates of between 6-42% of RA patients having a diagnosis of clinical depression (Fifield et al., 
2001; Murphy, Dickens, Creed & Bernstein, 1999; Pincus et al., 1996; Walsh, Blanchard, Kremer & 
Blanchard, 1999) compared to around 5% for elderly people without RA (Beekman, Deeg, Geerlings, 
Schoevers & Smit, 2001). As well as the distressing and debilitating effects that negative mood has 
on the patient, there are also consequences for their family and society as outpatient visits and 
inpatient stays are disproportionately higher in depressed RA patients (Katz & Yelin, 1993).  
As well as the joint damage characterised by rheumatoid arthritis, patients often also suffer from 
fatigue and general malaise (Belza, 1995; Huyser et al., 1998) which can have a negative impact both 
on physical and psychological wellbeing (Nikolaus, Bode, Taal & van de Laar, 2010; van Hoogmoed, 
Fransen, Bleijenberg & van Riel, 2010). Fatigue can also increase as the disease progresses (Belza, 
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Henke, Yelin, Epstein & Gillis, 1993) which, when coupled with joint erosion and functional 
impairments can leave patients highly disabled.  
1.8.2: Impact on society 
The greatest impact of rheumatoid arthritis on society is the economic burden through the direct 
cost of treating patients and the indirect cost of loss of productivity through disability and mortality. 
As previously mentioned, a large proportion of RA patients stop work prematurely, with 
approximately one third doing so within the first two years and more as disease duration increases 
(Young et al., 2002).  
An inception cohort of early inflammatory polyarthritis in Norfolk, UK found that the mean cost for 
the first six months from symptom onset was approximately £2800 per person, of which 14% were 
due to costs of medication, hospitalisation and other costs of treatment (Cooper, Mugford, 
Symmons, Barrett & Scott, 2002). The costs of loss of earnings and productivity are often higher than 
treatment costs (Liang et al., 1984; Meenan, Yelin, Henke, Curtis & Epstein, 1978; Stone, 1984) 
although this can alter dramatically if a patient is experiencing a flare as inpatient hospital costs can 
be particularly high. As a general rule, medication, physician and inpatient care costs contribute the 
most to treatment costs for the National Health Service (NHS), although the National Audit Office 
(2009) have shown that by treating patients earlier and more aggressively, long term treatment costs 
can be reduced. The National Rheumatoid Arthritis Society (NRAS) calculated in 2010 that RA costs 
the UK economy an estimated £8bn per year which includes £700m of direct costs to the NHS (NRAS, 
2010). Despite the lack of data and knowledge surrounding the true costs of rheumatoid arthritis, it 
is clear that as well as the direct cost on the NHS (in the UK), there are additional costs through lost 
productivity, increased disability and co-morbidity creating a significant burden on society. For a 
more comprehensive discussion of the economic costs of rheumatoid arthritis, see Chapter 10.  
1.9: Self-management  
It is clear from this chapter that a diagnosis of rheumatoid arthritis can be a major obstacle for many 
patients. Adequate adjustment to the requirements of a chronic illness is key to effective 
management and improved psychological wellbeing in patients (de Ridder, Geenan, Kuijer & van 
Middendorp, 2008). The pain, functional limitation and loss of identity by some patients can lead to 
serious problems in self managing their illness; however it is recommended that patients have an 
active and equal participatory role in treatment decisions to improve outcomes and adherence to 
recommendations (Stevenson, Cox, Britten & Dundar, 2004). As well as managing the initial 
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symptoms, RA patients are also required to take an active role in monitoring and managing many 
other complementary treatment requirements shown in Table 1.2. 
Table 1.2: Typical self-management behaviours required by rheumatoid arthritis patients 
Self-management behaviours 
 Booking and attending outpatient appointments 
 Taking medication as prescribed including the correct timing, dosage, any special requirements (e.g. with 
food) as well as ordering and collecting repeat prescriptions 
 Having timely monitoring blood tests (usually every eight weeks) 
 Monitoring and reporting side effects, particularly potentially serious episodes such as contraction of 
viral infections (e.g. chicken pox) 
 Remembering to have recommended vaccinations (e.g. annual influenza) and not have prohibited 
vaccinations (e.g. Yellow Fever) 
 Modifications  to diet and exercise, particularly for physiotherapy or occupational therapy 
 
Given the demands that are made of patients, in addition to coping with a painful and disabling 
chronic illness, it is clear that some RA patients may struggle to effectively manage all areas of their 
treatment at all times. For this reason, issues surrounding self-management are being actively 
researched with an aim of improving the patient-provider relationship and providing patients with 
the tools that they need to successfully manage their disease.  
1.10: Rheumatoid Arthritis in the context of this programme of research  
The aim of this chapter was to give an overview of the burden that patients with rheumatoid arthritis 
face in order to successfully manage their disease, both physically and psychologically. After 
diagnosis, patients typically endure a changeable course of treatment until remission is promoted, 
however many will experience an unpredictable disease course which will last for the remainder of 
their life (Weinblatt & Maier, 1989; Young, 1992). This often leads to a heterogeous clinic population 
for clinicians and specialist nurses to manage as patients move through the stages of illness 
described in section 1.7, resulting in different needs and difficulties with self-management and 
adherence. Patients are also required to make substantial changes to their lifestyle as well as 
incorporate and manage a number of new health behaviours including attending outpatient 
appointments, taking medications and the associated monitoring tests that are necessary. As 
effective and continued therapy is paramount to maintaining function and quality of life for patients 
(Fries et al., 1996; Tsakonas et al., 2000), the correct management of medication is clearly an 
important part of managing and coping with RA. However, advertisement of serious side effects 
through pharmacy leaflets, contra-indications with alcohol intake and pregnancy and requirements 
for regular blood tests and vigilant side-effect monitoring have the potential to seriously 
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compromise DMARD adherence. For this reason, this programme of research will focus on 
adherence to medication required for the disease and the different ways in which patients at 
different stages in their disease progression cope with this demanding and sometimes unpleasant 
requirement to stay as healthy as possible.   
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Chapter 2 
Literature review of using social cognition models to explain 
adherence to treatment regimens in chronic illness.  
2.1: Introduction 
There have been a number of excellent reviews published in recent years focussing on the issue of 
adherence to treatment regimens, particularly in chronic illnesses (DiMatteo, 1994, 2004; Elliott, 
2008; Hill, 2005a, 2005b) including Cochrane reviews (Haynes, 2001; Kripalani, Yao & Haynes, 2007) 
and a World Health Organisation publication (WHO, 2003) as well as hundreds of studies 
investigating various issues of adherence in a number of chronic illnesses. For these reasons, a 
systematic review of all of the literature on medication adherence is inappropriate for this chapter. 
However, definitions of adherence, its importance and current issues surrounding adherence are 
introduced and discussed, as well as a narrative review of the literature that has measured or utilised 
the current social cognition models of health behaviour to explain adherence to treatment by 
rheumatoid arthritis patients. The aim of this chapter is to give a comprehensive overview of the 
literature surrounding treatment adherence and to guide the reader towards an understanding of 
how social cognition models, which concern beliefs individuals hold about health behaviours, have 
been used to explain adherence behaviour in rheumatoid arthritis.  
2.2: Definitions of adherence 
Adherence to medical regimens is an important part of treatment, particularly in a chronic illness 
such as rheumatoid arthritis. The terms “adherence” and “compliance” have been used 
interchangeably in the literature but adherence is defined by Treharne, Lyons, Hale, Douglas & Kitas 
(2006; pg 1) as “the extent to which patients take prescribed medication “as directed””. A variation 
of this definition has been used by many adherence researchers (e.g. Haynes et al., 1979; WHO, 
2003). It is important to differentiate between adherence and compliance as adherence implies that 
people are free to choose to undertake the behaviour, whereas compliance implies obeying a 
prescription. There is a clear motivational difference between the two which is paramount as most 
of the models of health behaviour have a motivational aspect inherent within them (Brawley & 
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Culos-Reed, 2000), therefore the term “adherence” will be used throughout this programme of 
research.  
Adherence to treatment has been a popular area for research over the past fifty years, however the 
evidence is still disparate as to which factors influence adherence to different regimens and 
therefore the best interventions to employ.  
2.3: Different types of adherence; intentional and unintentional 
Non-adherence is complex and multifaceted and can comprise of a deliberate decision not to take 
medications (which will hereafter be termed “intentional non-adherence”), or can simply be a result 
of forgetting to take all of the doses prescribed (which will be termed “unintentional non-
adherence”). Unintentional non-adherence can be due to a number of reasons, and has been shown 
to increase as patients become older (Salzman, 1995), if they are out of their usual routine (for 
example on holiday; de Klerk, van der Heijde, van der Tempel & van der Linden, 1999) or if the 
regimen is complex (McDonald, Garg & Haynes, 2002). 
Intentional non-adherence has been shown to be related to a number of factors surrounding 
experience of illness and treatment (Johnson, Williams & Marshall, 1999; Lumme-Sandt, Hervonen & 
Jylha, 2000; Svensson, Kjellgren, Ahlner & Saljo, 2000) and will be discussed in more detail below. 
Unintentional non-adherence has received less attention and there have been conflicting results for 
chronic illness, particularly among older people. Woods et al. (2008) found that deficits in 
prospective memory (i.e. “remembering to remember”) was a strong predictor of medication non-
adherence by HIV positive patients. However, Hertzog, Park, Morrell & Martin (2000) found that 
although prospective memory and cognitive ability decreased with age in RA patients, adherence 
increased. They speculate that this may be because older patients were compensating for memory 
loss with other cues, a view supported by Kippen, Fraser & Ellis (2005) who found that older people 
often link medication taking to other daily activities such as eating and Elliot, Ross-Degan, Adams et 
al. (2007) who found through interviewing older patients that levels of forgetting were very low 
because they used written aids or dose boxes as cues. 
These types of non-adherence are not mutually exclusive but it is expected that they would have 
different underlying mechanisms; unfortunately, the type of non-adherence is often not reported in 
the literature. However, the importance of differentiating between intentional and unintentional 
non-adherence is starting to receive more attention with Johnson (2002) developing a model of 
adherence in elderly patients incorporating the different types. Lehane & McCarthy (2006) and 
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Lowry, Dudley, Oddone & Bosworth (2005) demonstrate how important this differentiation is as they 
reported much higher levels of unintentional non-adherence than intentional. However, few 
researchers have systematically measured and evaluated the two appropriately.    
2.4: Rates of non-adherence 
Typical rates of treatment non-adherence in chronic illnesses have been variable but relatively high 
at 30-50% (Barber, Parsons, Clifford, Darracott & Horne, 2004; DiMatteo, 1994; Dunbar-Jacob & 
Schlenk, 2001; Haynes, 2001), although a meta-analysis by DiMatteo (2004) reported average non-
adherence of 24.8%. However, non-adherence rates for DMARDs in RA are often higher with Viller et 
al. (1999) reporting 41% and Grijalva et al. (2007) finding 54% of patients stopped their DMARD for 
more than 90 days. When a more stringent measure of adherence is used including correct dosing 
and/or timing, non-adherence rises with Park et al. (1999) claiming 62% and de Klerk, van der Heijde, 
Landewe, van der Tempel & van der Linden (2003) showing 75% for Sulfasalazine. During the 
literature search three systematic reviews and meta-analyses were found that attempt to quantify 
non-adherence (DiMatteo, 2004; Haynes et al., 2001; Kripalani et al., 2007). Although reported 
adherence rates differ depending on the method of measurement and type of treatment, there is a 
consistently held opinion in the literature that non-adherence is a major factor contributing to poor 
outcomes that will only worsen as populations increase and morbidity rates worsen.  
2.5: Importance of adherence to treatment regimens 
Non-adherence to treatment in chronic illness leads to poor prognosis for patients (Irvine et al., 
1999) and has been shown to be the primary cause of unsatisfactory blood pressure control in 
hypertensive patients (Waeber, Burnier & Brunner, 2000) whereas good adherence leads to reduced 
complications (Rogers & Bullman, 1995). Non-adherence in RA has the potential to increase illness 
progression as DMARDs are most effective when taken as prescribed by the specialist doctor. A 
patient who regularly misses or changes doses of prescribed medication may experience personal 
effects such as delayed recovery (Grijalva et al., 2007), increased morbidity and mortality (DiMatteo, 
1994) and increased treatment complications (Hughes, Bagust, Haycox & Walley, 2001; ten Wolde et 
al., 1996). This will also have a societal effect as patients with increased disease activity are more 
likely to require frequent hospital and GP visits (DiMatteo, 1994; Steiner & Prochazka, 1997) and the 
apparent treatment “failure” can then lead to unnecessary escalation of treatment. Ausburn (1981) 
reviewed admittance details for 205 patients in hospital medical wards and found that 20% had 
probably been admitted due to non-adherence to prescribed medication. This subsequently results 
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in higher health service costs (DiMatteo, 1994; Grijalva et al., 2007; Hughes et al., 2001; Urquhart, 
1999). As adherence is a primary determinant of the effectiveness of treatment (Cramer, 1998), poor 
adherence attenuates optimum clinical benefit (Dunbar-Jacob & Schlenk, 2001; Sarquis et al., 1998). 
For this reason, Haynes (2001) concludes that increasing the effectiveness of adherence 
interventions may have a greater impact on public health than improved medical treatments.  
2.6: How has adherence been measured? 
Non-adherence has been measured in a number of ways with various degrees of success and 
accuracy. The World Health Organisation (2003) publication on adherence highlights these problems 
as both healthcare providers (Norell, 1981) and patient self-report generally overestimate adherence 
which could be due to inaccurate memory or socially desirable reporting of behaviour. The gold 
standard for assessing medication adherence in patient groups is to test biological markers of the 
drugs in the blood, however this is very expensive and can be subject to contaminated results 
through variable levels of absorption, excretion and pharmacokinetics of the drug in individuals 
(Vitolins, Rand, Rapp, Ribisl & Sevick, 2000). Pill counts have also been used whereby the number of 
pills left over after a given period of time (e.g. one month) are counted and compared to the number 
of pills that should have been taken in that period as per the prescription. This method has been 
used in a number of studies, however there is no guarantee that the pill has actually been taken and 
information regarding correct dosing or timing is not available (Matsui et al., 1994). These limitations 
have been improved upon to some extent by using electronic medication event monitoring (eMEMs) 
to record the time and date of pill bottle opening to infer adherence. However, both of these 
measures are costly and time consuming and can be subjected to “white coat compliance” where 
patients are deliberately more adherent in the run up to a clinic appointment (de Klerk, van der 
Heijde, Landewe, van der Tempel & van der Linden, 2003) because they are aware that their 
adherence is being measured. 
The more objective measures mentioned above are not compatible with long term adherence 
monitoring, particularly in the case of polypharmacy which is common among chronic illness and the 
elderly.  To increase the utility in large scale clinical studies, the most common methods of assessing 
medication adherence are self-report questionnaires. Questionnaires can measure attitudes, 
intentions and behaviours and although they are prone to biased results from socially desirable 
answering, if item construction and validation is carried out correctly, these problems can be 
overcome. An additional advantage of questionnaires is that they can help to establish how and why 
a patient is non-adherent which can then be addressed, whereas eMEMs and biological monitoring 
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give very basic information which cannot help to inform interventions. The descriptive data given by 
the questionnaires therefore increases the predictive validity of identifying the different types of 
non-adherence. Garber, Nau, Erickson, Aikens & Lawrence (2004) reviewed concordance between 
self-reported adherence and more objective measures such as pill counts or eMEMs. Of 86 pairs of 
self-report and objective measures, 43% were highly concordant.  Questionnaires were the best self-
report measure (compared to diaries or interviews) with 55% being highly concordant with the 
objective measure. Of those pairs that were not highly concordant, the self-report measure over-
estimated adherence. However, there was no indication of how accurate the objective measure was 
at actually measuring adherence. For this reason, it is advisable to use a multi-method approach 
which combines self-report and an objective measure (WHO, 2003). However as this is often not 
feasible, self-report questionnaires seem to have the most clinical utility to not only identify people 
with low adherence, but to establish the reasons behind it which can then be addressed in the 
clinical setting.   
Although there are a number of ways to measure adherence, it is worth considering the purpose of 
measurement and its clinical utility. Most often, “percentage of adherence” is reported but it is 
important to consider what this means. For example, as Pullar (1991) rightly acknowledges, an 
“adherence rate of 60%” does not convey whether each patient took 60% of their doses or whether 
60% took all of their doses. He suggests that the most appropriate method of reporting would be the 
number of patients falling into adherence bands (e.g. good, bad). However, this banding in itself has 
some inherent problems as thresholds defining “good” and “bad” adherence are generally arbitrary 
based on clinical expertise rather than any empirical evidence base (WHO, 2003). It would be 
incredibly difficult to definitively define a universal level of “good” adherence for a number of 
reasons. Firstly, the response to treatment for chronic progressive illnesses like RA is generally a 
continuum over a long period of time. Secondly, the efficacy of a drug is based upon its performance 
during clinical trials in which adherence rates are particularly high and thirdly, periodic or low levels 
of non-adherence (for example taking a break to reduce side effects or forgetting the third of a thrice 
daily dose) may not be clinically important. The acceptable threshold for non-adherence would also 
depend heavily on the type of illness and treatment as not taking insulin for a few days could prove 
fatal to someone with Type I diabetes, whereas missing the same number of DMARD doses would 
not have as large an effect for RA patients. It is therefore important to consider for each patient 
group what the effect of non-adherence would be over the short and long term and what the 
optimum adherence rate might be (Elliott, 2008). 
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Although there are weaknesses inherent in measuring adherence, with estimated non adherence 
rates being as high as 60%, it is important to establish adherence patterns, causes (intentional or 
unintentional) and psychosocial determinants in order to improve self-management among patients, 
particularly those with a chronic illness. Based on the evidence presented above, self-report 
questionnaires appear to offer a reasonably reliable and cheap method of measuring adherence and 
also have the advantage of providing additional explanatory information. For this reason, a self 
report questionnaire has been chosen to measure adherence in this programme of research.  
2.7: Measuring adherence in this programme of research 
The Compliance Questionnaire for Rheumatology (CQR19; de Klerk et al., 1999) is a nineteen item 
scale that measures behaviours and attitudes concerning medication taking which is measured on a 
4 point Likert scale ranging from “Don’t agree at all” to “Agree very much”. The authors have 
reported excellent sensitivity at detecting low adherers at 98% with a kappa of 0.78. This was 
established by validating the scale against eMEMs and suggests that it is a good questionnaire for 
establishing medication adherence to DMARDs. Other researchers have also successfully used this 
scale as a measure of adherence (de Thurah, Norgaard, Harder & Stengaard-Pedesen, 2010; Garcia-
Gonzalez et al., 2008; Treharne, Lyons & Kitas, 2004). However, de Klerk, van der Heijde, Landewe, 
van der Tempel & van der Linden (2003) report a moderate level of internal consistency. As the only 
adherence questionnaire specifically designed for use by rheumatoid arthritis patients, the CQR will 
be used in this programme of research to measure intentional non-adherence. The structure, 
reliability and validity of the CQR are discussed further in Chapter 6. However, a limitation of the 
CQR is that it does not measure unintentional non-adherence and therefore one statement from the 
Reported Adherence to Medication scale (RAM; Horne, Weinman & Hankins, 1999); “I sometimes 
forget to take my medication” will also be used. Patients are asked to indicate the level to which they 
agree from “definitely do not agree” to “definitely agree”.  
2.8: Introducing the social cognition models of illness 
Based on the evidence established over the past five decades, it is clear that there is a triad of factors 
that influence self-management and adherence to treatment regimens. These include; 1) the 
patient-provider relationship which refers to the level of satisfaction with communication between 
the doctor and patient and concordance, 2) organisational factors including the structure of 
collecting prescriptions and different economic models (e.g. the UK’s National Health Service or an 
insurance scheme) and 3) patient factors which include demographics, attitudes and behaviour of 
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the patient. Although the patient-provider relationship (Viller et al., 1999) and factors relating to the 
healthcare organisation (for example the logistics of seeing a doctor or collecting a prescription) are 
associated with adherence (WHO, 2003), this programme of research will concentrate on patient 
factors as these are some of the least well known and researched areas that can and need to be 
addressed in rheumatoid arthritis. 
An obvious dimension of patient related factors are demographics such as age, gender, education 
and socioeconomic status. Although these have been researched, there has been little evidence to 
suggest that they reliably and actively impact on adherence to medications. For example, there 
appears to be no consistent association between gender and adherence in RA (Brus, van de Laar, 
Taal, Rasker & Weigman, 1999; Treharne et al., 2004; Viller et al., 1999). There is conflicting evidence 
surrounding age with the assumption that non-adherence will increase as cognitive ability decreases, 
however Treharne et al. (2004) and Park et al. (1999) both found that adherence to DMARDs 
improved with age. Issues surrounding ethnicity, education and socio-economic status have also 
been variable, which is partly due to different healthcare systems around the world. For example, 
African-American and Hispanic patients in the US tend to have worse adherence than white 
Americans (Garcia-Gonzalez et al., 2008; Garcia Popa-Lisseanu et al., 2005) although this is likely to 
be confounded by reduced levels of education and employment resulting in worse levels of health 
insurance. Although adherence may mediate the effect of demographics on disease status, there is 
not enough evidence thus far to determine whether demographics can reliably predict adherence 
(Elliott, 2008). 
Self-efficacy, motivation and intentions to perform a health behaviour are related to adherence 
(Armitage & Conner, 2001) and are best conceptualised within the social cognition models of illness 
that have been extensively researched since the 1960s. The three most useful models are the Theory 
of Planned Behaviour (TPB), Health Belief Model (HBM) and the Self Regulatory Model (SRM) which 
are described in more detail below. These are all social cognition models of illness that are based on 
the concept of expected utility (Edwards, 1954) which assumes that people make a rational decision 
of behaviour based on the expected costs and benefits of performing the behaviour.  
2.8.1: The Theory of Planned Behaviour 
The Theory of Planned Behaviour (Ajzen, 1988; Figure 2.1) is an extension of the Theory of Reasoned 
Action necessitated by the assumption by Ajzen (1988) that the performance of any behaviour is 
dependent on the amount of volitional control an individual has over the behaviour. This builds on 
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Bandura’s (1977) work on self-efficacy and control. Intention to perform the behaviour is central to 
the theory and is assumed to capture the motivational aspect of behaviour (Ajzen, 1991). Intention 
to perform the behaviour is the single most predictive factor of behaviour (Ajzen, 1991) and in 
general, the stronger the intention, the more likely the behaviour will be performed. Attitudes and 
Subjective Norm are taken from the Theory of Reasoned Action and Perceived Behavioural Control is 
added, which all explain behavioural intention. Perceived Behavioural Control is also a direct 
predictor of behaviour as even if intention is high, if the person feels that they are not capable of 
carrying out the behaviour, the likelihood of success is low.  
 
Figure 2.1: The Theory of Planned Behaviour from Ajzen I. (1991) The Theory of Planned Behaviour. 
Organizational Behavior and Human Decision Processes 50; 179-211 (pg 182) 
 
Ajzen (2007) proposes that behaviour can usually be predicted with considerable accuracy from 
intention and control. There are three factors that are seen to influence intention in the TPB; 
Attitudes, subjective norms and perceived control. Attitudes refer to the accessible beliefs about the 
behaviour and the perceived consequences. This follows an expectancy-value model of the perceived 
likelihood that the behaviour will lead to a particular outcome and the evaluation of that outcome. 
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Armitage & Conner (2001) performed a meta-analysis across different behaviours and found a 
correlation of 0.5 between Attitudes and actual behaviour. Similarly, Albarracin, Johnson, Fishbein & 
Muellerleile (2001) found a correlation of 0.56 in a meta-analysis between Attitudes and condom 
use. Subjective norm refers to the subjective assessment by the individual that “important others” 
think that they should (or shouldn’t) perform the behaviour. Subjective Norm must be evaluated 
with respect to the motivation the individual has to comply with the wishes of the reference group 
(which can include friends, family and health professionals). Armitage & Conner (2001) found similar 
correlations of 0.5 between Subjective Norm and behaviour. Perceived Behavioural Control is 
influenced by the individual’s belief that they have access to the necessary resources and skills to 
perform the behaviour successfully. This may be based in part on past experience but can also be 
influenced by information from others and the media. 
Although the evidence suggests that the TPB is good at predicting behaviours under volitional 
control (Alberaccin et al., 2001; Armitage & Conner, 2001; Azjen, 2007), behaviours which require 
particular skills, knowledge or resources that the individual does not possess will not be well 
predicted by the TPB (Fishbein, 1993). This may prove challenging with respect to medication taking 
if there are cognitive, financial or logistic barriers to the behaviour such as an inability to pay for the 
medication or a lack of transport to collect the prescription.  
Although there have been a number of studies investigating the utility of the Theory of Planned 
Behaviour to explain preventive health behaviours such as condom use, exercise and smoking 
cessation which have prompted a number of reviews (e.g. Abraham, Sheeran & Johnston 1998; 
Armitage & Conner, 2001), few have used it to explain adherence to medications. Some studies have 
implicitly measured Perceived Behavioural Control and social norms but have not truly used them to 
determine adherence. For example, DiMatteo (2004) performed a meta-analysis of the effect of 
social support on adherence and found that adherence is likely to mediate the effect of social 
support on adjustment to chronic illness but that the quality of the relationship has a stronger effect 
than the number of relationships.  
2.8.1.1: Empirical findings of the Theory of Planned Behaviour and medication adherence 
in rheumatoid arthritis 
There have been no studies that explicitly evaluated the Theory of Planned Behaviour in relation to 
medication taking in rheumatoid arthritis. There has been a little research that has focussed on social 
support and Owen, Friesen, Roberts & Flux (1985) found that a strong motivation for adhering to 
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medications for rheumatoid arthritis patients was pressure from their spouse and the doctor. 
Although it is safe to assume that a patient’s family and doctor will encourage them to take their 
prescribed medication, the level of motivation that the patient has to comply with this 
encouragement will affect the influence that they have.  
2.8.2: The Health Belief Model 
In response to public health failures in the US in the 1950s, the Health Belief Model was designed by 
Rosenstock (1966) and further refined by Becker and colleagues during the 1970s and 1980s and 
therefore is one of the earliest and most cited models to attempt to explain health behaviour 
(Harrison, Mullen & Green, 1992). Initially, the model relied on the expectancy value model and 
stated that the perceived cost of carrying out a health behaviour would be weighed against the 
perceived benefit. The model was originally applied to preventive health behaviours but has been 
amended and applied to other health behaviours more recently.  
The HBM focuses on two aspects of health and health behaviours; threat perception and behavioural 
evaluation. Each of these components can each be further broken down (Figure 2.2). Firstly, threat 
perception can be broken down into perceived susceptibility and perceived severity. Susceptibility is 
related to the possibility or probability of becoming ill with a new or recurrent illness compared to a 
reference group of either other people of the same age or a patient’s personal health related history. 
The severity refers to the perceived consequences of suffering from the illness (Rosenstock, 1966). 
Although traditionally, the threat perception constructs of the HBM have referred to contracting an 
illness, they can also be applied to medication taking with the patient’s perceived susceptibility of 
experiencing side effects and the perceived severity of those side effects. The second part of the 
model refers to behavioural evaluation and includes the perceived benefits of undertaking a 
behaviour which is weighed against the perceived costs. Later versions of the model added a health 
motivation component (Becker, Haefner & Maiman, 1977b) and cues to action (Mattson, 1999) 
which include internal (symptoms) or external (health leaflet) cues. Harrison et al. (1992) carried out 
a meta-analysis of studies that included all four of the major constructs (susceptibility, severity, 
benefit, barriers) and found that they all had significant correlations (r≥0.3) to health behaviours, 
although the effect sizes were largest for the benefits and barriers constructs. The four constructs 
together generally explained about 10% of the variance in behaviour, although this could potentially 
decrease further had the constructs been allowed to correlate, allowing for covariance in the model. 
Perceived severity has been shown to be a weak correlate of health behaviour (Janz & Becker, 1984; 
Schwarzer & Fuchs, 1996). It may be that severity needs to exceed a threshold before it has an 
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effect. Once the threshold has been met, susceptibility may then have more of an effect on 
motivation (Schwarzer, 1998; Sheeran & Abraham, 1996). 
 
Figure 2.2: The Health Belief Model 
The Health Belief Model has been used for a variety of health behaviours including preventive, 
adherence behaviours and clinical use, and therefore there is no standard questionnaire that can be 
used (Abraham & Sheeran, 2005). However, health beliefs have been elicited from physiological 
measures (Brady et al., 1987), behavioural observations (Hay et al., 2003), interviews (Grady, 
Kegeles, Lund, Wolk & Farber, 1983; Volk & Koopman, 2001) and self-report questionnaires 
(Champion, 1984; Nexoe, Kragstrup & Sogaard, 1999).  
2.8.2.1: Empirical findings of the Health Belief Model and medication adherence in 
rheumatoid arthritis 
A number of studies have implicitly or explicitly measured components of the Health Belief Model 
with respect to adherence, although there have been few specifically looking at adherence to 
medication in rheumatoid arthritis. Perceived efficacy of medication and a fear of side effects are 
often associated with adherence (Johnson et al., 1999; Kane, 2006; Lumme-Sandt et al., 2000; 
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Svensson et al., 2000) which clearly demonstrates aspects of the benefit and cost constructs of the 
model. Berry, Bradlow & Bersellini (2004) found that the main benefits of medication given by 
rheumatoid arthritis patients were reduction of pain (71%), easing joint stiffness (73%) and reduced 
joint swelling (52%) but that side effects were perceived to be the biggest costs. Existing patients 
perceived the costs to be significantly higher than new patients, although they did not report more 
side effects. However, although they perceived the costs to be greater, the existing group had better 
adherence than the new group suggesting that they still perceived the benefits to be greater. 
Similarly, Owen et al. (1985) interviewed 178 RA patients and found that the biggest motivations 
were the benefits of pain relief and treating the arthritis.  
Goodacre & Goodacre (2004) sought to add to the social cognition models by interviewing 16 
established and 13 newly diagnosed RA patients over a nine month period. Patients believed that 
they had “no choice” about taking DMARDs because they were necessary to preserve joint function 
and quality of life. However, they expressed concern about becoming reliant on the “powerful” and 
“toxic” medication and compensated for their perceived “dependence” on drugs by minimising their 
intake of other medication such as analgesia. When the RA medication was not perceived to be 
beneficial, patients reported more side effects and the rationale for the medication was questioned. 
This clearly demonstrates the cost-benefit decision being made about DMARDs as although these 
patients perceive there to be high costs to taking DMARDs, they still persevere in order to gain the 
benefit of reduced stiffness and increased quality of life. These patients go even further by limiting 
their intake of other drugs in order to keep the cost-benefit balance for DMARDs.  This also seemed 
to be a dynamic process as newly diagnosed patients were more confident that the DMARDs would 
be beneficial than the established patients who had more experience on which to base their cost-
benefit decision.    
Although there have been a few studies testing the Health Belief Model in relation to adherence to 
DMARD medication in rheumatoid arthritis, they have mostly been cross sectional and looking at 
purely bivariate associations between the components and self-reported adherence. Also, many 
studies have not specifically measured the subdivisions of the illness threat, i.e. susceptibility or 
severity of either RA itself or the practice of taking the DMARD medication. Most studies specifically 
in rheumatoid arthritis have been mainly qualitative with very small samples and a lack of a valid 
measurement of adherence. Although reviews of other health behaviours have demonstrated some 
promising results for the Health Belief Model (e.g. Harrison et al., 1992), there is clearly a lack of 
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evidence regarding the predictive value of the full HBM to explain medication adherence in 
rheumatoid arthritis. 
2.8.2.2: Beliefs about Medications 
An extension to the Health Belief Model which directly addresses the perceived benefits and barriers 
of taking medication was developed by Horne, Weinman & Hankins (1999). The Beliefs about 
Medications Questionnaire (BMQ; Horne et al., 1999) was developed with the aim of determining 
whether there are ranges of specific and general beliefs about medications which can be 
summarized into common themes and how these may relate to each other and to adherence 
behaviours. Scales were derived from items identified in the literature and in interviews about 
medication beliefs. The factor structure revealed two main factors (specific and general), each with a 
further two factors (“specific-necessity” and “specific-concern”, “general-overuse” and “general-
harm”). The specific scale represents the two sides of the cost-benefit analysis of the cognitive 
models; the necessity of the drugs and the undesirable affects that they can have. These were tested 
in a chronic illness sample of 524 patients which reflected a variety of illnesses and treatment 
characteristics. This was to ensure that items both represented the attitudes of different patient 
groups and that they could be used to discriminate between them.  
2.8.2.2.1: Empirical findings of Beliefs about Medications and medication adherence in 
rheumatoid arthritis 
Few researchers have investigated the effects of “general” medication beliefs on adherence in 
chronic illness, possibly because they are perceived both by researchers and patients as less 
important once a chronic illness has been diagnosed. The internal reliability of this scale was also not 
as good in the original construction (Horne et al., 1999). Owen et al. (1985) investigated general 
medication beliefs in RA patients through interview and found that those that had no objection to 
taking medications in general were more adherent to their NSAID medication.  
More commonly, the “specific” factor of the BMQ has been evaluated with regards to medication 
adherence. Treharne et al. (2004) measured necessity and concerns about DMARD medication in 85 
RA patients aged between 29 and 86 years. They found that necessity was highly correlated with 
adherence (r=0.69) but that concerns was not. After controlling for the number of medications and 
demographic variables, they found that the explained variance in adherence was increased by 43% 
with the addition of psychosocial variables including the BMQ subscales. However, only the necessity 
and overuse variables were significant showing that higher perceptions of the necessity of DMARDs 
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to treat RA and lower perceptions that medications in general are overused by doctors lead to better 
adherence. More recently de Thurah et al. (2010) measured adherence to Methotrexate by 85 RA 
patients using the CQR19 over nine months and termed non-adherence as having a CQR19 score in 
the bottom quartile. Twenty-three percent of patients were identified as non-adherent, which did 
not change over the nine month follow-up. For the non-adherers, 37% had low perceptions of 
necessity whereas only 14% had high perceptions of necessity. This did not differ between baseline 
and follow-up. At baseline, there was no variation in levels of concern, but at follow up, only 18.9% 
had low concerns whereas 37.7% had high concerns. This indicates that people who do not adhere to 
their Methotrexate generally have lower perceptions of its necessity but concerns differ over time 
and increase as patients have more experience. However, the authors found that only necessity was 
related to adherence, which supports the findings of Treharne et al. (2004).  
A number of studies have utilised the BMQ to investigate medication adherence in other chronic 
illnesses and Horne (1999) found that specific medication beliefs have explained 15-20% of the 
variance in adherence across different illness groups. Across a number of different studies it would 
appear that specific beliefs do go some way to explain adherence to medications but that patients’ 
perceptions of the necessity of their medication is most important. This appears to be a useful 
addition to the Health Belief Model and many researchers have used it to extend both this model 
and the Self Regulation Model to improve knowledge about medication adherence and to design 
interventions.  
 2.8.3: The Self Regulation Model (and Illness Perceptions) 
Leventhal and colleagues (Leventhal, 1980, 1984) developed a model of health behaviour based on 
problem solving models with an emphasis on the cognitive and emotional processes that are elicited 
from an illness threat. Traditional problem solving models involve three stages; 1) interpretation of 
the problem, 2) coping with the problem and 3) appraisal (assessment) of the coping strategy. 
Leventhal aimed to model patients’ representation of a health threat (presentation of an illness), the 
procedures used to cope with the threat and the evaluation of the coping mechanism (Leventhal, 
Diefenbach & Leventhal, 1992). The model has two largely independent processing systems, the first 
being the objective psychological representation of the health threat and the second being an 
emotional processing system that runs in parallel to the representational arm (Figure 2.3). Leventhal 
proposed the need to describe how emotional processes interact with the psychological illness 
representation and the appraisal of the interaction. The model posits that it is not possible to 
evaluate an illness solely objectively without an emotional response to the threat.  
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The Self Regulation Model retained the three processing stages of traditional problem solving 
models. The first of these is interpretation of the illness threat. This involves accessing illness 
cognitions that a patient has based on the information they already have and their experience of the 
symptoms. Five dimensions of illness cognitions were elicited through multidimensional scaling and 
interviews (Bishop, 1987; Linz et al., 1982) which were termed illness perceptions (Table 2.1). These 
dimensions are interrelated (Petrie, Jago & Devcich, 2007; Petrie & Weinman, 2006; Weinman et al., 
1996) and have good discriminant validity as different types of illness showed different patterns of 
illness perceptions. For example, life threatening diseases are often perceived to be chronic, caused 
by internal factors with severe consequences whereas infectious diseases are the opposite. 
Table 2.1: the Illness Perceptions of the Self Regulatory Model 
Perception Definition  
Identity The illness label or diagnosis and the associated symptoms 
Consequences The expected effects of having an illness on the patient’s life 
Timeline Perceptions of the expected duration of the illness. Typically acute, cyclical or chronic 
Control/cure Perceptions of the extent to which the illness can be controlled or cured through treatment 
or behaviour 
Cause The factors that the patient believed caused the illness. Generally subdivided into internal 
(e.g. genetic) and external (e.g. environment) factors 
 
The underlying processes of each of the stages rely on integration of current information using two 
types of memory structure. Schematic memory refers to memory of prior illness episodes. This is 
important for the automatic elicitation of emotional reactions to an illness. Conceptual memory 
refers to memory about illness with causal and outcome expectations based on judgements about 
illness. This is important for labelling and reasoning about the illness state and the emotional 
reaction (Leventhal, 1980, 1984).  Symptoms form an important part of the Self Regulation Model as 
it is attention to the stimuli that guide behaviour (Cioffi, 1999; Lazarus, 1966; Leventhal, 1970; 
Leventhal, Brown, Schacham & Engquist, 1979). This is where memory about an illness may be 
combined with memory of an illness to create an erroneous representation which leads to non-
adherence. This has been demonstrated with asymptomatic illnesses such as hypertension where 
patients attribute headaches as a symptom of high blood pressure and therefore take their 
hypertension medication only when they have a headache.  
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“I know I can tell when my blood pressure is up, like if I have a headache... I take it, I have a 
[blood pressure] cuff and it’s high! And I take my medications, whenever I have a headache 
or if my face feels warm. So, I know I can tell and I don’t need meds all the time” [a nurse 
describing her self-care routine: She only takes her blood pressure when she experiences 
symptoms] (Leventhal, Diefenbach & Leventhal, 1992 pg 144) 
 
Here, the information about illness (that an illness must have symptoms) is combined with the 
memory of illness (the patient has high blood pressure when she has a headache) to create a 
representation which leads to non-adherence as she does not take her blood pressure reading when 
she does not have a headache. This can also cause conflict within rheumatoid arthritis as the patient 
may believe that having RA must mean that they should experience symptoms. Therefore, if a 
patient is in remission without symptoms, the illness must have gone away, leading to non-
adherence to medication.   
 
Figure 2.3: The Self Regulatory Model 
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The SRM is self regulatory because the model of illness and behavioural response to the threat is 
continually updated by the information and experience the patient acquires through the appraisal of 
the coping strategy. The aim for the patient is to maintain the status quo; therefore as more 
symptoms develop or more information is gathered which is at odds with the current representation, 
the patient must employ different coping strategies in order to return to “normality”. For example if 
a patient becomes more disabled because of the increased joint damage caused by rheumatoid 
arthritis, they may decide to use a walking stick to help them move around. If this helps them to walk 
more easily, they would appraise this coping system favourably. In this circumstance, the patient 
may now perceive their RA to have higher consequences, more symptoms and less controllability 
than previously. As this model is regulatory, it would be expected that the illness perceptions also 
change as circumstances change. It is assumed that this regulation is based on common sense 
(indeed the model is sometimes referred to as the common sense model of illness; Leventhal, Meyer 
& Nerenz, 1980). 
Ongoing research has shown that patient behaviour is influenced by illness representations, for 
example patients who feel they have a high level of control or low levels of identity features 
generally have a better prognosis than those that do not. Changing these perceptions has been 
shown to improve recovery through self regulatory interventions in acute and chronic illnesses 
(Petrie, Cameron, Ellis, Buick & Weinman, 2002; Petrie et al., 2003). 
The Illness Perception Questionnaire (IPQ) developed by Weinman, Petrie, Moss-Morris & Horne 
(1996) is based on the five cognitive constructs of the Self Regulatory Model and has a total of 80 
items. Scharloo et al. (1998) used the 80 item IPQ to test for coping and functioning in patients with 
chronic illnesses including RA. They found good internal consistency for most of the factors although 
the Cronbach’s alpha coefficients were lower in the RA group with the timeline, consequences and 
control being 0.53, <0.5 and 0.55 respectively. For this reason, the authors did not use the 
consequences and control items in the subsequent multiple regression analysis. The IPQ items and 
answers to a coping scale were entered into a multiple regression analysis to predict functioning in 
each of the illness groups. After controlling for disease duration and severity, the “identity” and 
“control” factors explained the most amount of variance in functioning in RA patients at 
approximately 20% each. 
Moss-Morris et al. (2002) developed the Revised Illness Perception Questionnaire (IPQ-R) which 
consists of eight factors measuring Leventhal’s five constructs (with control being split into “personal 
control” and “treatment control”) as well as an emotional representation and comprehensibility of 
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the disease. Broadbent, Petrie, Main & Weinman (2006) proceeded to test the validity and reliability 
of the IPQ-R in six chronic illness groups, most of which had more than one hundred participants. 
Test-retest was used in the renal group to test the reliability. Pearson’s r correlations of between 
0.42 and 0.75, (all significant to p<0.001) were found for all questions three and six weeks after initial 
presentation. 
2.8.3.1: Empirical findings of the Self Regulatory Model and adherence in chronic illness 
As emotional response is an important component of the SRM that is not included in the other social 
cognition theories, there has been a tendency in the literature to use illness perceptions to 
investigate psychological wellbeing and adjustment to chronic illness rather than health behaviours 
such as medication adherence. However, there have been some studies that have looked at various 
adherence behaviours. Cooper, Lloyd, Weinman & Jackson (1999) measured illness perceptions of 
152 patients that had suffered myocardial infarction and measured their adherence to clinic 
appointments up to six month later. Those that displayed lower perceptions of controllability and 
didn’t consider their lifestyle to be a causal factor were less likely to attend follow-up clinic 
appointments. As 60% of patients did not attend these appointments, these perceptions are 
potentially playing an important role in the way these patients react to their situation.  
Although illness perceptions in respect of DMARD taking have not been investigated in RA, there 
have been a number of studies that have looked at adherence to treatment in long term illness, 
although they have demonstrated variable results. In univariate analysis, Chilcot, Wellsted & 
Farrington (2010) found that patients with end-stage renal disease that did not adhere to fluid 
restrictions had significantly lower perceptions of the chronicity and consequences of the illness than 
adherent patients. However, in regression analysis, only lower perception of consequences was a 
significant predictor of non-adherence. In contrast, Ross, Walker & MacCleod (2004) and Patel & 
Taylor (2002) found that lower emotional reaction, and less personal control significantly predicted 
non-adherence to hypertension medication.      
In other studies, illness identity, which is based upon symptoms, has been shown to be important in 
the regulation of the response to illness. Llewellyn, Miners, Lee, Harrington & Weinman (2003) 
measured adherence to prophylaxis medication by haemophilia patients and found in regression 
analyses that only illness identity and necessity of medications (measured by the BMQ) significantly 
predicted non-adherence. Similarly, Horne & Weinman (2002) found that if asthma patients modeled 
their illness on their symptoms and therefore considered themselves to be well when they were 
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symptom free differed in their illness perceptions and did not adhere to preventer medication. Those 
who perceived their illness as chronic with potentially serious consequences were more adherent to 
corticosteroids.  
Although the studies reviewed above have shown variable results with regards to medication 
adherence, this may partly be due to the fact that the aetiology and treatment of these illnesses is 
quite disparate which could lead to the development of different illness perceptions. For example, 
haemophilia patients would be aware of their illness from birth and self-managing regular treatment 
from a young age, whereas end-stage renal disease patients will generally be older at onset and less 
aware of how to manage treatment until they develop some experience. Generally, perceptions of 
consequences and controllability show univariate and bivariate differences although do not 
necessarily predict adherence in multivariate analysis. The model as a whole has been shown to 
explain around 20% of the variance in adherence. However, the studies that have been carried out to 
date are mostly cross sectional and have not taken into account the self regulatory process of 
adjustment to illness and how this would affect health behaviours. Reviewing studies that have used 
the SRM to explain adherence shows clearly that this model needs to be explored more efficiently in 
longitudinal studies to establish the changes that are likely to occur from initial diagnosis to self-
management. There is a particular need for this within rheumatoid arthritis as illness perceptions 
have not been effectively explored in this patient group. This would be particularly interesting given 
the flare/remission nature of the disease and the fact that patients will inevitably face serious 
threats to their quality of life through the progression of the illness.    
2.8.4: Addressing the chronic and variable nature of rheumatoid arthritis when using social 
cognition models 
Although a number of studies have evaluated the social cognition models above in relation to 
medication adherence, few have addressed the specific difficulties faced by RA patients that would 
impact both on medication taking and the relative importance of various constructs of the models. 
For example, although rheumatoid arthritis is chronic, it also often has a flare/remission cycle which 
has the potential to greatly impact on DMARD adherence. Firstly, patients are required to continue 
taking their DMARDs when they are not experiencing symptoms (remission), which requires them to 
overcome the costs of side effects in a period when they will see no immediate benefit (e.g. reduced 
swelling of the joints). Secondly, it is possible that some patients will experience a flare in their 
symptoms despite taking their DMARDs adequately, leading to an unfavourable appraisal of 
medication taking.  
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Some studies have attempted to investigate some of these differences. For example, Berry et al. 
(2004) recruited both newly diagnosed and established rheumatoid arthritis patients. They clearly 
demonstrated the effect that knowledge and experience has on perception of illness as established 
patients perceived the risks of taking medication to be higher than newly diagnosed patients, 
although they did not report more side effects. Interestingly, the established patients also had better 
adherence than the new patients, indicating that although their perception of the costs were higher, 
they were placing less weight on them in the final decision. Similar results were found by Goodacre 
& Goodacre (2004) who also recruited newly diagnosed and established RA patients. Here, there was 
a clear cost-benefit analysis being carried out by the patients, however the newly diagnosed patients 
were more confident that the DMARDs would be beneficial. Again, this provides some evidence of a 
dynamic process of decision making as new information and experience is integrated. However, 
Goodacre & Goodacre (2004) did not find any change in these perceptions over a nine month follow-
up period for any patients.  
Few studies that have used these models longitudinally have found any change over the follow-up 
period. However, de Thurah et al. (2010) did find that patients that were non-adherent had higher 
concern scores on the BMQ at 9 months than at baseline using the Beliefs about Medications 
Questionnaire. In RA, the perceptions towards DMARDs would be especially important to measure 
over the evolution of the disease. For example, it has been shown above that newly diagnosed 
patients have different perceptions of DMARDs due to their inexperience of taking them. This would 
also be true of patients that have escalated up to biologic medication as DMARDs alone would have 
failed to initiate remission in these patients, although they are still expected to take them. As 
necessity has been shown to be a strong predictor of adherence, it could be assumed that patients 
on biologic medication would perceive their DMARDs to be less necessary and therefore not adhere 
to them. However, no studies have currently investigated adherence to DMARDs specifically by 
patients that are also prescribed biologics and therefore the changing model of medication 
adherence in these patients is unknown. 
It is clear that aspects of all of the models would be susceptible to changing perceptions as patients 
become more experienced and knowledgeable about their treatment. It is particularly important to 
identify these changes in order to target specific interventions. For example, the Attitudes towards 
taking medications and Perceived Behavioural Control that are aspects of the Theory of Planned 
Behaviour are liable to change as patients become more experienced. However, by knowing how 
these changes occur, it may be possible to aid the patient to be more adherent; for example by 
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addressing concerns with the medication and talking through exactly how to take them. Similarly, 
the perceptions of threat and the behavioural evaluation at the core of the Health Belief Model 
would also change as patients understand more about their RA. A dynamic, changing model is 
particularly important with regards to the Self Regulation Model because it explicitly describes the 
process of adjusting to various coping mechanisms and the appraisal process. However, there is a 
serious lack of longitudinal studies with a sufficiently large sample size and follow-up period to 
evaluate how exactly illness perceptions change over time within the individual and the effect this 
has on medication adherence. Although this is important for any chronic illness, it is especially so for 
rheumatoid arthritis because of the unpredictable nature of flares and the progressive damage that 
impacts on treatment choice and therefore changing regimens for patients to cope with.  
2.9: Summary of social cognition models 
There are many similarities between the models, primarily because they are all based on an 
expected-utility model (Edwards, 1954) which assumes that a cost-benefit decision is made based on 
information available to the patient. The two major components of all of the models are social 
involvement from family, friends, doctors and other patients and self-efficacy. Perceived control in 
particular is a very strong predictor of both intention and actual behaviour. Although the models 
assume that all patients will carry out the same basic information processing, differences in 
behaviour occur because of the subjective nature of information gathering and the relative 
importance that each patient will place on each of the components.  
Despite the similarities, Weinstein (1993) noted that there had been very little research comparing 
these health models empirically and there has been very little done since. To date, only one study 
has compared more than one model to explain adherence behaviour. Orbell, Hagger, Brown & Tidy 
(2006) used the Theory of Planned Behaviour and the Self Regulatory Model to predict prospectively 
whether 660 women with abnormal cervical screening tests would complete their course of 
treatment. Of these women, 83% attended all of their appointments, 7% attended all appointments 
after a prompt and 10% ceased treatment prematurely, even after a reminder. Factors from both the 
TPB and SRM correlated with intention and behaviour. In logistic regression, higher socioeconomic 
status, being employed and shorter travel time to clinic predicted intention. After controlling for 
these, illness perceptions accounted for an extra 4% of the variance in intention, although only 
treatment control was significant. The TPB variables however increased the variance over and above 
demographics by 42% with all variables being highly significant, although Perceived Behavioural 
Control had the highest β value at 0.59. With the two models combined in the second step, the 
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illness perceptions were no longer significant predictors of intention. However, the results for actual 
adherence to appointments were less encouraging as no illness perceptions were significantly 
related and only Perceived Behavioural Control of the TPB was related with an odds ratio of 1.85 
(1.20:2.86). However, when intention was added to the model, this became the only significant 
predictor with patients with higher intention being 2.81 times more likely to complete the course of 
treatment. Although the Self Regulatory Model was not capable of predicting adherence in 
hierarchical regression, it was able to discriminate between attenders and non-attenders with the 
former reporting higher identity and coherence than non-attenders. These results show that 
although both models are good at discriminating between attenders and non-attenders, it is only 
demographic and personal control variables that can actually predict adherence behaviour. 
However, this study is important because it has actually compared the utility of two models within a 
prospective setting which is lacking considerably in the literature on health behaviour as a whole, but 
particularly with regards to adherence to treatment.  
2.10: Conclusions and justification for this programme of research 
A strong limitation of the research reviewed above is that most have not compared more than one 
model and few studies have systematically measured adherence to medication in a chronic but 
variable disease such as rheumatoid arthritis. For this reason, it would be useful to test each of the 
full models in an RA population to determine which aspects are most strongly predictive of 
adherence to medications. As well as measuring adherence per se, few studies have evaluated the 
effect that the models have on disease outcomes such as functional disability or quality of life. 
Although it is useful to know what psychological factors influence adherence, it is also very 
important to establish exactly what clinical effect this has on patients in order to identify the most 
appropriate areas for intervention.  
A review by Hagger & Orbell (2003) of the Self Regulatory Model in various coping behaviours also 
established the need for more prospective work and, particularly in the case of the SRM, more 
studies that look specifically at the psychological process of adherence in newly diagnosed patients. 
This is especially important in RA as any damage that occurs to the joints before satisfactory 
remission is established is permanent, leading to more disability in the long term.  
To address the issues raised in this review and to gain more explanatory and predictive knowledge 
about the social cognition models of adherence to DMARDs by RA patients, this programme of 
research will aim to test the three most prominent models of health behaviour; the Health Belief 
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Model, the Theory of Planned Behaviour and the Self Regulatory Model as well as Beliefs about 
Medications prospectively over six months in relation to adherence to DMARDs. In order to test the 
discriminant validity of each model it is also necessary to recruit patients with different treatment 
regimens as their motivation to adhere to treatment may differ. Therefore, patients that have been 
newly diagnosed, that are established in their DMARD treatment and those that have progressed to 
biologic therapy (but receiving at least one DMARD concurrently) will be recruited. Mechanisms of 
intentional and unintentional non-adherence will be evaluated separately in order to provide an 
understanding of these very different behaviours. Importantly, the effects of the social cognition 
models and of the different types of adherence themselves will be investigated in relation to disease 
related outcomes such as quality of life, disease activity, functional disability and healthcare costs in 
order to provide a more complete view of the concrete effects that non-adherence can have in 
rheumatoid arthritis. 
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Chapter 3 
General Methods 
3.1: Introduction 
The rationale of this programme of research was to investigate non-adherence to DMARDs by 
rheumatoid arthritis patients. The main focus was to establish whether three social cognition models 
were able to predict and explain medication non-adherence over a period of six months. In addition, 
a number of complementary studies were carried out to provide a more holistic and comprehensive 
approach to tackling adherence in the clinical setting. Although the main focus of this research 
involves a large, prospective longitudinal study establishing the psychological predictors of 
adherence, the issue of measuring adherence, the clinical effects that non-adherence has and 
potential ways of addressing non-adherence were also investigated and are presented in subsequent 
chapters. Given this holistic approach, a number of methodologies and statistical analyses were 
carried out to provide a comprehensive evidence-base on which to consider the importance of 
research into medication non-adherence in rheumatoid arthritis. These methods are discussed in the 
chapters of the studies to which they pertain.  
In order to fulfil the rationale, there were five distinct aims of this programme of research which are 
discussed in more detail below:  
1) Establish the feasibility of using Information and Communication Technology (ICT) in the 
rheumatology clinic to provide a cheap, portable reminder to prevent unintentional non-
adherence to treatment. 
2) Establish a feasible and reliable method of measuring DMARD adherence in the clinic.  
3) Investigate the ability of three social cognition models of illness to predict and explain 
DMARD non-adherence in a large, multicentre cross-sectional study.  
4) Extend the cross-sectional study by investigating whether the social cognition models can 
predict non-adherence in a prospective longitudinal study over six months.  
5) Investigate the clinical impact of non-adherence to DMARDs though health economic 
analysis.  
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3.2: Rationale of establishing the feasibility of using Information and Communication 
Technology to prevent unintentional non-adherence in the rheumatology clinic 
The introduction of cheaper and more sophisticated ICT in recent years presents the opportunity for 
healthcare to implement services with the potential for improving care and reducing costs. 
Specifically, the practice of sending SMS (Short Message Service) text messages to remind patients of 
outpatient appointments has become routine within the NHS. However, there is little research that 
has evaluated the success of these messages, or the potential to extend them to prevent 
unintentional non-adherence to medication, particularly with patients with rheumatoid arthritis who 
are generally older and have more disabilities than the general population. For this reason, Chapter 5 
reports on a survey assessing the feasibility of communicating with RA patients via email and/or SMS 
message that was carried out in the rheumatology clinic. The survey asked patients about 
accessibility to the internet and mobile phones, current use of email and SMS messages and whether 
they would accept appointment and medication reminders in the future.  
3.3: Rationale for establishing a clinically viable measure of adherence to DMARDs  
In order to investigate adherence to DMARDs, an effective measure of adherence was required for 
use in subsequent studies. Objective measures of adherence such as eMEMs and pill counts were 
not suitable for these studies because of the prohibitive cost and resource requirements from both 
researcher and patient and the fact that they are unsuitable for polypharmacy which is a common 
requirement of rheumatoid arthritis management. As discussed in Chapter 2, section 2.6, self-
reported adherence measures are often used in research and a validated measure designed 
specifically for RA was chosen for this programme of research. The 19 item Compliance 
Questionnaire for Rheumatology (CQR19; de Klerk et al., 1999) has been shown to have good 
sensitivity and specificity in detecting non-adherence to DMARDs compared to eMEMs. However, a 
number of items have been shown not to add to the exploratory power of the tool (de Klerk, van der 
Heijde, Landewe, van der Tempel & van der Linden, 2003), making them redundant and therefore 
reducing the parsimony of the questionnaire. In addition, a nineteen item questionnaire was 
deemed too long to use regularly in the clinical setting and within the battery of questionnaires in 
the main study. Therefore, to increase the clinical utility and to improve the reliability by removing 
redundant questions, an exploratory factor analysis was carried out in Chapter 6 with a confirmatory 
factor analysis to check the fit of the reduced questionnaire. 
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3.4: Rationale of testing the social cognition models of illness in relation to the stage of 
illness and adherence to DMARDs 
This study contributed to the main focus of the programme of research. Three commonly used 
models of illness were evaluated in relation to adherence to DMARDs by RA patients. All three 
models were tested simultaneously to establish which was most predictive of non-adherence to test 
which psychological factors should be targeted for intervention in the future. As the aetiology of 
chronic illness differs, it is recommended to establish the models in each patient group (Hagger & 
Orbell, 2003) and very little research has systematically evaluated all three models in the same 
dataset. Therefore, in order to establish the possible psychological causes of non-adherence to 
DMARDs, a large, multicentre study was carried out across six hospitals in Hertfordshire and north 
London between February and October 2010. The cross-sectional analyses are shown in Chapter 7. 
As this type of research had not been carried out in rheumatoid arthritis, there was little previous 
information of effect size and power on which to base a sample size calculation. Therefore, the 
target sample size was based on the standard five cases per item required for regression analyses 
(Tabachnick & Fidell, 2007). To test all of the models simultaneously, 80 patients for each treatment 
group were required. As this study was longitudinal, an attrition rate of 20% over six months was 
assumed meaning that 100 patients per group were required for individual analysis and at least 100 
in total for whole group analysis. 
Patients were followed-up six months after recruitment and asked to complete the questionnaire 
again. There were two aims for the longitudinal analysis; firstly, to establish the stability of the social 
cognition models of illness over six months, particularly for newly diagnosed patients and secondly 
to identify the best predictors of non-adherence over six months. Chapter 8 focuses on the stability 
of the social cognition models with a particular emphasis on the different treatment groups to 
establish whether the social cognition models of illness are stable over time or subject to change in 
response to the illness. There is currently very little research investigating medication adherence 
longitudinally, but those that have, typically employed regression analyses to test the predictors of 
interest (e.g. Abraham, Clift & Grabowski, 1999; Orbell et al., 2006; Ross, Walker & MacLeod, 2004; 
Schuz et al., 2011). A more powerful way of testing causal pathways is to use Structural Equation 
Modelling (SEM) which allows for multiple regression analyses to be carried out simultaneously and 
is shown in Chapter 9. 
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3.5: Rationale of using health economic analysis in relation to adherence to DMARDs  
A number of related health economic analyses were carried out to investigate the effect that non-
adherence to DMARDs has on patients and the NHS. Firstly, a Cost of Illness (COI) analysis was 
carried out in relation to intentional, unintentional and overall non-adherence. The COI took an NHS 
perspective and aimed to establish the total cost of medications, GP visits, inpatient hospital stays, 
Accident and Emergency contacts and outpatient appointments over six months for patients that 
have low adherence. COI studies are carried out to gain economic information about an illness in 
order to raise the public profile. Although many standard COI studies have been carried out for RA in 
numerous countries, none have so far focussed specifically on the cost of medication non-
adherence. For this reason, a pilot study measuring NHS costs prospectively over six months was 
carried out using the patients recruited for the social cognition models of illness and adherence 
study to provide preliminary evidence of the costs generated by these patients. The aim of this 
analysis was to provide a clinically useful, concrete outcome for non-adherence to encourage 
clinicians to become more aware of its importance. 
Health Related Quality of Life (HRQoL) of patients was assessed using the EQ5D (Dolan, 1997; 
EuroQol Group, 1990). This measures five components of health which are combined into a single 
composite score ranging from 0 (death) to 1 (perfect health). The EQ5D utility score is used to 
calculate Quality Adjusted Life Years (QALYs) which combine quantity and quality of life to produce a 
standardised measure which can be used to compare different interventions for different illnesses. 
The QALY was calculated for each patient using the baseline and follow-up EQ5D scores and used to 
produce mean QALYs for adherence groups. More details of these calculations are presented in 
Chapter 10.  
Finally, a simulated Cost-Utility Analysis (CUA) was carried out in Chapter 11 based on the QALYs 
calculated in Chapter 10 and evidence for a potential SMS based intervention provided by Chapters 4 
and 5 and a study by Petrie, Perry, Broadbent & Weinman (2011). CUA is a special type of cost-
benefit analysis which assesses the ratio of costs (measured in monetary terms) and HRQoL, usually 
via QALYs. As QALYs are designed to be universal, CUA can be used to compare across illnesses 
whereas traditional cost-benefit analysis cannot, however there have been criticisms of using QALYs 
in this way which are reviewed by Stamuli (2011) but discussion of which is beyond the scope of this 
chapter. By using CUA, a cost per QALY gained was generated to evaluate the utility of an SMS based 
medication reminder service which is presented in Chapter 11.  
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3.6: Summary of methods used 
In order to provide a complete and comprehensive evaluation of the effects of non-adherence to 
DMARDs, a number of studies were carried out. Firstly, a measure of adherence with high clinical 
utility and easy interpretation was created using exploratory and confirmatory factor analysis of an 
existing measure specific to RA. Following that, the psychological predictors of adherence were 
evaluated in a large, multicentre prospective longitudinal study over six months in 2010. Using 
statistical modelling, the best predictors of adherence were identified with the aim of targeting these 
perceptions in a future intervention to improve adherence. In order to provide more evidence as to 
the importance of researching treatment non-adherence, a health economic analysis was carried out 
to determine the costs of non-adherence from the NHS perspective. A simulated cost-utility analysis 
was then carried out based on a feasibility survey of implementing an SMS reminder service for 
medication adherence. By using these different methodologies, a more comprehensive analysis of 
non-adherence was possible giving more evidence on which to base future interventions.  
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Chapter 4 
 Using technology to aid adherence in rheumatology clinics: 
Systematic review of the use of electronic reminders for chronic 
health management  
4.1: Background 
The issue of unintentional non-adherence (forgetting) affects all aspects of patient self-management 
including clinical review appointments, medication taking and monitoring tests (e.g. blood tests). 
However, forgetting could potentially be addressed with the use of reminders which would act as the 
“cue to action” proposed by the Health Belief Model for the patient to initiate the behaviour in 
question (e.g. taking medication or attending medical appointment). This could potentially overcome 
the issue of people that have a strong intention of performing the behaviour, but simply forget to do 
so. The Hospital Episode Statistics (HESonline) state that in England during 2010, 6.9 million 
outpatient appointments were classified as DNA (did not attend), constituting 8% of all outpatient 
appointments wasted due to patients not attending. This is a problem facing all NHS trusts which 
costs millions of pounds per year.  
There has been little research that systematically differentiates between forgetting and other 
medication non-adherence, therefore there is little known about the prevalence. However, a study 
by Atkins & Fallowfield (2006) found that 38.9% of women prescribed medication for stable breast 
cancer sometimes forget to take it. Forgetting was also much more prevalent than intentional non-
adherence at 83.6% of the non-adherent sample. “Forgetting” and “being busy” are two of the most 
common reasons given by HIV positive patients to miss medication (Chesney, 2000).  
Woods et al. (2008) found that deficits in prospective memory (i.e. remembering to remember) were 
a strong predictor of medication non-adherence by HIV positive patients. They suggest: “a 
programmable electronic device that prominently notifies the patient when it is time to take a 
medication with a detailed text message that includes the medication dosage... might be maximally 
effective” (Woods et al., 2008; page 268). With the market penetration of information and 
communication technologies (ICT) such as the internet and mobile phones increasing year on year 
(Office of National Statistics, 2009), the potential to utilise these existing resources in an appropriate 
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way to aid self-management and adherence by chronic illness patients is huge. However, to date, 
there are no guidelines on the best way to initiate and integrate this type of reminder into clinical 
care in the most effective way to produce an improvement in adherence rates without over-
burdening the patient. For this reason, a systematic review of the literature was carried out to 
determine how electronic reminders have been used to aid self-management in chronic disease and 
the best strategies to implement an intervention.  
4.2: Methods 
4.2.1: Search 
Three frequently used Psychology databases were used to carry out a literature review of technology 
used to address adherence in chronic illnesses in the week commencing 6th April 2009; ISI Web of 
Science, PsycINFO and PubMed. For areas such as the disease type, the search terms needed to be 
reasonably wide (i.e. chronic illness as opposed to specifically rheumatoid arthritis) whereas the 
technology terms needed to be specific (SMS or email produced good results). This reflects the fact 
that there has not been a large amount of research conducted in this area as yet. 
Table 4.1: Results for each of the search terms 
Search terms Search terms prefixed with 
Boolean operator AND 
Search terms prefixed with 
Boolean operator AND 
Retrieved Title 
review 
Abstract 
review 
Adheren* 
OR 
complian* 
Rheumatoid arthritis OR ra Technolog* 8 0 0 
Adheren* 
OR 
complian* 
Rheumatoid arthritis OR ra 
OR chronic illness 
Email OR text message OR 
mms OR mobile telephone 
OR msn OR computer 
32 19 9 
Elder* OR 
old* 
Chronic illness OR disease 
OR pain OR patient OR 
health 
Email OR text* OR sms OR 
internet 
7 7 6 
 
Appendix 4.1 shows the full list of available articles that were produced by this search. There were a 
total of 4 duplicated references. It is clear that the vast majority of papers are concerned with 
various aspects of internet use, with only twelve concerned with SMS or email use in chronic 
illnesses.  
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 4.2.2: Eligibility 
Studies were eligible if they included an email or SMS based reminder for any part of self-
management in a patient sample. Participants had to be over 18 years of age and receive the 
reminder themselves. Due to the small number of eligible studies retrieved, all designs were 
considered. Eligible studies had to be in English but did not have to conform to the NHS model.   
4.2.3: Scrutiny and data abstraction 
Titles and abstracts of each of the studies returned were reviewed. A number of studies were 
removed because the intervention was entirely internet based or because the patients were <18 
years. Although these studies will provide valuable information on integrating technology more 
generally into healthcare, they were deemed unsuitable to inform a reminder service to improve 
adherence. A standardized data extraction form was designed and completed for each eligible study. 
Due to the heterogeneity of the studies, it was not possible to do a meta-analysis and so articles 
were grouped into the type of reminder employed (appointment, medication, self-management). 
4.3: “Results” 
 A small number of studies were found for each of the three categories above (Table 4.2) totalling 11. 
Due to this and the differences in design, it was difficult to compare equivalent results and so a 
narrative review of each of the sub-groups was undertaken in order to establish what research had 
already been carried out, what results could be gleaned and where these technologies could be 
employed in the future and how the research could support this.  
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Table 4.2: Eligible papers retrieved from the systematic search of the literature 
Article category First 
author 
Year  Study design N Mean 
age 
Setting  Outcome measure 
Appointment 
reminder 
Casey 2007 Survey 76 - Urology outpatient clinic in Ireland Percentage of DNA patients that requested a 
reminder 
Appointment 
reminder 
Chen 2008 RCT 1859 51 Heath promotion centre in China Attendance rates for outpatient clinic (%) and 
cost per patient 
Appointment 
reminder 
Koshy 2008 Prospective 
observational  
9959 - Ophthalmology outpatient clinic in UK Attendance rates for outpatient clinic and cost 
per DNA avoided 
Appointment 
reminder 
Leong 2006 RCT 993 38 2 public and 5 private primary care 
clinics in Malaysia 
Attendance rates for outpatient clinic (%) and 
cost per DNA avoided 
Self-
management 
Anhoj 2004 Intervention 12 39 Asthma patients home Response rate of diary SMS messages (% days) 
Self-
management 
Faridi 2008 Phase 1 clinical 
trial 
30 - Community health setting in USA – Type 
II diabetes 
1) Adherence to uploading data to server 
2) HbA1c control 
Self-
management 
Kwon 2004  185 42 Home management – Type I & Type II 
diabetes 
HbA1c, blood glucose, HDL cholesterol, weight, 
patient satisfaction 
Communication Castren 2005 Questionnaire 82 49 Physicians in Finland Student Health 
Centre 
Use of email and telephone consultation 
Communication Huang 2006 Cross sectional 
intervention 
177 - Surgery patients in Taiwan Participant satisfaction 
Communication Neville 2008 Qualitative 180 - Appointment booking and repeat 
prescription ordering in GP practice in 
Scotland 
Uptake rates and interviews related to service 
Adherence Vilella 2004 Intervention 2348 - Travel vaccination clinic in Spain 1) Booster adherence rates 
2) Correct timing of booster  
4
6
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4.3.1: Appointment reminders 
Three papers were found that investigated the use of SMS appointment reminders for adults in 
health care (Table 4.3). One of these was a prospective observational study in an outpatient clinic in 
a UK hospital. Two were randomised controlled trials (RCT) based in all outpatient clinics in hospitals 
outside of the UK (one in China and one in Malaysia). An additional survey carried out in a UK urology 
clinic asked patients that did not attend their appointment whether they would like a reminder, 
although these were not implemented.  
A study by Koshy, Car & Majeed (2008) audited all patients that had an ophthalmology outpatient 
appointment at Barts and the London NHS Trust between April and September 2006 (N=9959 
appointments). Patients that received an SMS reminder were opportunistically selected; those that 
had a mobile phone number recorded on the internal Patient Administration System (PAS) were sent 
a reminder (N=447, 4.5%) and those without a number were not sent a reminder (N=9512, 95.5%). 
The time between the reminder and scheduled appointment differed by when the patient had 
booked. If the appointment was booked less than 7 days previously, the reminder was set for the day 
before, but if the appointment was booked more than 7 days previously, the reminder was set for 4 
days prior to allow for cancellations. The following information was collected; whether the patient 
had received an SMS reminder, whether they were a DNA, and whether they cancelled. The authors 
found that patients that received an SMS reminder were 38% less likely to DNA than those not 
receiving a reminder (Risk Ratio RR=0.62, p=0.0002) and that there was an absolute reduction in DNA 
of 6.9% from 18.1% (no reminder) to 11.2% (SMS reminder). However, the authors acknowledge that 
they were not aware of the proportion of patients without a mobile number on PAS who also did not 
own a mobile phone and therefore would not be accessible via this method. These patients would 
also likely be of a lower socio-economic status and therefore at higher risk of DNA (McClure, Newell 
& Edwards, 1996; Hamilton, Round & Sharp, 2002). The authors report that the cost of an SMS 
reminder was 7.2p and that the number needed to be sent to prevent 1 DNA was 14 (10-31) at a cost 
of approximately £1. The cost of an appointment is cited as £65 making a saving of £64 for every DNA 
avoided.  
The two RCTs carried out by Leong et al. (2006) in Malaysia and Chen, Fang, Chen & Dai (2008) in 
China have very similar designs but were carried out in different health care settings where the 
expectations of the patients are quite different. For example, at the health promotion centre in 
China, patients are assigned specific appointment times which they are expected to attend whereas 
in Malaysia, attendance was defined as any time during clinic hours of the allotted day. There was 
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also the issue that there were 7 clinics included in the Malaysian trial, 5 of which were private, 
whereas only one university based centre was included in the RCT in China. However, the procedure 
was the same for both studies. Patients were randomised into one of three groups; i) telephone 
reminder made by office staff to a landline number, ii) SMS reminder with the same information as 
the telephone reminder (name and appointment details) or iii) no reminder (control). Successful 
contact was assumed when the patient answered the telephone and when a “message sent” 
message was received for the SMS reminder. Leong et al.’s (2006) sample consisted of 993 patients, 
64% of which were female with a mean age of 38. Chen et al.’s (2008) sample consisted of 1859 
patients with a mean age of 50 with 43% being female. Within each setting, RCT groups were 
matched for age and sex. Both of these studies found that a reminder of any type resulted in higher 
levels of attendance than the control groups and that there was not a significant difference between 
attendance rates for the phone or SMS reminders. However, the authors of both studies conclude 
that an SMS reminder is more cost-effective as they are approximately 1.5 times cheaper than a 
telephone call. This was due to the increased staff time needed for the telephone calls as well as 
increased telecommunications costs. This could be further reduced in the future with an automated 
reminder system, eliminating the need for dedicated staff time.  
A survey by Casey et al. (2007) asked patients that did not attend their appointments the reasons for 
this and also if they would like a reminder in the future. A large proportion of patients either forgot 
about their appointment or claimed that they did not receive the original notification. When asked, 
34% requested an SMS reminder, 37% a phone reminder, 36% letter reminder and 6% email 
reminder.  
4.3.2: Disease self-management  
Three studies were retrieved through the search however the types of self-management 
interventions, patient groups and outcome measures are disparate. The majority were internet 
based with an additional SMS message component to send or receive clinical information.   
Anhoj & Moldrup (2004) tested the feasibility of using a reciprocal SMS diary service for asthma 
patients to upload information about their peak flow measurement and sleeping patterns. This 
information could then be used to encourage and empower patients to tailor their medication for 
better self-management. Twelve patients ranging from 13 to 57 years (median = 38.5 years) received 
a sequence of text messages each day for two months at a self-selected time of day. The first two 
messages were reminders for controller medication and measuring peak flow. Patients were then 
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required to reply to the following messages giving information on; peak flow measurement, waking 
up because of asthma symptoms and the number of rescue doses in the past 24 hours. As this was a 
feasibility study to determine whether information could be provided via SMS message, only the 
percentage of responses and patient satisfaction were recorded. The authors found that the 
response rate was approximately 60% which did not decline over time. In any one day, patients 
tended to either reply to all of the messages or none, so the level of information gathered was 
generally high. Generally, patients felt the system gave them more confidence and control over their 
asthma and preferred this type of daily contact to face to face with a health professional. However, 
patients did complain of too many messages per day with too long a delay between them. They also 
wanted the messages to be tailored to arrive later on weekends and holidays. Overall, the SMS 
messages appeared to work well and provide a feasible way of capturing health related data. 
However, these patients were relatively young and highly motivated which could lead to a positive 
bias towards adherence. The authors have shown that is it possible and desirable to use SMS 
messages in conjunction with an online self-management programme for these patients.  
Two studies were found that incorporated SMS messages into a web-based self-management 
programme for diabetes. A study by Kwon et al. (2004) required patients to upload information on 
blood glucose, blood pressure, body weight and any questions to a secure website via SMS message 
to be converted into an electronic chart for both the patients and medical team to review. HbA1c, 
blood glucose and weight were measured pre and post the 3 month period that the website was 
used. The authors found that patients were reasonably happy with technical aspects of the website 
and that there was a trend towards improved diabetes control, although this was non-significant 
over a relatively short period of time. It appears this website could be a useful aid for self-
management, however there does not seem to be any benefit of uploading the information via SMS 
as opposed to directly online or whether the system would be cost-effective based on the improved 
blood glucose control. The authors also noted that older patients got their children to upload the 
information, prompting questions about the suitability of such a system for older patients less 
experienced with the intricacies of uploading and reviewing information online.  
Faridi et al. (2008) implemented a similar diabetes self-management website called NICHE which sent 
personalised SMS messages based on pedometer and blood glucose readings uploaded daily by the 
patient. This intervention had only 15 patients plus 15 control patients who did not receive the SMS 
messages over a 3 month period. The authors found that adherence to uploading blood glucose and 
pedometer readings were very low with a third never submitting readings. Patients identified a 
number of technical issues that acted as barriers to use, however they indicated that they would 
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prefer the NICHE to usual care if it was simpler and more reliable. There was a trend towards better 
blood glucose management and self-efficacy in the intervention group only, although this was not 
statistically significant. There was no change in control patients. It would appear that the SMS 
component of the NICHE study is well received and perceived to be useful by these patients to 
improve self-efficacy and control although improvements to the methodology  and a larger sample 
are needed to clarify how efficacious and cost-effective the system is.  
4.3.3: Adherence to treatment 
Only one study was found that investigated the use of electronic reminders on adherence to 
treatment. Vilella et al. (2004) sent SMS reminders to travellers requiring Hepatitis A+B or Hepatitis A 
vaccination. Participants were recruited opportunistically from two offices from the International 
Clinic Vaccination Centre in Barcelona in the summer of 2001. Those that had a mobile phone were 
offered a reminder for their second and third booster jabs for the respective vaccinations. People 
attending a third office at the centre during the same period acted as controls with no reminder 
offered. Only one person who was offered a reminder refused. Although patients were not 
randomised, post hoc analysis of the demographics found that patients did not differ on socio-
economic status or duration of holiday. Results were based on i) whether a participant attended 
follow-up for a second and third booster at any time and ii) whether the attendance was within the 
recommended time period of 30 days +/- 10 days for the second dose and 190 days +/- 30 days for 
the third dose from initial administration.  
For the Hepatitis A+B vaccine, the reminder did not make any difference to attendance rates for the 
second dose at any time (RR=1.00), however, those that had a reminder were 10% more likely to 
attend within the recommended timing. There was a larger effect of a reminder on the third dose as 
they were 44% more likely to attend at any time and 75% more likely to attend within the 
recommended 190 days. For Hepatitis A, those receiving a reminder were 60% more likely to attend 
for a second dose and 69% to attend within the recommended timing.  
Vilella et al. (2004) found that an SMS reminder increased attendance for the final administration of 
the Hepatitis A+B vaccine by 17.2% in absolute terms from 39.2% (control) to 56.4% (reminder). A 
similar increase of 13.7% from 23% (control) to 36.7% (reminder) was found for follow-up 
administration of Hepatitis A vaccine. Patients were also more likely to attend within the 
recommended time for follow-up if they received a reminder. Although the absolute rates of 
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attendance are still relatively low for each vaccination, it has been shown that a reminder can 
significantly increase the level of adherence to this treatment course and is well received by patients.  
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            Table 4.3: Results from each of the interventions 
Study Participants Duration 
(months) 
Procedure Measures Outcome 
Casey et al. 
(2007) 
76 urology outpatients, 
Ireland 
1 Audit of DNA rates following 
reminder and survey 
1) DNA rates 
2) Reasons for DNA & reminder 
DNA mostly related to forgetting or not knowing appointment date. 
34% requested SMS reminder, 6% email 
Chen et al. 
(2008) 
1859 outpatients, China 2 RCT of SMS appointment 
reminder 
1) DNA rates 
2) Cost per patient 
1) SMS and telephone reminder significantly reduced DNA rates 
2) SMS reminder more cost effective; cost per patient = 0.42Y 
Koshy et al. 
(2008) 
9959 ophthalmology 
outpatients, UK 
6 Prospective audit of SMS 
appointment reminder 
1) DNA rates 
2) Cost per DNA avoided 
1) SMS 38% less likely to DNA with absolute reduction of 6.9% 
2) 14 reminders needed to avoid 1 DNA at a cost of £1 (saving 
£64) 
Leong et al. 
(2006) 
993 outpatients, 
Malaysia 
7 RCT of SMS appointment 
reminder 
1) DNA rates 
2) Cost per patient 
1) SMS and telephone reminder increased attendance by 50% 
2) SMS reminder more cost-effective; cost per patient = RM0.45 
Anhoj & 
Moldrup 
(2004) 
12 asthma patients, 
Denmark 
2 Feasibility study of using 
SMS to collect diary data 
1) Response rate per patient 
2) Response rate per day 
3) Participant experience 
1) Median response rate/patient = 0.69 (0.03-0.98) 
2) 57% of days participants responded to all messages 
3) Liked medication reminder but too many technical problems 
Faridi et al. 
(2008)  
30 Type II diabetes 
patients, USA 
3 Phase 1 clinical trial of 
NICHE; self-management 
website with personalized 
SMS messages 
1) Adherence to uploading  
2) Participant experience 
3) HbA1c 
1) 13.3% completely adherent, 53.3% partially adherent, 33.3% 
completely non-adherent 
2) Too many technical issues but happy to use if simplified 
3) Trend towards improved HbA1c (-0.1) in intervention group 
only 
Kwon et al. 
(2004) 
185 diabetes patients, 
North Korea 
3 Pre-post self-management 
website with SMS upload 
1) HbA1c 
2) Triglyceride 
3) Patient experience 
1) HbA1c mean reduction of 0.5 (p=.003) 
2) Triglyceride mean reduction of 24.4 (p=.007) 
3) Well tolerated but older patients needed help 
Vilella et al. 
(2004) 
2348 travel vaccinations, 
Spain 
4 Case control SMS reminder 
for booster vaccination 
1) Percentage of patients getting 
booster 
2) Percentage of correct timing of 
booster 
1) No difference for second dose but 46% improvement for third 
dose 
2) Significantly improved optimum timing for all doses 
5
2
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4.3.4: Communication  
Only one paper was found which formally investigated the potential for electronic media to improve 
communication between patients and physicians. Castren, Niemi & Virjo (2005) asked doctors at the 
Finland Student Health Service how many of their patient contacts were face to face, via telephone 
or via email and whether they felt that any of the contacts could be replaced by email. In the one 
working week in 2003 in which the study was set, 79% of the doctors had used email to contact 
patients and 98% had used the telephone. Email and phone usage by the doctor did not differ by age, 
gender or specialism. Over half of the sample were positive about the use of email for patient 
contact. The participating doctors estimated that 2% of the face to face contacts and 21% of the 
phone calls could be replaced with email. However, the authors found that approximately 73% of the 
emails sent were not recorded on patient files leading to questions of patient safety.   
Although this study is useful in terms of identifying how email is currently being used within 
healthcare and the ways in which it could be used to reduce unnecessary face to face and telephone 
contacts, this study did not seek to determine the patients’ opinions of this method of 
communication, particularly with regards to security and safety of advice offered via email. This 
would be pertinent before trying to reduce the number of phone contacts by 21% as suggested in the 
paper if, for example these patients would not be willing or comfortable with replacing a phone call 
with an email. However, particularly with this type of student patient group, it would appear that 
email contact allows doctors to reduce the cost of face to face appointments whilst maintaining 
contact with their patients.  
4.4: Discussion 
The few studies that have evaluated the use of SMS messages for outpatient appointments add 
evidence that these reminders are capable of reducing DNA’s significantly for very little cost. Any 
type of reminder (i.e. by telephone call, letter or SMS message) would work well to remind people of 
a scheduled appointment, particularly for routine review appointments for chronic illnesses such as 
RA as these are often booked up to six months in advance increasing the potential to forget about it. 
Although the prospective audit by Koshy et al. (2008) measured whether appointments were 
subsequently cancelled after the reminder was sent (the appointment can then be offered to 
another patient), they did not evaluate the optimum time to send the reminder to allow for 
cancellations without leaving enough time for the patient to forget again. This was also not 
addressed by Leong et al. (2006) or Chen et al. (2008). The evidence given by these studies indicates 
that SMS reminders are a cheap and effective way to reduce the number of DNA appointments, 
however it is now imperative to establish i) the optimum window for the reminder to be sent, ii) how 
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well received these messages are by patients and iii) whether the reminders are being received by 
those most at risk of non-attendance, for example people from a lower socio-economic status or 
those that aren’t highly motivated and therefore do not sign up to a reminder system. Only once this 
information is available will the true benefit of these reminders be known and therefore the true 
cost-effectiveness of a reminder system evaluated. However, due to the very low cost of SMS 
messages, it could be assumed that “blanket reminders” that are not targeted will still be effective at 
reducing the wasted cost of DNA appointments. There appears to be a dearth of evidence from the 
NHS, with many trusts already employing outpatient reminders and reporting reduced DNA rates 
without seeming to properly evaluate the consequences.  
Only the study by Vilella et al. (2004) explicitly sought to improve adherence rates, in this case to 
booster Hepatitis A and A+B vaccination. Although this was not an RCT, the large number of people 
that did receive an SMS reminder had better adherence rates than controls. The effect was 
heightened when the timing of the booster was taken into account with a large improvement, 
although the absolute values remained low. The authors reported that only one person refused a 
reminder suggesting a well tolerated approach. Although the cost of such an intervention is less 
relevant for this type of reminder because of the nature of the travel clinic, it does provide a model 
to remind people of routine tests that are not immediately required, such as 8 weekly blood 
monitoring tests required for rheumatoid arthritis patients. The increase in timing adherence could 
be particularly beneficial for RA patients to ensure that the result of a recent blood test is available to 
review in their clinic appointment in order to discuss potential problems with the clinical care team. 
It would appear that this type of reminder removes the burden from the patient of remembering 
when a test is required and planning it to coincide with the appointment as this could be 
automatically generated by the clinic.  
The quality and relevance of the self-management studies was not particularly high as they dealt 
with asthma and diabetes and suffered from a lot of technical problems leading to low participation 
rates, impacting on the generalisability of the studies. However, despite the small sample sizes and 
intensive interaction with the clinical care team that these patients experienced, it seems that SMS 
reminders and interactive exchanges can be used to prompt patients to perform self-management 
behaviours and share the information to improve self care. Again, the focus of these studies was not 
specifically on the SMS system and therefore unanswered questions remain with regards to the 
optimum timing and number of reminders and the ability of all patients to respond with relevant 
questions. Some patients complained at the frequency of messages in the study by Anhoj & Moldrup 
(2004) and indicated that one message a day that was tailored for weekends and holidays would be 
preferable. Others had difficulties with uploading information due to the level of technical 
 55 
 
knowledge required. Although these studies did not specifically seek to find the optimum reminder 
schedule, they give some indication that a single reminder that is tailored to their circumstances is 
preferred which requires very little specialist knowledge. Technological advances since these studies 
were carried out have made it possible to more simply upload information to a website via SMS 
message which would circumvent some of these problems.  
Overall, although the studies that actually report using electronic reminders are very heterogeneous 
in their design and outcomes, they provide some evidence that SMS reminders are a cheap, well 
accepted method to provide patients with a prompt for self-management behaviours. It was 
interesting to find that none of these studies used email as a way of communicating information 
which may be easier than SMS message. However, SMS messages have the advantage of being more 
portable and readily available at times when a behaviour may be required (for example taking a 
tablet or testing blood glucose). Although there are gaps in the evidence provided by some of these 
studies; for example the proportion of patients who have this type of technology already and 
whether patients who are not highly motivated would be willing to participate in this type of service, 
the results are encouraging. However, the relevance to a rheumatology patient sample is limited due 
to the mostly younger age of participants in these studies and the fact that very few of them would 
be expected to suffer from a disability that could potentially impact on technology use (such as joint 
deformity in the hands).  
4.5: Conclusion  
The conclusion that can be drawn from this systematic review is that currently there is not enough 
evidence published to be able to confidently predict who will benefit from a reminder system or in 
what guise. The optimum recruitment and administration system has not been reported to guide an 
intervention and no studies have been published concerning rheumatology patients. Therefore, it 
would seem that technology can and is being used effectively in a clinical setting but that further 
research is needed to determine the optimum intervention, both for all patients in the case of 
appointment reminders and for particular illness groups for self management programmes.   
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Chapter 5 
Using technology to aid adherence in rheumatology clinics: testing the 
feasibility of implementing electronic reminders in a rheumatology 
patient sample 
5.1: Introduction 
The systematic literature review presented in the previous chapter demonstrates that although the 
use of ICT in healthcare is starting to receive some research attention, there is still a lack of 
knowledge about who regularly uses this type of technology and how best to utilise it for chronic 
illness patients. There is data available for the general population in the UK with the Office for 
National Statistics (ONS) Internet Access survey in 2009 stating that 18.31 million households in the 
UK have access to the internet in their homes; 70% of the population. The survey also stated that the 
most popular online activity was sending and receiving emails with 90% of respondents participating 
in this activity (up from 87% in 2008). This suggests that the possibility of utilising emails in a health 
setting, particularly by reminding patients about medications or appointments is becoming more 
plausible. A survey by Wilson et al. (2008) in South Australia found that 65% of those surveyed with 
internet access would be willing to receive unsolicited health information via the internet, suggesting 
that health related emails would be welcomed. 
In 2008, a survey aggregating real time data from all UK mobile phone operators stated that there 
were 65 million active mobile devices and that 216 million SMS messages were sent per day on 
average; a growth of 38% from 2007 (Mobile Data Association, 2009). The systematic review in 
Chapter 4 indicates that the area of SMS messaging in health settings is becoming more evident. A 
number of mobile phone based interventions have been found to be successful in dietary education 
and weight loss (Kubata, Fujita & Hatano, 2004; Wang, Kogashiwa & Kira, 2006) and smoking 
cessation (Bramley et al., 2005; Lazev, Vidrine, Arduino & Gritz, 2004; Obermayer, Riley, Asif & Jean-
Mary, 2004; Rogers et al., 2005; Vidrine, Arduino, Lazev & Gritz, 2006a, 2006b), as well as in chronic 
illness (Anhoj & Moldrup, 2004; Faridi et al., 2008; Kwon et al., 2004).  
Although there have been some studies relating to chronic illness, they have tended to focus on 
younger patients and those that are not expected to have some of the potential disabilities that 
rheumatoid arthritis patients might have. There is some encouraging research as Dey, Reid, Godding 
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& Campbell (2008) found that 75% of women aged 41-88 years use a computer and Wilson et al. 
(2008) found that 59% of people aged 50-76 had internet access. van Lankveld, Derks & van den 
Hoogen et al. (2006) and Tak & Hong (2005) found that older patients with arthritis did not have 
additional difficulties using the internet, but that overall access rates were low at 28%.   
Very little research has been carried out regarding the current usage of mobile phones in older 
people. Qualitative studies by Kurniawan (2006, 2008) and Bachu, Hine & Arnott (2008) indicated 
that people over 60 used their mobile phones infrequently, mostly to call family to notify them of an 
emergency. They reported rarely sending SMS messages, although they received them on average 
once a week and were able to access and understand them. Some potential problems with small 
buttons and screens were identified in all of these studies as barriers to use, although this was not 
the case for the actual participants.  
A review of the literature indicated no studies had asked about the current use of text messaging 
among older people, particularly by patients with arthritis who would be especially prone to 
problems handling a mobile phone. This would obviously impact on a potential ICT intervention to 
improve adherence. For this reason, a feasibility survey was carried out to determine the levels of 
current use of email and SMS messaging among rheumatology patient groups to determine whether 
the interventions that have been successful in other healthcare settings such as smoking cessation 
and appointment attendance would be possible to implement in this cohort without the need for 
extensive training or set up costs.  
5.1.1: Aims 
1) Establish current use of the internet, email and SMS messaging among rheumatology patients. 
2) Assess the acceptability of using email and/or SMS reminders for appointments and medication 
doses in the future. 
5.2: Methodology 
5.2.1: Patients 
A total of 121 patients were eligible and 112 agreed to take part, giving a response rate of 93%. 
Patients that refused were all female and aged over 40. The median age range was 55-64 and 67.8% 
of patients were female (Table 5.1), which is consistent with the demographics of rheumatic disease. 
Over half of the sample (58.9%) were educated to GCSE or A-level, 29.9% to degree or postgraduate 
level and 11.2% had no formal qualifications. All patients came from the local Hertfordshire area. 
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Table 5.1:  Age distribution of the sample 
Age range Frequency (%) Percentage 
female 
Percentage high school 
education only 
18-24 5 (4.5) 40.0 20.0 
25-34 10 (8.9) 88.8 11.1 
35-44 12 (10.7) 81.8 25.0 
45-54 24 (21.4) 75.0 33.0 
55-64 29 (25.9) 75.9 55.2 
65-74 23 (20.5) 52.2 66.6 
75+ 9 (8.1) 37.5 57.1 
Total 112 (100) 67.8 43.9 
 
5.2.2: Procedure 
All patients attending a Rheumatology outpatient appointment at two Hertfordshire hospitals over 
eight half-day sessions in February 2010 were approached by a researcher and invited to participate 
in a survey of current technology use. An explanation of the content and purpose of the survey was 
given to patients and they were then left to decide whether or not to participate. Consent was 
assumed with submission of a completed survey. Patients were left to complete the survey alone 
unless they requested help from the researcher. All questionnaires were paper based and took 
approximately 15 minutes to complete. A full copy of the survey is shown in Appendix 5.1. Every 
effort was made to include patients in the survey who do not routinely use ICT. This study was given 
ethical approval by the Hertfordshire NHS Research Ethics Committee (REC); 09/H0311/105. 
5.2.3: Office for National Statistics survey 
The Office for National Statistics produces an annual survey called “Internet Access; Households and 
Individuals” which gives data on internet access for the UK population as well as some of the typical 
online activities such as email and shopping for adults aged over 16 years. Approximately 1800 adults 
were contacted each month between January and March 2009 with a response rate of 60%.  
The population data available in the ONS survey is particularly useful for this feasibility study as these 
patients could potentially differ from the population through socio-economic status and disabilities. 
Firstly, the fact that the patients were all taken from the same geographical area could impact on 
internet access due to high broadband availability in Hertfordshire and the traditionally high socio-
economic status, increasing the likelihood of uptake (Fogel, Albert, Schnabel, Ditkoff & Neugut, 2002, 
2003; Wilson et al., 2008). Secondly, the reduced dexterity resulting from the arthritis (Weiner, 1967) 
could reduce the uptake of these technologies. 
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Therefore, in order to establish whether or not the sample differed from the population, the current 
survey was designed to be used in conjunction with the ONS survey, regarding age groups and 
frequency of internet and email used.   
5.2.4: Statistical analysis 
It is important to consider how many patients overall could potentially be accessed as well as those 
that are already very familiar with the technology in order to gain an understanding of potential 
barriers to implementing a reminder service in this patient group. Therefore, results are generally 
presented in two ways; i) the percentage of the entire sample (N=112) to establish the proportion of 
the entire patient population that could be accessed via ICT and ii) the percentage of patients that 
have stated that they already use the internet at least once per week (N=86) or own a mobile phone 
(N=104) to establish the proportion of patients that would be immediately accessible via these 
technologies.  
For all technologies, differences between age groups are considered using χ2 tests and odds ratio 
statistics. The χ2 tests were used to identify differences between all of the age groups. To determine 
odds ratios, the sample are dichotomised into those that are aged 18-64 and 65+ years. These age 
ranges were chosen because they created the most homogenous groups to determine differences 
between older and younger patients to establish whether patients over 65 were less likely to benefit 
from any potential ICT based interventions. Given the traditional view that older people do not use 
ICT, odds ratios were used to look at a younger versus older patient group. 
It is expected that younger patients will be very familiar with ICT and so as well as calculating odds 
ratios, the absolute percentage of patients using email and SMS are shown to determine current 
experience of older adults.  
5.3: Results  
5.3.1: Internet access and use 
Of this sample, 81.6% had internet access at home, which is comparable to the ONS (2009) survey for 
the London area (80%). Ninety-three percent of these patients had broadband access, again 
comparable to the ONS survey. Of those aged over 65, 76.5% had internet access at home. 
Home internet access increased with education, with 97% of patients with a degree or above having 
access, 100% with A levels, but only 66% of those with GCSEs or no formal qualifications having home 
internet access. Again, this trend is comparable to the ONS survey which gives 95%, 89%, 81% and 
52% respectively. Although χ2 (3) = 7.82, p = 0.05 this is on the cusp of being significant, indicating 
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that the patient sample and the ONS survey do not differ substantially on home internet access by 
education groups.  
Table 5.2: Frequency and percentage of patients in each age group that have used the internet 
Age range < 3 months > 3 months ago Never 
 N % N % N % 
18-24 5  100 0 0 0 0 
25-34 10  100 0 0 0 0 
35-44 11 92 0 0 1 8 
45-54 23 96 0 0 1 4 
55-64 23 79 1 3 5 18 
65-74 12 52 2 9 9 39 
75+ 3 33 0 0 6 66 
<65 72 90 1 1.2 7 8.8 
65+ 15 46.9 2 6.3 15 46.9 
Total 87 77.7 3 2.7 22 19.6 
 
The majority (77.7%) of patients indicated that they had used the internet within the last 3 months 
(Table 5.2). A very small minority had used it more than 3 months ago and 19.6% had never used it, 
showing that if patients have used the internet it has been relatively recently. Table 5.2 shows that 
the patients that have never used the internet are generally older, which is supported by the fact 
that the OR shows that patients <65 are 8.4 (2.8 : 25.7) times more likely to be weekly users than 
older patients.  
 
Figure 5.1: Percentage of patients in this sample and in the ONS survey that have used the internet within the 
past 3 months  
The same proportion of patients across the age groups had accessed the internet in the past 3 
months as in the ONS survey; χ2(4) = 4.02, p = 0.40. A small difference is shown in Figure 5.1 in the 
45-54 and 55-64 age groups as the patient sample had a very high level of internet use in these ages 
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at over 79%. There was however a sharp decline at 65+ with only a third of patients having accessed 
the internet within the past 3 months both in this sample and the population. For those patients that 
had accessed the internet within the past 3 months only, (N=87) there was no difference between 
the patients and the ONS survey, χ2 (4) = 2.7, p = 0.61, in frequency of internet access. The absolute 
values were also very high at >93% of the patient sample accessing at least once per week.   
5.3.2: Email 
There is no information regarding the use of email in the ONS survey and therefore comparisons 
cannot be made between the patients and the general population. 
The proportion of patients with an email address was high for the total sample (79.1%); however this 
dropped to just over half for patients over 65. A high proportion of weekly internet users <65 had an 
email address (98.5%) as well as those aged over 65 (86.7%). Nearly all of these email addresses were 
personal with only 3.4% of patients having only a work address. The majority of patients up to 75 
years that had an email address accessed it at least once per week, shown in Figure 5.2.  
  
Figure 5.2: Percentage of patients for the total sample (N=112) and only those with internet access (N=87) that 
access emails at least once per week 
5.3.3: Mobile phone use 
Mobile phone ownership was very high with only 8 patients stating that they did not own a mobile 
phone in the entire sample, a trend which was maintained across the age groups. The majority of 
patients had their phones switched on at least during the day. Although there was a tendency for 
older patients to report having it on less often, the differences between age groups was not 
significant, χ2 (18) = 26.70, p=0.09.  
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Figure 5.3: Distribution of mobile phone use among patients of all ages that own a mobile phone (N=104) 
Patients were asked about their usual mobile phone activity, specifically whether they use their 
phone mainly for calls, mainly for SMS messaging or about the same for both. Over half (57.4%) of 
the total sample used their phones mostly for SMS messaging or equally for SMS and phone calls. 
However, Figure 5.3 indicates that the older patients were more likely to use their phones mostly for 
phone calls with a gradual decline from age group 45-54 in using the phone mostly for SMS 
messaging.  
The decline in Figure 5.3 is not mirrored when it comes to how often patients receive SMS text 
messages on average. Although those aged 45-64 report that they use phone calls more frequently, 
there is still a large proportion of them that receive text messages at least once a week and a very 
small minority (N=3) that report never receiving a text message. Therefore, although these patients 
report that they mostly use phone calls, the majority are also receiving SMS messages on a regular 
basis.  
 
Figure 5.4: Percentage of participants that are confident at reading SMS text messages 
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In anticipation of the likely one way application of an SMS reminder, patients were asked how 
confident they were in reading text messages. Figure 5.4 shows that all age groups, other than those 
aged 75+, had more people reporting that they are confident (either very or quite confident) in 
reading text messages than not confident. Only group 75+ had a higher proportion that were not 
confident whereas the other age groups had only 30%, showing a decline with age.  
5.3.4: Disease specific difficulties with ICT use 
Due to the nature of arthritis, patients were asked whether or not they experienced some specific 
difficulties when using a computer which could potentially be a barrier to its use. Only 8% of patients 
reported problems using a computer with only one patient claiming that these difficulties were a 
barrier to use (Table 5.3). Five people accounted for 13 out of the 17 problems reported. The most 
problematic element was movement of the mouse with 7% of people indicating problems with this. 
There were twice as many arthritis related problems (pressing keys and moving mouse; N=10) as age 
related (sight; N=5). However, there were very few incidences of technical difficulties. None of the 
problems identified differed between the age groups. 
Table 5.3: Potential difficulties experienced by patients when using ICT 
 
 
Similarly, very few people identified difficulties using mobile phones as sixteen people accounted for 
40 out of the 46 problems reported. The most problematic area was pressing the buttons with 15% 
of people responding positively to this. As with computers, there were twice as many arthritis related 
problems (holding the phone and pressing the buttons; N=23) as age related (sight; N=12). In 
contrast to the computer problems, there were a lot more technical difficulties reported with SMS 
(N=11) than with email (N=2). As with the computer based difficulties, none of these differed 
between the age groups and no patients reported not using a mobile phone because of these 
problems. 
Difficulty when using a computer (N=87) N 
Seeing the screen 4 
Seeing the keyboard 1 
Pressing the keys 4 
Moving the mouse 6 
Maintaining email 2 
Difficulty when using a mobile phone (N=104) N 
Seeing the screen 6 
Seeing the buttons 6 
Holding the phone 8 
Pressing the buttons 15 
Using SMS features  11 
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5.3.5: Electronic reminders 
Patients were asked whether or not they would be willing to receive an electronic reminder for 
appointments and/or medications that are due in the future. Table 5.4 shows the percentages of 
patients willing to receive a particular reminder for the total sample as well as only those with access 
to the relevant ICT. A large number responded positively to an appointment reminder and about a 
quarter of people would be willing to receive a medication reminder.  
Table 5.4: Percentage of all patients wanting electronic reminders 
 Appointment 
reminder email  
Appointment 
reminder SMS  
Medication 
reminder email  
Medication 
reminder SMS  
Total sample (N=112) 43.8  44.6  25.9  25.9  
Have email address (N=87) 56.3  NA 33.3  NA 
Own mobile phone 
(N=104) 
NA 48.1 NA 27.9 
 
There was no difference between all age groups for an email appointment reminder, email 
medication reminder or an SMS appointment reminder. There was a small difference, χ2 (6) = 13.52, 
p=0.04 for SMS medication reminders with a higher proportion of younger patients willing to receive 
one. Younger patients were more willing to using SMS as fifty percent of those under 65 would be 
happy to receive an SMS appointment reminder compared to 29% of those aged 65+. Similarly, 
28.8% of the under 65s would be happy to receive an SMS medication reminder compared to 18.8% 
of the over 65s. There was no preference between the mode of reminder with very similar results for 
SMS and email. 
5.4: Discussion 
This survey found that a large proportion of patients within the rheumatology outpatient clinic had 
access to and frequently used ICT. It is encouraging to find that this patient sample did not differ in 
their levels of access to the internet from the general population, as shown in the ONS (2009) survey. 
As has been found in previous research (Fogel et al., 2002, 2003; Wilson et al., 2008) as well as the 
ONS survey, internet access increased with education. For those with no formal qualifications in 
particular, there were low levels of internet access (66% in the patient sample and 52% in the 
population). This could potentially impact on any healthcare interventions involving internet 
delivered programmes as a subset of people that are already at increased risk of adverse health 
outcomes (Eysenbach, 2000; Gordon-Larsen, Nelson, Page & Popkin, 2006) would be less likely to 
benefit from these interventions. This is an area that the UK government is aiming to address with 
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the Digital Britain initiative which plans to roll out 2mg/second broadband internet across the 
country by 2015.  
A high proportion of people that had an email address accessed it at least weekly which indicates 
that if a reminder was sent sufficiently in advance, particularly of an outpatient appointment, the 
majority of patients with an email address would read it. This is maintained across the age groups 
until age 75+ wherein this type of reminder would not be particularly useful as there was a only small 
proportion with an email address and even those that did have one did not check it regularly. 
However, as an additional means of reminding patients of information that they are already aware of 
(e.g. appointment times), email seems a cheap and feasible method.  
The penetration of mobile phones was very high with ownership at 93% of the total sample. There 
appears to be an age effect as seven of the people who did not own a mobile phone were aged over 
45. As the majority of people had their phones switched on during the day and are confident in 
reading text messages this could be a very effective method of reminding patients about 
appointments and medications that are due. Also, as mobile phone ownership was so high, the 
overall effect on the clinic population would be strong and it would not be necessary to give 
additional training or hardware thus reducing the cost of a potential intervention. This suggests that 
it would be possible to obtain similar levels of success at reducing missed appointments as those in 
Paediatrics (Milne, Horne & Torsney, 2006) and Ophthalmology (Koshy et al., 2008) despite the 
typically older average age of patients.   
Interestingly, there were very low levels of “problems” reported for both computers and mobile 
phones by these patients. A very small number were responsible for the majority of the problems 
reported, which were mostly arthritis based, i.e. pressing buttons and holding small objects, as 
opposed to sight related problems. Only two people reported “technical” problems with computers 
such as maintaining an email account whereas 11 people reported equivalent problems with mobile 
phones. This suggests that although mobile phone ownership is higher than internet access, more 
people struggle with complicated phone features such as predictive text than with using an email 
account. Although they may find mobile phones more difficult to use, this is not acting as a barrier as 
they still report regular use. 
A quarter of the sample would like a medication reminder and approximately 44% would like an 
appointment reminder. Patients did not discern between email or SMS for the reminders indicating 
that patients would take advantage of any type of reminder to improve their ability to self-manage. 
More patients requested an appointment reminder which may be due to the fact that most patients 
would be monitored via outpatient clinics every six months whereas medication has to be taken 
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much more regularly allowing people to develop a routine. Reducing the number of forgotten doses 
would not only improve the prognosis for the patient but also help to save costs on unnecessary 
treatment and hospital contacts. As email and SMS messages are so cheap to deliver, any potential 
savings would far outweigh the costs of an intervention.    
There was a marked decrease in technology use for those aged over 65 although there was only a 
very small sample for this age group. However, as Figures 5.2 and 5.3 show, over 70% of patients 
aged up to 75 were regularly using ICT which would result in a high penetration rate of reminders 
across the entire sample. It may be more difficult to introduce these measures in an older sample 
that are not already competent with the technology and who rely on paper based or telephone call 
reminders for appointments. However, these technologies are firmly entrenched in society with 
cheaper hardware becoming available to improve access for everyone. Therefore, as the patient 
sample ages, they will become more adept at using email and SMS messages which can be used to 
the advantage of the patient and healthcare provider to improve self-management and save wasted 
resources.   
This survey reports current use of ICT among the rheumatology patient population which had the 
potential to be different from the general population due to the typically older age and likely 
disability from joint damage. Although the cross section of patients recruited was representative of 
the rheumatology clinics in this area, it should be noted the socio-economic status of this geographic 
area is historically high given its proximity to London and therefore may overestimate ICT access 
compared to the general population across the country (Fogel et al., 2002, 2003; Wilson et al., 2008). 
Encouragingly, the patient population did not differ from the general population for the area and so 
rheumatology patients should not be assumed to have reduced ICT use, particularly for mobile 
phones as no patients reported not using a mobile phone despite some functional difficulty. The 
sample size for the two oldest age groups was a little low, particularly for the over 75 group and 
more research is needed into how exactly these patients prefer to manage chronic illness and 
whether reminders would be suitable given that they are more likely to be given assistance from 
family and/or carers.  
5.5: Conclusion 
Current penetration of ICT is high within the rheumatology population in these Hertfordshire 
hospitals. These patients are also regularly using email and SMS text messaging up to age 75. The 
high level of knowledge and experience of this group suggests that implementing appointment and 
medication reminders would be feasible without additional training or hardware and that it would be 
welcomed by a number of patients to improve self-management of their rheumatic disease. This 
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survey has provided detailed information on how this patient group currently uses ICT to inform 
future interventions to use technology to aid self-management of chronic illness in light of a 
population that is becoming more technologically aware and more prone to serious chronic disease 
as life expectancy and morbidity increases.  
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Chapter 6 
Exploratory and confirmatory factor analysis of the 19 item 
Compliance Questionnaire for Rheumatology  
6.1: Introduction 
As discussed in Chapter 2, the “gold standard” for assessing medication adherence in patient groups 
is to test biological markers of the drugs in the blood or to use electronic medication event 
monitoring to record the time and date of pill bottle opening to infer adherence. However, both of 
these measures are costly and time consuming and can be subject to “white coat adherence” 
resulting in patients being deliberately more adherent immediately prior to a clinic appointment (de 
Klerk, van der Heijde, Landewe, van der Tempel & van der Linden, 2003). A cheaper and simpler way 
of measuring adherence is to use self-report questionnaires. These have the additional benefit of 
attempting to measure the psychological constructs behind medication adherence by measuring 
attitudes and emotions associated with illness and medication taking to infer adherent behaviour. 
This can provide some indication of areas to target to improve sub-optimal adherence. They have 
been shown to be strongly correlated with adherence as measured by other questionnaires, and 
more direct measures such as prescription filling and eMEMs (Garber et al., 2004). 
The number of questionnaires that directly measure medication adherence behaviour has been very 
limited. Those that have been used are often dichotomous and have not been statistically validated 
(Butler, Peveler, Roderick, Horne & Mason, 2004; Morisky, Green & Levine, 1986). One questionnaire 
that has been developed specifically for this reason is the Compliance Questionnaire for 
Rheumatology (CQR19; de Klerk et al., 1999). The authors have reported excellent sensitivity at 
detecting low compliers at 98% with a kappa of 0.78. This was established by validating the scale 
against eMEMs and suggests that it is a good questionnaire for establishing medication adherence. 
Other researchers have also used this scale as a measure of adherence successfully (de Thurah et al., 
2010; Garcia-Gonzalez et al., 2008; Treharne et al., 2004). However, de Klerk, van der Heijde, 
Landewe, van der Tempel & van der Linden (2003) report a moderate level of internal consistency. 
This could be due to the fact that the authors claim that the scale is uni-dimensional and analyse it as 
such, although as part of construction, the instrument was classified as being multi-dimensional and 
no factor analysis has been reported detailing the factor structure. As self-report measures can be 
problematic with regards to construct validity, it is important to subject scales to rigorous statistical 
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testing to ensure that they are reliable and valid. To reduce the CQR19, factor analysis will be carried 
out to check the factor structure of the scale. This will also give statistics that can be used to assess 
the suitability of each item with regards to the construct validity and the amount of variance that the 
items share.  The reduced version will also be validated using confirmatory factor analysis to ensure 
that it provides good model fit.  
6.1.1: Instrument 
The CQR (Table 6.1) is a 19 itemed, self-administered questionnaire that is designed to measure the 
level of adherence to the prescribed medication regimen of patients suffering from a range of 
rheumatic diseases (de Klerk et al., 1999; de Klerk, van der Heijde, Landewe, van der Tempel & van 
der Linden, 2003). The items were generated from patient interviews and focus groups and 
categorised by two Rheumatology consultants. The most descriptive statement for each category 
was then chosen for the questionnaire, resulting in 19 items which are measured on a 4 point Likert 
scale ranging from “Strongly agree” to “Strongly disagree”. The aim of the questionnaire was to 
correctly identify patients that were classified as “low” adherers (taking <80% of their medication 
correctly). Further validation by the authors with eMEMs found that a weighted CQR19 explained 
46% of the variance in adherence as measured by the eMEMs (de Klerk, van der Heijde, Landewe, 
van der Tempel & van der Linden, 2003). Four items (items 3, 5, 7 and 12) combined explained 35% 
of the variance, indicating that it may be possible to reduce the number of items whilst still 
predicting an acceptable amount of medication adherence.  
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Table 6.1: The original Compliance Questionnaire for Rheumatology (CQR19) 
 Questions 
Q1 If the rheumatologist tells me to take the medicines, I do so 
Q2 I take my anti-rheumatic medicines because I then have fewer problems 
Q3 I definitely don’t dare to miss my anti-rheumatic medications 
Q4 If I can help myself with alternative therapies, I prefer that to what my rheumatologist 
prescribes 
Q5 My medicines are always stored in the same place and that’s why I don’t forget them 
Q6 I take my medicines because I have complete confidence in my rheumatologist 
Q7 The most important reason to take my anti-rheumatic medicines is that I can still do what I 
want to do 
Q8 I don’t like to take medicine. If I can do without them, I will 
Q9 When I am on vacation, it sometimes happens that I don’t take my medicines 
Q10 I take my anti-rheumatic drugs, for otherwise what’s the point of consulting a 
rheumatologist? 
Q11 I don’t expect miracles from my anti-rheumatic medicines 
Q12 If you can’t stand the medicines you might say: “throw it away, no matter what” 
Q13 If I don’t take my anti-rheumatic medicines regularly, the inflammation returns 
Q14 If I don’t take my anti-rheumatic medicines, my body warns me 
Q15 My health goes above everything else and if I have to take medicines to keep well, I will 
Q16 I use a dose organizer for my medications 
Q17 What the doctor tells me, I hang on to 
Q18 If I don’t take my anti-rheumatic medicines, I have more complaints 
Q19 It happens every now and them, I go out for the weekend and then I don’t take my 
medicines 
 
6.1.2: Aim 
The aim of this study was to reduce the number of items in the CQR19 whilst retaining a high level of 
explained variance and internal reliability. This will be achieved by carrying out an exploratory factor 
analysis of the CQR19 to reduce the number of items (Study 1) and the model fit will be tested using 
Confirmatory Factor Analysis (Study 2). 
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Study 6.1: Exploratory factor analysis of the Compliance 
Questionnaire for Rheumatology (CQR)  
6.2: Methodology 
6.2.1: Participants  
A total of 70 patients were recruited that had been diagnosed with any poly inflammatory arthritis 
disease and were currently taking at least one of the following DMARDs; Methotrexate, Sulfasalazine, 
Hydroxychloroquine or Leflunamide. Patients were required to be aged between 18 and 75 years to 
participate. Table 6.2 shows the demographic and clinical details of these 70 patients (Hertfordshire 
dataset). In accordance with arthritis prevalence rates, the majority of the participants were aged 
over 40 years (84.3%) and most were female (71.4%). The most commonly prescribed DMARD was 
Methotrexate (50%) with 24.3% prescribed more than one.  
Table 6.2: Demographics of the Hertfordshire and Dudley (and combined) datasets 
 Hertfordshire dataset Dudley dataset Combined dataset 
 Number Percentage  Number Percentage  Number Percentage  
Total sample 
size 
70  155  225  
Gender       
Male 19 27.1 33 21.3 52 23.1 
Female 47 67.1 122 78.7 169 75.1 
Missing 4 5.7 0 0 4 1.8 
Age category       
18-29 4 5.7 2 1.3 6 2.6 
30-39 7 10 13 8.4 20 8.8 
40-49 15 21.4 20 12.9 35 15.6 
50-59 15 21.4 35 22.6 50 22.2 
60-69 15 21.4 51 32.9 66 29.3 
70+ 10 14.3 34 21.9 44 19.6 
Missing 4 5.7 0 0 4 1.8 
Disease 
duration 
      
<1 year 0 0 1 0.6 1 0.4 
1-4 years 21 33.3 25 16.6 46 20.4 
5-9 years 14 22.2 63 42 77 34.2 
10-19 years 18 28.6 35 23.3 53 23.5 
20-29 years 4 6.3 12 8 16 7.1 
30+ years 6 9.5 13 8.6 19 8.4 
Missing 7 10 5 3.3 12 5.3 
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6.2.2: Procedure 
Participants were recruited in two ways; i) consecutive patients arriving for a scheduled outpatient 
appointment were approached by the researcher and invited to participate in the study, and ii) in 
order to increase the sample size, questionnaires were posted to eligible patients to be completed 
and returned in a pre-paid envelope. The CQR19 was given among a battery of questionnaires in 
order to obtain comparative measures with which to establish the validity of the scale. 
Exploratory factor analysis (EFA) was carried out on the CQR19 to determine how many factors were 
present and how each item loaded onto the factors, to aid item reduction. To reduce the number of 
items in the CQR19, those with an MSA value of <0.5, and therefore not adequately sampling the 
construct of adherence, were removed from the analysis. Ethical approval was granted for this study 
by the Hertfordshire NHS REC: 08/H0311/74. 
6.2.3: Statistical Analysis 
Initially, the CQR19 was subjected to an exploratory factor analysis as this allows for analysis of the 
dimensionality of the scale and to reduce the number of items by removing those not adding to the 
explained variance of the latent variable (in this case adherence). In order to carry out EFA, a sample 
size of at least 3 cases per item are required (Tabachnick & Fidell, 2007), which was fulfilled by this 
study. EFA using the unweighted least squares with non-orthogonal rotation was used to extract 
factors which were defined as having Eigen values >1, as well as through inspection of scree plots. 
Before carrying at the EFA, the measures of sampling adequacy were interrogated to establish 
suitability for factor reduction. Firstly, the inter-item correlations and anti-image correlations were 
established to be >0.5. Secondly, the Kaiser-Meyer-Olkin (KMO) measure was required to be >0.7 and 
Bartlett’s test of sphericity to be significant for EFA to be suitable. Following the extraction of factors, 
each item was tested for suitability by insuring that the communalities of the items, the factor 
loadings and inter-item correlations were all above the threshold of 0.3 (Tabachnik, 1989). Once the 
final model was determined, the internal consistency was tested using Cronbach’s α with a threshold 
of >0.8 being considered as having high internal consistency (Nunnally, 1978).  
6.3: Results 
The initial analysis of all 19 items showed that the Kaiser-Meyer-Olkin (KMO) measure of sampling 
was not very high at 0.71. This indicates that there is some degree of inter-correlation leading to a 
possibly weak factor structure. This is supported by the fact that there were 6 Eigen values of >1 
which explained 57.77% of the total variance. This suggests that the items included were not all 
suitable to measure the adherence construct as the factor loadings were mostly very low on all but 
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the first factor. For factors 2, 4 and 5 the highest loadings were around 0.5 but this was only for one 
or two items per factor.  
Table 6.3: Exploratory factor analysis of the full and reduced versions of the Compliance Questionnaire for 
Rheumatology (CQR) 
Factor 
analysis – 
no. of items 
KMO Items 
removed 
MSA of 
removed 
items 
Highest factor 
loading of 
removed item 
Number of 
factors 
Total 
variance 
explained 
1-CQR19 0.711 NA NA NA 6 57.77% 
2-CQR15 0.809 4 
8 
11 
12 
0.428 
0.443 
0.417 
0.448 
0.569 
0.574 
0.590 
0.576 
5 74.52% 
3-CQR13 0.836 1 
19 
0.681 
0.633 
-0.420 
0.578 
4 70.96% 
4-CQR10 0.851 7 
15 
16 
0.770 
0.797 
0.605 
0477 
0.492 
0.434 
4 70.96% 
5-CQR9 0.829 9 0.836 0.423 2 61.96% 
6-CQR8 0.846 5 0.746 0.504 2 66.4% 
7-CQR7 0.822 18 0.905 0.582 2 70.24% 
8-CQR6 0.813 13 0.794 0.668 1 58.58% 
 
Table 6.3 shows that for EFA 2, 3 and 4, the MSA values of the items removed were all below 0.8 and 
the factor loadings were all low. After each successive EFA, the MSA and factor loadings were re-
calculated. Although from the fifth analysis on, some of the MSA values are above 0.8, they are still 
the lowest of the remaining items and the factor loadings are still low. The necessity of reducing the 
number of items to increase the utility of the scale justified removing more items. A uni-dimensional 
factor structure was suggested by the Eigen values and scree plot shown in Figure 6.1. The 
percentage of explained variance of the one factor CQR6 is reasonably good at >50%. The uni-
dimensional nature of the CQR6 also allowed for the construct validity to be tested, with a high 
Cronbach’s α of 0.85. 
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Figure 6.1: Scree plot of the factor structure of the CQR19 
The final scale has a KMO value of 0.81 and the amount of variance that is explained by these six 
items is 58.58% which is satisfactory for this type of scale. The communalities of the items after 
extraction are all reasonably high at >0.42 indicating that the items share some common variance. 
The factor loadings are also high at 0.65 (item 3) to 0.80 (item 17), indicating that they are all 
strongly related to the latent construct. The inter-item correlations for the CQR6 were checked and 
the Pearson’s r correlations between the items were at or above the recommended level of 0.30 
(Tabachnik, 1989) at between 0.30 (items 3 and 13) and 0.64 (items 13 and 14). In contrast, the 
CQR19 had inter-item correlations of between 0.004 (items 8 and 15) and 0.68 (items 14 and 18) 
with the majority being below 0.30. The Cronbach’s α for the CQR6 is 0.85 which shows a high level 
of internal consistency. To check the criterion validity, Pearson’s r correlations were calculated 
between the items on the CQR6 and the Beliefs about Medications Questionnaire. The correlations 
between the BMQ and CQR6 were all >0.3 with the highest being 0.53 (CQR item 14 and BMQ item 
3), indicating that the CQR is closely related to beliefs about medications.  
6.4: Discussion 
The CQR19 was developed by de Klerk et al. (1999) based on literature reviews and interviews with 
patients. However, the authors report moderate levels of internal consistency (de Klerk et al., 1999). 
Although the CQR19 was validated against eMEMs and regression analyses showed 98% sensitivity of 
the scale for detecting low adherence, a factor analysis has not been reported meaning the factor 
structure is unknown. This could explain the low Cronbach’s α that is reported by de Klerk, van der 
Heijde, Landewe, van der Tempel & van der Linden (2003).  
The CQR19 was also found to be weak in this study. A number of items were shown to not 
adequately measure the construct of adherence. The study by de Klerk, van der Heijde, Landewe, van 
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der Tempel & van der Linden (2003) also suggested that some items were superfluous as when they 
carried out a multiple regression analysis, they found that four items explained 35% of the variance 
(items 3, 7, 5 and 12) and that the remaining 15 items together explained only 10% of the variance. 
Added to this, they performed a stepwise regression with each of the 19 items entered as a separate 
step. This would have inflated the amount of variance explained by each step by chance alone 
suggesting that the 15 items explained an inconsequential amount of the variance and were 
therefore unnecessary. Although the aim of this study was simply to reduce the number of items 
substantially, the apparently weak structure of the CQR19 warranted a factor analysis with the view 
to identifying the factor structure to allow a reduction in the number of items, therefore increasing 
the reliability. The first four factor analyses using the unweighted least squares method allowed nine 
items to be removed as they had low MSA values and low loadings on all of the extracted factors. 
This suggests that they were not adequately measuring the construct of adherence and therefore 
were reducing the reliability of the measure. Removing these items also reduced the number of 
factors from 6 to 4, indicating that they were not factors at all but that individual or small numbers of 
items were not loading onto the main factor and therefore creating new “factors” in themselves. It is 
interesting to note that the first items to be removed were those that were worded negatively. 
Although using reversed items is common in questionnaire research to increase the reliability of a 
measure, in this case they appear to have had the opposite effect. This may be because they have 
been worded in a confusing manner, thereby eliciting variable responses.  
At EFA 5, it was decided to remove item 9 because this was cited by de Klerk et al (1999) as being one 
of the questions that was left answered, although this was not the case in this sample. Items 13 and 
18 were missed most often in this sample. This could be because patients who had not missed doses 
of their medication cannot accurately answer the questions, which was expressed to the researcher 
by respondents on a number of occasions. Also, the issue of increased symptoms as a result of not 
taking the medications is addressed by items 2 and 14 which have been included in the final CQR6 
and therefore the decision was made to use this version of the scale as a final measure of adherence. 
This also means that the scale has been greatly reduced, increasing the clinical utility.   
The CQR6 appears to be a more reliable measure than the CQR19 because the Cronbach’s α is 
reasonably high at 0.85. The unidimensional factor structure is also much clearer with high factor 
loadings of all of the items in the CQR6 whereas the factor structure was unclear and weak in the 
CQR19. The amount of explained variance is satisfactory at 58.58% and is comparable to other scales 
of this type. As no objective measure of adherence was used in this study, it is unclear as to how 
useful the CQR6 is in measuring and predicting medication adherence. This should be tested in a 
larger cohort as the reduction is based on a sample size of 59 as only fully completed questionnaires 
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were included. As the structure of the inter-item covariance was not clear in the original CQR19 and 
an objective measure of adherence was not available in this study to compare missing answers, it 
was not possible to replace the missing items with substitutes. The EFA resulted in a questionnaire 
that is short, appears to have good internal consistency, correlated well with other validated 
measures and is easy to use due to its unidimensionality. 
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Study 6.2: Confirmatory factor analysis of the reduced CQR in two 
datasets.  
6.5: Introduction 
Study 6.1 showed that reducing the number of items in the CQR19 is possible without losing a sizable 
amount of explained variance, creating a briefer, more clinically viable questionnaire. The reduction 
from 19 items to 6 also allowed for a more comprehensive factor structure with each question 
loading highly onto a single factor.  
As the sample size in Study 6.1 is relatively small at 66 (4 removed due to missing data), the same 
methodology was used to carry out an exploratory factor analysis in a separate sample 
Rheumatology patients from Dudley, UK (hereafter termed the “Dudley” dataset). This sample was 
collected independently of this programme of research and is used with permission of the primary 
author (Dr Gareth Treharne, Department of Psychology, University of Otago, New Zealand). Using the 
same methodology as for the original sample (hereafter termed the “Hertfordshire” dataset), this 
larger sample (N=155) also demonstrated that the original 19 item CQR could be reduced without 
losing significant amounts of explained variance. As the methodology was identical to that described 
for the Hertfordshire dataset and the results very similar, the exploratory factor analysis for the 
Dudley dataset is not shown but is summarised below. The Dudley dataset produced a reduced CQR 
with 10 items (CQR10), retaining all of the same items as the CQR6 with the exception of item 10 
which was removed due to a lack of validity in the Dudley sample. This produced a uni-dimensional 
scale that explained 41% of the variance in the sample. In order to determine whether the CQR6 or 
CQR10 is more suitable, it is necessary to carry out a confirmatory factor analysis (CFA). This will test 
the fit of the identified model, showing how much each item contributes to the measurement of the 
latent construct of adherence. Therefore, the CFA will show how much variance in medication 
adherence as measured by the CQR is explained by the reduced models as a whole, as well as 
clarifying which individual items are most useful. The aim of the second study therefore is to test the 
reduced versions of the CQR and determine which models produce the best fit to explain adherent 
medication taking behaviour. 
6.6: Methodology 
6.6.1: Samples 
Two separate samples were used in this study, which were combined to increase the power of the 
confirmatory factor analysis. The details of each of the samples are shown in Table 6.2. The first 
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sample, named the “Hertfordshire” dataset was collected at St Albans City Hospital and Hemel 
Hempstead General Hospital during the summer of 2008. The method of collection is described in 
Study 6.1. The second sample, named the “Dudley” dataset was collected in Dudley and is described 
by Treharne et al. (2004). An ANOVA test showed that the mean age of the Hertfordshire dataset was 
significantly younger than the Dudley dataset (F(1, 219) = 7.27 p=0.01), but that the two samples did 
not differ significantly on gender or disease duration. However, as the effect size of the differences 
between the ages was small with Cohen’s d = 0.17, the two datasets were combined to increase the 
power of the confirmatory factor analysis.  
6.6.2: Procedure 
Following the exploratory factor analyses that created the CQR6 and the CQR10 in the Hertfordshire 
and Dudley datasets respectively, a confirmatory factor analysis was carried out using Lisrel 8 student 
edition. Firstly, each of the models that resulted from the EFA in each of the datasets was tested in 
the other dataset; i.e. the CQR6 model that was generated by the Hertfordshire dataset was tested in 
the Dudley dataset and the CQR10 model that was generated in the Dudley dataset was tested in the 
Hertfordshire dataset. These two datasets were then combined in order to increase the sample size, 
and subsequently the power of the CFA. As the data were categorical, new polychoric and asymptotic 
covariance matrices were created from which the subsequent analyses were performed as there was 
a non-normal response pattern. Datascreening was then carried out in order to check for univariate 
and multivariate normality and missing cases. The three models that were identified a priori by the 
EFA were tested using Robust Maximum Likelihood and their fit to the data was evaluated using 
standard goodness-of-fit indices. As these models did not provide a satisfactory fit, some model 
modification was carried out using the modification indices given by Lisrel. These included analysing 
the correlated residuals and covariances among items. Models that showed sufficient fit to the data 
had their measurement and structural models tested. The final models were tested in a random 
sample of 500 created using the bootstrap test in Stata with the user written “cfa” command by 
Kolenikov (2009). New goodness-of-fit indices and R2 values were generated for each item. These 
were assessed to the same criteria as above. 
6.6.3: Statistical Analysis 
Goodness-of-fit indices were chosen to include at least one index from each fit class; absolute, 
parsimony and comparative, as recommended by Brown (2006). It is necessary that the specific 
indices that are used are tailored to each study as they are each influenced by different aspects such 
as sample size or the use of categorical data. For the purposes of this analysis, the following fit 
indices were used with the respective cut-off values, recommended by Hu & Bentler (1999). Absolute 
 79 
 
fit indices; χ2 and Satorra-Bentler Scaled χ2 because the latter adjusts for the fact that a polychoric 
correlation is being used, Root Mean Square Residual (RMR; <0.08). Parsimony fit indices; NCP and 
Root Mean Square Error of Approximation (RMSEA; <0.08). Comparative fit indices; Normed Fit Index 
(NFI; >0.9) and Comparative Fit Index (CFI; >0.9).    
In addition to these model fit indicators, the measurement and structural parts of the model were 
also inspected. To test the structural model, the direction and strength of the estimated parameters 
were checked to ensure that they were in the hypothesised direction. For this model, all parameter 
estimates should be positive, with a t value of >1.96 (significant to α=0.05). 
To test the measurement model, two calculations were carried out by hand to determine i) the 
composite reliability and ii) the average variance extracted. Both equations make use of the indicator 
loadings and indicator error variances. These tests can show how reliable the model is as well as how 
much of the variance is captured by the construct in relation to the amount of variance due to 
measurement error.      
 
   
(∑ )  
(∑ )   ∑( )
 
Where ρc = composite reliability 
 λ  indicator loadings 
 θ  indicator error variances 
 ∑  summation over the indicators of the latent variable 
(Equation 6.1) 
Using equation 6.1 allows the composite reliability to be calculated using information provided by 
Lisrel (Diamantopoulos, 2000). This shows the reliability of the latent construct, and values should be 
>0.6 (Bagozzi & Yi, 1988). 
   
∑  
∑   ∑( )
 
(Equation 6.2) 
Equation 6.2 (Diamantopoulos, 2000) enables a calculation of the average variance that is extracted 
and shows directly the amount of variance that is captured by the construct in relation to the 
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amount of variance due to measurement error (Fornell & Larcker, 1981). Therefore, ρv>0.5 indicates 
that more than half of the variance is accounted for by the construct, whereas ρv<0.5 indicates that 
most of the variance is accounted for by measurement error alone. Therefore, in order to evaluate 
how reliable the model is, it is desirable for ρv>0.5. 
Bootstrap tests were used to test the final models in a randomly selected sample of the combined 
datasets. The method in Stata by Kolenikov (2009) sets the seed at 1010101 and uses Bollenstine 
strapping with 500 repetitions in 20 iterations. This gives parameter estimates and R2 values for each 
item, as well as fit indices for the model as a whole. These were all assessed to the same criteria as 
for the models in the combined dataset.  
The original authors of the CQR19 give a weighted regression model that can be used to classify 
patients as “high” (>80% of medication taken) or “low” (<80% of medication taken) medication 
adherers (de Klerk, van der Heijde, Landewe, van der Tempel & van der Linden, 2003). In order to 
test the discriminant ability of the CQR5, each patient was classified as either a “high” or “low” 
adherer, based on this regression model and a discriminant function analysis was carried out. This 
determined whether the model can reliably distinguish between high and low adherers. This test also 
gives the weights for each question to create a regression equation to be used with the reduced 
questionnaire to optimise classification. The sensitivity, specificity, positive and negative prediction 
value were calculated by hand.                                                                                                                                                                             
6.7: Results 
The CQR6 model that was extracted from the Hertfordshire dataset appears to fit reasonably well to 
the Dudley dataset (Table 6.4) however, the average amount of unique variance explained in the 
model by the latent factor of adherence is very low at 0.39. The reasonable fit indices could be the 
product of a more parsimonious model, rather than being a result of an actually well fitting model.  
Table 6.4: Goodness-of-fit tests for the Hertfordshire and Dudley models 
 Hertfordshire CQR10 Dudley CQR6 
χ2 1086.55 (p<0.001) 75.62 (p<0.001) 
Satorra-Bentler Scaled χ2 282.57 (p<0.001) 26.93 (p=0.0014) 
NCP (90% CI) 247.57 (197.7 ; 304.92) 17.93 (6.00 ; 37.47) 
RMSEA (90% CI) 0.17 (0.16 ; 0.19) 0.093 (0.054 ; 0.13) 
NFI 0.91 0.95 
CFI 0.92 0.97 
RMR 0.11 0.077 
Construct validity 0.919 0.778 
Average variance extracted 0.536 0.389 
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As the a priori models did not fit well in the individual datasets, they were combined in order to 
create more power for the CFA. In addition, as the CQR6 was a nested model of the CQR10 but with 
the addition of item 10, a model that included all of the items retained across both datasets 
(subsequently called the CQR11) was tested in the combined dataset. Datascreening of the combined 
dataset showed that there were 11 missing values and 1 missing case. Once listwise deletion had 
been implemented, the resulting effective sample size was N=187. Of these 187 cases, there were 
154 distinct response patterns, indicating that the majority of participants responded completely 
differently to everybody else. The two most common patterns were; i) answering “strongly agree” to 
every question (N=17) and ii) answering “agree” to every question (N=7). A similar pattern was not 
found with the “disagree” responses; therefore it is possible that these participants were showing 
social response bias as “agree” responses indicate high adherence rates. However, the bivariate 
normality appeared to hold with nearly all of the p values being non-significant and two being very 
close to non-significant (item 10 vs item 2, p=0.01 and item 18 vs item 3, p=0.03). 
The 2 values and goodness-of-fit tests of the three a priori models in the combined dataset are 
shown in the first three rows of Table 6.5. The RMSEA, NFI, CFI and RMR values are all outside of the 
acceptable thresholds indicating that the models do not fit the data sufficiently well. The CQR6 
model appears to fit slightly better although both the parameter estimate and R2 value for item 10 
are very low, and there are five standardized residuals that are higher than the accepted 2.00 (not 
shown) indicating that the CQR6 is not a well fitting model, particularly with the inclusion of item 10.  
Table 6.5: Goodness of fit tests for model comparison 
Model 
2
 (p value) Satorra-Bentler 

2
 (p value) 
NCP (90% CI) RMSEA (90% CI) NFI CFI RMR 
CQR11 465.34 
(p<0.001) 
172.05 (p<0.001) 128.05 
(91.48;172.2) 
0.11 (0.095 ; 0.13) 0.94 0.95 0.094 
CQR10 420.64 
(p<0.001) 
144.78 (p<0.001) 109.78 
(76.38;150.7) 
0.12 (0.097 ; 0.14) 0.94 0.96 0.097 
CQR6 95.42 
(p<0.001) 
28.65 (p=0.001) 19.65         
(7.13 ; 39.77) 
0.097 (0.06 ; 0.14) 0.96 0.97 0.071 
CQR5 56.64 
(p<0.001) 
14.14 (p=0.015) 9.14          
(1.49 ; 24.38) 
0.089 (0.036 ; 0.15) 0.98 0.99 0.054 
 
Model modification was carried out by looking at the residuals and suggested modification indices 
given by Lisrel. As item 10 showed very little unique variance accounted for by the latent factor (R2 = 
0.16), model modification was carried out on the CQR10 model, as this doesn’t include item 10.  
Through subsequent modifications, it was found that 6 items consistently had the highest 
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standardised residuals and the lowest R2 values, indicating that these items produced the most error 
and explained little of the variance in medication adherence. For these reasons, they were removed 
from the model to produce the CQR5 shown in Figure 6.2. 
 
Figure 6.2: Model diagram with parameter estimates for the CQR5 
The fit indices for the CQR5 were much improved and showed an acceptable model. Although the χ2 
values were beyond the acceptable values for a good fit, these are susceptible to sample sizes >100 
(Hu & Bentler, 1999), making p>.05 overly sensitive and so it should be interpreted in conjunction 
with other indices.  The RMSEA, NFI, CFI and RMR are all within the acceptable levels and show a 
good fit to the data. All of the t-values for the parameter estimates are positive and highly significant, 
which is indicated by the large parameter estimates shown in Figure 6.2. The R2 values for the 
parameter estimates range from R2=0.65 (Q17) to R2=0.84 (Q6) showing that each of the items 
explained a large amount of variance in medication adherence.  The average variance extracted is 
above the threshold of 0.5 (Bagozzi & Yi, 1988) at 0.53 showing that there is more variance explained 
by the items than by error and the construct validity is acceptable at 0.85, indicating a reliable 
measure (Bagozzi & Yi, 1988).  
Although this model appears to be a good fit for the data, this may simply be that the model 
modification carried out ad hoc had over fit the model to this dataset only, which could result in it 
not being well applied to other datasets. In order to test this, a bootstrapping method was used to 
test the CQR5 in 500 randomly selected samples from the dataset. The goodness-of-fit indices show 
that the model still has adequate fit and so the CQR5 was tested for discriminant ability.  
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6.7.1: Discriminant Function analysis of the CQR5 
Once the CQR5 model was established as a good fit, discriminant function analysis was carried out to 
determine whether it was as successful as the CQR19 at classifying patients as high or low medication 
adherers. The canonical linear discriminant analysis was highly significant, F(5, 228) = 45.10, p<.001, 
indicating that the CQR5 can effectively discriminate between high and low adherers. The effect size 
η2 is large at 0.50 and the explained variance is very high at 70.5%. The structure matrix gives the 
correlation between the items and the function showing an indication of which variables are most 
closely associated with the function. Question 3 (0.84), Q17 (0.30) and Q5 (0.20) are the most 
strongly related. This is supported by a one way ANOVA of the item means between groups which 
shows that these questions produce significantly lower means by patients classified as low adherers, 
indicating that they “do not agree” more often than those classified as high adherers.  
As was found by the de Klerk, van der Heijde, Landewe, van der Tempel & van der Linden (2003), the 
discriminant function of the CQR5 showed that it is most effective when used as a regression 
equation, rather than simply as a summed score and the structure matrix gives the optimal linear 
combination of the questions to maximise the discriminant ability. Fisher’s classification function 
coefficients result in the following equations: 
 
D0 = -27.611 + (4.407*Q2) + (0.939*Q3)  + (6.101*Q5) + (2.366*Q6) + (2.531*Q17) 
(Equation 6.3) 
D1 = -33.304 + (2.801*Q2) + (5.008*Q3) + (6.471*Q5) + (1.215*Q6) + (3.252*Q17) 
(Equation 6.4) 
Given the two parameters D0 and D1, if D0 is greater than D1 then the respondent should be classified 
as likely to be a low adherer. Conversely, if D1 is greater than D0 then the respondent should be 
classified as likely to be highly adherent. Table 6.6 shows the percentage of cases correctly classified 
by the CQR5. 
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Table 6.6: Classification results for the CQR5 
CQR5   Predicted group membership  
  Group  0 1 Total  
Original Count 0 48 22 70 
  1 5 159 164 
 % 0 68.6 31.4 100 
  1 3 97 100 
88.5% of original grouped cases correctly classified 
The sensitivity of the CQR5 for correctly classifying low adherers was 69% and the specificity was 
97%. The positive predictive value was 0.91 and the negative predictive value was 0.88 indicating 
that the CQR5 is adequate at identifying patients with low adherence to DMARDs. 
6.8: Discussion 
This chapter found that reducing the CQR to just 5 items did not dramatically reduce its explanatory 
power and the sensitivity of identifying low adherers remained high. The exploratory factor analysis 
allowed for the factor structure to be made simpler and more robust with the removal of extraneous 
items, which reduces the burden on the patients whilst completing the questionnaire, and makes 
interpretation easier for clinicians.  
The confirmatory factor analysis confirms that the CQR5 fits the data well and explains a good 
amount of variance in medication adherence for a very short, self-administered questionnaire. The 
parameter estimates are high and the whole questionnaire explains 52.9% of the variance in 
adherence, which is good for this type of measure. The CQR5 also performed at a similar rate in a 
bootstrapped sample of 500 repetitions, confirming that the scale had not been over-fitted to this 
particular dataset, but that it is likely to be applicable to the wider RA population. 
Further evidence of this generalisability is shown by the fact that two of the items identified in the 
CQR5 (Q3 and Q5) correspond to two of the four items that the original authors found to explain 35% 
of the variance in their sample (de Klerk, van der Heijde, Landewe, van der Tempel & van der Linden, 
2003). As the full CQR19 only explained 46% of the variance in their sample, these items are clearly 
highly predictive of medication adherence.  
The discriminant function analysis of the CQR5 suggests good specificity by identifying 97% of the 
high adherers classified by the full CQR19 and sensitivity of 69% at identifying low adherers. As the 
CQR5 is a nested model of the CQR19, which was used as the dependent variable to classify patients, 
good sensitivity and specificity would be expected. However, the good discriminatory power that the 
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CQR5 shows provides more evidence that the other 14 items of the CQR19 are extraneous and are 
not providing additional explanatory power over and above the five retained items, demonstrating 
the clinical utility of the more parsimonious questionnaire. The CQR5 performs equally as well as the 
CQR19 at correctly classifying patients, but with only a quarter of the number of questions. However, 
as the CQR19 was used as the dependent variable for the discriminant function analysis, the 
sensitivity and specificity of the CQR5 should be interpreted with caution unless it is shown to be as 
good when using an objective measure of adherence (such as electronic medication event 
monitoring) as the dependent variable. 
As was found by de Klerk, van der Heijde, Landewe, van der Tempel & van der Linden (2003), the 
CQR5 is most predictive when used as a weighted discriminant equation. This is the optimum 
combination of weighted questions to classify patients as either high or low adherers, and is the 
function that should be used when implementing the CQR5.  The structure matrix indicates that Q3; 
“I definitely don’t dare to miss my anti-rheumatic medication” is the most indicative of high or low 
adherence as high adherers tend to “agree” whereas low adherers tend to “disagree”. It may 
therefore be possible to get an indication of the overall result from the answer to this question with 
a positive (answer 3 or 4) response indicating high adherence and a negative (answer 1 or 2) 
response indicating low adherence.  
The utility of the CQR5 is also suggested by the fact that within this sample of 234 patients, 22% 
(N=53) were classified as being low adherers based on their CQR5 scores. This is in accordance with 
previously published figures (DiMatteo, 1994; Treharne et al., 2004; Treharne et al., 2006) of sub-
optimal adherence to medication regimens.  
Four of the removed items explore issues of medications in general and the patients’ expectations of 
their medications. These constructs are well measured in Horne et al.’s (1999) Belief’s about 
Medications Questionnaire (BMQ) which has been tested and found to be reliable and valid. It could 
therefore be suggested that the BMQ should be used in conjunction with the CQR5 to specifically 
address this construct. The two other removed items are concerned with reduced medication 
adherence on weekends and holidays. Unsurprisingly, it was found that these two items were 
strongly correlated (r = 0.64, p<0.001), although neither of them correlated strongly with any other 
item. Higher non-adherence when away from the home is common (Garcia-Gonzalez et al., 2008) 
and should be acknowledged within the clinical setting to plan and account for periods of sub-
optimal adherence to DMARDs.  
Above all, this study shows that it is possible to reduce the number of questions of the CQR19 
without losing its explanatory properties, thus improving the clinical utility.  
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6.9: Conclusions 
 Although electronic medication event monitoring remains the gold standard, the CQR5 is cheap and 
easy enough to be widely used in the clinic and is short enough so as not to burden patients. This 
makes it ideal as an indicator of medication adherence when assessing efficacy of medications, as 
well as for research involving medication adherence as it can easily be incorporated into the 
appointment or within a battery of questionnaires. A further advantage of the CQR5 over other more 
expensive monitoring techniques is that the answers to the questions could give an indication of the 
reasons behind the non-adherence that can then be addressed by the clinical care team. For these 
reasons, the CQR5 will be used in this programme of research to assess adherence to DMARDs by 
rheumatoid arthritis patients.  
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Chapter 7 
Using social cognition models of illness to predict adherence to 
DMARDs by rheumatoid arthritis patients: Cross-sectional analysis 
7.1: Introduction 
Chapter 1 discussed the significant burden of self-management on patients once diagnosed with RA. 
Patients are required to attend outpatient appointments, have regular blood tests as well as manage 
an often demanding treatment regimen consisting of polypharmacy with differing administration 
requirements, all whilst the patient copes with the pain and malaise generated by the disease itself. 
There is strong evidence that early and sustained treatment with disease modifying anti-rheumatic 
drugs (DMARDs) leads to better outcomes in the short term (van der Herijde et al., 1996) as well as in 
the long term (Fitzcharles et al., 2000; Fries, Williams, Morfeld, Singh & Sibley, 1996) because 
continued synovitis leads to irreversible joint damage (Neidel, Schulze & Lindschau, 1995). However, 
medication non-adherence has been shown to be as high as 41-75% in RA (de Klerk et al 2003; Viller 
et al., 1999). Non-adherence can result in delayed recovery (Grijalva et al., 2007) and increased 
mortality and morbidity (DiMatteo, 1994) leading to higher health service costs (DiMatteo, 1994; 
Grijalva et al., 2007; Hughes et al., 2001; Steiner & Prochazka, 1997; Urquhart, 1999). A Recent 
estimate of the annual cost to the NHS of treating RA in the UK was £689 million with an additional 
£7.9 billion per year of lost productivity due to sick leave and early retirement (NRAS, 2010). As well 
as the cost to society, as being employed has been shown to improve psychological functioning 
(Albers et al., 1999) it is clear that reducing the effects of RA through appropriate drug management 
is imperative for both patients and the wider society.  
DMARDs are the corner-stone of treatment for RA and should be initiated within three months of 
symptom onset (NICE, 2009) and sustained over the duration of the disease to maintain disease 
suppression (Nikiphorou & Young, 2010). Many patients can be maintained on DMARDs such as 
Methotrexate, however some patients require escalation to anti-TNF α therapy although this is very 
expensive and has potentially more serious side effects. However, the benefits of DMARDs can be 
difficult for patients to perceive because of a delay of 8-12 weeks to experience positive effects 
whereas unpleasant side effects can emerge very quickly (Young, 2008). This is particularly relevant 
for newly diagnosed patients who will be required to take at least one DMARD whilst coming to 
terms with their diagnosis and potentially experiencing no benefit for three months. As well as 
 88 
 
developing a routine for taking medication, their beliefs about their illness and treatment could be 
strongly influenced by the lack of an immediate effect of DMARDs leading to potentially low 
adherence. DMARDs are also required to be taken regularly even during periods of quiescence where 
the lack of an immediate association with the benefit can increase the likelihood of non-adherence 
(Garcia-Gonzalez et al., 2008; Kane, Cohen, Aikens & Hanauer, 2001; Kane, Huo, Aikens & Hanauer, 
2003). This would be relevant to patients with established but low-activity disease who may struggle 
with the cost-benefit analysis of taking DMARDs that is inherent in the social cognitive models of 
illness if the benefit is difficult to see. Despite this delay, DMARDs have been shown to be very 
efficacious at promoting and maintaining remission and are well tolerated by most patients (ten 
Wolde et al., 1996) and so it is imperative that patients with established disease continue to adhere 
to their prescription to avoid joint damage and disability. For these reasons, adherence to DMARDs is 
the focus of this study to reduce the burden to the patient and the NHS of non-adherence to these 
cheap and mostly efficacious medications.  
Although adherence to DMARDs has been researched in RA (de Klerk et al., 2003; de Thurah et al., 
2010; Goodacre & Goodacre, 2004; Grijalva et al., 2007; Park et al., 1999; Treharne et al., 2004; Viller 
et al., 1999), patients in different stages of the disease have rarely been separated to identify 
differences both in adherence and in the social cogntion models of illness. As experience of the 
illness forms a fundamental part of the models, there is a need to specifically target newly diagnosed, 
established and patients who have escalated to biologic therapy to establish the differences in 
adherence to DMARDs and the social cogntion models of health that these patients may exhibit.  
As discussed in Chapter 2, non-adherence can be intentional, where a deliberate decision is made 
not to perform the behaviour or unintentional which is largely due to forgetting. Although there are 
likely to be different causes and effects of different adherence types, they have not been reliably 
separated in the literature. Studies by Lehane & McCarthy (2006), Lowry et al. (2005) and Atkins & 
Fallowfield (2006) have demonstrated very different prevalence of intentional and unintentional 
non-adherence to treatment in chronic illnesses other than RA with forgetting being much more 
apparent than intentional non-adherence. Although a thorough review by Clifford, Barber & Horne 
(2008) demonstrated the importance of differentiating between the two, few researchers have 
consistently and reliably measured and reported the differences in their research, particularly in 
rheumatoid arthritis. Therefore, this study will use the CQR5 developed in Chapter 6 to measure 
intentional non-adherence along with a separate measure of unintentional non-adherence to 
provide more evidence of the different processes behind them. 
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The review of social cognition models of health in Chapter 2 showed that there are three main 
models that have been used to explain health behaviours including medication adherence. The 
Theory of Planned Behaviour (TPB) and the Health Belief Model (HBM) were developed in the 1980s 
and 1960s respectively  and have been applied extensively to preventive health behaviours but less 
so to medication adherence in chronic illness. Aspects of social influence have been measured by 
Owen et al. (1985) and DiMatteo (2004) who found that the quality of the relationship with friends, 
family and the healthcare team can influence adherence to treatment. Although not directly 
measuring the HBM, Johnson et al. (1999), Kane (2006) and Goodacre & Goodacre (2004) 
demonstrated that patients with RA consider the costs and benefits of medications which are related 
to adherence. The Self Regulatory Model and more specifically Illness Perceptions have been the 
focus of much recent research into adherence behaviours in chronic illness. There have been mixed 
results as higher perceptions of the chronicity and seriousness of an illness generally leads to worse 
outcomes (Hagger & Orbell, 2003), however with regards to treatment adherence in chronic, 
progressive illnesses similar to RA, these perceptions have been shown to be beneficial (Chilcot et al., 
2010; Horne & Weinman, 2002). However, the review by Hagger & Orbell (2003) acknowledges the 
fact that the aetiology and experience of each disease will alter the illness perceptions and therefore 
they should be investigated separately to provide information for potential interventions. The 
addition of treatment beliefs as measured by the Beliefs about Medications Questionnaire (BMQ) 
have generally improved the predictability of the SRM to treatment adherence with higher 
perceptions of necessity being significantly associated with better adherence (de Thurah et al., 2010; 
Horne, 1999; Llewellyn et al., 2003; Treharne et al., 2004). 
 All of these models are based on a cost-benefit decision performed by the patient and therefore 
there is considerable collinarity with the factors that are being measured. For this reason, and the 
fact there are a number of proposed models of health, it would be advantageous to test each of the 
models in the same dataset to establish which factors or which models are the best predictors of 
adherence. However, only one study has tested the Theory of Planned Behaviour and the Self 
Regulation Theory together. Orbell et al. (2006) found that when combining the two models, 
Perceived Behavioural Control (TPB) was predictive of adherence to colposcopy follow-up treatments 
but that none of the illness perceptions were predictive, although treatment control was predictive 
when the SRM was tested alone. This suggests that illness perceptions are related to Perceived 
Behavioural Control and demonstrates the importance of testing these models together to establish 
which factors are redundant due to a lack of predictive validity and/or colliniarity. Being able to 
identify the most predictive and parsimonious model would increase the clinical utility by making it 
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easier to identify the reasons behind non-adherence to medications and suggesting areas for 
intervention.  
To increase the clinical utility of identifying and understanding non-adherence to DMARDs, it is 
important to establish the effects that it may have on disease activity, disability and changes in 
medication to establish the effects on prognosis. With limited time and resources available for each 
patient, the ability to identify which patients are struggling to adhere to their treatment regimen and 
the possible psychological mechanisms behind it could incentivise clinicians to address the problem 
and provide information for targeted intervention. For this reason, clinical outcomes such as disease 
activity, functional disability, service use including medication changes and quality of life will also be 
measured in this study to provide a more complete picture of how adherence affects patients and 
the progression of rheumatoid arthritis. Although there is now a raft of literature concerning 
treatment adherence in many different conditions (DiMatteo, 1994, 2004; Elliot, 2008; Haynes et al., 
2001; Haynes et al., 2007; Hill, 2005a, 2005b; Kripalani et al., 2007; WHO, 2003), there have been a 
lack of interventions to address the problem to improve adherence in the long-term.  
7.1.1: Aims and hypotheses 
The aim of this study is to test the predictive value of three commonly used social cognition models 
of health behaviour in a large sample of patients with rheumatoid arthritis to explain non-adherence 
to DMARDs. In addition, patients in different stages of the disease, namely newly diagnosed, 
established and concurrent biologic treatment will be investigated separately to establish differences 
in adherence and social cognition models of illness that may be evident. Clinical measures of disease 
activity will also be collected to establish the effects of DMARD adherence on disease progression. 
The majority of research into medication adherence has been cross-sectional which prohibits causal 
inferences being made and therefore this study will follow-up patients over six months to establish 
the causal effects of the social cognition models on adherence. The aim is to provide evidence of the 
psychological factors of medication adherence based on a large sample of rheumatoid arthritis 
patients which is currently lacking in the literature, on which a future intervention could be based to 
improve medication adherence and therefore prognosis for patients.  
Based on previous research on adherence and the social cognitive models of illness, it is 
hypothesised that there will be a number of differences between the three treatment groups: 
1) Intentional non-adherence will be higher in the biologic group because of previous 
failure of DMARDs to promote remission. 
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2) Unintentional non-adherence will be higher in the newly diagnosed group because of a 
lack of routine in taking medications (Atkins & Fallowfield, 2006; de Thurah et al., 2010; 
Woods et al., 2008).  
3) Factors of the social cognition models will differ between the three treatment groups 
because of the influence of the differing experience of the disease (Berry et al., 2004; 
Goodacre & Goodacre, 2004). 
4) Demographics of the three treatment groups will differ with the newly diagnosed group 
being younger with less severe disease activity. 
 
There has been a large amount of previous research on the effects that social cognitive models of 
illness have on adherence on which the following hypotheses are based for the entire sample: 
5) Different factors of the social cognition models will be predictive of intentional and 
unintentional adherence because of the different mechanisms behind them. 
6) Theory of Planned Behaviour; higher Perceived Behavioural Control and perceptions of 
Subjective Norms will be predictive of higher adherence (Ajzen, 1991; DiMatteo, 2004; 
Owen et al., 1985). 
7) Health Belief Model; higher perceptions of barriers to medication taking will be 
predictive of lower adherence whereas higher perceptions of disease severity will be 
predictive of higher adherence (Berry et al., 2004; Johnson et al., 1999; Kane, 2006; 
Lumme-Sandt et al., 2000; Svensson et al., 2000). 
8) Self Regulation Model; higher perceptions of chronicity, consequences and treatment 
control will be predictive of higher adherence (Chilcot et al., 2010; Horne & Weinman, 
2002). 
9) Beliefs about medications; higher perceptions of necessity of DMARDs will be predictive 
of higher adherence but concerns about DMARDs and general beliefs will not be 
predictive (de Thurah et al., 2010; Horne, 1999; Llewellyn et al., 2003; Treharne et al, 
2004). 
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The effects of adherence on rheumatoid arthritis specifically have received little attention cross-
sectionally but based on evidence that lower adherence results in worse disease outcomes 
(DiMatteo, 1994; Grijalva et al., 2007; Hughes et al., 2001; ten Wolde et al., 1996) the following 
hypothesis was generated: 
10) Non-adherence to DMARDs will be related to lower quality of life and worse disease 
outcomes. 
 
7.2: Methodology 
7.2.1: Patients 
In total, 238 of the 263 patients approached agreed to participate, although 49 did not return 
questionnaires or later withdrew.  An additional 161 questionnaires were mailed to less accessible 
patients including those concurrently prescribed biologic therapy and those who received a diagnosis 
of RA within the past 12 months. Thirty-eight (24%) postal questionnaires were returned.  Analysis 
was thus performed on 227 participants. Figure 7.1 shows the recruitment process. The mean age 
was 57.69 (SD=15.03) years and 75.78% were female. Demographic and clinical details for the whole 
sample are shown in Table 7.2.   
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Figure 7.1: Recruitment flow chart 
 
7.2.2: Materials and procedure 
All consecutive patients aged over 18 diagnosed with rheumatoid arthritis and currently prescribed 
at least one DMARD in six hospitals across Hertfordshire and north London were invited to 
participate. In order to recruit patients in specific phases of treatment, dedicated clinics were 
targeted for recruitment and postal questionnaires were sent to patients. Patients were made aware 
that they would be required to complete the questionnaires again six months later and all patients 
gave written informed consent. Patients completed the questionnaires by themselves in the clinic or 
at home and returned in a stamped addressed envelope. A number of clinical variables were 
collected from the notes of patients who consented to the study including; DAS28, current 
prescription, date of diagnosis, date of first DMARD prescription and latest inflammatory blood 
markers (ESR and CRP). All data were confidential and assigned an anonymity identification number. 
The data were subject to double data entry to ensure there were no errors. The study was approved 
by the Hertfordshire NHS REC (09/H0311/102) and all data handling conformed to Good Clinical 
Practice Guidelines. 
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The full questionnaire is shown in Appendix 7.1 and described in more detail below. Questions 
included self-reported adherence (CQR5, RAM), quality of life (EQ5D and visual analogue scale), 
social cognition models of health behaviour including; Theory of Planned Behaviour (Orbell et al., 
2006), Health Belief Model (Nexoe et al., 1999), Illness Perceptions (IPQ-R; Moss-Morris et al., 2002), 
Beliefs about Medications (BMQ; Horne et al., 1999) and self-reported functional status (HAQ; Fries 
et al., 1980). 
Theory of Planned Behaviour 
Attitudes 
Participants are presented with eight pairs of statements that represent attitudes towards their 
DMARDs. They are instructed to circle one statement from each pair that would indicate a positive or 
negative attitude.  
Subjective Norm 
Three questions regarding the perception of other people’s opinion of whether or not the patient 
should take their medication are scored on a 5 point Likert scale. A sumscore is generated to give a 
score of the patient’s perceived level of subjective norm with regards to taking medications. Higher 
scores indicate a higher perception that other people think they should take their DMARDs. 
Perceived Behavioural Control 
Seven questions relating to the amount of control the person feels over successfully overcoming 
obstacles in order to take their medications accurately are scored on a 5 point Likert scale.  Higher 
scores indicate more confidence by the patient that they have control over their medication taking.  
Intention 
Patients are asked to indicate their intention to take all prescribed doses of their DMARDs over the 
next month by circling one of four statements ranging from “not at all” to “all of the time”.  
The Health Belief Model 
Barriers 
The barriers section contains six questions relating to various factors that could act as barriers to 
taking medications. They refer to conceptual and logistic issues such as “I do not want to take 
medications” and “my medications are too expensive” respectively. A sumscore for all of the barriers 
questions ranges from 6 to 30 with higher score indicating more barriers to taking medications. 
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Benefits 
Four questions related to the potential for DMARDs to prevent the patient from becoming ill are 
scored on a 5 point Likert scale. The sumscore ranges from 4 to 20 with higher scores indicating a 
higher potential for benefits of taking DMARDs. 
Severity                                                                                                                                                         
The final five questions relate to the arthritis itself and how a “flare up” could affect the patient’s life. 
The questions are scored on a 5 point Likert scale with sumscores ranging from 5 to 25. Higher scores 
indicate that the patients perceive a flare up to be very severe.  
 Self Regulatory Model 
Identity 
Patients were presented with a symptom index of fourteen symptoms; 5 of which were specifically 
related to arthritis (e.g. swelling of the joints) and 9 of which were generic (e.g. headache). Patients 
were required to indicate i) whether they had experienced each symptom over the past two months 
and ii) do they believe this symptoms was caused by their arthritis. In line with guidelines, a 
sumscore of symptoms that were believed to be caused by the arthritis was used as the identity 
score.  
Chronicity 
Five questions relating to the chronicity of the arthritis were scored on a 5 point Likert scale from 
“strongly disagree” to “strongly agree”. Two of the items were reverse scored. After reversing, the 
sumscore ranged from 5 to 25 with higher scores indicating longer perceived chronicity of the 
arthritis.  
Cyclical timeline 
Four questions describing a cycling course of symptoms were scored on a 5 point Likert scale. 
Sumscores ranged from 4 to 20 with higher scores indicating more cycling or variability in symptoms.  
Consequences 
The consequences factor refers to factors that have a strong impact on the patient’s life for example 
“my arthritis has serious financial consequences”. Six questions are scored on a 5 point Likert scale 
with one question being reverse scored (“My arthritis does not have much effect on my life”). The 
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sumscore generated ranges from 6 to 30 with higher scores indicating higher perceived 
consequences of the arthritis.  
Personal control 
Personal control refers to the level of perceived control by the patient to influence the symptoms 
and course of the arthritis. There are six questions, two of which are reversed. Sumscores range from 
6 to 30 with higher scores indicating higher perceived personal control.  
Treatment control 
Six questions relating to the ability of medications to control arthritis are scored on a 5 point Likert 
scale with two reverse scored questions. Sumscores range from 6 to 30 with higher scores showing a 
higher perception that medications can improve arthritis.  
Coherence 
Five questions measured patients’ perceived knowledge about their arthritis and the symptoms such 
as “I don’t understand my arthritis”. It is important to note that the patients’ actual knowledge about 
arthritis is not tested but rather it is an indication of how confident they feel about their knowledge. 
One question is reverse scored and sumscores range from 5 to 25. Higher scores indicates that the 
patient does not consider themself to have a high level of knowledge about their arthritis.  
Emotional effects 
A factor measuring general emotional affects of arthritis includes questions about feeling depressed, 
upset, anxious, afraid and angry specifically about having arthritis. Six questions are included, of 
which one is reverse scored. Sumscores range from 6 to 30 with higher scores indicating a more 
negative emotional effect of arthritis.  
Beliefs about Medications Questionnaire  
The BMQ has two subscales; general and specific which each have two further subscales. The general 
subscale has eight questions and refer to patients’ feelings that in general, medicines are harmful 
(General Harm) and that in general, medications are over used (General Overuse). The specific 
subscale has ten questions that refer directly to the medications prescribed for rheumatoid arthritis 
and include five questions referring to concerns patients might have about taking these (Specific 
Concerns) and five questions related to the patients’ perceptions that the medications are necessary 
in order to stay well (Specific Necessity). In all cases, questions are scored on a 5 point Likert scale 
with higher scores demonstrating a stronger association with the subscale.    
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Adherence measures 
The Compliance Questionnaire for Rheumatology (CQR5) 
The reduced Compliance Questionnaire for Rheumatology (CQR5) that was developed in Chapter 6 
was used to measure intentional non-adherence. Based on the discriminant function scores, patients 
were classified as being “high” or “low” adherers.  
Reported Adherence to Medications (RAM) 
Two questions from the reported adherence to medication scale were used which measure 
unintentional non adherence (“I sometimes forget to take my medicines”) and intentional non 
adherence (“I sometimes alter the dose of my medicines to suit my own needs”). These were scored 
on a 4 point Likert scale from “don’t agree at all” to “agree very much”. For the purposes of the 
analysis, responses were dichotomised as agree/disagree.  
Disease related measures 
Health Assessment Questionnaire (HAQ) 
The HAQ measures the level of difficulty that a patient has faced in the past week carrying out eight 
everyday tasks such as dressing, walking and reaching for objects. It also measures whether a patient 
has needed an aid or device and/or help from another person to carry out the task. An index 
between 0 and 3 is calculated with 0 indicating no problems with these tasks and 3 indicating 
extreme disability. Although there is no specific cut-off value, scores over 2 are considered to 
indicate high disability.  
DAS28  
The DAS28 is described in Chapter 1, section 1.4.2 and was measured on the day of recruitment and 
taken from patients’ medical notes.  
Quality of Life (QoL) measures 
EQ5D 
The EQ5D (Dolan, 1997; EuroQol Group, 1990) is a measure of quality of life developed by the 
EuroQol group to be used for patients with a physical illness. It consists of a 200mm Visual Analogue 
Scale (VAS) asking patients to indicate their health state today from worst imaginable health state (0) 
to best imaginable health state (100) as well as a questionnaire measuring five components of 
health; mobility, self care, usual activities, pain and anxiety/depression. The five components are 
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measured on a three point scale; no problems-some problems-unable to complete the task. These 
five scores are then transformed into a weighted sumscore to give a utility value scoring from 0 
(death) to 1 (perfect health). Due to the nature of the questions, it is possible to achieve a negative 
value which is considered to be “worse than death”. The two measures are scored separately but 
used in conjunction to give a measure of quality of life.  
 7.2.3: Statistical analyses 
Patients were classified into treatment and adherence based on the following criteria; 1) newly 
diagnosed patients, diagnosed within the six months prior to recruitment, 2) established patients, 
diagnosed more than six months prior to recruitment and not currently prescribed biologic therapy 
and 3) biologic patients, prescribed traditional DMARD concurrently with anti-TNF α therapy. Three 
adherence scores were obtained for each patient. Firstly, using the discriminant function analysis 
reported in Chapter 6, patients were classified as being either high (1) or low (0) intentional 
adherers. Secondly, using the RAM question 1, patients were classified as forgetting (agree or 
strongly agree) or not forgetting (disagree or strongly disagree). The overall adherence measure is a 
composite of these scores. If a patient was scored as a high intentional adherer and does not forget, 
overall adherence is high. If a patient scores as a low adherer on either the CQR5 or RAM or on both, 
they are classified as a low overall adherer.   
Sumscores were generated for each psychological factor for each of the models for each patient. 
Mean sumscores were then established for; i) the entire sample, ii) each treatment group and iii) 
each adherence group. Differences in illness and treatment perceptions were tested using one way 
ANOVA with Bonferroni correction for multiple testing. Differences between categorical variables 
were tested using χ2. All significance testing used α level of 0.05. In addition to univariate analyses, 
Pearson’s r correlation was used to assess bivariate associations between all of the psychological 
factors and adherence. 
To establish the predictive ability of the models to predict non-adherence, adherence was 
dichotomised so that 1=high adherence and 0=low adherence and logistic regression was carried out. 
Logistic regression is the most suitable analysis for binary categorical dependent variables 
(Tabachnik, 1989) and is evaluated by the -2 log likelihood statistics which can be interpreted as χ2. 
The analysis also provides statistics of the number of cases correctly identified in each group based 
on the independent variables to evaluate the utility of the model. Although a true R2 statistic 
indicating the amount of variance explained by the model is not possible with logistic regression, a 
number of proxies have been designed and Naglekerke’s R2 is used in this analysis to aid comparison 
of the different models. Each variable is evaluated using Wald’s χ2 statistic and the associated odds 
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ratio to interpret the effect that the variable has on predicting the dependent variable. Comparison 
of the models in this way was also carried out by Orbell et al. (2006) and allows comparability across 
the studies. 
In order to establish the different social cognition models of illness for the treatment groups, a 
discriminant function analysis was carried out between the three treatment groups. The 
methodology is the same as that described in Chapter 6, section 6.6.3. To establish the utility of the 
social cognition models to predict non-adherence, logistic regression was carried out.  
7.3: Results 
7.3.1: Data screening 
Missing data for most questionnaires was negligible, ranging between 0 and 3%. However, there 
were large numbers of missing responses for the Theory of Planned Behaviour Attitudes questions 
ranging from 26.9% for necessary-unnecessary to 52.9% for pleasant-unpleasant. Closer inspection 
indicated that this was likely due to patients misunderstanding how to answer the question as often 
only one option out of the eight possibilities was marked (e.g. only “necessary” was marked), rather 
than patients choosing the most appropriate response for each option (e.g. marking “wise”, 
“important”, “satisfying” etc). As so much of the Attitudes data was missing and it was not missing at 
random, this factor had to be excluded from further analysis.  
The Theory of Planned Behaviour aims to explain both intention to perform the behaviour and the 
behaviour itself. For this reason, a question measuring patients’ intention to take all of their DMARD 
doses over the next month was measured with the question; “over the next month, my goal is to take 
my disease modifying anti-rheumatic medications: (not at all - some of the time - most of the time - 
all of the time)”. However, Figure 7.2 shows that there was very little variability in the responses to 
this question as 91.2% of patients responded “all of the time” and therefore it was not appropriate to 
use it as a dependent variable in any of the analyses. 
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Figure 7.2: Distribution histogram of responses to Theory of Planned Behaviour “intentions” question 
Most statistical packages use listwise deletion to remove cases that have incomplete datasets. 
However, as most of the data was shown to be missing at random (other than TPB Attitudes), it was 
possible to replace missing values with a suitable substitute. Ten multiply-imputed data sets were 
generated using the ICE package in Stata 11.1 for variables other than TPB Attitudes, which performs 
multiple imputation by chained equations (Royston, 2004). Analyses were then conducted separately 
on each of these datasets and averaged using Rubin’s rule (Carlin, Galati & Royston, 2008).  
Disease related factors were measured by the HAQ which is a questionnaire that was included in the 
battery of questionnaires completed by patients and the DAS28 which was entered by the physician 
on the day of the clinic visit. However, DAS28 can only be completed if a blood test was available on 
the day of the visit which led to 63 missing cases (27.8%). However, there is no reason to believe that 
cases are missing in a systematic way and so for analyses involving DAS28, listwise deletion was 
employed.  
On inspection of the data, most of the categorical variables were negatively skewed. For this reason, 
all independent variables were z transformed so as not to violate the assumption of normality which 
is necessary for many of the statistical analyses that were carried out.  
7.3.2: Reliability of scales used 
The reliability of the scales used to measure the social cognition models of illness was tested for 
internal reliability using principle components analysis and Cronbach’s α shown in Table 7.1. The 
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principle components analyses highlighted some issues with weak questions. Most notably, although 
three components were extracted for the Health Belief Model which would be expected, 
examination of the rotated component analysis shows that the loadings of the questions do not 
correspond to the predefined factor structure (Appendix 7.2). This is supported by the fact that the 
Cronbach’s α for the named factors are less than satisfactory for barriers and benefits at 0.63 each. 
However, the internal consistency of the newly defined components was not improved (Appendix 
7.2) and so the predefined structure was maintained for subsequent analyses in order to be 
comparable to previous research.  
Table 7.1: Internal consistency shown by Cronbach’s α for each of the psychological factors  
Scale Cronbach’s α 
Theory of Planned Behaviour  
Social Norm 0.53 
Perceived Behavioural Control 0.78 
Important others 0.76 
Health Belief Model  
Barriers  0.63 
Benefits 0.63 
Severity 0.85 
Self Regulatory Model  
Identity 1 – general unwell 0.74 
Identity 2 – RA symptoms 0.66 
Identity 3 – weight 0.66 
Chronic timeline 0.85 
Cyclical timeline 0.76 
Consequences 0.82 
Personal control 0.81 
Treatment control 0.65 
Cohesion 0.92 
Emotion 0.88 
Beliefs about Medications 
Questionnaire 
 
General harmful 0.67 
General overuse 0.83 
Specific concerns 0.80 
Specific necessity 0.90 
 
For the most part, the internal consistency was good for each of the other factors. Exceptions include 
the BMQ general overuse scale at 0.67, however similar α levels have been found in other studies 
(Menckeberg et al., 2008; Treharne et al., 2004). In the present sample, this is likely to be due to the 
fact that two questions also load onto the concerns factor. Similarly, the treatment control factor of 
the Self Regulation Theory had a low Cronbach’s α at 0.65, but this has also been observed in both 
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RA (Groake, Curtis, Coughlan & Gsel, 2004) and non-RA samples (Chilcot et al., 2010; Scharloo et al., 
1998).  
The social norms factor of the Theory of Planned Behaviour also had low internal consistency 
(Cronbach’s α = 0.53), however this was caused by the second question; “most people who have 
rheumatoid arthritis take all of their medications”. When this was removed, the internal consistency 
improved (Cronbach’s α = 0.76) and so this new factor, termed “important others” was used in 
subsequent analyses.  
7.3.3: Treatment groups 
It was hypothesised that patients that newly diagnosed patients (diagnosed with RA within the past 
six months) would score differently for the social cognition models and that the scores would be 
more variable over time as patients’ experience modifies their social cognition model of illness 
(through self-regulation). However, NICE guidelines have categorised “recent onset” RA to be within 
the first two years (NICE, 2009) and as the sample size of patients prescribed DMARDs in the past six 
months was small, the factor sumscores were compared for these patients (N=33) and those 
prescribed DMARDs in the past two years (N=49) shown in Appendix 7.3. No differences were found 
between these groups and so, to increase the power of subsequent analyses, patients starting 
DMARDs within the past two years were classified as “new”. Although this also reduced the number 
of patients in the “established” group from 110 to 94, this group still had enough power to detect 
significance.  
7.3.3.1: Adherence in the three treatment groups 
The level of adherence was good as overall, only 37.4% of patients demonstrated sub-optimal 
adherence. Specifically, 25.6% of the sample showed intentional non-adherence and 18.5% 
sometimes forget their DMARDs. It was hypothesised that the biological group would have the 
highest levels of intentional non-adherence due to their previous experience of DMARD failure; 
however the highest reported level of intentional non-adherence was among the established group 
at 30.9%. Although this was not significant; χ2 (2) = 1.86, p=0.40, it was substantially higher than 
newly diagnosed patients at 18.4% (Table 7.2). 
Conversely, there was a trend for new patients to have the highest rates of forgetting at 20.4% which 
is consistent with the hypothesis, however this was again not significantly different from the other 
treatment groups as χ2 (2) = 0.717, p=0.70. 
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Table 7.2: Mean sumscores for each model factor and disease outcome for the three treatment groups and the 
entire sample 
 Whole sample Newly diagnosed Established Biologic 
Total N 227 49 94 84 
Demographics  
Female (%) 171    (75.7%) 32  (65.3) 68  (72.3) 71  (84.5) 
Age  57.39    (15.03) 56.91  (16.41) 60.73*  (14.14) 54.29*    
(14.57) 
Disease duration 12.54    (10.77) 6.48  (10.90)*+ 13.99+  (9.43) 14.20*    
(11.09) 
Theory of planned behaviour 
Important others  12.27    (1.76) 12.00  (1.76) 12.36  (1.81) 12.32    (1.71) 
Personal control  30.60    (3.73) 29.96  (4.30) 30.72  (3.35) 30.84    (3.79) 
Health Belief Model 
Barriers  15.65    (4.10) 16.16  (4.65) 15.57  (4.23) 15.48    (3.63) 
Benefits  12.19    (2.29) 11.77  (2.61) 12.01  (2.34) 12.61    (2.00) 
Severity  16.62    (4.09) 16.30  (4.67) 15.93*  (4.10) 17.58*    (3.57) 
Self regulation model 
Identity 3.65      (1.34) 3.53  (1.37) 3.43*  (1.43) 3.96*      (1.16) 
Chronic timeline  21.97    (3.64) 20.11*+  (4.83) 22.33+  (3.01) 22.62*    (3.18) 
Cyclical timeline  13.44    (3.44) 13.30 (3.44) 13.55  (3.39) 13.39    (3.53) 
Consequences  21.48    (4.77) 20.17*  (4.88) 20.58+  (4.93) 23.24*+  (3.99) 
Personal control 18.93    (4.51) 19.79  (4.14) 18.57  (4.68) 18.84    (4.49) 
Treatment control  20.10   (3.15) 20.89  (3.20) 19.77  (3.15) 20.02    (3.09) 
Cohesion 12.43    (4.48) 13.43*  (4.14) 12.81  (4.68) 11.44*  (4.29) 
Emotional effect  18.12    (5.42) 18.19  (5.31) 17.37  (5.48) 18.93    (5.38) 
Beliefs about medications 
General harm  8.86      (2.51) 9.00  (2.67) 9.16  (2.60) 8.43      (2.26) 
General overuse  10.41    (2.81) 10.66  (2.81) 10.52  (2.60) 10.15    (3.04) 
Specific concern  13.50    (3.94) 13.98  (4.28) 13.41  (4.02) 13.34    (3.66) 
Specific necessity 19.32    (3.78) 16.89*+  (4.46) 19.51+  (3.24) 20.52*  (3.31) 
Necessity-concerns 
differential 
5.81 (4.86) 2.91 (0.65)*+ 6.10 (0.48)+ 7.18 (0.54)* 
Depression, Anxiety and Positive Outlook 
Depression  8.62     (4.39) 8.85  (4.31) 8.20  (3.94) 8.99      (4.91) 
Anxiety  5.42      (3.15) 5.72  (3.30) 5.17  (2.91) 5.53      (3.34) 
Positive outlook 10.50    (3.14) 10.17  (3.40) 10.36  (3.27) 10.86    (2.83) 
Disease outcomes 
HAQ 1.27   (0.84) 0.98* (0.79) 1.26  (0.88) 1.44*  (0.78) 
DAS 3.52     (1.51) 3.52  (1.56) 3.07* (1.22) 3.95* (1.63) 
EQ5D VAS  61.50    (20.45) 63.04  (19.52) 63.76  (20.84) 58.10  (20.30) 
EQ5D utility 0.57    (0.28) 0.57  (0.27) 0.60  (0.29) 0.53   (0.28) 
Adherence  
Low intentional  58    (25.7%) 9    (18.4%) 29  (30.9%) 20    (23.8%) 
Forget 42    (18.6%) 10  (20.4%) 16  (17.0%) 16    (19.0%) 
Overall low  85    (37.6%) 16  (32.7%) 38  (40.4%) 31    (36.9%) 
*difference between pairs p<0.05,  +differences between pairs p<0.05 
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7.3.3.2: Demographic and disease factors 
One way ANOVA was carried out to determined differences between means of the treatment groups 
for psychological and disease related factors. As expected, the disease duration is approximately 
twice as long for the established and biological groups compared to the new group (ps<0.001). The 
biologic patients were also significantly younger than the established group (p=0.019) and had a 
higher proportion of females at 85.5% (χ2 (2) = 7.82, p=0.02). This is in line with current prescribing 
practices for biologic medications.  
The level of functional disability measured by HAQ was higher for the biologic group compared to 
new patients (mean difference 0.36) which is expected given the longer disease duration and active 
disease of the biologic group. However, both the new and biologic groups had DAS28 scores 
indicating moderate disease activity at 3.52 and 3.95 respectively. The established group however 
had a significantly lower DAS28 score than the biologic group at 3.07 (p=0.002). Based on current 
guidelines, all of the groups showed active disease with a DAS28 score >2.6 indicating low to 
moderate activity.  
7.3.3.3: Psychological factors 
7.3.3.3.1: Univariate analysis 
Table 7.2 shows that there were no differences in mean sumscores for the three treatment groups 
on a number of factors including the Theory of Planned Behaviour factors and the psychological 
wellbeing factors. Most of the Beliefs about Medications scores did not differ, however the new 
patients perceived their medications to be less necessary than both the established and biologic 
patients (ps <0.001). As their concern scores were equally moderate, the necessity-concern 
differential was significantly lower for new patients than for both established and biologic patients 
(ps<0.05). The majority of the mean differences that were found were within the Illness Perceptions 
of the Self Regulation Theory and are shown in Figure 7.3.  
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Figure 7.3: Mean sumscores for the model factors for each treatment group 
7.3.3.3.2: Bivariate analysis 
Table 7.3 shows that there were a number of significant correlations between the treatment group 
and the social cognition models, although the effect sizes ranged from small for the HBM factors to 
moderate for the BMQ necessity factor (r=0.34). The correlations were all positive suggesting that 
generally speaking, as patients become more experienced with their RA, their perceptions of illness 
severity, chronicity and understanding become higher and their perceptions of their medications 
become more favourable. However, there were no correlations between treatment group and the 
Theory of Planned Behaviour factors.     
 HBM severity 
 SRM chronicity 
 SRM consequences 
 SRM coherence 
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Table 7.3: Correlations between adherence groups, treatment groups and the model factors  
 Intentional 
adherence 
Forget Overall 
adherence 
Age Gender Treatmen
t group 
Intentional adherence 
0= low 1=high 
      
Forget  
1=forget 0=does not forget 
      
Overall adherence 
0=low 1=high 
.752** -.610**     
Age  .238** -.283** .337**    
Gender  
0=male 1=female 
      
Treatment group 
1=new 2=established 3=biologic 
    .183*  
Theory of Planned Behaviour       
TPB important others       
TPB Perceived Behavioural Control  -.206* .159*    
Health Belief Model       
HBM barriers -.137*   -.330** .141*  
HBM benefits    -.178* .192* .143* 
HBM severity    -.254** .210* .139* 
Self Regulatory Model       
SR Identity    -.228**  .141* 
SR timeline      .234** 
SR cyclical       
SR consequence .263**    .149* .262** 
SR personal control -.158*  -.180* -.164*   
SR treatment control       
SR cohesion      -.173* 
SR emotion    -.312** .222**  
Beliefs about Medications       
BMQ harmful       
BMQ overuse       
BMQ concern    -.212*   
BMQ necessity     .300** .337** 
BMQ necessity-concerns framework    .204* .151* .306** 
HAQ .196*   .262** .192* .201* 
DAS  .182*    .172* 
EQ5D -.216*      
*p<0.05,  **p<0.001       
 
7.3.3.3.3: Multivariate analysis 
In order to determine effectively how the social cognition models differ between the treatment 
groups, a discriminant function analysis was carried out using the psychological factors that 
correlated significantly with treatment group which were; SRM chronicity, SRM consequences, SRM 
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cohesion, BMQ necessity and BMQ necessity-concerns framework. Fifteen cases had at least one 
missing discriminating variable and therefore the analysis was carried out on 212 cases.  
Two discriminant functions were calculated, with both of them being significant (ps<0.05). Function 1 
explains 75.5% of the between-group variance and has an effect size of 0.18. The second function 
explains 24.5% of the between-group variance but has a small effect size of 0.06. Therefore, the 
functions account for 18% and 6% respectively of the relationship between predictors and groups. 
Table 7.4: Structure matrix for the discriminant functions of treatment groups  
 Function 
 1 2 
BMQ necessity 0.810 0.132 
BMQ necessity-concerns framework 0.735 0.205 
SRM chronicity 0.492 0.268 
SRM coherence -0.364 0.298 
SRM consequences 0.421 -0.672 
 
Table 7.4 and Figure 7.4 show the structure matrix and group centroids respectively. The first 
function is mostly related to perceived necessity of medications and the perceived chronicity of RA 
and discriminates the newly diagnosed patients from the established and biologic groups. Here, the 
perceptions of the necessity of medication is clearly correlated most strongly with the function; 
however this does not take into account covariance that would be evident, particularly for the two 
BMQ factors. The second function is related to perceived consequences of having RA and 
discriminates the established patients from those in the newly diagnosed and biologic groups. 
However, Figure 7.4 also demonstrates a lot of variability for the discriminant function means for all 
three groups.  
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Figure 7.4: Group centroids and groups means of treatment groups for each discriminant function.  
Using the two discriminant functions above, the patients were classified as being newly diagnosed, 
established or on biologic medication. Using sample proportions as prior probabilities, 56.1% of 
patients were correctly classified (Table 7.5). Most errors occurred by misclassifying new and biologic 
patients as established. However, this shows that the predictors can discriminate between treatment 
groups with more accuracy than by chance alone. This provides some evidence that illness 
perceptions and beliefs about medications differ between patients in different phases of their 
treatment.   
Table 7.5: Predicted and actual treatment group membership using the discriminant functions 
  Predicted group membership 
 
Actual group 
membership 
 New  Established Biologic  
New 17 (38.6%) 21 (47.7%) 6 (13.6%) 
Established 6 (6.5%) 64 (69.6%) 22 (23.9%) 
Biologic 7 (9.2%) 31 (40.8%) 38 (50.0%) 
 
7.3.4: Adherence groups 
The mean sumscores for each psychological factor, disease related variables and demographics are 
shown in Table 7.6 for each of the adherence groups. Overall adherence is considered first (section 
7.3.4.1) which is then separated into Intentional (section 7.3.4.2) and unintentional (section 7.3.4.3) 
due to the hypothesis that they will have different underlying psychological processes.  
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Table 7.6: Mean factor sumscores and demographics for each of the adherence types 
 Intentional low Intentional 
high 
Forget Do not forget Overall low Overall high 
Total N 58  (25.6%) 157  (69.2%) 42  (18.5%) 174  (76.7%) 85  (37.4%) 131  (57.7%) 
Demographics  
Female (%) 43  (20%) 118  (54.9%) 33  (15.3%) 129  (59.7%) 64  (29.6%) 98  (45.4%) 
Age  51.86**(16.08) 59.92   (13.96) 49.18**(13.44) 59.85   (14.52) 51.47** 
(14.97) 
61.76   
(13.45) 
Disease duration 10.90 (8.98) 13.21   (11.33) 9.24*   (7.71) 13.26   (11.22) 10.53* (8.93) 13.87 (11.61) 
Theory of Planned Behaviour 
Important others  12.22 (1.65) 12.32   (1.80) 12.48   (1.38) 12.22   (1.88) 12.24   (1.57) 12.29   (1.93) 
Personal control  30.34   (3.79) 30.86   (3.52) 29.14*  (4.25) 31.04   (3.43) 29.95* (3.96)   31.14   (3.41) 
Health Belief Model 
Barriers  16.48*   (3.99) 15.25   (4.03) 16.31   (4.50) 15.48   (4.01) 16.19   (4.19) 15.28   (4.04) 
Benefits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12.02 (2.03) 12.28 (2.39) 12.26   (2.04) 12.21 (2.36) 12.20 (2.07) 12.24 (2.44) 
Severity  15.95   (3.65) 16.87   (4.17) 17.67   (3.79) 16.37   (4.08) 16.82   (3.92) 16.50   (4.14) 
Self Regulatory Model 
Identity   3.53   (1.35) 3.73  (1.32)  3.95  (1.29)  3.59  (1.36)  3.76  (1.33) 3.59   (1.36) 
Chronic timeline  22.34   (2.38) 21.79   (4.00) 22.50   (2.78) 21.78   (3.81) 22.32   (2.58) 21.66   (4.18) 
Cyclical timeline  13.07   (3.19) 13.58   (3.58) 14.24   (3.30) 13.24   (3.49) 13.72   (3.31) 13.25   (3.57) 
Consequences  19.45** (3.86) 22.23   (4.81) 22.00   (4.81) 21.37   (4.73) 20.89   (4.39) 21.90   (4.94) 
Personal control  20.10*   (3.80) 18.53   (4.62) 19.55  (3.34) 18.74   (4.77) 19.89* (3.57) 18.23   (4.98) 
Treatment 
control  
20.50   (2.48) 20.12   (3.24) 19.81   (3.51) 20.25   (3.09) 20.06   (2.87) 20.23   (3.37) 
Cohesion  11.50   (3.60) 12.70   (4.68) 12.93   (4.01) 12.29   (4.58) 12.09   (3.97) 12.63   (4.78) 
Emotional effect  16.98   (5.47) 18.57   (5.24) 19.52   (6.15) 17.84   (5.10) 18.07   (5.76) 18.24   (5.08) 
Beliefs about Medications Questionnaire 
General harm  8.78   (2.58) 8.99   (2.49) 8.71   (2.91) 8.98   (2.41) 8.90   (2.76) 8.95   (2.34) 
General overuse  10.64   (2.23) 10.36   (2.97) 10.15   (3.42) 10.54   (2.65) 10.55   (2.81) 10.41   (2.82) 
Specific concern  12.74   (3.99) 13.76   (3.83) 13.98   (4.10) 13.41   (3.87) 13.35   (4.23) 13.63   (3.71) 
Specific 
necessity  
18.88   (3.30) 19.64   (3.73) 18.80   (4.01) 19.59   (3.51) 18.86   (3.62) 19.81   (3.58) 
Necessity-
concerns 
differential 
6.14  (0.64) 5.88  (0.38) 6.23  (0.37) 4.83  (0.73) 6.23  (0.37) 4.83  (0.73) 
Depression, Anxiety and Positive Outlook 
Depression  9.21   (4.53) 8.42   (4.33) 11.02**(5.67) 8.12  (3.89) 9.58*   (5.03) 8.09   (3.89) 
Anxiety  5.58   (2.97) 5.37   (3.22) 6.73*   (3.73) 5.16   (2.97) 5.84   (3.36) 5.22   (3.05) 
Positive outlook  10.93   (2.92) 10.36   (3.22) 10.20   (3.57) 10.55   (3.07) 10.67   (3.09) 10.36   (3.22) 
Disease outcomes 
HAQ 1.01*   (0.84) 1.38   (0.82) 1.25   (0.80) 1.29   (0.85) 1.17   (0.82) 1.35   (0.85) 
DAS 3.19   (1.39) 3.57   (1.54) 4.03*   (1.49) 3.33   (1.48) 3.54   (1.48) 3.43   (1.53) 
EQ5D VAS  67.47* (21.41) 59.60   (19.75) 56.29 (22.78) 63.02   (19.65) 62.21 (22.19) 61.33 (19.26) 
EQ5D utility 0.67*   (0.26) 0.53   (0.29) 0.53   (0.30) 0.58   (0.28) 0.60   (0.29) 0.55   (0.29) 
Treatment groups 
Newly diagnosed 9  (19.6%) 35  (76.1%) 10  (21.7%) 34  (73.9%) 16  (34.8%) 28  (60.9%) 
Established 29  (30.9%) 64  (68.1%) 16  (17.0%) 78  (83.0%) 38  (40.4%) 56  (59.6%) 
Biologic  20  (23.8%) 58  (69.0%) 16  (19.0%) 62  (73.8%) 31  (36.9%) 47  (56.0%) 
*p<0.05,  **p<0.001 
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7.3.4.1: Overall non-adherence 
7.3.4.1.1: Univariate analysis 
If a patient is classified as a high intentional adherer and does not forget then they are classified as 
high overall adherence. If they have low intentional adherence or they forget or both then they are 
classified as low overall adherence. Table 7.6 shows that 37.4% of patients had sub-optimal 
adherence.  Low adherers were ten years younger on average at 51.47 (SD=14.97) than high overall 
adherers at 61.76 (SD=13.45) years (t(195) =-5.00 p<0.001) and had a shorter disease duration 
(t(209) = -2.22, p=0.03).  
 
Figure 7.5: Mean differences for model factors between overall high and low adherence 
As Figure 7.5 shows, the only factors that showed a significant difference between overall high and 
low adherence were personal control. The different models measure slightly different aspects of 
control with the TPB concentrating on the ability to take medication as prescribed whereas the SRM 
refers to the “power to influence the course of rheumatoid arthritis”. Low adherers perceive 
themselves to have more influence over RA (p=0.01) but less confidence in being able to take 
DMARDs as directed (p=0.02). This demonstrates that when taking adherence as a whole, it is the 
patients’ perceptions of their own ability to self-manage their illness that is most related to 
medication adherence.  
7.3.4.1.2: Bivariate analysis 
Few variables correlated with overall adherence (Table 7.3). Higher perceptions of TPB behavioural 
control were related to higher adherence (r=0.16) and lower levels of SRM personal control were 
 TPB personal control 
 SRM personal control 
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related to lower adherence (r=-0.18). Age was also strongly correlated with older age related to 
higher adherence (r=0.34). 
7.3.4.1.3: Multivariate analysis 
Stepwise logistic regression analysis was employed to determine if the social cognition models of 
illness could predict overall adherence. For logistic regression, it is recommended that there are 5 
cases per predictor (Tabachnick & Fidell, 2007). There are a total of fifteen predictors and 212 cases 
used meaning there is adequate power to undertake logistic regression in the sample.    
 Each of the social cognition models were tested separately, along with beliefs about medications 
and are presented in separate columns of Table 7.7. For all models, age was entered as the first step 
as a continuous variable and in all cases was significantly related to adherence with Nagelkerke R2 
showing it explained between 13.5% (in the HBM model) and 15.5% (in the BMQ model) of the 
variance in adherence alone.  
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Table 7.7: Stepwise logistic regression of social cognition models on overall adherence 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory 
Model 
Beliefs about 
Medications 
Variable Wald’s β OR Wald’s β OR Wald’s β OR Wald’s 
β 
OR 
Step 1         
Age 16.02 1.05** 15.10 1.05** 15.42 1.05** 22.08 1.06** 
Step 2         
TPB important others 2.40 0.82       
TPB perceived 
control 
6.18 1.14*       
HBM barriers   1.43 0.95     
HBM benefits   0.71 1.09     
HBM severity   0.07 1.02     
SRM identity     0.001 0.996   
SRM chronicity     1.48 0.94   
SRM cyclical     2.10 0.93   
SRM consequences     3.36 1.09   
SRM personal 
control 
    4.05 0.92*   
SRM treatment 
control 
    4.27 1.14*   
SRM coherence     0 1   
SRM emotion     0.81 1.04   
BMQ harmful       0.13 0.97 
BMQ overuse       1.15 0.93 
BMQ necessity        2.57 1.08 
BMQ concern       1.97 1.08 
Model ∆χ
2
 (2) = 7.05, p=0.03 ∆χ
2
 (3) = 2.43, p=0.49 ∆χ
2
 (8) = 14.43, 
p=0.07 
∆χ
2
 (4) = 6.35, 
p=0.18 
 Model χ
2
 (3) = 27.33, 
p<0.001  
Model χ
2
 (4) = 22.89, 
p<0.001 
Model χ
2
 (9) = 36.58, 
p<0.001 
Model χ
2
 (5) = 29.44, 
p<0.001 
 ∆Nagelkerke 
R
2
=0.180 
∆Nagelkerke R
2
=0.150 ∆Nagelkerke 
R
2
=0.234 
∆Nagelkerke 
R
2
=0.194 
 69.6% correct            
(47.4% low) 
68.3% correct         
(46.1% low) 
70.5% correct   
(50.0% low) 
71.7% correct         
(50.0% low) 
*p<0.05,  **p<0.001     
 
The only psychological model that was shown to improve the fit of the data to predict overall 
adherence was the Theory of Planned Behaviour; ∆χ2 (2) = 7.05, p=0.03, although the Self Regulation 
Model was close as ∆χ2(8) = 14.43, p=0.07. The Theory of Planned Behaviour variables explained an 
additional 18% of the variance in overall adherence and this model as a whole was able to correctly 
classify 47.4% of low adherers. The only significant predictors for this model were; age (Wald’s 
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β=16.02, p<0.001) where a one point increase led to a 5% increase in the odds of high overall 
adherence and TPB Perceived Behavioural Control (Wald’s β=6.18, p=0.013) where a one point 
increase in perceived control over taking medications led to a 14% increase in the odds of higher 
adherence. 
7.3.4.2: Intentional non-adherence 
7.3.4.2.1: Univariate analysis 
In order to more clearly investigate adherence, patients were identified as “high” or “low” 
intentional adherers based on answers to the CQR5 (see Chapter 6 for a description of how 
intentional adherence in classified). Twenty-five percent of patients were categorised as low 
intentional adherers (Table 7.6). They were significantly younger at 51.86 (SD=16.08) years than high 
intentional adherers at 59.92 (SD=13.96) years; t(194) = -3.41, p=0.001. Interestingly, the low 
adherence group showed better functioning and better quality of life demonstrated by higher EQ5D 
utility and VAS values (Table 7.6). Figure 7.6 clearly shows that there is an interaction between age 
and intentional adherence on DAS28 and EQ5D VAS score. There is a much stronger effect of 
intentional adherence on both of these variable for younger patients (<58 years) than older patients.  
  
Figure 7.6: Interaction of age and intentional adherence for i) DAS28 and ii) EQ5D VAS score 
There were few differences between model factor scales; however the low adherence group 
demonstrated interesting mean differences on some key factors, shown in Figure 7.7. Importantly, 
the low adherence group had higher HBM barrier scores (p=0.049) which refer directly to issues 
surrounding taking medications for RA. They also perceived lower consequences of having RA 
(p<0.001) and higher personal control over influencing the course of their RA (p=0.021). Although the 
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differences were not significant, there was also a trend towards lower negative emotional response 
to RA by low adherers and a lower perception of the necessity of DMARDs.  
 
Figure 7.7: Mean sumscore differences for model factors between intentional adherence groups 
7.3.4.2.2: Bivariate analysis 
Table 7.3 shows the correlations between intentional adherence and the model factors. There was a 
strong correlation between SRM consequences and adherence (r=0.26) whereas there were negative 
correlations with HBM barriers (r=-0.14) and SRM personal control (-0.16) indicating that if patients 
perceive there to be more barriers to medication taking and that they have less control over the 
course of their RA then they have lower intentional adherence.  
The correlations between intentional adherence and age, HAQ and EQ5D mirror the univariate 
analyses as patients with better intentional adherence were older (r=0.24), had higher functional 
disability (r=0.20) and better quality of life (-0.22). 
7.3.4.2.3: Multivariate analysis 
Stepwise logistic regression analysis was employed to determine if the social cognition models of 
illness could predict intentional adherence, shown in Table 7.8. Separate regressions were carried 
out for each of the models and then with all models combined (shown in the last column of Table 
7.8) with the overall model fit shown at the bottom of the table. For all models, age was entered as 
the first step as a continuous variable and in all cases was significantly related to intentional 
adherence. Adding the Theory of Planned Behaviour variables did not improve the fit of the data as 
∆χ2 (2) = 2.03, p=0.36. The three other models however did improve the fit over and above age with 
the Self Regulatory Model proving to be the best as ∆χ2 (8) = 21.67, p=0.01 and Nagelkerke R2 = 0.225 
 HBM barriers 
 SRM consequences 
 SRM personal control 
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showing that the addition of Illness Perceptions increased the fit of the data by 22.5%. This model 
also proved to be the best at correctly classifying the adherence of patients as 27.5% of low adherers 
were correctly classified. However, on further inspection of the model, only SRM consequences 
proved to be significant with Wald’s β = 7.60 showing that a one point increase in the perception of 
consequences increased the odds of high adherence by 16%. 
As three of the models; the Health Belief Model, Self Regulatory Model and Beliefs about 
Medications were significantly related to intentional adherence in the logistic regressions, these 
models were combined in an effort to improve the explained variance in intentional adherence and is 
shown in the final two columns of Table 7.8. Combining the models proved to explain the most 
variance as Naglekerke R2 for the second step only was 0.358 indicating that the social cognition 
models explained 35.8% of the variance over and above age. By combining the models, 42.0% of low 
intentional adherers were correctly classified using the predictors, which is better than any of the 
models alone. This combined model showed that one standard deviation increase in age led to 4% 
increase in the odds of intentional adherence (Wald’s β=5.97, p=0.02), one point increase in HBM 
barriers led to 21% decrease in odds of adherence (Wald’s β=9.63, p=0.002), one point increase in 
SRM chronicity led to 14% decrease in odds of adherence (Wald’s β=4.27, p=0.04), one point increase 
in SRM consequences led to 25% increase in odds of adherence (Wald’s β=10.48, p=0.001) and one 
point increase in BMQ concerns led to 23% increase in odds of intentional adherence (Wald’s β=4.81, 
p=0.03).  
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            Table 7.8: Stepwise logistic regression of social cognition models on intentional adherence 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about Medications Combined 
Variable Wald OR Wald OR Wald OR Wald OR Wald OR 
Step 1           
Age 8.15 1.03* 7.69 1.04* 9.37 1.04* 14.60 1.05** 5.97 1.04* 
Step 2           
TPB important others 1.49 0.84         
TPB perceived control 1.20 1.06         
HBM barriers   6.98 0.86*     9.63 0.79* 
HBM benefits   0.14 0.96     0.11 0.96 
HBM severity   6.85 1.19*     1.11 0.90 
SRM identity     0.14 1.07   0.07 1.05 
SRM chronicity     3.28 0.89   4.27 0.86* 
SRM cyclical     0.03 0.99   0.01 1.01 
SRM consequences     7.60 1.16*   10.48 1.25** 
SRM personal control     1.08 0.95   0.93 0.95 
SRM treatment control     1.30 1.08   0.17 1.03 
SRM coherence     0.05 1.01   0.12 1.02 
SRM emotion     0.97 1.05   1.62 1.08 
BMQ harmful       0.18 0.96 0.36 0.94 
BMQ overuse       3.83 0.86* 2.66 0.86 
BMQ necessity        1.33 1.06 0.63 1.06 
BMQ concern       5.75 1.15* 4.81 1.23* 
Model ∆χ2 (2) = 2.03, p=0.36 ∆χ2 (3) = 12.53, p=0.006 ∆χ2 (8) = 21.67, p=0.006 ∆χ2 (4) = 11.22, p=0.024 ∆χ2 (15) = 41.67, p<0.001 
 Model χ2 (3) = 11.58, 
p=0.009 
Model χ2 (4) = 21.85, 
p<0.001 
Model χ2 (9) = 32.17, 
p<0.001 
Model χ2 (5) = 22.44, 
p<0.001 
Model χ2 (16) = 51.69, 
p<0.001 
 ∆Nagelkerke R2 = 0.086 ∆Nagelkerke R2 = 0.159 ∆Nagelkerke R2 = 0.225 ∆Nagelkerke R2 = 0.163 ∆Nagelkerke R2 = 0.358 
 75.3% correct (9.8% low) 72.9% correct (15.7% low) 74.5% correct (27.5% low) 75.8% correct (16% low) 77.5% correct (42.0% low) 
*p<0.05,  **p<0.001      
1
1
6
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7.3.4.3: Unintentional non-adherence (forgetting) 
7.3.4.3.1: Univariate analysis 
Patients were dichotomised based on their answer to the statement “I sometimes forget to take my 
medicines” with those that agreed being classified as forgetters and those that disagreed classified as 
not forgetting. Table 7.6 shows that 18.5% of the sample sometimes forget their medicines. Again, 
patients that forget their medication were significantly younger at 49.18 (SD=13.44) years compared 
to 59.85 (SD=14.52) years for those that do not forget; t(195) = 4.13, p<0.001. They also had a 
shorter mean disease duration at 9 years compared to 13 years (p=0.03). The functional status and 
quality of life scores were all similar for those that do and do not forget, although there was a trend 
for the forgetting group to have a lower EQ5D VAS score. However, the DAS28 score for forgetters 
was significantly higher at 4.03 indicating moderate disease activity.  
There were very few differences between the forgetters and non-forgetters for the psychological 
factors. The only scale on which there was a significant difference was for TPB personal control which 
refers directly to the patients’ perceived ability to take their medication as prescribed. The forgetting 
group had a lower mean score at 29.14 than the non-forgetters at 31.04 (t(211) = 3.06, p=0.003) 
indicating that these patients do not feel confident in their ability to take DMARDs correctly. The 
forgetting group also showed higher levels of depression (p<0.001) and anxiety (p=0.004) than the 
non-forgetting group. There were no other differences for the social cognition models between the 
forgetting and non-forgetting group.  
7.3.4.3.2: Bivariate analysis 
In line with the univariate analysis, only one of the psychological factors correlated with forgetting 
(Table 7.3). Patients who had higher perceptions of TPB Perceived Behavioural Control were less 
likely to forget (r=-0.21). Forgetting also correlated negatively with age (r=-0.28) so younger people 
were more likely to forget and forgetters also had higher DAS28 scores (r=0.18). 
7.3.4.3.3: Multivariate analysis 
Stepwise logistic regression was carried out to determine the predictive ability of the social cognition 
models to identify patients that forget their medications. Again, age was entered as a continuous 
variable at the first step and was significant in each model shown in Table 7.9 explaining 
approximately 12% of the variance alone. Conversely to intentional adherence, the only 
psychological model which was significantly related to forgetting was the Theory of Planned 
Behaviour; ∆χ2 (2) = 11.27, p=0.004 which improved the fit of the model by an additional 20% over 
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and above age. However, only Perceived Behavioural Control was significant showing that a one 
point increase in TPB Perceived Behavioural Control led to 17% decrease in the odds of forgetting 
(Wald’s β=9.75, p=0.002). As the other social cognition models were not significantly related to 
forgetting, a combined model was not tested. 
As age and working status were highly correlated (Pearson’s R=-0.55, p<0.001), the effect of working 
status mediating the effect of age on forgetting was investigated. However, only 23.5% of the effect 
of age on forgetting was mediated by working, with Sobel’s test = -1.46, p=0.14, making the 
mediation non-significant. Also, when working status and the interaction were entered into the 
logistic regression model with the Theory of Planned Behaviour, they did not significantly improve 
the fit of the model (final column of Table 7.9).      
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             Table 7.9: Stepwise logistic regression of social cognition models on unintentional adherence (forgetting) 
 Theory of Planned Behaviour Health Belief Model Self Regulatory Model Beliefs about Medication Working 
Variable Wald’s β OR Wald’s β OR Wald’s β OR Wald’s β OR Wald’s β OR 
Step 1           
Age 10.28 0.96** 11.55 0.95** 9.27 0.95* 11.32 0.95** 3.12 0.97 
Working         0.23 1.29 
Age-working interaction         0.15 1.01 
Step 2           
TPB important others 3.61 1.42       4.31 1.49* 
TPB perceived control 9.75 0.83*       10.91 0.81** 
HBM barriers   0.14 0.98       
HBM benefits   2.60 0.82       
HBM severity   3.10 1.14       
SRM identity     0 1     
SRM chronicity     0.39 1.04     
SRM cyclical     2.37 1.10     
SRM consequences     0.003 0.98     
SRM personal control     1.68 1.07     
SRM treatment control     0.75 0.94     
SRM coherence     0.20 1.02     
SRM emotion     0.01 1.00     
BMQ harmful       0.44 0.94   
BMQ overuse       0.69 0.93   
BMQ necessity        1.32 0.94   
BMQ concern       1.08 1.07   
Model Step χ
2
 (2) = 11.27, p=0.004 Step χ
2
 (3) = 3.56, p=0.31 Step χ
2
 (8) = 5.91, p=0.66 Step χ
2
 (4) = 2.99, p=0.56 ∆ χ
2
 (2) = 13.04, p=0.001 
 Model χ
2
 (3) = 25.73, 
p<0.001  
Model χ
2
 (4) = 17.76, 
p=0.001 
Model χ
2
 (9) = 21.29, p=0.011  Model χ
2
 (5) = 18.53, p=0.002  Model χ
2
 (5) = 29.7,  p<0.001 
 Nagelkerke R
2
 = 0.200  Nagelkerke R
2
 = 0.142  Nagelkerke R
2
 = 0.166 Nagelkerke R
2
 = 0.148 Nagelkerke R
2
 = 0.229 
 79.6% correct                      
(13.2 forget) 
80.4% correct                           
(7.9% forget) 
79.3% correct                                    
(0% of forget) 
79.6% correct                                 
(2.7% forget) 
80.6% correct                               
(18.4% forget) 
*p<0.05,  **p<0.001      
1
1
9
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7.3.5: Using adherence and social cognition models to predict functional status 
A hierarchical regression analysis was used to predict functional status (HAQ) using age, intentional 
adherence and the psychological factors. Table 7.10 shows that 48.2% of the variance in HAQ was 
explained by the final model. However, once the psychological factors are added to the model, 
adherence is no longer a significant predictor of HAQ. A very large percentage of the variance is 
explained by the psychological models (43.6%), however as this is cross-sectional, the direction of 
causality is not clear. This is highlighted by the fact that the consequences of having RA is the 
strongest predictor, which itself is likely to be influenced by functional status. 
Table 7.10: Hierarchical regression of age, intentional adherence and social cognition models on functional 
status 
Variable B SE B  β p Variance 
Step 1      
Age 0.016 0.004 0.271 0.001 7.3% 
Step 2      
Age 0.014 0.004 0240 0.001 5.5% 
Intentional adherence 0.275 0.137 0.145 0.047 2.0% 
Step 3      
Age 0.018 0.004 0.315 <0.001 7.0% 
Intentional adherence -0.105 0.119 -0.055 0.197  
SRM identity 0.090 0.044 0.139 0.043 1.3% 
SRM chronicity -0.023 0.016 -0.091 0.141  
SRM cyclical -0.004 0.015 -0.019 0.762  
SRM consequences 0.098 0.015 0.533 <0.001 13.0% 
SRM personal control -0.015 0.012 -0.077 0.230  
SRM treatment control <0.001 0.019 -0.001 0.985  
SRM coherence -0.007 0.013 -0.039 0.564  
SRM emotion 0.015 0.013 0.097 0.259  
HBM barriers -0.015 0.015 -0.067 0.337  
HBM benefits 0.036 0.030 0.098 0.224  
HBM severity -0.017 0.021 -0.083 0.405  
TPB important others 0.023 0.030 0.048 0.447  
TPB personal control -0.031 0.015 -0.130 0.045 1.3% 
Note R
2
 = 0.074 (p<0.001), ∆R
2
 = 0.094 (p=0.047), ∆R
2
 = 0.436 (p<0.001)   
 
7.3.6: Correlations between the model factors 
Table 7.11 shows the correlations between the psychological factors. A number of factors from each 
model correlate highly with other model factors, suggesting that the models themselves are 
measuring the same psychological processes. This is particularly evident when an element of 
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consequence or negative emotion is included as these seem to underlie and inform other factors 
related to rheumatoid arthritis and medication taking. These correlations are in line with other 
studies using these models (Chilcot et al., 2010; Orbell et al., 2006) and indicate that there is a large 
amount of overlap, suggesting that they could be more usefully combined to create a more 
parsimonious model of health behaviour.  
parsimonious model of health behaviour.
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             Table 7.11: Correlations between the model factors  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
Self Regulatory Model 
1) SRM identity 1                 
2) SRM chronicity .142* 1                
3) SRM cyclical .235**  1               
4) SRM 
consequences 
.458** .249** .212** 1              
5) SRM personal 
control 
   -.212* 1             
6) SRM treatment 
control 
-.236** -.150*  -
.353** 
.425** 1            
7) SRM cohesion  -.144* .199*  -
.267** 
-
.232** 
1           
8) SRM emotion .364**  .219** .510** -.206* -
.297** 
.348** 1          
Theory of Planned Behaviour 
9) TPB important 
others 
 .186*    .134*   1         
10) TPB personal 
control 
 .153*     -
.301** 
-
.241** 
.412** 1        
Health Belief Model 
11) HBM barriers .176*  .173* .261**  -
.256** 
.255** .389** -.159* -
.312** 
1       
12) HBM benefits .240**  .153* .442**  -.139*  .453**  -.138* .349** 1      
13) HBM severity .346**  .248** .595** -.157* -
.224** 
.210* .633**  -
.226** 
.433** .695** 1     
Beliefs about Medications 
14) BMQ harmful  -.162*    -.148* .330** .222** -
.227** 
-
.248** 
.299** .181* .193* 1    
15) BMQ overuse  -.188*    -
.245** 
.306** .204* -
.249** 
-.211* .347** .178* .151* .529** 1   
16) BMQ concern .135*  .299** .270**  -.150* .396** .544** -.209* -
.438** 
.531** .400** .536** .512** .432* 1  
17) BMQ necessity .215* -.183*  .389**    .300**    .385** .419**   .206* 1 
18) Necessity-
concerns 
 .215* -.153*    -
.346** 
-.206* .238** .413** -
.348** 
  -.401* -.336* -
.650** 
.609** 
*p<0.05,  **p<0.001                  
1
2
2
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7.4: Discussion 
There were a number of relationships between the social cognition models and the treatment 
groups, adherence types and disease factors. 
7.4.1: Treatment groups 
The fact that the mean sumscores for each of the variables did not differ between patients diagnosed 
with RA six months previously and two years previously is surprising as it was expected that the 
social cognition models would be more variable until the patient has had more experience of having 
rheumatoid arthritis. However, as this was not the case but there were differences between the 
newly diagnosed and established group, it could be possible that the changeable and unpredictable 
course of disease and treatment that patients experience before remission is successfully established 
generally takes a couple of years which informs the social cognition models of illness. Although 
previous research does not appear to have objectively tested this period, most assume a cut-off 
period of two years to be “early” RA (Emery, Breedveld, Dougados, Kalden, Schiff & Smolen, 2002; 
NICE, 2009).  
The mean differences that were found between the treatment groups for each of the psychological 
factors support the hypothesis that the patient’s experience is influencing their social cognition 
models. For factors relating to serious consequences of the illness, the biologic group generally had 
higher mean sumscores than both the new and established group, reflecting their worse experience 
of RA. Similarly, perceptions of chronicity and necessity of medications were lower in the new group 
which could indicate that they are not yet aware or have come to terms with the fact that their 
illness is progressive and chronic. However, even those with a longer disease duration do not score 
very well on the SRM coherence scale which measures their perception of their understanding of RA, 
implying that none of the patients feel that they are particularly well informed.  
It was interesting to note that the biologic patients did not differ on their scores for SRM treatment 
control which asks them to evaluate the ability of DMARDs to successfully control their RA. As these 
patients have previously failed standard DMARD therapy in order to receive biologics, it was 
expected that these patients would have a lower treatment control score. This could be due to 
patients incorrectly answering these questions in relation to their current biologic medication, rather 
than the DMARD which was asked.  
The discriminant function analysis showed that the social cognition models differed between the 
illness groups and did so in a way that is likely to be related to their experience of having had RA and 
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taking DMARDs. This supports the hypothesis that the social cognition models will change as patients 
“self regulate” based on their experiences and knowledge. There was variability in the function 
means for each group and the discriminant functions were only able to correctly classify 56.1% of 
patients, however as this is better than by change alone, these results add validity to the models and 
the assumption that they will change during the course of the disease.  
7.4.1.1: Adherence in treatment groups 
The rate of non-adherence did not differ significantly between any of the treatment groups, which 
does not support the hypothesis that the experience of the patient would affect adherence. 
However, the rates of forgetting were highest for the new patients whereas their rate of intentional 
non-adherence was lowest. This suggests that these patients are keen to follow instructions to 
improve the symptoms that they are having, but have yet to form a habit for taking their medication, 
leading to forgetting. More of the new patients were working which may have an effect on forgetting 
as a busy, non-structured day away from the home can lead to forgetting (Chesney, 2000; Garcia-
Gonzalez et al., 2008). However, the mediation of working on the effect of age on adherence was not 
significant. This may be because the majority of people who were not working were either retired 
(due to age) or were homemakers and therefore generally younger women. It would be beneficial in 
the future to determine some of the reasons why people think that they forget their medications to 
determine whether working status has a true effect.  
The established group had the highest rates of intentional and overall non-adherence. This could be 
due to the fact that they have learnt to cope with having RA but as their disease activity is remaining 
relatively low (i.e. they do not yet require biologic therapy), they are less concerned with keeping to 
medication regimens than biologic patients who have experienced worse flare ups.  
It is important to consider the different treatment groups separately, particularly those that have 
been newly diagnosed or who are also prescribed biologic medication as these results show that the 
different experiences that these patients have had has a strong effect on their social cognition model 
of illness which can impact on interpretation of interventions in RA. Little previous research has 
investigated these groups separately or adequately separated their results for analysis and so little is 
known about the differing perceptions that these patients have. As these results indicate that there 
are clear differences in levels of adherence for different treatment regimens, future research should 
try to quantify exactly why these differences are occurring and what effect it has on the disease.  
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7.4.2: Adherence groups 
There were a number of differences between the different adherence types, most notably the fact 
that there was a higher rate of intentional non-adherence than forgetting. This is contrary to other 
researchers who have found higher unintentional than intentional non-adherence (Atkins & 
Fallowfield, 2006; Garcia-Gonzalez et al., 2008; Lowry et al., 2005). They were both relatively low at 
less than 25%, however when considering both, the overall non-adherence rate was 37.4%. This is in 
line with published adherence rates (Barber et al., 2004; Haynes, 2001), however most previous 
research has not specifically focussed on the differences between intentional and unintentional non-
adherence and so individually, the rates appear quite low.  
7.4.2.1: Overall non-adherence 
A number of hypotheses concerning adherence were generated based on previous research. 
Notably, it has been found previously that demographics cannot reliably predict adherence 
(DiMatteo, 2004; Elliott, 2008; McDonald, Garz & Haynes, 2002; Treharne et al., 2004; Vermeire, 
Hearnshaw, van Royen & Denekens, 2001), which was also the case in this sample, other than age.  
Non-adherers were significantly younger and had shorter disease duration.  
The focus of this study was to determine the differences between intentional and unintentional 
adherence as it was hypothesised that they would have different underlying processes. The results 
highlight this important difference as there was little difference in the psychological process of 
overall adherence/non-adherence.  
7.4.2.2: Intentional non-adherence 
Low adherers were approximately eight years younger than high adherers and had shorter disease 
duration, although this was not statistically significant. Contrary to the hypothesis, the low adherers 
showed better functioning and quality of life than high adherers. This could be related to adherence 
in that patients that find themselves functioning well whilst not taking DMARDs may continue to be 
non-adherent to lessen the burden of medication taking, although as this study is cross-sectional it is 
not possible to determine causality. There was a strong interaction between age and adherence for 
both DAS28 and quality of life with age. It would appear that for younger patients, their decision to 
adhere is strongly related to disease activity and those that are not taking their medications having 
less pill burden and also less disease activity. However, those that have high adherence tend to have 
high disease activity and worse quality of life, possibly because they are not seeing an improvement 
in their symptoms despite taking the medication. The effect is much less pronounced for older 
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patients whose disease activity is more in line with what would be expected so that those with low 
adherence have worse disease activity and quality of life. It may be that the decision to take 
medications by older patients is not as reactive to disease activity.  
The psychological factors that differed between the high and low adherers suggest that low adherers 
perceive themselves more able to control their RA via means other than medication and that they 
perceive DMARDs to be less necessary and have more barriers to taking them than high adherers. 
This is reinforced with the logistic regression analysis as in the combined model HBM Barriers, SRM 
Consequences and SRM Chronicity were significant. The regression also shows that the Theory of 
Planned Behaviour is not related to intentional adherence at all, which is surprising as this theory 
claims to predict the intention a person has to perform a health behaviour, however Perceived 
Behavioural Control was only related to forgetting which is contrary to most research using the 
Theory of Planned Behaviour (Ajzen, 2005). This could be due to the fact that the Attitude factor had 
to be excluded from the analysis because of missing data as Albarracin et al. (2001) and Armitage & 
Conner (2001) found Attitudes to be good predictors of behaviour. 
Although the Health Belief Model, Self Regulatory Model and Beliefs about Medications were all 
separately related to intentional adherence, a model combining all of these factors proved to be the 
best with 42% of low adherers correctly classified. This supports the fact that each of these models is 
useful in explaining adherence behaviour, which has been found in previous research (Orbell et al., 
2006). However on combining the models, some previously significant factors became non-
significant. As logistic regression enhances shared variance between the variables, this provides 
evidence that there is considerable collinearity between the models, indicating that they are 
measuring the same psychological processes. This is also supported by the high correlations between 
some factors in Table 7.11. This study provides evidence that there is a need to identify the most 
predictive factors and combine some elements of the models to provide a coherent, parsimonious 
model of intentional medication adherence, particularly as most previous research using these 
models individually have not been able to explain a lot of the variance in adherence  (Armitage & 
Conner, 2001; DiMatteo, Haskard & Williams, 2007; Groarke et al., 2004; Hagger & Orbell, 2003; 
Harrison et al., 1992; Hurkmans et al., 2010). 
7.4.2.3: Unintentional non-adherence (forgetting) 
As with intentional adherence, patients that forget their medication were generally younger and had 
shorter disease duration. Unlike for intentional non-adherence, the forgetters had worse disease 
activity and quality of life, which would be expected if DMARDs were not being taken correctly and 
supports the hypothesis.  
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The only social cognition model associated with forgetting was the Theory of Planned Behaviour and 
the patient’s confidence in being able to take their medication correctly “as prescribed” which 
explained 20% of the variance in forgetting. Patients that forget were also 3.75 times more likely to 
be working than non-forgetters. This suggests that the effect of age on adherence was mediated by 
working, however only 23.5% of the direct effect of age on forgetting was mediated which was non-
significant.  
The lack of association between the social cognition models and forgetting supports the hypothesis 
that intentional non-adherence is based on a deliberate decision whereas forgetting is completely 
unintentional, reiterating the importance of addressing these different types of non-adherence 
differently. The only factor that appears to be related is the patient’s confidence to take their 
DMARDs, however this could be as a result of the patient’s realisation that they often forget to take 
their medication. It is not possible to determine the direction of this relationship in a cross-sectional 
study.  
7.4.3: Beliefs about medications 
Both the general and specific aspects of beliefs about medications were measured in this sample. 
However, contrary to previous research (de Thurah et al., 2010; Horne, 1999; Treharne et al., 2004), 
perceptions of necessity were not related to either intentional or unintentional non-adherence. This 
is surprising as this has been found to explain approximately 15-20% of the variance in medication 
adherence previously (Horne, 1999), however univariate analyses showed that there was no 
difference between necessity scores for any of the adherence groups. The means were reasonably 
high for all groups indicating that all patients, regardless of their adherence perceived their DMARDs 
to be necessary for their treatment which could explain why there was no effect in multivariate 
analysis. However, this is at odds with other research looking at adherence to DMARDs by RA 
patients (de Thurah et al., 2010; Treharne et al., 2006) and removes a potential avenue for 
intervention through education about DMARD treatment.  
7.5: Conclusions  
Overall, the differing relationships between the social cognition models and intentional and 
unintentional adherence provide evidence for the fact that patients use information and experience 
to develop a model of illness to make a logical decision to take medication. Patients that have more 
disease activity and have longer to develop a model are more likely to decide to take their DMARDs 
than patients who have not had to endure the negative consequences of RA for as long. As only 
confidence in taking DMARDs as prescribed was related to forgetting, it can be assumed that 
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forgetting is in fact unintentional and not related specifically to treatment or illness perceptions. This 
suggests that interventions to tackle each type of adherence would be necessary in order to improve 
prognosis. A reminder or cue to action to prompt patients who forget might be sufficient for them to 
take their medication whereas information regarding possible effects and consequences of non-
adherence would be needed to inform those patients who have chosen not to take their DMARDs. 
These results demonstrate that it is imperative for the different types of adherence to be 
investigated separately in order to determine exactly why patients are non-adherent and the best 
ways to address this as they have very different underlying mechanisms that will not respond to a 
“one size fits all” approach. All future research must take this into account when measuring non-
adherence in chronic illness. 
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Chapter 8 
Stability and change in social cognition models of illness in 
rheumatoid arthritis patients over six months: Longitudinal analysis 
8.1: Introduction 
From a theoretical perspective, the social cognition models of illness posit that a patient’s experience 
and knowledge of their illness will influence the expression of various factors such as perceived 
severity and attitudes towards self-management behaviours. For example, Leventhal, Nerenz & 
Steele (1984) argued that a patient’s representation of their illness is constantly updated with new 
knowledge and experience and so it would be expected that there would be changes in perceptions 
over time. Given the unpredictable and changeable nature of RA progression, patients from a 
rheumatology clinic would be expected to have very different experiences of disease activity and 
treatment regimens from which they draw knowledge of their illness. Changes in illness perceptions 
over a relatively short period of time would be expected for newly diagnosed patients who may have 
many contacts with a Rheumatologist and adjustments to treatment directly after diagnosis. In 
addition, patients who have experienced a changeable disease leading to biologic therapy would also 
be required to adjust to a different routine. A literature search revealed a paucity of research that 
has specifically identified which factors are more susceptible to change and at what point in a chronic 
illness stability is likely to occur with only three studies that had investigated any of the social 
cognitive models of illness longitudinally in chronic illness. However, the empirical studies suggest 
that Leventhal’s theory is not supported as Rutter & Rutter (2007) found that illness perceptions 
were stable over 12 months for patients with Irritable Bowel Syndrome. Stability of medication 
necessity beliefs have also been found over nine months in RA (de Thurah et al., 2010) and 12 
months in ischemic heart disease (Allen LaPointe et al., 2010), although concerns about medication 
increased in both studies. 
However, these studies had small sample sizes and all patients had established disease. It is likely 
that these patients had already incorporated the new knowledge and experience gathered rapidly 
after diagnosis into an illness representation that remained stable at the point of measurement. For 
this reason, it is important to establish at what point in the disease illness representations become 
stable and which factors are most susceptible to initial change which has not been carried out 
previously. Although Leventhal’s theory that patients subject to a changeable illness would have 
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changes in illness perceptions is not supported by these studies, this could be due to methodological 
issues within the current literature.   
The baseline results shown in Chapter 7 showed that newly diagnosed rheumatoid arthritis patients 
had significantly different psychological sumscores than more experienced patients suggesting that 
there could be more change in these patients’ representations as they become more accustomed to 
the disease and its treatment. To test the stability of the social cognition models over time, the 
patients were followed-up over six months and asked to complete the psychological questionnaires 
again. The aim of this prospective longitudinal study is to test Leventhal’s theory that new knowledge 
and experience leads to changes in illness representations.  
8.1.1: Hypotheses 
Based on Leventhal’s assumption, a number of hypotheses were generated: 
1) Patients with long-term disease (the established group), will have stable Self Regulatory 
Model and Beliefs about Medications sumscores over six months (Allen LaPointe et al., 2010; 
Rutter & Rutter, 2007).  
2) Newly diagnosed patients will have significantly different psychological sumscores at six 
months than at baseline (Berry et al., 2004), specifically those concerning the potential 
severity of RA and the treatment requirements as they gather more experience and 
knowledge.  
3) There will be similar changes in Health Belief Model sumscores as Self Regulatory Model 
sumscores (based on cross-sectional results, Chapter 7).   
4) Patients with concurrent biologic treatment will demonstrate some changes in psychological 
sumscores due to fluctuating disease experience but they will be mostly stable.  
8.2: Methodology 
8.2.1: Materials and procedure 
Patients were required to complete a follow-up questionnaire six months after initial recruitment, as 
detailed in the information sheet and consent form that they received at baseline. The questionnaire 
was identical to that at baseline (Appendix 7.1) except for the omission of demographic questions 
such as age and gender. 
Follow-up questionnaires were sent by post to patients along with an explanatory letter and stamped 
addressed envelope in order to return it to the researcher. Questionnaires were sent approximately 
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one week prior to the date required. If a questionnaire had not been returned within 18 days of it 
being sent, and there were no other reasons for non-response (e.g. death) then a reminder letter 
with another copy of the questionnaire and stamped addressed envelope was sent. Clinical data 
including changes in RA prescription, number of outpatient appointments since baseline, number of 
inpatient days since baseline, number of Accident and Emergency contacts since baseline, latest 
DAS28 score and latest inflammatory blood markers were recorded from patients’ notes.  
8.2.2: Patients 
Figure 8.1 shows the response rate for the follow-up questionnaires at six months. After reminders 
were sent there was an excellent follow-up rate of 75.3% (N=171). Successful follow-up was highest 
for the new patients with 82.9%, although the established and biologic groups did not differ very 
much at 71.4% and 76.25% respectively. There was some variation between the six different 
hospitals from which patients were recruited with the lowest successful follow-up being 60% and the 
highest at 90.6%, although on average it was good at 72.4%. 
 
 
Figure 8.1: Follow-up response rates 
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Demographic variables for all patients are shown in Table 8.1. A total of 171 patients responded at 
six months and there were very few differences between responders and non-responders. Non-
responders tended to be younger at 53.3 (16.3) years than responders at 59.1 (14.3); t(222) = 2.56, 
p=0.01 and were more likely to be working; χ2 (1) = 7.59, p=0.01, although this may be because they 
were younger. Non-responders were also more likely at baseline to report unintentional non-
adherence at 35% compared to just 15% of the responders reporting forgetting; χ2 (1) = 10.20, 
p=0.001. This may impact on the results as the prevalence of unintentional non-adherence is likely to 
be underestimated in the follow-up analysis, although the number of non-responders that report low 
intentional adherence did not differ.  
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Table 8.1: Demographic variables for responders and non-responders 
 Total (N=227) Responders at six 
months (N=171) 
Non-responders at 
six months (N=56) 
Bivariate analysis 
 N (%) Mean 
(SD) 
N Mean N Mean Statistic df p 
Age 224 57.7 
(15.0) 
168 59.1 (14.3) 56 53.3 
(16.3) 
2.56 222 0.011* 
Gender          
Male 55 (24%)  45 (26%)  10 (18%)  1.01 1 0.315 
Female 172 (76%)  126 
(74%) 
 46 (82%)     
Education          
Secondary 
school 
110 (50%)  86 (50%)  24 (45%)  0.45 3 0.930 
College 61 (27%)  46 (28%)  15 (28%)     
University 32 (14%)  23 (13%)  9 (17%)     
Postgraduate 19 (9%)  14 (9%)  5 (9%)     
Working          
No 131 (58%)  107 
(63%) 
 24 (43%)  7.59  1 0.006* 
Yes 96 (42%)  64 (37%)  32 (57%)     
Disease 
duration 
222 12.6 
(10.8) 
165 13.1 (11.4) 57 11.3 
(8.8) 
1.05 220 0.295 
DAS28 175 3.6 (1.5) 137 3.49 (1.47) 38 3.9 (1.7) 1.49 173 0.139 
HAQ 227 1.1 (0.8) 170 1.04 (0.76) 57 1.1 (0.8) 0.63 225 0.527 
Intentional 
adherence 
         
Low 58 
(25.7%) 
 44 (27%)  14 (27%)  NA   
High 157 
(69.2%) 
 120 
(73%) 
 38 (73%)     
Unintentional 
adherence 
         
Forget 42 
(18.6%) 
 24 (15%)  18 (35%)  10.20 1 0.001* 
Do not forget 174 
(76.7%) 
 141 
(85%) 
 34 (65%)     
Note: statistics for the bivariate analysis are student’s t test for continuous variables and χ
2 
for categorical variables. 
*p<0.05 
8.2.3: Statistical analyses 
Patients’ adherence and treatment groups were classified in the same way as at baseline. Univariate 
analyses were carried out in the same way as at baseline with ANOVA with Bonferroni correction for 
continuous variables and χ2 for categorical. Repeated measures student’s t tests were used to assess 
differences between baseline and six month sumscores for the same variable.  
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8.3: Results 
8.3.1: Missing data 
Missing data at six month follow-up was very similar as at baseline with between 5.5% and 23% for 
individual questions with the exception of the Theory of Planned Behaviour Attitudes questions and 
DAS28 score. Inspection of the missing data suggested that other than TPB Attitudes and DAS28, the 
data was missing at random and so other than for these variables, missing data was imputed using 
the same methodology as at baseline. 
8.3.2: Reliability of scales used 
The scales were tested for internal reliability using Cronbach’s α for six month follow-up. Very similar 
values were found for most scales indicating that the majority remained above 0.70. All of the 
Cronbach’s α values are shown in Appendix 8.1. In summary the BMQ overuse scale had better 
internal consistency at six months with Cronbach’s α = 0.71 compared to 0.67 at baseline. However, 
two scales had worse internal consistency at six months; HBM benefits (Cronbach’s α = 0.52) and 
SRM treatment control (Cronbach’s α = 0.55), although this has also been found by other researchers 
(Menckeberg et al., 2008; Treharne et al., 2004). To retain consistency between baseline and follow-
up, no changes to the scales were made.  
8.3.3: Social cognition models in treatment groups 
As there was a very good response rate at six months, the number of patients for each treatment 
group remains high. The established and biologic groups retained 72.3% and 72.6% of patients 
respectively and there was very little attrition in the new group with 85.7% of patients successfully 
followed-up. The actual sample size for each treatment group is shown in Table 8.2 and indicates 
that there were still sufficient numbers of cases per variable in order to carry out logistic regression, 
indicating that there remains sufficient power at six month follow-up.  
8.3.3.1: Stability of social cognition models within treatment groups 
Table 8.2 shows the mean differences in sumscores from baseline to 6 month follow-up to identify 
whether factors of the social cognition models changed over time. The sample as a whole had very 
little variation, however, the scores for the different treatment groups varied greatly as the newly 
diagnosed patients had statistically significant changes on five factors whereas the established 
patients’ psychological scores were stable. At six months, the newly diagnosed patients perceived 
their RA to have significantly higher consequences (repeated measures t(37) = -2.37, p=0.02) and 
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that they have lower personal control (t(37) = 2.11, p=0.04) and lower treatment control (t(37) = 
2.87, p=0.01) than at baseline. They also perceived their DMARD medication to be more necessary 
with an increase of 1.14 points (t(35) = -2.06, p=0.047). The biologic group showed statistically 
significant differences from baseline on only two factors; they perceived there to be more barriers to 
taking medication (t(60) = -4.10, p<0.001) and that their RA had fewer cyclical symptoms (t(61) = 
3.26, p=0.002). In contrast, the established group showed no statistically significant changes from 
baseline in their sumscores. 
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Table 8.2: Mean changes in sumscores from baseline to 6 months for each treatment group 
 Whole sample Newly diagnosed Established Biologic 
Total N 171 42 68 61 
Theory of Planned Behaviour 
Important others -0.10 (1.50) 0.19 (1.43) -0.19 (1.31) -0.18 (1.72) 
Personal control  0.09 (3.58) 0.72 (3.47) 0.30 (3.49) -0.49 (3.71) 
Health Belief Model 
Barriers  0.88 (3.09) -0.06 (3.16) 0.68 (2.91) 1.62 (3.09)* 
Benefits  0.23 (1.90) 0.44 (1.87) 0.10 (2.07) 0.25 (1.74) 
Severity  0.14 (2.68) 0.06 (2.71) 0.53 (3.16) -0.20 (2.05) 
Self Regulation Model 
Identity 0.27 (2.12) 0.18 (2.35) 0.32 (1.71) 0.29 (2.39) 
Chronic timeline  0.26 (3.86) 0.68 (5.16) 0.13 (3.93) 0.17 (2.89) 
Cyclical timeline  -0.54 (3.14) -0.68 (3.67) 0.27 (2.70) -1.27 (3.08)* 
Consequences  -0.02 (2.89) 1.0 (2.60)* -0.42 (3.35) -0.25 (2.44) 
Personal control -0.05 (3.98) -1.42 (4.14)* 0.63 (3.94) 0.10 (3.77) 
Treatment control  -0.75 (3.31) -1.97 (4.23)* -0.18 (2.60) -0.59 (3.16) 
Cohesion 0.15 (3.14) 0.32 (3.73) 0.02 (3.05) 0.19 (2.89) 
Emotional effect  -0.35 (3.39) -0.21 (3.11) -0.03 (3.69) -0.73 (3.27) 
Beliefs about medications 
General harm  0.27 (2.13) 0.03 (2.20) 0.20 (2.03) 0.50 (2.20) 
General overuse  0.36 (2.49) 0.18 (2.90) 0.16 (2.26) 0.68 (2.45) 
Specific concern  0.33 (3.03) -0.03 (3.03) 0.36 (2.88) 0.51 (3.21) 
Specific necessity -0.03 (2.90) 1.14 (3.31)* -0.42 (3.02) -0.31 (2.30) 
Necessity-concerns 
differential 
-0.35 (4.27) 1.17 (4.60) -0.78 (3.95) -0.81 (4.26) 
Depression, Anxiety and Positive Outlook 
Depression  0.02 (3.20) 0.76 (2.83) -0.38 (3.48) 0.00 (3.07) 
Anxiety  0.19 (2.26) 0.29 (2.30) 0.14 (2.57) 0.18 (1.89) 
Positive outlook 0.07 (2.78) 0.13 (2.80) -0.17 (3.31) 0.28 (2.10) 
Disease outcomes 
HAQ 0.01 (0.43) 0.06 (0.51) -0.06 (0.45) 0.04 (0.34) 
DAS -0.66 (1.57) -1.62 (0.59)* -0.09 (1.39) -0.66 (1.70) 
EQ5D VAS  0.27 (21.12) 0.92 (21.57) -2.80 (22.32) 2.97 (19.46) 
EQ5D utility 0.01 (0.25) 0.002 (0.24) 0.01 (0.24) 0.01 (0.26) 
*p<0.05     
 
The changes between baseline and follow-up within treatment groups resulted in different 
relationships between treatment groups. At six months, new patients had significantly lower SRM 
timeline scores at 20.86 than biologic patients at 22.69; F(2, 161) = 3.25, p=0.04, Bonferroni p=0.04 
(see Appendix 8.2). This mimics the relationship at baseline; however the scores of the newly 
diagnosed patients had risen so that at follow-up they did not differ from the established patients. 
Similarly, the SRM consequences sumscore for the new patients had risen so that at six months it did 
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not differ from the biologic group, whereas the established group was significantly lower at 19.52 
than both the new patients at 21.90 (Bonferroni p=0.04) and biologic patients at 22.69 (Bonferroni 
p=0.001). 
Similar changes were seen for the Beliefs about Medications variables as the necessity scores for new 
patients had risen so that there was no difference to established patients (Figure 8.2). At six months, 
the new patients had significantly lower BMQ necessity scores (Bonferroni p=0.046) and necessity-
concerns differential (Bonferroni p=0.02) than the biologic patients. 
  
 
Figure 8.2: Follow-up mean sumscores for the model factors for each treatment group 
 
8.4: Discussion 
8.4.1: Responders versus non-responders 
A very high proportion of patients were successfully followed up over six months with completed 
questionnaires received for 76.3% of the sample. The only differences found between patients who 
responded and those who failed to respond were age, working status and unintentional non-
adherence. This suggests that patients who were younger, working and forgetful found it more 
difficult to remain in the study. The fact that more of the non-responders self-reported forgetting 
their medication at baseline than responders could impact on the longitudinal results by 
underestimating the prevalence of forgetting. Overall, the sample of 171 patients available at six 
months appeared to be a good representation of the sample as a whole.  
 SRM chronicity 
 SRM consequences 
 BMQ necessity 
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8.4.2: Social cognition models in treatment groups 
The small amount of previous research that has assessed psychological factors of chronic illness 
previously had varying results with regards to the potential changes in psychological measures over 
time (Allen LaPointe et al., 2010; de Thurah et al., 2010; Rutter & Rutter, 2007). Therefore, in line 
with the concept of appraisal and self regulation proposed by Leventhal, hypothesis 1 stated that the 
social cognition models would be stable for the established patients but that there would be changes 
in illness and treatment beliefs (SRM and BMQ) for the newly diagnosed patients in response to their 
growing knowledge and experience of RA. It was also hypothesised that the biologic patients would 
show some changes in the social cognition models as they have less stable disease but to a lesser 
extent than the newly diagnosed patients. These hypotheses was supported to a large extent as the 
newly diagnosed patients had a number of significantly different sumscores, namely increased SRM 
consequences and BMQ necessity but decreased SRM personal and treatment control. These 
changes brought the new patients’ sumscores to be more in-line with the established and biologic 
patients meaning there were fewer differences between the treatment groups than at baseline. 
Although these results support the underlying theory of the Self Regulation Model, previous 
longitudinal studies have shown mixed results as Allen-LaPointe et al. (2010) demonstrated a very 
small effect of increased BMQ necessity perceptions over one year whereas Rutter & Rutter (2007) 
found no changes in illness perceptions for patients with Irritable Bowel Syndrome over one year. 
This discrepancy may be due to methodological issues in these studies including small sample sizes 
and the fact that the patients recruited had established disease and it would therefore be expected 
that they have a stable illness representation. The lack of adaptation found later in the disease 
course for both RA and Irritable Bowel Syndrome suggests that interventions that aim to modify 
illness or treatment beliefs should be aimed at newly diagnosed patients who may be more open to 
information that challenges their illness representation than patients with a lot of experience and 
persistent beliefs.  
As there was no previous research which demonstrated a longitudinal analysis of the Theory of 
Planned Behaviour or Health Belief Model in health behaviours in chronic illness, the aim of this 
study was to establish whether these concepts are stable over time or subject to similar processes as 
the Self Regulatory Model and Beliefs about Medications model. Based on the cross-sectional results 
(Chapter 7), it was hypothesised that the HBM factors would also be variable in newly diagnosed 
patients but not in more established patients. However, none of the HBM factors changed 
significantly for the new patients and only the biologic patients scored significantly higher on HBM 
barriers at six months. It would appear that these factors remain stable over time, although it is 
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possible that more time is required for the newly diagnosed patients to score differently on these 
scales, which was not possible to determine from this study. 
Overall, it seems that the social cognition models perform differently over time. In line with 
Goodacre & Goodacre (2004), answers to the Health Belief Model were mostly stable whereas the 
Self Regulatory Model was more subject to change, particularly for newly diagnosed patients. As 
Leventhal et al. (1992) claimed that the illness representations of patients would change as they 
acquire new knowledge and experience, the expected change in illness perceptions was supported 
by these data.  
8.5: Conclusions 
The theoretical assumptions that patients’ perceptions of their illness are influenced by knowledge 
and experience are supported by these data as newly diagnosed patients showed changes in the 
psychological sumscores whereas the established patients had stable representations over time. This 
demonstrates the importance of acknowledging the likely heterogeneity of a clinic population and 
therefore separating newly diagnosed patients both for research into illness perceptions and in any 
intervention relating to the social cognition models of illness.  
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Chapter 9 
Using social cognition models of illness to predict adherence to 
DMARDs by rheumatoid arthritis patients over six months: 
Longitudinal analysis 
9.1: Introduction 
In order to understand the effects that social cognition models of illness have on medication 
adherence over and above other aspects such as demographics and what effect adherence has on 
wellbeing in patients with a chronic illness, longitudinal studies must be carried out in order to 
establish causality. Although there have been a number of studies that have investigated this cross-
sectionally (e.g. Chilcot et al., 2010; Horne & Weinman, 2002; Llewellyn et al., 2003; Niklas et al., 
2010; Ross et al., 2004) including in rheumatoid arthritis (Carlisle, John, Fife-Shaw & Lloyd, 2005; 
Goodacre & Goodacre, 2004; Scharloo et al., 1998; Treharne, Lyons, Kitas & Booth, 2005), there is 
currently a scarcity of prospective, longitudinal studies with large sample sizes in order to effectively 
model the causal impact of the social cognition models on adherence.  
A literature search found only three studies that had used any of the four social cognition models 
being studied in longitudinal analysis. Ediger et al. (2007) investigated the effects of beliefs about 
medications on adherence in Inflammatory Bowell Disease. The two studies that included RA 
patients had psychological (Scharloo et al., 2000) and functional outcomes (Frostholme et al., 2007) 
and did not investigate adherence. There is therefore little known about how adherence changes in 
chronic illness or the best ways to predict non-adherence. In order to establish influences on 
adherence to medication, how this changes over time and the best ways to intervene to improve 
illness, more evidence is required, particularly in an unpredictable and progressively disabling disease 
such as rheumatoid arthritis.  
Three studies have specifically used the social cognition models in this study to predict adherence to 
treatment in a prospective study. Orbell et al. (2006) compared the Theory of Planned Behaviour and 
Self Regulatory Model in predicting attendance to treatment for abnormal cervical smear tests over a 
period of 15 months. Although a number of factors from both models significantly predicted the 
intention to attend the follow-up appointments, only Perceived Behavioural Control (TPB) was a 
significant predictor of actual attendance, although perception of treatment control (SRM) was also 
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successful in discriminating between attenders and non-attenders. Although attendance at follow-up 
treatment appointments is a different health behaviour that may have different underlying 
psychology than medication adherence, this study does provide some evidence that some 
psychological factors, namely perceived efficacy of the treatment and confidence to carry out the 
behaviour can successfully predict adherence to follow-up colposcopy treatment.  
Allen LaPointe et al. (2010) measured Beliefs about Medications in 812 patients with ischemic heart 
disease over 12 months. As has been found cross-sectionally (Ross et al., 2004; Treharne et al., 2005), 
only necessity scores were related to medication adherence. In a study investigating adherence to 
Methotrexate by rheumatoid arthritis patients, de Thurah et al. (2010) measured Beliefs about 
Medications and adherence by patients who were newly diagnosed and nine months later. They 
found very little variation in the prevalence of low adherence; however they do not report intra-
individual variation. Like Allen LaPointe et al. (2010), higher necessity scores were associated with 
higher adherence but there was little change in necessity or concern scores over nine months. 
Although BMQ and adherence were measured at two time points, de Thurah et al. (2010) do not use 
baseline scores to predict adherence and so this study only provides information on the variability of 
psychological factors and adherence, not any causal effects.  
An interesting effect that has been demonstrated cross-sectionally is the fact that some illness 
perceptions have been shown to impact on beliefs about medications which in turn have an effect on 
treatment adherence. Horne & Weinman (2002) found that perception of the likely length of the 
illness (SRM chronicity) and the potential seriousness of the outcomes (SRM consequences) are 
mediated by the perceived necessity of the medication (BMQ necessity) which impacts on adherence 
to asthma preventer medication. Similarly, Niklas et al. (2010) found again that SRM consequences 
impacted on BMQ necessity and also that the emotional effects (SRM emotions) influenced the level 
of concern about the medication (BMQ concerns) which in turn explained variance in adherence to 
pharmacological treatment for non-malignant pain. These studies clearly demonstrate that the social 
cognition models are strongly related and that by modelling potential mediators it is possible to 
understand more of the nuances of the psychology behind medication adherence. However, as these 
studies were cross-sectional, the effects of illness and treatment beliefs on adherence over time are 
not clear.  
The studies mentioned above start to provide some knowledge and evidence of which psychological 
factors are predictive of treatment adherence over time, although only the Self Regulatory Model 
and Beliefs about Medications have been investigated longitudinally in chronic illnesses. However, 
these studies have involved patients with chronic illnesses other than RA and there are a number of 
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issues that prevent applicability to rheumatoid arthritis. Firstly, as illness perceptions are expected to 
differ for different illnesses (Hagger & Orbell, 2003) studies in asthma and heart disease are not 
directly comparable to adherence to DMARDs by RA patients. The longitudinal studies also tended to 
have very small sample sizes with adherence measured and analysed in different ways. For example, 
de Thurah et al. (2010) measured Beliefs about Medications at baseline but did not use this to 
predict adherence to DMARDs at nine months. Although establishing how these beliefs change over 
time and the corresponding changes in adherence is desirable, being able to predict which patients 
will be non-adherent through baseline psychological measures is more clinically useful as a means of 
targeting interventions in the future. For this reason, this study will investigate adherence to 
DMARDs prospectively over six months by patients with rheumatoid arthritis in an attempt to 
identify which social cognition models at baseline best predict non-adherence at six months.  
9.1.1: Aims and hypotheses 
The cross-sectional results shown in Chapter 7 indicate that the Self Regulatory Model and Beliefs 
about Medications perform better than the other models at predicting intentional non-adherence to 
DMARDs. None of the models reliably explained unintentional adherence. The primary aim of this 
prospective longitudinal study is to test how well the social cognition models at baseline predict 
adherence six months later. The secondary aim is to establish the changes in adherence over six 
months; particularly for the newly diagnosed patients who are expected to differ more than the 
experienced patients. This will provide the evidence upon which future interventions could be based 
as identifying “negative” illness representations allows for more targeted development of effective 
interventions to improve adherence.  
As discussed, there has been little previous research using the social cognition models to predict 
medication adherence longitudinally and none of these studies have separated intentional and 
unintentional adherence. Therefore, many of the aims of this study are exploratory; however a 
number of hypotheses were generated for overall adherence: 
1) There will be little variation in adherence over six months for the established and 
biologic patients (de Thurah et al., 2010). 
a. Contrary to de Thurah et al. (2010), it is hypothesised that patients newly 
prescribed DMARDs will have variability in their adherence from baseline as they 
become accustomed to the regimen. 
2) Higher baseline SRM identity, SRM consequences, SRM timeline and BMQ necessity will 
predict better adherence at six month follow-up (Hagger & Orbell, 2003; Hampson, 
Glasgow & Ziess, 1994, Horne & Weinman, 2002; Wallston, 1993). 
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3) Treatment beliefs (BMQ) will mediate the relationship between illness perceptions (SRM) 
and adherence (Horne & Weinman, 2002; Nicklas et al., 2010). 
As there has been no previous research investigating adherence over time for patients with high or 
low adherence, or using the Theory of Planned Behaviour and Health Belief Model to predict 
adherence over time, a number of exploratory aims will also be tested: 
1) Determine whether the Theory of Planned Behaviour and Health Belief Model predict 
adherence status at six months. 
2) Determine whether adherence is more likely to improve or worsen over time. 
3) Determine which social cognition models best predict changes in adherence over six 
months to identify potential areas for intervention. 
9.2: Methodology 
9.2.1: Materials and procedure 
The follow-up procedure for this study is described in Chapter 8, section 8.2.2. 
9.2.2: Patients 
After one reminder, a total of 171 (75.3%) patients were successfully followed-up after six months. 
Demographic information for all patients is shown in Table 8.1.  
9.2.3: Statistical analyses 
The variability in adherence over six months was examined for each of the treatment groups. 
Patients were categorised based on whether their adherence status did or did not change for 
intentional, unintentional and overall adherence groups. Differences in baseline psychological 
sumscores and the odds ratio of changing adherence were calculated.  
Logistic regression was used to assess the predictive power of the psychological factors of each 
model to predict adherence. To establish the best predictors of adherence, the analysis was split into 
three for each adherence type creating six regression tables. These included; i) using baseline 
psychological sumscores to predict six month adherence status, ii) using baseline psychological 
factors sumscores to predict change in adherence status and iii) using changes in psychological 
scores to predict change in adherence. Changes in adherence were from high to low and low to high 
intentional adherence and from forgetting to not forgetting and from not forgetting to forgetting. 
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The χ2 test, percentage of correctly classified cases and Nagelkerke’s R2 were used to assess the 
suitability of each of the social cognition models to predict the dependent variable. 
In order to test causal pathways and the hypothesised mediating relationship of treatment beliefs on 
illness perceptions, structural equation modelling (SEM) was carried out which allows for multiple 
regression analyses to be carried out simultaneously. Multiple independent variables, labelled 
“exogenous variables” can be used to predict multiple dependent variables (“endogenous variables”) 
which can either be directly observed or latent variables. SEM is also particularly useful for testing 
mediating and moderating relationships which were expected in relation to treatment and illness 
beliefs and the effects on adherence. Variables can also be set to correlate with each other which 
allows for more sophisticated models that more accurately represent the likely complex decision 
making involved in health behaviours. The method of estimation was maximum likelihood which 
assumes that the observed variables are representative of the population. Standard goodness-of-fit 
indices were used to assess the suitability of the models tested including χ2, CFI, RMSEA, and SRMR 
which are discussed in Chapter 6, section 6.6.3. Standard thresholds are used except for χ2 which is 
often significant in SEM simply due to a large sample size and is therefore interpreted with caution. 
Initially, two models of medication adherence developed in other chronic illnesses (Horne & 
Weinman, 2002; Nicklas, Dunbar & Wild, 2010) were tested for model fit in the current sample. Two 
models based on the correlations and regression analysis of the current samples were then tested to 
determine the best model of medication adherence for rheumatoid arthritis. 
9.3: Results 
At six months, a total of 23.4% (N=40) patients self-reported low intentional adherence and 21.6% 
(N=37) reported forgetting. Using the same categorisation methodology as described in Chapter 3, 
36.3% of the total sample were classified as overall low adherers.  There were some differences 
between treatment groups as newly diagnosed patients had the highest rates of forgetting and 
overall low adherence at 29.3% and 39% respectively but the lowest rates of intentional low 
adherence at 17.1%. In contrast, the established patients had the highest rates of intentional low 
adherence (27.3%) but the lowest self-reported forgetting at 16.7%.  
9.3.1: Variability in adherence over six months 
Figure 9.1 shows that there was some variation in adherence from baseline to 6 month follow-up and 
that the amount of variation differed both for the type of adherence (intentional/unintentional) and 
for treatment groups. The biggest changes were for unintentional non-adherence with an increased 
proportion of patients forgetting at six months relative to baseline rates. There was less of a change 
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for intentional adherence although at follow-up, the established patients had a slightly lower 
percentage of patients with low intentional adherence (27.3%) than at baseline (34.8%). 
 
 
Figure 9.1: Percentage of patients with low adherence at baseline and six month follow-up for each treatment 
group  
Although the total proportion of patients with low intentional adherence remained similar at 
baseline and six months, approximately 30% of patients’ scores changed. As a similar number of 
patients changed in both directions, the net effect was low. In contrast, more patients who did not 
forget at baseline started forgetting at six months than vice versa.  
9.3.2: Variability in social cognition models within adherence groups 
Table 9.1 shows that there were significant mean psychological sumscore changes from baseline to 
follow-up for the low intentional adherence group only. The significant changes shown in Table 9.1 
are an increase of 1.10 (2.87) points for HBM barriers (t(39) = -2.42, p=0.02) and a decrease of 1.20 
(3.14) points for SRM treatment control (t(39) = 2.42, p=0.02) for the low intentional group showing 
24.6 
14 
33.3 
23.4 21.6 
36.3 
0
10
20
30
40
CQR low Forget Overall
Fig 1: Whole sample 
Baseline 6 months
12.2 
17.1 
24.4 
17.1 
29.3 
39 
0
10
20
30
40
CQR low Forget Overall low
Fig 2: New patients 
Baseline 6 months
34.8 
9.1 
37.9 
27.3 
16.7 
34.8 
0
10
20
30
40
CQR low Forget Overall low
Fig 3: Established patients 
Baseline 6 months
21.9 
17.2 
34.4 
23.4 21.9 
35.9 
0
10
20
30
40
CQR low Forget Overall low
Fig 4: Biologic patients 
Baseline 6 months
 146 
 
that at six months, they perceive there to be even more barriers to their medication taking and have 
less confidence in the ability of their DMARDs to control their RA.  
The mean changes over six months have resulted in a number of changes in the differences between 
adherence groups from baseline (see Appendix 9.1 for six month mean sumscores). There is now only 
a significant difference for HBM severity with low intentional adherers having a sumscore of 15.73 
(3.71) compared to 17.19 (3.82) for high intentional adherers; t(161) = -2.12, p=0.04. This difference 
was not apparent at baseline, however at 6 months there is no longer a difference between 
sumscores for HBM barriers, SRM consequences, and SRM personal control as there was at baseline. 
Overall high adherers also perceive their medications to be more necessary than low adherers (t(161) 
= -3.09, p=0.002). The only difference for unintentional adherence is for TPB Perceived Behavioural 
Control as forgetters have significantly lower scores (29.92) than those who do not forget (31.17). 
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Table 9.1: Mean changes in sumscores for adherence groups from baseline to six month follow-up 
 Intentional 
low 
Intentional high Forget Do not 
forget 
Overall low Overall high 
Total N 40 (24.25%) 125 (75.75%) 37 (22.7%) 126 (77.3%) 62 (37.6%) 103 (62.4%) 
Theory of Planned Behaviour 
Important 
others  
-0.13 (1.36) -0.9 (1.56) <0.01 (1.94) -0.13 (1.37) -0.03 (1.72) -0.15 (1.37) 
Personal control  0.30 (3.52) 0.04 (3.64) -0.14 (4.31) 0.14 (3.39) 0.02 (3.66) 0.16 (3.58) 
Health Belief Model 
Barriers  1.10 (2.87)* 0.74 (3.19) 0.46 (2.83) 0.94 (3.18) 0.73 (3.04) 0.89 (3.16) 
Benefits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.03 (1.49) 0.32 (2.01) 0.09 (2.03) 0.29 (1.85) 0.13 (1.85) 0.32 (1.91)
Severity  -0.65 (2.59) 0.33 (2.66) -0.40 (2.71) 0.22 (2.65) -0.52 (2.64) 0.45 (2.64) 
Self Regulation Model 
Identity  0.40 (2.30) 0.24 (2.10) 0.08 (2.16) 0.36 (2.15) 0.05 (2.19) 0.42 (2.11) 
Chronic timeline  -0.38 (3.06) 0.56 (4.07) 0.18 (3.31) 0.36 (4.01) -0.22 (2.95) 0.64 (4.27) 
Cyclical timeline  -0.35 (3.39) -0.65 (3.09) -0.34 (3.42) -0.65 (3.11) -0.70 (3.30) -0.50 (3.09) 
Consequences  0.30 (2.77) -0.22 (2.92) 0.64 (2.64) -0.26 (2.91) 0.30 (2.89) -0.33 (2.86) 
Personal control  -1.03 (3.68) 0.37 (4.03) -1.06 (3.89) 0.36 (3.95) -0.87 (3.79) 0.57 (4.02) 
Treatment 
control  
-1.20 
(3.14)* 
-0.55 (3.39) -0.47 (4.01) -0.79 (3.14) -0.92 (3.77) -0.59 (3.04) 
Cohesion  0.10 (3.30) 0.24 (3.09) 0.22 (2.77) 0.20 (3.26) 0.10 (2.94) 0.28 (3.26) 
Emotional effect  -0.45 (3.34) -0.29 (3.47) -0.43 (3.19) -0.31 (3.52) -0.58 (3.21) -0.18 (3.56) 
Beliefs about Medications Questionnaire 
General harm  0.73 (2.22) 0.14 (2.09) 0.40 (2.51) 0.26 (2.02) 0.42 (2.37) 0.21 (1.99) 
General overuse  0.38 (2.55) 0.31 (2.50) 0.83 (2.49) 0.19 (2.50) 0.62 (2.58) 0.15 (2.46) 
Specific concern  -0.62 (2.28) 0.62 (3.19) 0.44 (3.46) 0.28 (2.92) 0.08 (3.05) 0.45 (3.03) 
Specific 
necessity  
0.08 (2.99) -0.05 (2.89) <0.01 (3.47) -0.02 (2.75) -0.02 (2.94) -0.02 (2.90) 
Necessity-
concerns 
differential 
0.69 (3.71) -0.67 (4.41) -0.44 (4.97) -0.31 (4.09) -0.10 (4.33) -0.47 (4.26) 
Depression, Anxiety and Positive Outlook 
Depression  -0.13 (3.56) 0.06 (3.15) -0.14 (3.58) 0.02 (3.14) 0.03 (3.34) <0.01 (3.20) 
Anxiety  -0.03 (2.44) 0.25 (2.24) 0.20 (2.95) 0.16 (2.09) 0.12 (2.59) 0.22 (2.10) 
Positive outlook  -0.05 (3.33) 0.08 (2.60) -0.24 (2.57) 0.14 (2.86) -0.03 (3.06) 0.09 (2.63) 
*p<0.05       
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9.3.3: Predicting adherence status at six month follow-up 
Logistic regression was employed to determine if baseline psychological sumscores were able to 
reliably predict intentional adherence at six month follow-up. As collinearity was expected within 
each model (Petrie & Weinman, 2006) all of the factors for each model were included to extract the 
variance common to all factors. Each of the three social cognition models were tested separately and 
then combined to determine the best predictor of adherence (Table 9.2). Both the Self Regulatory 
Model and the Beliefs about Medications Questionnaire performed well with Nagelkerke R2 being 
20.5% and 13.1% respectively. However, neither the Theory of Planned Behaviour nor the Health 
Belief Model were able to reliably predict adherence at six months (χ2 for both >0.05) and fared 
particularly badly for low adherers with less than 9% correctly identified.  
The most accurate way of predicting six month intentional adherence was to use a combination of all 
of the models and add the baseline intentional adherence category (shown in the final column of 
Table 9.2). For this model, χ2 (17) = 33.53, p=0.01 and 81.6% of cases were correctly identified, 
including 35.5% of low adherers. The odds ratios for each of the model factors are shown in Table 
9.2. The trends for an increase in TPB important others scores leading to an increased odds of 
adherence whilst an increase in BMQ concern scores leading to a decrease in the odds of adherence 
were expected. Unsurprisingly, the most useful predictor of adherence at follow-up was adherence 
at baseline with patients who had high adherence at baseline being 3.84 times more likely to have 
high adherence at 6 months. 
Although some factors included in the social cognition models at baseline adequately predicted 
intentional adherence at six months, they were not able to reliably predict forgetting at six months. 
Table 9.3 shows that none of the models separately were able to predict those who forgot their 
medication at six months. Combining the models with age and baseline forgetting status was 
significant; χ2 (19) = 62.06, p<0.001 with Nagelkerke R2 = 54.7%. Using this model, 96.1% of cases 
were correctly identified including 72.7% of forgetters. However, on closer inspection it is mostly age 
(Wald’s β = 9.48) and baseline forgetting (Wald’s β = 17.07) that were significant with only baseline 
SRM personal control significantly predicting forgetting at six months as a 1 point increase in 
personal control led to a 17% increase in the odds of forgetting.   
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                Table 9.2: Logistic regression using baseline model factor sumscores to predict intentional adherence at six month follow-up 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about 
Medications 
Combined 
Variable Wald β OR Wald β OR Wald β OR Wald β OR  Wald β OR 
TPB important others 4.13 1.03*       3.13 1.37 (p=0.077) 
TPB perceived control 1.89 1.21       0.004 1.01 
HBM barriers   2.09 0.92     0.001 1.00 
HBM benefits   1.22 1.15     1.74 1.25 
HBM severity   0.17 1.03     0.38 0.93 
SRM identity     3.45 1.40   1.56 1.39 
SRM chronicity     4.18 0.86*   4.74 0.78* 
SRM cyclical     0.59 0.95   0.12 0.97 
SRM consequences     0.43 1.04   0.12 1.03 
SRM personal control     0.63 0.96   1.39 0.93 
SRM treatment 
control 
    4.46 1.17*   2.38 1.19 
SRM coherence     0.24 0.97   0.11 0.98 
SRM emotion     3.27 1.10   2.71 1.13 
BMQ harmful       5.81 1.30* 5.25 1.40* 
BMQ overuse       0.42 0.95 0.27 1.06 
BMQ necessity        1.34 0.92 0.02 1.01 
BMQ concern       2.38 1.09 3.35 0.81 (p=0.067) 
Age         1.77 1.03 
Baseline adherence         4.48 3.84* 
Model χ2 (3) = 7.36, p=0.061 χ2 (4) = 8.26, p=0.083 χ2 (9) = 21.95, p=0.009 χ2 (5) = 13.30, p=0.021 χ2 (19) = 36.33, p=0.01 
 Nagelkerke R
2
 = 0.073 Nagelkerke R
2
 =0.083 Nagelkerke R
2
 = 0.205 Nagelkerke R
2
 = 0.131 Nagelkerke R
2
 = 0.358 
 77.4% correct           
(8.3% of low) 
75.5% correct        
(2.8% of low) 
81.2% correct             
(25% of low) 
77.9% correct             
(20% low) 
81.5% correct                             
(35.5% low) 
*p<0.05      
 
1
4
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           Table 9.3: Logistic regression using baseline model factor sumscores to predict unintentional adherence at six month follow-up 
 Theory of Planned 
Behaviour 
Health Belief 
Model 
Self Regulatory Model Beliefs about 
Medications 
Demographics Combined 
Variable Wald β OR Wald β OR Wald β OR Wald β OR Wald β OR Wald β OR 
TPB important 
others 
0.30 0.93         1.78 0.75 
TPB perceived 
control 
1.16 0.94         0.23 1.05 
HBM barriers   3.73 1.11*       0.70 1.09 
HBM benefits   0.04 0.97       0.29 0.89 
HBM severity   0.50 0.95       1.94 1.25 
SRM identity     0.39 0.90     1.34 0.75 
SRM chronicity     1.38 0.94     0.18 0.96 
SRM cyclical     0.41 1.04     0.24 0.96 
SRM consequences     0.60 0.96     0.08 1.02 
SRM personal 
control 
    6.04 1.14*     3.62 1.17* 
SRM treatment 
control 
    4.06 0.86*     0.71 0.91 
SRM coherence     0.03 0.99     0.001 1.00 
SRM emotion     0.95 1.05     1.61 0.90 
BMQ harmful       1.10 0.90   0.07 0.96 
BMQ overuse       1.96 1.13   3.08 1.29 
BMQ necessity        3.22 0.91   2.56 0.84 
BMQ concern       0.13 1.02   2.10 0.83 
Age         6.54 0.96* 9.48 0.93* 
Baseline adherence         19.14 11.09** 17.07 27.20** 
Model χ2 (2) = 2.19, p=0.334 χ2 (3) = 3.91, 
p=0.27 
χ2 (8) = 10.20, p=0.252 χ2 (4) = 5.21, p=0.266 χ2 (2) = 36.41, p<0.001 χ2 (19) = 62.06, p<0.001 
 Nagelkerke R2 = 0.021 Nagelkerke 
R2=0.038 
Nagelkerke R2 = 0.093 Nagelkerke R2 = 0.050 Nagelkerke R2 = 0.326 Nagelkerke R2 = 0.547 
 77.4% correct            
(0% of forget) 
77.7% correct              
(0% of forget) 
77.6% correct            
(2.7% of forget) 
78.6% correct              
(0% of low) 
82.2% correct               
(45.9% of forget) 
96.1% correct                   (72.7% 
of forget) 
*p<0.05,  **p<0.001       
1
5
0
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9.3.4: Predicting change in intentional adherence 
9.3.4.1: Predicting change in intentional adherence at six month follow-up using baseline 
sumscores 
Equally as important as being able to predict adherence after six months, is the ability to predict and 
explain changes in adherence that may occur, as detailed in the exploratory aims. In section 9.3.1 it 
was clear that a significant proportion of patients changed over six months from high to low 
intentional adherence (and vice versa) and from not forgetting to forgetting (and vice versa) and so it 
would be advantageous to be able to predict these changes.  
Logistic regression analysis was used to identify the best psychological predictors of patients whose 
adherence status changed over six months. Two regressions using baseline social cognition models 
scores were carried out to predict; i) baseline high intentional adherence changing to low and ii) 
baseline low intentional adherence changing to high. 
Using baseline psychological scores to predict patients who changed from high to low intentional 
adherence was not successful as none of the social cognition models could reliably predict change 
(see Appendix 9.2 for details). Similarly, the social cognition models could not reliably predict change 
in adherence from low intentional at baseline to high intentional adherence at six months (Appendix 
9.3).  
9.3.4.2: Predicting change in intentional adherence at six month follow-up using change in 
sumscores 
As well as using the baseline psychological sumscores, the change in sumscores over the six month 
follow-up period was also investigated to predict change in adherence because it was found in 
section 9.3.2 that there were significant changes in psychological sumscores for low intentional 
adherers only. Again, logistic regression was used to test each social cognition model as well as all of 
them combined to predict change in adherence from high to low and from low to high. For those 
with high baseline intentional adherence, it was not possible to reliably predict change to low 
intentional adherence; χ2 (17) = 21.43, p=0.21 (Table 9.4).  
Two of the logistic regression models predicting change in adherence from low at baseline to high at 
six months produced significant results (Table 9.5). The Health Belief Model correctly identified 
68.3% of cases including 71.4% of those who changed from low to high intentional adherence. In this 
model, a 1 point increase in the change in HBM barriers led to a 41% increase in the odds of 
remaining a low adherer. Combining the psychological models also led to a marginally significant 
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regression model; χ2 (17) = 27.54, p=0.051. The combined model correctly identified 86.8 % of cases 
including 89.5% of those whose adherence changed. Nagelkerke’s R2 is also very high at 68.7%. 
Although none of the individual variables are significant by themselves, there was a trend for an 
increase in the change of scores for HBM barriers (Wald’s β = 2.64) to lead to an increase in the odds 
of remaining a low adherer and an increased change in SRM personal control (Wald’s β = 2.60) and 
BMQ concern (Wald’s β = 3.40) to lead to a decrease in the odds of remaining a low adherer. 
However although there appears to be an association between a change on some of the 
psychological factors and change in adherence, the direction of the change and the direction of the 
association (i.e. the change in psychological factors could impact on change in adherence or vice 
versa) is not available.   
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        Table 9.4: Logistic regression using change in model factor sumscores to predict change in intentional adherence from high at baseline to low at follow-up 
 
 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about 
Medications 
Combined 
Variable Wald  β OR Wald  β OR Wald  β OR Wald  β OR Wald  β OR 
TPB important others 1.27 0.84       1.79 0.76 
TPB perceived control 0.18 0.97       0.03 1.02 
HBM barriers   0.05 0.98     1.89 0.83 
HBM benefits   1.90 0.80     2.39 0.74 
HBM severity   4.12 1.28*     4.13 1.39* 
SRM identity     0.004 1.01   0.38 1.11 
SRM chronicity     2.90 1.13   3.16 1.20 
SRM cyclical     0.65 1.08   1.63 1.16 
SRM consequences     0.30 0.94   0.73 0.88 
SRM personal control     2.17 1.12   2.31 1.15 
SRM treatment control     0.03 0.98   0.12 0.96 
SRM coherence     0.98 0.92   0.82 0.91 
SRM emotion     0.93 1.09   0.56 1.09 
BMQ harmful       0.03 0.97 0.003 0.99 
BMQ overuse       0.42 0.93 0.34 1.10 
BMQ necessity        0.62 0.93 1.08 0.88 
BMQ concern       4.63 1.28* 2.44 1.24 
Model χ2 (2) = 1.46, p=0.482 χ2 (3) = 5.56, p=0.14 χ2 (8) = 7.88, p=0.45 χ2 (4) = 5.95, p=0.20 χ2 (17) = 21.43, p=0.21 
 Nagelkerke  R
2
=0.024 Nagelkerke  R
2
=0.088 Nagelkerke  R
2
=0.125 Nagelkerke  R
2
=0.092 Nagelkerke  R
2
=0.333 
 85.3% correct            
(0% of changers) 
84.4% correct            
(0% of changers) 
84.1% correct              
(6.3% of changers) 
85.8% correct                
(0% of changers) 
83.7% correct                
(12.5% of changers) 
*p<0.05      
1
5
3
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Table 9.5: Logistic regression using change in model factor sumscores to predict change in intentional adherence from low at baseline to high at follow-up 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about 
Medications 
Combined 
Variable Wald β OR Wald β OR Wald β OR Wald β OR Wald β OR 
TPB important others 0.44 0.85       0.19 0.74 
TPB perceived control 0.38 0.95       1.79 0.51 
HBM barriers   4.33 1.41*     2.64 1.89 
HBM benefits   2.20 0.70     0.25 0.75 
HBM severity   1.10 0.87     0.11 0.78 
SRM identity     0.59 1.18   0.62 0.39 
SRM chronicity     1.38 0.81   0.46 0.55 
SRM cyclical     1.21 1.16   1.63 2.28 
SRM consequences     0.10 0.95   0.12 1.13 
SRM personal control     0.35 0.93   2.60 0.35 
SRM treatment 
control 
    3.40 0.75   1.95 0.37 
SRM coherence     0.06 0.96   0.15 1.21 
SRM emotion     0.17 0.96   0.37 1.19 
BMQ harmful       3.36 1.40 0.29 1.35 
BMQ overuse       0.03 0.98 0.33 0.75 
BMQ necessity        0.49 0.90 0.30 1.33 
BMQ concern       1.18 0.88 3.40 0.19 
Model χ2 (2) = 0.84, p=0.66 χ2 (3) = 8.21, p=0.042 χ2 (8) = 7.47, p=0.49 χ2 (4) = 5.61, p=0.23 χ2 (17) = 27.54, p=0.051 
 Nagelkerke R
2
=0.026 Nagelkerke R
2
=0.242 Nagelkerke R
2
=0.227 Nagelkerke R
2
=0.171 Nagelkerke R
2
=0.687 
 47.6% correct             
(68.2% of changers) 
68.3% correct      
(71.4% of changers) 
65% correct                   
(65% of changers)   
63.4% correct                
(72.7% of changers) 
86.8% correct            
(89.5% of changers) 
*p<0.05      
 
1
5
4
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9.3.5: Predicting change in unintentional adherence (forgetting) 
9.3.5.1: Predicting change in unintentional adherence at six month follow-up using 
baseline sumscores 
One of the exploratory aims was to determine if the Theory of Planned Behaviour or Health Belief 
Model explained adherence. An interesting finding showed that those who did not forget at baseline 
and also had low TPB important others scores were 10.5 times more likely to become forgetters than 
those with high baseline TPB important others scores (χ2 (1) = 8.87, p=0.003). These patients also 
perceived significantly higher HBM barriers to medication taking (F(1, 128) = 4.15, p=0.04). 
To test the models more fully, using the same regression method as for intentional adherence, the 
baseline psychological model sumscores were used to predict change in unintentional adherence 
from i) those who became forgetful at six month follow-up and ii) those who forgot at baseline but 
ceased to forget at six month follow-up. For patients who at baseline did not forget, it was not 
possible to reliably predict change in adherence; χ2 (17) = 26.02, p=0.07 (Table 9.6). However, there 
was a trend for a 1 point increase in TPB important others scores led to a 50% increase in the odds of 
a patient continuing to remember their medication.  
The Self Regulatory Model produced a significant regression model (χ2 (6) = 14.40, p=0.03) with 
Nagelkerke R2 = 64.4% to successfully predict change from baseline forgetting to not forgetting 
(Table 9.7). This model correctly identified 87.5% of cases including 57.1% of those who changed 
from forgetting at baseline to not forgetting at 6 months. More specifically, a 1 point increase in 
baseline SRM personal control scores led to the odds of remaining a forgetter being 2.08 times 
higher. Also, a 1 point increase in SRM treatment control scores led to a 36% decrease in the odds of 
remaining a forgetter. Based on the associations found cross-sectionally between personal and 
treatment control and forgetting (see Chapter 7), the relationship of these variables to change in 
unintentional adherence are in the expected direction.  
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9.3.5.2: Predicting change in unintentional adherence at six month follow-up using change 
in sumscores 
In contrast to the intentional adherence, the change in psychological scores was not predictive of 
change in unintentional forgetting in either direction. None of the social cognition models alone or 
combined were able to reliably predict patients whose unintentional adherence status changed with 
Nagelkerke R2 being less than 15% for all of the models tested. The logistic regressions are 
summarised in Appendices 9.4 and 9.5. 
 
 157 
 
 
            Table 9.6: Logistic regression using baseline model factor sumscores to predict change in unintentional adherence when at baseline patients do not forget 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about 
Medications 
Combined 
Variable Wald β OR Wald β OR Wald β OR Wald β OR Wald β OR 
TPB important others 3.30 1.33       3.73 1.50* 
TPB perceived control 0.08 0.98       0.85 0.91 
HBM barriers   4.19 0.86*     4.76 0.74* 
HBM benefits   0.01 1.02     0.29 1.14 
HBM severity   0.26 1.05     4.23 0.71* 
SRM identity     1.67 1.31   4.02 1.76* 
SRM chronicity     5.65 1.16*   1.23 1.10 
SRM cyclical     1.96 0.88   1.80 0.85 
SRM consequences     0.01 0.99   0.80 1.10 
SRM personal control     2.25 0.91   2.11 0.89 
SRM treatment 
control 
    3.61 1.21*   0.17 1.06 
SRM coherence     0.48 1.05   0.14 1.04 
SRM emotion     0.35 1.04   3.13 1.19 
BMQ harmful       0.25 1.07 1.18 1.21 
BMQ overuse       1.51 0.87 0.42 0.89 
BMQ necessity        0.01 1.01 0.04 1.02 
BMQ concern       1.45 1.09 2.33 1.30 
HAQ           
EQ5D utility           
Model χ2 (2) = 3.32 p=0.19 χ2 (3) = 4.58, p=0.21 χ2 (8) = 11.39, p=0.18 χ2 (4) = 2.84, p=0.59 χ2 (17) = 26.02, p=0.074 
 Nagelkerke R
2
=0.044 Nagelkerke R
2
=0.063 Nagelkerke R
2
=0.143 Nagelkerke R
2
=0.039 Nagelkerke R
2
=0.340 
 86.4% correct              
(5.3% of changers) 
86.2% correct               
(0% changers) 
86.6% correct               
(15% of changers) 
86.5% correct                 
(0% of changers) 
90.6% correct                                                              
(29.4% of changers) 
*p<0.05      
 
1
5
7
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            Table 9.7: Logistic regression using baseline model factor sumscores to predict change in unintentional adherence when at baseline patients do forget 
 Theory of Planned 
Behaviour 
Health Belief Model Self Regulatory Model Beliefs about Medications 
Variable Wald β OR Wald β OR Wald β OR Wald β OR 
TPB important others 0.18 1.24       
TPB perceived control 0.12 0.95       
HBM barriers   0.53 1.09     
HBM benefits   0.13 1.14     
HBM severity   1.46 0.82     
SRM identity     Not entered    
SRM chronicity     1.15 1.44   
SRM cyclical     0.88 0.79   
SRM consequences     1.81 0.77   
SRM personal control     2.62 2.08   
SRM treatment 
control 
    2.54 0.64   
SRM coherence     Not entered    
SRM emotion     1.54 1.24   
BMQ harmful       0.02 1.05 
BMQ overuse       1.34 1.30 
BMQ necessity        2.34 0.78 
BMQ concern       0.17 0.93 
HAQ         
EQ5D utility         
Model χ2 (2) = 0.24 p=0.89 χ2 (3) = 1.94, p=0.58 χ2 (6) = 14.40, p=0.025 χ2 (4) = 5.16, p=0.27 
 Nagelkerke R
2
 = 0.014 Nagelkerke R
2
 = 0.111 Nagelkerke R
2
 = 0.644 Nagelkerke R
2
 = 0.284 
 70.8% correct              
(0% of changers) 
70.8% correct                        
(14.3%  of changers) 
87.5% correct                  
(57.1% of changers) 
82.6% correct                           
(57.1% of changers) 
 
1
5
8
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9.3.6: Structural equation modelling of social cognition models and adherence 
Structural Equation Modelling (SEM) allows for more of the effects of multiple exogenous variables 
on multiple endogenous variables to be tested with multiple regressions being carried out 
simultaneously. SEM also allows for the hypothesised mediated effect of illness perceptions through 
treatment beliefs on adherence to be tested whilst controlling for multiple testing. As opposed to 
logistic regression, the endogenous variable can also be an unobserved latent variable which is more 
sensitive than a dichotomised outcome. Goodness-of-fit indices with standard cut-off thresholds are 
used, as detailed in Chapter 6, section 6.3.3. The thresholds recommended by Hu & Bentler (1999) 
are; CFI ≥ 0.95, RMSEA ≤ 0.06, SRMR ≤ 0.08. To take into account the hypothesised predictors of 
adherence as well as the results of the exploratory aims, a number of SEMs were carried out.  
Firstly, two a priori models developed by Horne & Weinman (2002) and Nicklas et al. (2010) were 
tested for model fit in the current dataset. The first model, originally developed by Horne & 
Weinman (2002) in an asthma patient group is shown in Figure 9.2 with the parameter estimates 
generated for the current dataset. Although the direction of the paths are all the same as those 
found by Horne & Weinman (2002), the strength of the associations are not the same and two paths 
are not statistically significant. In the current dataset, SRM consequences does not directly impact on 
adherence, although there is a significant mediation through BMQ necessity for both datasets. The fit 
of the model for the current dataset is not satisfactory as CFI = 0.85, RMSEA = 0.075 and SRMR = 
0.075. However, although Horne & Weinman (2002) report a good fit to their data for the model 
shown in Figure 9.2, the RMSEA was 0.14 which indicates that the fit of that model could also have 
been improved in their sample. 
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The second model by Nicklas, Dunbar & Wild (2010) was carried out in a chronic non-malignant pain 
sample and was based on the model by Horne & Weinman (2002). This model was tested in the 
current dataset and is shown with parameter estimates in Figure 9.3. As with the model shown in 
Figure 9.2, the current dataset does not match all of the paths identified by Nicklas et al. (2010). 
Most notably, SRM consequences does not impact on BMQ treatment concerns in the current 
dataset as it does in the chronic pain sample. The relationship between SRM consequences and 
adherence is also not mediated by treatment concerns although it is mediated by treatment 
necessity. These non-significant pathways contribute to the lack of fit shown in the dataset as CFI = 
0.87, RMSEA = 0.071 and SRMR = 0.074 compared to CFI = 0.97 and RMSEA = 0.058 found by Nicklas 
et al. (2010). 
 
χ2 (291) = 548.69, p<0.001. 
CFI = 0.85 
RMSEA = 0.075 
SRMR = 0.075 
Figure 9.2: Structural equation model of illness perceptions and treatment beliefs explaining adherence based 
on Horne & Weinman (2002) 
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Although the a priori models were not developed in rheumatoid arthritis patients, they included 
factors from the Self Regulatory Model and Beliefs about Medications model that were shown cross-
sectionally to be predictors of adherence in this study. The fit of these models was not ideal, 
however there were common elements such as increased perceptions of consequences and 
treatment necessity leading to better adherence. As these factors were shown in the correlations 
and logistic regressions to be predictive of adherence,  further models were tested that included 
factors of the Theory of Planned Behaviour in order to improve the fit of the data to explain 
adherence in this RA sample. Two models were found to have reasonable fit and are shown in 
Figures 9.4 and 9.5. 
χ
2
 (318) = 574.61, p<0.001 
CFI = 0.87 
RMSEA = 0.071 
SRMR = 0.074 
 
Figure 9.3: Structural equation model of illness perceptions and treatment beliefs explaining adherence 
based on Nicklas et al. (2010) 
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χ
2
 (585) = 924.44, p<0.001 
CFI = 0.86 
RMSEA = 0.06 
SRMR = 0.09 
 
Figure 9.4: Structural equation model of illness perceptions, treatment beliefs and Theory of Planned Behaviour 
variables explaining adherence 
χ
2
 (766) = 1166.75, p<0.001 
CFI = 0.86 
RMSEA = 0.06 
SRMR = 0.09 
 
Figure 9.5: Structural equation model of illness perceptions including chronic timeline, beliefs about medications 
and Theory of Planned Behaviour variables to explain adherence.  
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Both of these models which use baseline psychological factors to predict intentional adherence six 
months later show a reasonable fit to the data. For both, the CFI is above 0.85, although is below the 
accepted threshold for good fit (Hu & Bentler, 1999). Similarly, the RMSEA and SRMR are just above 
the thresholds for a good fit indicating overall that these models show a reasonable fit to predict 
adherence and are the best fitting models for this data. This is supported by the fact that these 
baseline predictors explain 24.7% of the variance in adherence at six months. The models 
incorporate pathways between the same illness perceptions and treatment beliefs as Horne & 
Weinman (2002) and Nicklas et al. (2010) and support the hypothesis that illness consequences are 
fully mediated by perceptions of treatment necessity which predict adherence (Horne & Weinman, 
1998; Horne & Weinman, 2002; Nicklas et al., 2010; Ross et al., 2004). As with Nicklas et al. (2010), 
higher illness related emotions impact on higher treatment concerns which create lower adherence. 
The relationship between illness emotions and adherence are fully mediated by treatment concerns. 
As was found by Horne & Weinman (2002) but not by Nicklas et al. (2010), higher perceptions of the 
illness duration create higher perceptions of treatment necessity, although there is no mediating 
effect on adherence.  
The addition of the Theory of Planned Behaviour variables increased the explained variance in 
adherence by 4.4% with both a direct effect of higher TPB Perceived Behavioural Control leading to 
higher adherence and a mediation of TPB important others on adherence through Perceived 
Behavioural Control. Although the inclusion of behavioural control would be expected to increase the 
likelihood of the behaviour being performed (Armitage & Conner, 2001), this relationship was not 
evident in the logistic regression. Overall, the best fitting models using baseline psychological 
variables to predict adherence at six months include SRM consequences, SRM emotion, SRM 
timeline, BMQ necessity, BMQ concern, TPB important others and TPB Perceived Behavioural 
Control. These models contain factors that have been shown by previous studies to be predictive of 
adherence, but were not statistically significant in the logistic regressions. This is likely due to the fact 
that the structural equation model used the 5 items of the Compliance Questionnaire for 
Rheumatology to estimate the latent variable of adherence whereas the logistic regressions relied on 
a dichotomised variable of high/low adherence therefore reducing the sensitivity to detect change.  
9.4: Discussion 
A number of interesting results were found both for the hypotheses that were identified as well as 
the exploratory associations predicted for the longitudinal relationship of psychological factors on 
adherence to disease modifying medication in rheumatoid arthritis. 
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9.4.1: Social cognition models in adherence groups 
Contrary to the baseline results, there were no statistically significant differences between any of the 
SRM factors for the adherence groups at six months as the scores for non-adherers had moved 
towards adherers for all three types. However, high overall adherers had significantly higher BMQ 
necessity scores than low adherers indicating that these patients perceived their medication to be 
more necessary at follow-up, a relationship which was not found at baseline. It would be expected 
that high adherers would have higher BMQ necessity scores based on research in hypertension (Ross 
et al., 2004), severe haemophilia (Llewellyn et al., 2003) and asthma (Horne & Weinman, 2002). The 
fact that this was not found in the cross-sectional analysis is surprising but most likely due to the fact 
that all patients had high necessity scores with high overall adherers increasing further at six months 
whilst low adherer’s perception of necessity remained stable over time.  
The combination of the sumscore changes for each group as well as the sumscore differences 
between groups provides an interesting insight into the relationship between social cognition models 
and adherence over time. Although the magnitude of change was only large enough to be 
statistically significant for two factors for the low intentional adherers only, a number of 
relationships between adherence groups had changed indicating that the combination of smaller 
changes for each group narrowed the differences, warranting them insignificant. As very few 
previous studies have demonstrated this variability, this is a very important step towards 
understanding how social cognition models and adherence interact over time which could present 
opportunities to develop interventions. For example, low intentional adherers perceive significantly 
higher barriers to medication taking and lower confidence in DMARDs to control their RA at six 
months, both of which could reassert low adherence. Addressing these perceptions could go some 
way to improving medication taking in these patients.  
9.4.2: Variability in adherence 
Very little previous research has measured adherence over time, although de Thurah et al. (2010) 
reported no change in adherence to Methotrexate over a nine month period. However, it was 
hypothesised that the newly diagnosed patients would have more variability as they become more 
experienced in taking a new medication.  
As approximately 30% of patients in this study changed on at least one type of adherence, there was 
more variation in this sample of RA patients than was found by de Thurah et al. (2010). On closer 
inspection, the new patients had the most variation, across all adherence types. A concerning result 
is that at six months the new patients reported higher proportions of low intentional adherence, 
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more forgetting and more overall low adherence showing that as time progresses, these new 
patients are demonstrating worse adherence to DMARDs. This is particularly worrying given that 
NICE (2009) guidelines recommend aggressive treatment of RA within the first three months of 
symptom onset to prevent irreversible joint damage (see Chapter 1) which will not be effective if 
patients are not adhering to the regimen.  
There was a relatively large increase in forgetting for all treatment groups from baseline to six 
months, which could be underestimated given that non-responders to the follow-up questionnaire 
were more likely to be forgetters. Although this may be expected for the new patients who would 
still be adapting to a new medication regimen, given the length of time that the established and 
biologic patients would have been prescribed DMARDs, it would be expected that they would be less 
prone to forgetting. However, as there is no previous research looking at patients forgetting DMARDs 
over time, these results give some insight into the behaviour of patients which appears to be more 
variable than was expected. However, as adherence was measured solely through self-report, some 
of the variation seen in this sample may be due to a lack of validity of the measures. It is not possible 
to test this in the current sample as there was no objective measure of adherence, but the nature of 
dichotomising patients as high/low adherers may lead to error over six months.  
9.4.3: Predicting adherence to medication at six month follow-up 
9.4.3.1: Predicting intentional adherence at six month follow-up 
It was hypothesised that SRM identity, consequences and timeline would be associated with 
adherence as well as BMQ necessity based on cross-sectional studies. None of the individual social 
cognition models at baseline predicted intentional adherence at six months. When the models were 
combined, only SRM chronicity and BMQ harmful were significant which only partly supports the 
hypothesis. It was expected that BMQ necessity would be predictive of intentional adherence as this 
has been found consistently cross-sectionally (de Thurah et al., 2010; Horne, 1999; Treharne et al., 
2004) and longitudinally in ischemic heart disease (Allen LaPoint et al., 2010) and in chronic illness 
including RA (Clifford et al., 2008), however DMARD necessity was not predictive of adherence in this 
sample. This is most likely due to the very high necessity scores for all patients indicating that all of 
these patients believe in the necessity of DMARDs but that this is not sufficient for adherence. 
Clinically, it would be more desirable to be able to predict low adherence, however the relatively 
small amount of variance explained by the social cognition models shows that improvements could 
be made to more effectively predict low adherence.  
 166 
 
Within clinical practice, it would be equally as useful to be able to predict which patients change 
from high to low adherence, particularly given that a substantial proportion of patients in this sample 
did change over the six month period. None of the models proved to effectively predict change in 
intentional adherence. Although the Beliefs about Medications model correctly identified 86.4% of 
patients who changed from low to high adherence, this is likely due to the fact that more of the 
sample were high adherers and that the model was not performing better than chance.  
Although the regression analyses could not reliably predict adherence, there were some interesting 
baseline differences for the psychological factors. For example, patients with high adherence at 
baseline who changed to low adherence had significantly lower SRM chronicity scores than those 
who remained high adherers. This suggests that although the difference was not strong enough to 
predict change in adherence, perceptions of a chronic illness may be related to patients’ adherence 
over time, providing a possible insight into an area for intervention and supporting the results of 
successful interventions in other patients groups (Broadbent, Ellis, Thomas, Gamble & Petrie, 2009; 
Petrie et al., 2002; Petrie et al., 2011).  
9.4.3.2: Predicting unintentional adherence at six month follow-up 
 As a large proportion of patients who did not forget at baseline subsequently started forgetting at 
six months, it would be particularly advantageous to be able to identify these patients and the 
reasons behind the change.  
As there has been no previous research looking specifically at forgetting over time in RA or other 
chronic illnesses, these analyses were exploratory with an aim of providing some of the first insights 
into this area of adherence. Simply using the baseline psychological scores to predict forgetting 
status at six months was not successful. When adding age and baseline forgetting status, 96.1% of 
cases were correctly identified; however only SRM personal control added any explained variance 
indicating that the social cognition models did not reliably predict forgetting.  
The logistic regressions used to predict change in forgetting scores produced interesting results. For 
patients who did not forget at baseline, a combination of all of the models performed the best with a 
number of factors being significant. These results support some previous less specific studies into 
adherence as Berry et al. (2004) found that RA patients perceived there to be risks to taking DMARDs 
with adherence being lower if the risks outweighed the benefits. Similarly, quality inter-personal 
relationships seem to aid medication taking (DiMatteo, 2004; Owen et al., 1985).  
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9.4.4: Using structural equation models to predict adherence 
Structural equation modelling allows for multiple regression analyses to be carried out 
simultaneously in order to test for causal pathways and mediation between variables. To test the fit 
of baseline social cognition models to predict adherence at six months, a number of models were 
tested included two a priori models developed by Horne & Weinman (2002) and Nicklas et al. (2010) 
as well as two models based on the correlation matrices of the current dataset.  
Although the a priori models were not developed in rheumatoid arthritis patients, as they contained 
factors from the Self Regulatory Model and Beliefs about Medications model that were shown cross-
sectionally to be predictors of adherence they were tested in the current sample. The overall fit of 
these models was reasonable, however not all of the pathways were significant indicating that the fit 
could be improved. The final model, shown in Figure 9.5 showed quite a good fit to the data, 
although it explained only 24.7% of the variance in adherence. Interestingly, it contains factors from 
the SRM and BMQ that have been shown by previous studies to be predictive of adherence, although 
were not significant in the logistic regressions. This is likely due to the fact that the structural 
equation model used the 5 items of the Compliance Questionnaire for Rheumatology to estimate the 
latent variable of adherence whereas the logistic regressions relied on a dichotomised variable of 
high/low adherence therefore reducing the sensitivity to detect change.  
The pathways are in the expected directions and support the claims that the effects of illness 
perceptions on adherence are medicated by treatment beliefs (Horne & Weinman, 1998; Horne & 
Weinman, 2002; Nicklas et al., 2010; Ross et al., 2004). Higher consequences and chronic timeline 
perceptions lead to higher BMQ necessity scores which in turn result in higher adherence. The 
addition of the Theory of Planned Behaviour factors in the SEM adds only 4.4% to the explained 
variance in adherence, although the pathways are highly significant. This is again a slightly surprising 
relationship as these variables were not able to reliably predict intentional adherence through 
logistic regression, although the SEM shows that higher scores on TPB important others results in 
higher perception of control over taking medications which contributes towards higher adherence. 
This supports previous research that has shown that the amount of confidence a person has in 
performing the behaviour increases the likelihood of that behaviour being performed (Armitage & 
Conner, 2001).  
9.4.5: Summary of predicting adherence to medication 
It is interesting to note that the relationships between the social cognition models and intentional 
and unintentional adherence changed over the six month period. In Chapter 7, it was shown that 
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cross-sectionally, the Self Regulatory Model, Beliefs about Medications and to a certain extent the 
Health Belief Model were significantly related to intentional adherence whereas the Theory of 
Planned Behaviour was only related to forgetting. However longitudinally, the only factors that were 
predictive of intentional adherence in logistic regression were the SRM chronic timeline and BMQ 
harmful scales. Based on previous research in arthritis (Carlisle et al., 2005; Scharloo et al., 1998) and 
other chronic illnesses (Llewellyn et al., 2003; Ross et al., 2004; Rutter & Rutter, 2007), it would be 
expected that SRM consequences would also be predictive of adherence at six months, although this 
wasn’t found in the logistic regression. However, SRM consequences were found to be predictive of 
forgetting at six months, a relationship that was not apparent cross-sectionally. Equally, the Theory 
of Planned Behaviour factors that were predictive of forgetting cross-sectionally were not related to 
forgetting six months later.  
Despite the lack of good models to predict changes in intentional adherence using a dichotomised 
high/low adherence outcomes, the structural equation modelling that used adherence as a latent 
continuous model did provide strong evidence for some of the associations between social cognition 
models and adherence over time that were hypothesised. In particular, SRM consequences became a 
significant predictor along with SRM chronicity, as did BMQ necessity. BMQ concern also had a 
significant negative impact on adherence showing that the full cost-benefit analysis of medication 
adherence that is suggested by these social cognition models is involved in the decision to undertake 
the behaviour. Although the structural equation model that best fit this dataset was not identical to 
that found by Horne & Weinman (2002) or Nicklas et al. (2010) there were a number of common 
variables which is to be expected as they were generated for different chronic illness patients. 
Following a large amount of research into illness and treatment beliefs in various chronic illnesses, it 
has been suggested that as the experience and aetiology will differ substantially, it is important to 
test these theories independently in each illness type (Hagger & Orbell, 2003). Although higher 
perceived chronicity and consequences have been found to be related to worse outcomes in some 
illnesses such as hypertension (Ross et al., 2004), for patients with RA, a more realistic representation 
of the chronic and progressive nature of the illness appears to be related to better adherence to 
medications.  
The effects of the Health Belief Model and Theory of Planned Behaviour have not been evaluated 
with regards to medication adherence in chronic illness, and so most of the analyses involving these 
models were exploratory. However, Orbell et al. (2006) compared the Self Regulatory Model and the 
Theory of Planned Behaviour to explain attendance at follow-up colposcopy treatment. Upon 
combining the models, they found that SRM consequences and TPB Perceived Behavioural Control 
significantly predicted attendance to treatment, two factors that were also found to be predictive of 
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medication adherence in the structural equation model. This study has made the first step in 
advancing the utility of the current models of illness by combining a number of models to predict 
medication adherence. The best fitting structural equation model included factors from each of the 
models tested other than the Health Belief Model and provides an insight into the multidimensional 
process that is involved in the decision to take medications and the way mediations of these factors 
are evident.  
9.5: Conclusions 
Although the social cognition models as a whole did not explain a very large amount of variance in 
adherence at six months, there were a number of associations that were able to reliably distinguish 
between high and low adherers and which were expected based on previous research in rheumatoid 
arthritis and other chronic illnesses. Higher perceived consequences in particular appear to be 
related to intentional adherence, although treatment necessities did not have as large an effect as 
was expected. This longitudinal analysis of the effects of social cognition models on adherence to 
DMARDs adds a considerable amount of information to the literature by supporting previous 
research that combines social cognition models of health to explain behaviour as well as indicating 
which areas could potentially be targeted for intervention to improve adherence to DMARDs in 
rheumatoid arthritis. 
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Chapter 10  
Health economic analysis of adherence to disease modifying 
medication by rheumatoid arthritis patients 
10.1: Introduction 
The progressive nature of rheumatoid arthritis and the need for aggressive and expensive treatment 
means that although only approximately 1% of the population in the United Kingdom are diagnosed 
with RA, the total costs associated with the disease are very high. The National Audit Office (NAO; 
National Audit Office, 2009) and the National Rheumatoid Arthritis Society (NRAS, 2010) have 
estimated the cost to the NHS of treating RA to be £689 million per year for the UK. An inception 
cohort of early inflammatory polyarthritis in Norfolk, UK found that the NHS costs were 
approximately £392 per person for the six months post symptom onset (Cooper et al., 2002). 
However this is likely to rise with the increased disease activity expected over time. 
Cost of Illness (COI) studies aim to describe the total cost of a particular illness by itemising, valuing 
and summing the costs involved and then applying them to prevalence rates to determine the overall 
cost to the economy. Cost of Illness studies should include direct and indirect costs in order to be 
accurate. Direct costs are borne by the health care system, patient and community when dealing 
directly with the problem. These would include medication costs (to both the healthcare system and 
the patient), hospital costs and travel costs to appointments. Direct costs can either be from the 
service provider, patient or societal perspective depending on the focus of the analysis. For example, 
direct costs from the service provider perspective would include only medication production costs, 
and all costs associated with primary and secondary care. Direct costs from the patient perspective 
would include only prescription costs and out-of-pocket costs associated with treatment such as 
travel to appointments, but inpatient and outpatient costs (in the UK) would not be included as they 
are free at the point of access. Indirect costs mostly relate to loss of productivity through sickness 
and early retirement and would be viewed mostly from the patient and societal perspective.  
A number of COI studies have been carried out for rheumatoid arthritis across different countries. 
Zhu, Tam & Li (2011) calculated that the average total cost of RA in Hong Kong is US$9286 per 
patient year with US$2051-13,349 being direct costs and $1426-43,012 being indirect costs. In the US 
in 1998 the estimates of total direct costs per patient were $1342-7244 and $1454-21,273 for 
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indirect costs (Cooper, 2000; Pugner, Scott, Holmes & Hieke, 2000). More recently in the UK, the 
total direct costs were estimated at £689 million per year with an additional £7.9 billion per year lost 
through lack of productivity (NRAS, 2010). Indirect costs are significantly higher than direct (NAO, 
2009; NRAS, 2010; Zhu et al., 2011) with a review of COI studies in rheumatoid arthritis by Fautrel & 
Guillemon (2002) reporting that indirect costs account for 50-70% of the total costs (Birnbaum et al., 
2000; Cooper, 2000; Pugner et al., 2000) and can be up to 90% (Jonsson & Husberg, 2000). The 
largest cause of indirect costs is loss of productivity (NRAS, 2010; Zhu et al., 2011) as work disability is 
high among RA patients with 45% of all UK patients being unemployed (NRAS, 2007) and 
approximately one third of those stopping work within the first two years (Barrett et al., 2000; Young 
et al., 2002). In addition to this, those RA patients who are employed have an average of forty sick 
days per year in the UK compared to 6.5 days per year for the average worker (NRAS, 2007). In 
contrast, direct costs account for less than half of the total costs with approximately 75% accounted 
for by inpatient hospital costs and medication costs accounting for less than 20% (Cooper, 2000; 
Cooper et al., 2002; Jonsson & Husberg, 2000; Pugner et al., 2000). However, the proportion of 
medication costs may change in the future as expensive anti-TNF α treatments become more 
widespread resulting in fewer hospitalisations. With the exception of the very recent costs calculated 
by the National Audit Office and the National Rheumatoid Arthritis Society, other Cost of Illness 
studies have often not included the effects of anti-TNF α and so may underestimate at least the 
direct costs, although the overall benefit in productivity may compensate for the increased 
treatment costs.  
Adherence to medications can have a big effect on the total costs of a condition as non-adherence 
can lead to less symptom control and more disability (Grijalva et al., 2007). This can also have a 
societal effect as these patients are more likely to require frequent hospital and GP visits and 
escalation to more aggressive and expensive treatments such as anti-TNF α (Hughes et al., 2001). 
Despite this high impact, the effect of adherence on costs has been largely neglected in the 
literature, particularly in health psychology. Although a review by Hughes et al. (2001) found a 
number of studies that demonstrated that as adherence decreased, costs increased, there were also 
some studies that found the opposite effect. Part of this incongruity may be due to the fact that the 
majority of these studies made assumptions and estimates based on clinical opinion to derive costs 
and benefits rather than measuring costs directly. Two studies have attempted to more robustly 
measure the costs associated with adherence to medication in chronic illness. Balkrishnan et al. 
(2003) used MediCare records in the US to determine the Medication Possession Ratio (MPR) for 
elderly patients with Type II Diabetes using the number of days a prescription is intended for, divided 
by the number of days between refills (perfect adherence = 1). The mean MPR across five years was 
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0.71-0.78 with mean total healthcare costs being US$5043.14-8305.89 per patient across five years. 
The level of adherence and costs remained relatively stable over the five years, however there was a 
significant reduction in costs for high (>90%) adherers compared with low (<50%) adherers. In 
multivariate regression analysis, the authors found that a 10% increase in adherence led to an 8.6% 
decrease in total costs. Very similar results were found for elderly patients with diagnosed urinary 
incontinence as Balkrishnan, Bhosle, Camacho & Anderson (2006) found using the same 
methodology that high adherers had significantly lower costs than low adherers and that a 10% 
increase in adherence led to a 5.6% decrease in costs. There are limitations to these studies, 
particularly concerning the method of measuring adherence and the fact that these patients were 
enrolled in a private health insurance scheme meaning that costs were measured retrospectively 
without applying standard discounting rates. However, they are unique in attempting to quantify the 
costs associated with non-adherence longitudinally in chronic illnesses affecting elderly patients.  
As well as the costs associated with the treatment of an illness, the Health Related Quality of Life 
(HRQoL) of a patient should also be considered and is required by NICE to evaluate health technology 
assessments (Whitehead & Ali, 2010). The common unit of measurement is the Quality Adjusted Life 
Year (QALY) which combines the quantity of life (years) with the quality of life. NICE recommend that 
the EQ5D (EuroQol group, 1990) or an equivalent that can be mapped onto the utility index is used to 
compare across illness types (NICE, 2008). The Health Assessment Questionnaire (HAQ) has been 
found to be highly correlated with both costs and quality of life (Bansback, Ara, Karnon & Anis, 2008; 
Kobelt, Jonsson, Lindgren, Young & Eberhardt, 2002) with higher HAQ being associated with higher 
costs and lower HRQoL. Although HAQ and HRQoL are often measured when evaluating new 
treatments for RA, HRQoL in particular is rarely assessed in relation to adherence to treatment. There 
is therefore little known about the effects of medication adherence on HRQoL or the associated costs 
in rheumatoid arthritis or other chronic illnesses.  
Although rheumatoid arthritis costs the UK economy billions of pounds per year, very little is known 
about the economic impacts of treatment non-adherence in this patient group. Two studies carried 
out in other chronic illnesses have indicated that reduced adherence leads to increased healthcare 
costs (Balkrishnan et al., 2003; Balkrishnan et al., 2006), but this has so far remained unexplored in 
rheumatoid arthritis. For that reason, this prospective longitudinal study takes the health service 
provider perspective and aims to calculate the direct costs associated with low intentional and 
unintentional adherence to DMARDs over a six month period by rheumatoid arthritis patients. In 
addition to this, HRQoL will also be investigated via the EQ5D to determine whether adherence also 
impacts on quality of life, by calculating the QALY associated with medication adherence, which has 
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not been carried out before. The aim of this study is to establish robust costs and benefits of 
medication adherence in rheumatoid arthritis. 
10.1.1: Aims and Hypotheses 
Based on previous research by Balkrishnan et al. (2003) and Balkrishnan et al. (2006), it is 
hypothesised that: 
1) Healthcare costs will be higher for patients with low medication adherence.  
As there is no previous research that has investigated quality of life in relation to adherence to 
DMARDs, an additional aim of this study is to: 
2) Determine if there is a difference between EQ5D scores for high and low medication 
adherers.   
10.2: Methodology 
10.2.1: Patients 
This study formed part of the larger study investigating social cognition models of health and 
medication adherence. The patient demographics are described in Chapter 7, section 7.2.1. In 
summary, a total of 227 patients were recruited (75.7% female) at baseline with a mean age of 57.39 
years and mean disease duration of 12.54 years. Eligible patients had received a diagnosis of 
rheumatoid arthritis and were prescribed at least one DMARD. Eighty-four patients were also 
prescribed an anti-TNF α medication. Patients completed a questionnaire including the five itemed 
Compliance Questionnaire for Rheumatology and the Reported Adherence to Medication 
questionnaire to assess adherence to DMARDs and the EQ5D to assess quality of life. Their current 
prescription was recorded from medical notes by the researcher. 
Patients were followed-up six months after baseline to complete the questionnaire again. A total of 
171 patients were successfully followed-up (75.3%). Non-responders were more likely to self-report 
forgetting their DMARDs at baseline but no other differences were found. Adherence, quality of life 
and current prescription were again recorded to calculate the costs of medications for each 
adherence group and the EQ5D utility index. In addition, the number of outpatient appointments, 
“did not attend” (DNA) outpatient appointments, inpatient days and Accident and Emergency 
contacts was recorded prospectively over the six month follow-up period for all patients. 
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10.2.2: Procedure  
Patients were categorised as high or low adherers for intentional, unintentional and overall 
medication adherence using the method described in Chapter 3. Current prescriptions for RA specific 
medications were recorded from patient notes and separated into the following categories; DMARDs 
(Methotrexate, Sulfasalazine, Hydroxychloroquine and Leflunamide), anti-TNF α (Enbrel, Humira & 
Remicade) and steroids (Prednisolone). To determine differences in DMARD costs, each of the four 
DMARDs were analysed individually for the proportion of patients that were prescribed them and 
the mean dose. This COI study took the NHS perspective and so the cost for NHS service use, disease 
modifying medication and all medication was calculated for each patient with mean costs for each 
adherence group being used for analysis.  
The EQ5D (EuroQol Group, 1990; Dolan, 1997) consists of five components of quality of life scored on 
a three point scale (none – some – extreme) including; mobility, self care, usual activities, 
pain/discomfort and anxiety/depression. Using a weighted formula developed by the authors, a 
continuous index is generated ranging from 0 (death) to 1 (perfect health). The formula chosen for 
this study is generated from population Time Trade Off (TTO) measures in which participants are 
asked on the basis of the answers given in the EQ5D to decide how many years of remaining life 
expectancy they would exchange for perfect health (Jefferson, DeMicheli & Mugford, 2000). 
The EQ5D utility scores are used to calculate Quality Adjusted Life Years (QALYs) which combines the 
quantity of life years with the quality to provide a standard unit of health gain against which 
treatments for different ailments can be compared. QALYs are measured on an interval scale so 1 
QALY can represent one year of perfect health or two years at “half” of perfect health.  
QALYs are calculated by multiplying the length of time spent in a health state by the utility score 
associated with that health state (Whitehead & Ali, 2010). The EQ5D scores were measured at 
baseline and six months and so the change in QALY can be determined for these patients over time. 
To calculate the mean QALY for each adherence group and the incremental difference in utility, the 
EQ5D utility index at baseline was determined for a period of six months (utility score * 0.5) and the 
follow up utility score determined for the following six months.  
10.2.3: Costs 
The costs for each drug were taken from the British National Formulary 60 (BNF, 2010). The total cost 
per patient for the three medication types above was then calculated. The cost of a GP visit, 
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outpatient appointment, inpatient day and Accident and Emergency contact was taken from the 
Heath Unit Costs of Health and Social Care (PSSRU, 2010).  
10.3: Results 
10.3.1: Cross-sectional results 
Cross-sectional results were based on the responses of 227 patients with rheumatoid arthritis who 
completed questionnaires assessing adherence to DMARDs, quality of life and their current RA 
prescription.  
10.3.1.1: Adherence 
The CQR5 resulted in 25.5% of patients being classified as “low” intentional adherers, 19% as 
“forgetting” and 37.7% as “overall non-adherent”, which are consistent with published rates of non-
adherence (Haynes, 2001). There were no differences between gender or anti-TNF α status for any of 
the adherence types and so all subsequent analyses focused on the differences between adherence 
groups only. 
10.3.1.2: NHS service costs 
The mean, median, minimum and maximum GP costs for each adherence group are shown in Table 
10.1. There was a trend towards higher GP costs in the previous four weeks for self-reported high 
adherers, however this was not statistically significant.  
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Table 10.1: Mean (median, range) cost of medication for adherence groups (in 2010 GBP £) 
Group GP cost past 4 
weeks 
DMARD cost per year All medication cost per 
year 
DMARD cost per year 
excluding 
Leflunamide 
Intentional 
adherence 
    
Low  15.25                                   
(0, 0-72.00) 
142.37                              
(22.41, 0.33-944.22) 
2530.40                                   
(116.65, 0-9921.29) 
83.12                               
(21.74, 0.33-341.07) 
High  21.28                                 
(0, 0-144.00) 
77.15                                 
(18.25, 0.33-781.51)* 
2347.96                                    
(58.24, 0-9632.06) 
63.12                               
(17.90, 0.33-449.54) 
Unintentional 
adherence 
    
Forget 20.45                                  
(0, 0-144.00) 
160.58                               
(108.47, 0.66-928.20) 
2420.68                              
(138.01, 0-9914.32) 
92.78                        
(50.94, 0.66-330.98) 
Do not forget 19.45                                  
(0, 0-144.00) 
76.40                                  
(17.73, 0.33-944.22)* 
2393.18                            
(23.82, 0-9921.29) 
62.04                               
(17.73, 0.33-449.54) 
Overall 
adherence 
    
Not adhering 17.56                                          
(0, 0-144.00) 
139.25                                
(25.90, 0.33-944.22) 
2451.42                              
(122.56, 0-9921.29) 
83.46                              
(23.82, 0.33-341.07) 
Adhering 21.00                                 
(0, 0-144.00) 
63.87                         
(17.73, 0.33-626.42)* 
2342.98                                  
(22.94, 0-9632.06) 
58.53                                
(17.73, 0.33-449.54) 
*p<0.05     
 
10.3.1.3: DMARD and all medication costs 
When all medication costs are considered, including DMARDs, biologics and steroids, the mean cost 
is higher in self-reported low adherence although this is not statistically significant. However, Table 
10.1 indicates that the mean cost of DMARDs only for self-reported low adherence was 
approximately twice as much as for self-reported high adherence. One way ANOVAs showed that the 
mean DMARD costs were significantly higher for self-reported low adherence for intentional 
adherence; F(1, 214) = 4.95, p=0.03, unintentional adherence; F(1, 216) = 10.22, p=0.002 and overall 
adherence; F(1, 215) = 10.41, p=0.001. 
To identify the reason behind the increased DMARD costs for low adherers, the prescriptions were 
investigated in more detail. The number of patients prescribed each DMARD and the mean dose for 
those prescribed the drug only is shown in Table 10.2. There were no differences between the rates 
of prescription or the mean dose for Methotrexate or Hydroxychloroquine for any of the adherence 
types. However, patients who forget were 2.1 (1.5 : 2.7) times more likely and those with overall low 
adherence were 1.9 (1.3 : 2.5) times more likely to be prescribed Sulfasalazine. However, there was 
no significant difference between the mean doses.   
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Table 10.2: Mean dose of DMARDs for each adherence group  
 MTX 
(mg) 
N (%) SASP 
(mg) 
N (%) HCQ 
(mg) 
N (%) LFM 
(mg) 
N (%) 
Intentional 
 adherence 
        
Low 15.14 37 (64.4) 1722.22 18 (30.5) 257.14 7 (11.9) 18.75 4 (6.8)* 
High 
 
15.39 114 (72.3) 1618.42 38 (23.9) 284.21 19 (11.9) 16.67
 
3 (1.9) 
Unintentional 
adherence 
        
Forget 16.52 28 (65.9) 1447.37 19 (43.2)* 266.67 3 (6.8) 18.75 4 (9.1)* 
Do not forget 
 
15.06 123 (71.6) 1756.76
 
37 (21) 278.26 23 (13.1) 16.67 3 (1.7) 
Overall adherence         
Not adherent 15.98 56 (66.7) 1564.52 31 (35.6)* 244.44 9 (10.3) 19.17* 6 (6.9)* 
Adherent 14.95 95 (72.7) 1760.00
 
25(18.9) 294.12 17 (12.9) 10.00 1 (0.8) 
*p<0.05   
There were large differences between the prescribing patterns of Leflunamide. Intentionally low 
adherers were 3.6 (2.0 : 5.3) times more likely to be prescribed Leflunamide, those that forget were 
5.6 (3.9 : 7.3) more likely and those with overall low adherence were 8.6 (6.3 : 10.9) times more likely 
to be prescribed Leflunamide. The dose was also significantly higher for overall low adherence at 
nearly twice as much; t(5) = 4.16, p=0.01. As Leflunamide is much more expensive at 170p per 20mg 
dose compared to 6.7p per 20mg dose of Methotrexate (British National Formulary 60), and there 
were few other differences in dosing between the high and low adherers, it was anticipated that 
Leflunamide prescribing may be causing the higher DMARD costs in low adherers. Therefore, to test 
the sensitivity of the DMARD costs, Leflunamide was omitted (shown in the last column of Table 
10.1). In this case, although the mean DMARD costs were still higher for low adherers, the difference 
was no longer significant. 
In an attempt to identify why patients with low adherence in particular were being prescribed 
Leflunamide, the clinical notes of these patients were reviewed. Most were prescribed Leflunamide 
because of a lack of efficacy of Methotrexate, although little is known as to why Methotrexate did 
not maintain remission in these patients. One patient experienced intolerable side-effects with 
Methotrexate and so was swapped to Leflunamide and Methotrexate was contra-indicated in one 
patient because of alcoholic fatty liver disease.  
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10.3.2: Longitudinal results 
To determine the effects of medication adherence on medication and NHS service costs, a number of 
contacts were recorded prospectively over a six month period for all patients. Using baseline 
adherence scores, the costs were then calculated for all adherence groups with the aim of identifying 
disparities in NHS contact and costs for high and low medication adherers.  
10.3.2.1: Adherence 
A total of 56 patients were lost to follow-up at six months. See Chapter 8, section 8.2.2 for a full 
description of the patients at follow-up. In summary, there remained 42 patients with low intentional 
adherence, 121 with high intentional adherence, 24 who forget their medication, 140 who did not 
forget, 57 patients with overall low adherence and 107 with high overall adherence.  
10.3.2.2: NHS service costs 
The number of outpatient appointments, the number of “did not attend” (DNA) outpatient 
appointments, the number of inpatients days and the number of Accident and Emergency contacts 
for each patient was recorded from medical notes for the six months between recruitment into the 
study and follow-up. Using standardised costs from the PSSRU (2010), the total cost for each of these 
secondary care contacts was calculated for each of the baseline adherence groups and are shown in 
Table 10.3. To create an accurate representation of the groups as a whole, each patient was included 
when calculating the costs, regardless of whether they had had contact with the NHS or not.  
There was a trend for low adherers to attend more outpatient appointments as well as to DNA more 
appointments. This is reflected in the costs as low adherers had higher outpatient costs, particularly 
for intentional adherence with outpatient costs being approximately £50 more over the six month 
follow-up period. Although there was a larger difference between those who forget their medication 
and those who do not forget for the frequency of DNA appointments, than for intentional adherence, 
there was a smaller difference in total outpatient costs, although those who forget still had a trend 
towards higher outpatient costs than those who do not forget. Although the mean differences 
between high and low adherence groups for the number of outpatient appointments and the 
associated costs were not significantly different, it appears that over the six month period low 
adherers had more outpatient contact than high adherers.  
There was a different association for inpatient costs however as high adherers had more inpatient 
days resulting in higher costs, although the total number of inpatient days was very low for the entire 
sample at 175 days for 16 patients. The inpatient stays were a mixture of planned and emergency 
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with some being related to rheumatoid arthritis and some not. The increased Accident and 
Emergency and inpatient contacts generated by the high medication adherers mean that their total 
service use costs were higher than the low adherers, although the differences were not significant.  
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Table 10.3: Mean (median, range) cost of NHS service contacts over six months for baseline adherence groups (in 2010 GPB £) 
Group No. of 
outpatient 
appointments 
Cost of outpatient 
appointments 
No. of DNA 
outpatient 
appointments 
Cost of outpatient 
including DNAs 
No. of 
inpatient 
days 
Cost of inpatient 
stays 
No. of A&E 
contacts 
Cost of A & E 
contacts 
Total service use costs 
Intentional 
adherence 
         
Low  1.83 (2,  0-5) 289.67 (316,  0-790) 0.14 (0,  0-2) 312.24 (316,  0-790) 0.57 (0,  0-15) 137.14 (0,  0-3600) None None 448.38 (316,  0-3600) 
High  1.52 (1, 0-6) 240.26 (158,  0-948) 0.09 (0,  0-2) 254.63 (316,  0-1106) 1.25 (0,  0-60) 299.50 (0,  0-
14400) 
0.02 (0,  0-1) 1.60 (0,  0-97) 555.74 (316,  0-14716) 
Unintentional 
adherence 
         
Forget 1.67 (2,  0-5) 251.21 (316,  0-948) 0.21 (0,  0-2) 296.25 (316,  0-790) 0.83 (0,  0-12) 200 (0,  0-2880) None  None  496.25 (316,  0-3196) 
Do not forget 1.59 (1,  0-6) 260.56 (316,  0-790) 0.09 (0,  0-2) 264.85 (316,  0-1106) 1.12 (0,  0-60) 267.63 (0,  0-
14400) 
0.01 (0,  0-1) 1.40 (0,  0-97) 533.87 (316,  0-14716) 
Overall 
adherence 
         
Not adhering 1.65 (2,  0-5) 260.56 (316,  0-790) 0.14 (0,  0-2) 282.74 (316,  0-790) 0.77 (0,  0-15) 185.26 (0,  0-3600) None None  468 (316,  9-3600) 
Adhering 1.58 (11,  1-6) 248.92(158,  0-948) 0.08 (0,  0-2) 262.34 (316,  0-1106) 1.24 (0,  0-60) 296.60 (0,  0-
14400) 
0.02 (0,  0-1) 1.83 (0,  0-97) 560.77 (316,  0-14716) 
 
Table 10.4: Mean (median, range) cost of medication at six month follow-up for baseline adherence groups (in 2010 GBP £) 
Group DMARD cost per year Biologic cost per year All medication cost per year DMARD cost per year excluding 
Leflunamide 
Intentional adherence     
Low  165.89 (18.77,  0-3730.63) 2916.40 (0,  0-9295.52) 3082.76 (137.16,  0-9916.02) 62.30 (17.55,  0-337.96) 
High  93.69 (19.81,  0-3893.46) 3238.57 (0,  0-9295.52) 3332.99 (186.97,  0-9922.47) 52.60 (19.81,  0-452.81) 
Unintentional 
adherence 
    
Forget 366.71 (23.82,  0-3893.46)** 3941.80 (436.58,  0-9295.52) 4309.63 (3814.65,  0-9324.54) 55.85 (23.12,  0-337.96) 
Do not forget 68.37 (18.25,  0-627.47) 3941.80 (436.58,  0-9295.52) 3088.75 (132.59,  0-9922.47) 54.97 (17.73,  0-452.81) 
Overall adherence     
Not adhering 199.52 (93.15,  0-3893.46)* 3541.89 (0,  0-9295.52) 3742.21 (221.32,  0-9916.02) 57.74 (17.73,  0-337.96) 
Adhering 65.39 (19.81,  0-627.47) 2947.81 (0,  0-9295.52) 3013.79 (155.32,  0-9922.47) 53.68 (19.03,  0-452.81) 
*p<0.05,  *p<0.001     
1
8
0
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10.3.2.3: DMARD and all medication costs 
The same method to calculate the medication costs for patients using the prescription at six months 
as at baseline was used and is shown in Table 10.4. A similar pattern of prescribing and costs was 
found as at baseline with low adherers having significantly higher DMARD costs but that overall 
medication costs do not differ. Again, the increased incidence of Leflunamide prescribing for low 
adherers accounted for the significantly increased DMARD costs. 
The dose of each DMARD decreased over the six months for all adherence groups with the exception 
of Leflunamide which increased by 2.50mg for patients who reported forgetting (see Appendix 10.1). 
There were also a number of changes with regards to which DMARD was prescribed with some 
patients starting and stopping each of the drugs in every adherence type (see Appendix 10.2). 
However, there remained a higher percentage of low adherers being newly prescribed Leflunamide.  
10.3.2.4: Quality of life and adherence to DMARDs  
Patients completed the EQ5D at baseline and six month follow-up and a utility score was calculated 
for each patient for both time-points. As shown in Chapters 7, 8 and 9, the EQ5D index ranges 
between approximately 0.55 and 0.65 for the different treatment and adherence groups. This 
demonstrated that the quality of life of these patients is not high, although it is in line with previous 
research of rheumatoid arthritis patients (Whitehead & Ali, 2010). 
Chapters 7 and 8 demonstrate that the HRQoL of patients with low adherence was higher than those 
with high adherence. There was an interaction between HRQoL and both age and disease activity, 
both of which were shown to impact on adherence so that patients with low disease activity and low 
adherence had higher quality of life. The EQ5D scores were relatively stable over time for each 
adherence group showing little variation over six months.  
10.3.2.4.1: Incremental difference in EQ5D utility scores  
To investigate how the EQ5D utility score may be related to changing adherence, the baseline and six 
month scores were assessed for those whose adherence changed only. There was more variability in 
EQ5D scores for those whose adherence status changed than for those who stayed the same, 
however the change was very small at a magnitude of approximately 0.05. An exception to this was 
for patients who reported forgetting DMARDs at baseline but changed to not forgetting at six months 
with EQ5D scores of 0.38 and 0.54 respectively, showing a moderate increase in quality of life for 
those who started remembering to take their DMARDs.  
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To compare those who forgot their medication at baseline and then did or did not start remembering 
at six months, the incremental difference in utility was calculated for both groups of patients. The 
QALYs for the first and second six months were determined and the difference between them 
calculated. The calculations are shown in equations 10.1 and 10.2. 
 
 Patients who forget at baseline (EQ5D = 0.38) and did not forget at six months (EQ5D = 0.54) 
QALY = (0.5*0.38) + (0.5*0.54) 
QALY for patients who forget at baseline and do not forget at six months is 0.46  
Equation 10.1 
 
Assuming that EQ5D remains at 0.38 for patients who remain forgetting 
QALY = (0.5*0.38) + (0.5*0.38)  
QALY for patients who remain forgetting is 0.38 
Equation 10.2  
 
The incremental difference in utility for patients who forget to take DMARDs at baseline but did not 
forget at six months was 0.08 and is shown in graphical form in Figure 10.1. Area A represents the 
EQ5D index at 0.38 for all patients who forgot at baseline for half a year. Area B represents the 
continued EQ5D index at 0.38 for patients who remained forgetters for the following half a year. 
Area C represents the incremental increase in EQ5D index of 0.08 to 0.54 for patients who did not 
forget their DMARDs for the following half a year.  
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Figure 10.1: Incremental increase in QALY for patients who forget their DMARDs at baseline but do not forget 
at six month follow-up 
 
For the current sample, seven patients who forgot their DMARDs at baseline subsequently did not 
forget at six months and so there was an overall gain of 0.56 QALYs. To gain 1 Quality Adjusted Life 
Year, it would be necessary for 13 patients to improve from forgetting their DMARDs to not 
forgetting.  
10.4: Discussion 
This study aimed to provide a health service provider perspective of the costs associated with 
adherence to DMARDs by patients with rheumatoid arthritis in a prospective longitudinal study. As 
this type of cost of illness study has not been previously carried out in rheumatoid arthritis, there 
was little previous research on which to base hypotheses, however it was anticipated that patients 
with low adherence would generate higher costs and that the health related quality of life would 
differ for high and low medication adherers.  
10.4.1: Medication costs related to adherence to DMARDs 
Although overall medication costs were higher for low adherers cross-sectionally, this was not 
significant. This is likely to be influenced by the fact that 37% of patients were prescribed a biologic 
medication which is very expensive, thus reducing the effect of small changes in other areas. This is 
supported by a study by Borah, Huang, Zarotsky & Globe (2009) who estimated adherence to 
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biologics by RA patients and found that high (>80%) adherers had significantly higher health care 
costs, mainly due to the high cost of biologic medication. To compensate for this, the cost of 
DMARDs only was calculated and it was found that low adherers, particularly those who forget had 
significantly higher DMARD costs. Further inspection found that this was directly due to increased 
prescribing of Leflunamide for these patients, a trend which continued longitudinally. Although not 
formally identified and recorded, a lack of Methotrexate efficacy or intolerable side-effects may have 
prompted patients to be non-adherent which could explain why these patients were more likely to 
be prescribed Leflunamide. Although Leflunamide has been shown to be efficacious where 
Methotrexate has previously failed (Kremer et al., 2002; Osiri et al., 2003; Strand et al., 1999), a cost-
effectiveness modelling study by Schipper et al. (2011) demonstrated that starting patients on 
Methotrexate plus Leflunamide provided no additional benefits on either disease activity or HRQoL 
but had substantially higher costs with an incremental cost-effectiveness ratio of €437,930 compared 
to €133,000 for Methotrexate monotherapy. The results of the current study indicate that there 
appears to be a particular prescribing pattern for patients with low medication adherence which 
makes them more likely to be prescribed the more costly Leflunamide. It is beyond the scope of this 
study to speculate as to the reasons why this may be the case but given that there appears to be no 
additional benefit for patients (Schipper et al., 2011) this is an area that requires more investigation 
to determine how adherence and Leflunamide prescribing are related to make healthcare 
practitioners more aware of the impact that adherence has on the cost of medications.  
10.4.2: NHS service costs related to adherence to DMARDs 
Based on research into Type II Diabetes (Balkrishnan et al., 2003) and urinary incontinence 
(Balkrishnan et al., 2006), it was hypothesised that the total costs would be higher for patients with 
low adherence than high adherence. However, the costs obtained showed differing results. There 
were no significant differences for total direct costs for any of the adherence groups, although when 
including biologic medication, there was a tendency for high adherers to have higher costs except for 
overall low adherers who had higher costs than high adherers. With biologics excluded, overall low 
adherers and forgetters had higher total costs but the difference was very low. The increased costs 
were mainly due to a larger number of inpatient days for higher adherence, which is consistent with 
the make-up of direct costs (Zhu et al., 2011). Based on the cross-sectional and longitudinal results 
for the main study (see Chapters 7 and 9), it is not surprising that the high adherers had more 
inpatient days as they tended to have worse RA disease activity and more disability than low 
adherers. This suggests that adherence is a product of disease activity and associated NHS contacts, 
rather than adherence causing increased service use, which has been suggested by Balkrishnan et al. 
(2003) and Balkrishnan et al. (2006). This discrepancy could in part be due to the fact that the 
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average disease duration for these patients was 12 years, meaning the disease would be well 
developed which is influencing adherence more than in an illness that is less progressive. There was 
also a very short follow-up on which to base service use costs which may underestimate the causal 
effect of adherence on NHS contacts. It would therefore appear that more adherent patients are in 
fact more costly to the NHS; however a longer follow-up may provide more insight into the 
relationship between adherence and costs.  
10.4.3: Quality of life related to adherence to DMARDs  
As little research has investigated quality of life in relation to medication adherence, the aim of this 
study was to provide some of the first information to describe HRQoL for RA patients with high and 
low adherence to DMARDs. In general, the QALY scores were quite low at between 0.55 and 0.65; 
however this is not uncommon for RA patients (Staples, March, Lassere, Reid & Buchbinder, 2011; 
Suarez-Almazor & Conner-Spady, 2001). There was a difference in EQ5D scores, but unexpectedly, 
they were generally higher for low adherers. This is again likely to be due to the interaction with 
disease activity with patients with low activity and low adherence having particularly high QALY 
scores whereas those with high adherence and high activity having very low EQ5D scores. However, 
it was found that patients who forget their DMARDs at baseline but then start to remember had a 
0.08 improvement in QALY scores. Although this gain seems very small, it nonetheless represents a 
desirable gain in quality of life. A study by Staples et al. (2011) showed that patients treated with 
biologic medication had an incremental QALY gain of 0.16 over six months whereas patients treated 
aggressively with DMARDs had a 0.19 incremental QALY gain over five years (NAO, 2009). The 
current study suggests that simply enabling patients to remember to take their medications could 
provide some improvement in quality of life. This should be further investigated with intervention 
studies that not only measure adherence but also HRQoL.  
10.5: Conclusions 
The results of this cost of illness study have provided valuable information relating to NHS service use 
and associated costs by RA patients that self-report high and low adherence to DMARDs. There was 
evidence that prescribing patterns differ for patients with low adherence, particularly those who self-
report forgetting their medication with these patients more likely to be prescribed Leflunamide, 
resulting in significantly higher DMARD costs. This association was previously unknown and provides 
valuable information for prescribers to monitor and establish why this may be the case. These 
preliminary results demonstrate the need to more formally establish the prescribing patterns for 
high and low adherent patients and the reasons behind this in the future. However, these differences 
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did not affect the total direct costs for adherence groups and with more wide-spread use of biologic 
medication, these differences may not be apparent in the future. This study does provide evidence 
that adherence should be carefully monitored in relation to prescribing practices in the future, 
particularly as more biologic medication becomes self-administered and therefore vulnerable to the 
same possible sub-optimal self-management as traditional DMARDs.  
Although the costs of adherence have been largely neglected in the literature, this study provides 
preliminary evidence that as well as being an outcome in itself, improved adherence could lead to a 
potential monetary saving as well as a gain in quality of life. More research should focus on this 
relationship over a longer follow-up period and incorporate more indirect costs through sick days 
and early retirement to create a fuller economic picture of the effects of non-adherence to DMARDs 
in rheumatoid arthritis to strengthen the argument for an increased awareness and clinical utility of 
addressing medication adherence in the clinic.  
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Chapter 11 
Using an electronic reminder service to increase adherence to 
DMARDs and improve quality of life: Applying theory to practice in a 
simulated cost-utility study 
11.1: Introduction 
The ultimate aim of research into adherence to treatment in chronic illness is to understand which 
patients struggle to adhere to their regimen and why. This allows interventions to be designed and 
implemented based on this knowledge to improve adherence with the aim of improving prognosis 
and quality of life for patients. Although there has been a raft of research into the reasons behind 
non-adherence which has led to a number of systematic reviews (DiMatteo, 1994, 2004; Haynes, 
2001; Haynes et al., 2007; WHO, 2003), there has been considerably less attention on evaluating 
interventions, with the overall comparability being poor due to heterogeneous samples and non-
standard designs and outcomes (Nichol, Venturini, Sung, 1999). Systematic reviews by McDonald et 
al. (2002) and Kripalani et al. (2007) found varying degrees of success at improving adherence and 
clinical measures in chronic illness interventions. Simple behavioural measures such as reducing the 
dose burden generally improved adherence in the short-term although this was not always sustained 
(Baird et al., 1984; Brown et al., 1997; Girvin, McDermott & Johnston, 1999). Otherwise, the most 
effective interventions were multifaceted, involving behavioural, educational and communication 
strategies as well as reminders and psychological training (Bailey et al., 1990; Gallefoss & Bakke, 
1999). Even with these complex and labour intensive interventions, the effect on adherence was not 
strong over time and clinical improvement was negligible (Berrien, Salazar, Reynolds & McKay, 2004; 
Tuldra et al., 2000). Although these interventions did not report the total cost of implementation; 
due to the complexity, it is likely that they would be very expensive with little benefit reducing their 
cost-effectiveness. It is therefore essential for researchers to start targeting interventions directly 
towards patients who require them and to acknowledge that different types of non-adherence (i.e. 
intentional and unintentional) are likely to require different methodologies (Lehane & McCarthy, 
2007). 
Chapter 9 showed that unintentional non-adherence is a substantial problem for patients with 
rheumatoid arthritis with 20 patients who did not report forgetting DMARDs at baseline 
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subsequently reporting forgetting at six months, in addition to the 17 patients who remained 
forgetters. Chapters 7 and 9 demonstrated that the social cognition models had little impact in 
explaining forgetting, with only factors measuring Perceived Behavioural Control and social support 
able to explain any of the variance. This suggests that a simple reminder could act not only as a cue 
to take the DMARDs but could increase confidence and self-efficacy as the patient becomes more 
able to successfully manage their medication. In addition to this, Chapter 10 showed that patients 
who improved from forgetting at baseline to not forgetting at six months had an incremental QALY 
gain of 0.08 suggesting that HRQoL could be improved in these patients simply by enabling them to 
remember to take their DMARDs. If this were possible, it could provide a very simple avenue to 
improve the quality of life of patients with a serious disease who generally have a lower QoL than the 
general public (Whitehead & Ali, 2010). 
As discussed in Chapter 4, a simple SMS message reminder could act as the cue to help patients to 
remember to take their medications. A study by Villella et al. (2004) found that SMS reminders 
improved adherence to Hepatitis A and B vaccinations by between 13.7% and 17.2% in real terms. 
Similarly, a study by Petrie, Perry, Broadbent & Weinman (2011) improved adherence to asthma 
preventer medication by 15% by using SMS messages to address maladaptive illness perceptions in a 
sample of young asthma patients. As well as addressing perceptions of the illness and treatment, as 
the SMS messages were all related to asthma and preventer medication, they would also act as 
reminders to patients who had a tendency to forget. These studies suggest that an SMS reminder has 
the potential to improve adherence to medication by approximately 15%. Although it may be 
expected that patients with a generally older age would not be contactable via this relatively new 
technology, the results of the technology use survey of RA patients in Chapter 5 shows that up to age 
65, the majority of patients are already regularly using mobile phones and SMS messaging. Based on 
the evidence presented in this programme of research, as well as previous studies by other 
researchers, this chapter aims to cost the potential of an SMS reminder in this patient sample and 
the cost per QALY gain in a simulated cost-utility analysis. The aim is to provide some preliminary 
evidence of putting the theory of medication non-adherence into practice using the evidence 
gathered from a number of previous chapters.  
11.2: Methodology 
11.2.1: Patients 
The sample of patients on which this analysis is based is described in Chapter 8, and focuses 
specifically on 42 patients who self-reported forgetting DMARDs at baseline but self-reported not 
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forgetting at six months. The health related quality of life of these patients was measured at baseline 
and six months using the EQ5D and the incremental QALY gain was calculated to be 0.08 (see 
Chapter 10, section 10.3.2.4.1).  
11.2.2: Procedure  
The technology use survey in Chapter 5 asked similar patients about their usual use of information 
and communication technology including email and SMS messages. One of the questions asked 
patients how confident they are in reading text messages (Chapter 5, section 5.3.3) and the answer 
to this question was used to base the accessibility and acceptability of an SMS reminder service in 
this sample.  
The likely success rate and cost of improving adherence to medications through an SMS reminder 
was based on previous research that is presented in the systematic review in Chapter 4. In addition, a 
recent study by Petrie et al. (2011) reported the success rate of an SMS based intervention to 
improve adherence to asthma preventer medication. 
Using the combined information above, a simulated cost-utility analysis was carried out based on 
sending SMS message reminders to the 42 patients who reported forgetting DMARDs at baseline to 
increase their adherence and therefore HRQoL over a one year period. The total cost per year for this 
sample and the cost per QALY gained were calculated. To test the robustness of the cost per QALY 
gained, a sensitivity analysis was carried out by changing the assumptions of i) the number of 
messages sent over one year, and ii) the cost per SMS message.  
11.3: Results 
The average age of patients who self-reported forgetting DMARDs at baseline was 49 years (see 
Table 7.6). Based on the results of the survey in Chapter 5, 90% of patients aged 45-54 were 
confident in reading SMS messages and would therefore be contactable. In the current sample, 42 
patients reported forgetting at baseline (Chapter 7) meaning that 38 patients would be contactable 
via SMS message. At an assumed improvement rate of 15% for unintentional non-adherence, as 
found by Petrie et al. (2011) and Villella et al. (2004), it could be assumed that six patients would 
experience the 0.08 increase in QALY scores that was calculated in Chapter 10. This would result in 
an overall QALY increase of 0.48 for the entire forgetting sample. To determine the cost per QALY 
gained, the total cost for sending the reminders should be divided by 0.48. In a study carried out by 
Koshy, Car & Majeed (2008) in the UK, the authors report the cost of an SMS reminder as 7.2p. Table 
11.1 shows the results of a sensitivity analysis for the cost per QALY of sending SMS medication 
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reminders to the current sample. Two key elements of the reminder service were tested; firstly, the 
frequency of reminders was set at either daily (365 messages) or weekly (52 messages). Secondly, 
the cost per SMS message was set at 10p each to be conservative and at 7.2p each as reported by 
Koshy et al. (2008).  
 
Table 11.1: Sensitivity analysis showing the cost per QALY gained (in GBP £) using a reminder service for 
patients who forget their medications 
Assumed cost of SMS 
message 
Total SMS cost for forgetting group (£) Cost per QALY gained (£) 
365*10p 1387 2889.58 
365*7.2p 998.64 2080.50 
52*10p 197.60 411.67 
52*7.2p 142.27 296.40 
 
Table 11.1 clearly demonstrates that the frequency of the SMS messages and the cost per message 
impacts strongly on the cost per QALY gained. The cheapest method would be to send a weekly 
message with an assumed cost of 7.2p per message which results in a cost per QALY gained of 
£296.40 which would demonstrate an incredibly cheap method to improve quality of life in 
rheumatoid arthritis patients. Sending a daily message at an assumed cost of 10p per message results 
in a cost per QALY gained of £2889.58 which is substantially more than a weekly message but still 
very cheap when compared to other methods to improve quality of life. As previous studies have 
demonstrated that daily messages are not well tolerated (Anhoj & Moldrup, 2004) and that some 
patients will only be prescribed weekly Methotrexate, an SMS reminder service that provides weekly 
medication reminders for the current sample of 38 eligible patients would cost between £197.60 and 
£142.27 per year and result in a cost of between £411.67 and £296.40 per QALY gained.  
11.4: Discussion 
The sensitivity analysis of the cost per QALY gain suggests that in this sample, the cost to gain one 
QALY would be between £296.40 and £2889.58 which is well below NICE’s unofficial threshold of 
£20,000 per QALY gain (Devlin & Parkin, 2004) and considerably less than adding biologic medication 
to the regimen. Although a true cost-utility analysis could not be carried out because the incremental 
QALY gain was not directly derived by the proposed intervention, this simulation study provides 
some preliminary evidence for the likely cost of an electronic reminder service with the potential to 
improve adherence and HRQoL. A randomised controlled trial by Elliott, Barber, Clifford, Horne & 
Hartley (2008) calculated the cost-effectiveness of a telephone based pharmacist-delivered 
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intervention to increase adherence to new medications for patients with a chronic illness (including 
RA). The incremental cost-effectiveness ratio was -£2168 showing that the intervention was both 
more effective (at improving adherence) and less costly (reduced inpatient, outpatient and A&E 
contacts) than usual care. Studies by Elliott et al. (2008), Petrie et al. (2011), Villela et al. (2008) and 
the results from the current study provide some evidence that a tailored distance or electronic 
adherence intervention could prove to be both effective in reducing the costs associated with non-
adherence to medication but also be cost-effective by providing cheap administration opportunities.  
11.5: Conclusion 
Although there is evidence suggesting that SMS reminders could provide a cheap and low-intensity 
method of improving medication adherence, neither this study nor those mentioned above have 
truly measured the potential for this type of service. Therefore it is imperative that future research 
implements a similar reminder service and robustly measures the costs and benefits (in adherence 
and quality of life) to provide a more accurate account of the cost-effectiveness and cost-utility to 
inform clinical practice. 
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Chapter 12 
General Discussion 
12.1: Summary of the aims of this programme of research 
The psychology of medication non-adherence has been explored in other chronic illnesses; however 
the psychological predictors have not been effectively established in rheumatoid arthritis. As there 
are a number of social cognitive models of illness available, there is currently a lack of consensus of 
which factors are implicated in adherence to DMARDs.   
The Self Regulatory Model and Beliefs about Medications have been investigated in rheumatoid 
arthritis with regards to psychological outcomes (Scharloo et al., 2000) and adherence (de Thurah et 
al., 2010; Goodacre & Goodacre, 2004; Treharne et al., 2005), however there is currently not enough 
evidence to establish which models provide the best explanation of adherence. The aim of this 
programme of research therefore was to establish the best ways to measure intentional and 
unintentional non-adherence to DMARDs, to measure a number of commonly used social cognition 
models of illness to establish which was the best predictor of non-adherence and to establish the 
monetary effects of non-adherence with respect to health service utilisation. Only one other study 
has measured more than one social cognitive model in adherence with Orbell et al. (2006) identifying 
that the Theory of Planned Behaviour explained a large amount of variation in intention to attend 
follow-up colposcopy treatment appointments but with neither the Theory of Planned Behaviour nor 
the Self Regulatory Model reliably predicting actual attendance. As adherence to medication in a 
chronic illness is expected to have a different psychological mechanism (Fishbein, 1993; Hagger & 
Orbell, 2003), a similar approach was used in this programme of research to identify the best 
predictors of adherence to DMARDs by RA patients.  
There were four parts to this research with the aim of providing a coherent and complete analysis of 
the importance of adherence to treatment in RA. Firstly, the feasibility of using Information and 
Communication Technology (ICT) was assessed and tested through a simulation study as a potential 
administrator of a simple reminder service. Although it is beyond the scope of this research to have 
designed and tested an intervention because there was not enough evidence in the literature on 
which to base one, the information presented in Chapters 4 and 5 indicate that it would be possible 
and desirable to use SMS messages to implement reminders to patients up to 65 years old. The focus 
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was then on how to measure adherence in this patient group with an established self-report 
measure being reduced to increase the clinical utility and to remove the redundant items (Chapter 
6). A large prospective longitudinal study was then carried out with 227 patients at baseline and 171 
followed-up over 6 months specifically measuring both intentional and unintentional non-adherence. 
This allowed for the effects of social cognition models on adherence over time to be evaluated, 
which has not been previously done to a high standard in RA (Chapters 7, 8 and 9). This also allowed 
for all three of the most commonly used models of illness to be tested simultaneously to determine 
which aspects are most useful in predicting medication non-adherence and offering some evidence 
of psychological factors to target in future interventions. Finally, a health economic analysis was 
carried out to establish the cost of non-adherence which has been very rarely done in any chronic 
illness with no published work in RA. The aim of the economic analysis was to highlight the 
importance of non-adherence and to provide stronger evidence for clinicians and decision makers 
that adherence is an important area to tackle and that it can be done in a cost-effective way to 
improve QoL and prognosis for patients.  
12.2: What this research has added to the current evidence base 
A number of results and conclusions can be drawn from this programme of research that have added 
to the current literature around adherence to treatment in chronic illness. 
1. The CQR5 is a shortened form of a self-report adherence measure that could be used in the 
rheumatology clinic to regularly screen for low medication adherence (Chapter 6). 
2. It is important to consider newly diagnosed patients separately, particularly when 
investigating social cognition models of illness or adherence as they have a very different 
experience to more established patients (Chapters 7 and 8). 
3. Adherence is a substantial problem in rheumatoid arthritis. However, it is important to 
measure intentional and unintentional non-adherence separately as they appear to have 
different psychological underpinnings (Chapters 7 and 9).  
4. In order to understand the complexities and nuances of adherence to chronic medication, 
the mediating and moderating effects of psychological factors on adherence need to be 
investigated (Chapter 9). 
5. An accurate representation of RA (i.e. higher perceptions of chronicity, consequences and 
the necessity of DMARDs) results in higher adherence (Chapter 9).  
6. Aspects of the Theory of Planned Behaviour, Self Regulatory Model and Beliefs about 
Medications are predictive of adherence to DMARDs; however the Health Belief Model does 
not accurately predict adherence (Chapters 7 and 9). 
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7. The health economic analysis showed varying results with regards to adherence and health 
service costs. However, in order to justify interventions that improve the self-management of 
illness, researchers need to start evaluating and reporting the cost-effectiveness in order to 
compete for the finite resources that are available (Chapter 10).  
8. ICT is a viable and underused method of engaging and communicating with patients which 
could provide a cheap and more acceptable method than face to face contact for patients up 
to 65 years old (Chapters 4, 5 and 11). 
12.3: Social cognition models of illness in rheumatoid arthritis patients  
The review of the commonly used social cognition models of illness in Chapter 2 demonstrated that 
they are based on the assumption that patients carry out a cost-benefit analysis of performing the 
health behaviour (in this case taking medication) and come to a logical conclusion based on the 
information available for the analysis. This means that as patients become more experienced with 
their illness and gather more information, the cost-benefit decision may be altered prompting 
changes in adherence to medication. Leventhal, Meyer & Nerenz (1980) explicitly state that the Self 
Regulatory Model is adaptive to patients’ experience and therefore patients will “regulate” their 
illness representation accordingly. However, very little research has studied the regulation and 
adaptation over time, particularly for patients that have been newly diagnosed with a chronic illness 
in whom less stability would be expected given the rapid accumulation of knowledge and experience 
over a short period of time. The results shown in Chapters 7 and 8 support the regulation of social 
cognition models based on experience as newly diagnosed patients differed significantly on the 
psychological sumscores compared to established patients and had more variation over the six 
month study period. This was particularly true for the Self Regulatory Model and the Beliefs about 
Medications with perceptions of severity of RA, the chronicity and efficacy of treatment and the 
patient to control the illness being more subject to change than aspects of the Theory of Planned 
Behaviour or Health Belief Model.  
The relative stability of the Theory of Planned Behaviour and Health Belief Model across all patients 
calls into question the applicability to explain behaviours in chronic illness as it would be expected 
that perceptions of severity, barriers, benefits and self-efficacy would change as the patient becomes 
more experienced. Although these models were primarily designed to explain preventive health 
behaviours such as exercise uptake (Ajzen, 1988, 1991; Rosenstock, 1966), they have been used 
separately to explain behaviours in chronic illness. The lack of sensitivity that they appear to display 
in detecting changes in patients’ experience suggests that they are not suitable for use in chronic 
illness.  
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As well as providing evidence for the regulation proposed by Leventhal et al. (1980), the variability 
shown by the newly diagnosed patients but not the more established patients in both the 
psychological measures and adherence shows that these patients should be considered separately in 
future research, something which only a minority of previous research has considered (de Thurah et 
al., 2010; Goodacre & Goodacre, 2004). As well as separating them for informative research 
purposes, the lack of stability suggests that interventions to address adherence should be aimed at 
patients as they are starting a new treatment in order to guide them towards beneficial, adaptive 
perceptions that promote good adherence.  
12.4: Predicting and explaining adherence to DMARDs in rheumatoid arthritis 
Using a measure of intentional adherence that was refined in Chapter 6 (CQR5) along with a measure 
of unintentional adherence (RAM), the different types of adherence to DMARDs were evaluated. The 
overall non-adherence rate was 37.5% at both baseline and six months which is at the low end of 
published rates (Barber et al., 2004; DiMatteo, 1994; Dunbar-Jacob et al., 2000; Haynes, 2001).  Rates 
of forgetting were quite low at 18.6% (baseline) and 21.6% (six months) compared to other illnesses 
(Atkins & Fallowfield, 2006; Lehane & McCarthy, 2007). This may be because there were a lot of 
older patients who have been shown previously to not forget because they use more cues and 
organisers than younger patients (Elliot et al., 2007; Hertzog et al., 2000; Kippen et al., 2005) but 
could also be related to the fact that non-responders at six months were more likely to report 
forgetting at baseline. The fact that some patients reported either intentional or unintentional non-
adherence highlights the importance of measuring the two types of adherence separately in order to 
gather a more accurate picture of medication taking behaviour. Unintentional non-adherence also 
appears to effect different patients as those that are younger, newly diagnosed and working are 
more likely to report forgetting their DMARDs than older, more experienced patients, which supports 
previous research (Elliot et al., 2007; Hertzog et al., 2000; Johnson, 2002). There also appears to be 
different underlying psychological mechanisms related to forgetting which will therefore require 
different interventions to improve. It was hypothesised that the social cognition models would not 
explain a large amount of variance in unintentional non-adherence because it is assumed to not be 
related to a deliberate decision to not take medication. This was mostly supported in the data as only 
TPB Perceived Behavioural Control was significantly associated with forgetting which could be as a 
result of patients being aware that they struggle with remembering their medication and so are 
acknowledging their difficulties upon questioning.  
This was the first study in rheumatoid arthritis to specifically separate intentional and unintentional 
adherence. As the social cognition models were not adequate in predicting or explaining forgetting 
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DMARDs, it appears that a reminder or cue could provide a simple way of reducing this type of non-
adherence. As changing perceptions to improve intentional non-adherence would be a complex and 
expensive procedure, the possibility of improving quality of life and prognosis with a simple 
intervention is highly desirable. The results of the simulated cost-utility analysis in Chapter 11 
suggest that SMS reminders sent to patients could provide an immediate, portable, cheap method of 
reminding patients about not only their medications but also other treatment requirements such as 
blood tests and outpatient appointments. As discussed in Chapter 1, there are a number of demands 
placed on patients, particularly in the first months following diagnosis that continue throughout the 
course of the disease, regardless of disease activity, such as twice-annual outpatient appointments 
and eight-weekly blood tests for most DMARDs. As the results from the cross-sectional (Chapter 7) 
and longitudinal studies (Chapter 9) into medication adherence suggest that these omissions are 
unrelated to perceptions about the illness or treatment and are therefore genuine memory lapses, 
patients may be receptive and appreciative for this type of reminder. This would have even more 
impact as the penetration of this media increases in the older generation and more patients are able 
to remain working following improved treatment, causing more conflict with hospital appointments. 
The popularity of using ICT for interventions is becoming more apparent (see Chapter 4), however 
more research is required to establish the optimum regimen as well as the latency of the effect after 
the messages are stopped. In order to justify these simple reminders, there is also a requirement of 
researchers to calculate the cost-effectiveness and cost-utility of these interventions in order to 
justify the expenditure compared to other methods.  
Using the Theory of Planned Behaviour, Health Belief Model and Self Regulatory Model as well as 
Beliefs about Medications allowed for all of these models to be evaluated and compared for their 
ability to explain and predict non-adherence to DMARDs. This is the first study that has used all of 
these models in rheumatoid arthritis and one of a minority that has explored adherence and social 
cognition models in a prospective longitudinal study with a large sample of patients. The rationale 
behind using all of these models was that they are all commonly used to explain health behaviour but 
there is a certain degree of assumed collinearity as they measure similar latent factors. There is 
currently a lack of good quality intervention studies addressing adherence (Kripalani et al., 2007; 
McDonald et al., 2002; Peterson, Takiya & Finley, 2003; Roter et al., 1998) and by establishing exactly 
which factors of which models are associated with adherence would enable more targeted and 
effective interventions to be designed and tested. It was found both cross-sectionally and 
longitudinally that the Health Belief Model did not effectively predict non-adherence. This may be 
due to the fact that similar concepts are measured by the SRM in a way that is more appropriate for 
chronic illness. Therefore, although the HBM directly measures concepts that are inherent in the 
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cost-benefit decision of health behaviours, it would appear that it is not a suitable model to use to 
explain medication adherence in rheumatoid arthritis.  
As has been found previously, perceptions of the illness and the treatment were best able to predict 
non-adherence to DMARDs in this study. This was true both for the logistic regression analyses and 
the structural equation modelling (SEM). The benefit of the current study is that baseline 
psychological models were used to predict adherence six months later. This starts to provide 
evidence for a causal relationship and indicates which areas may be best targeted for intervention. A 
more powerful method of evaluating causal paths is to use SEM, a method which has been previously 
employed by very few researchers (Horne & Weinman, 2002; Nicklas et al., 2010) and not at all in 
rheumatoid arthritis. As the SEM was much better at explaining adherence longitudinally than each 
of the models separately or combined in simple regression analyses, it is clear that this type of causal 
analysis is necessary for researchers to carry out in the future to determine the mediators and 
moderators of adherence. For example, it was shown that higher perceptions of DMARD necessity 
were directly related to higher adherence, but in the univariate analysis in Chapter 7, it was shown 
that all of the patients had high necessity perceptions; including those with low intentional 
adherence. Therefore, knowing that higher perceptions of consequences, chronicity and emotional 
response influence DMARD necessity, allows for manipulation of them to either raise perceptions of 
necessity further or make it a more prominent part of the cost-benefit analysis. This has been carried 
out with some success with asthma patients (Petrie et al., 2011), but as illness perceptions in 
particular are unique to each illness (Hagger & Orbell, 2003), this type of analysis that identifies the 
predictive factors is necessary for future interventions in RA.  
However, the results reported here need to be carefully considered in relation to both the illness in 
question and the desired outcome. For example, many previous studies have suggested that 
perceptions related to increased severity and chronicity result in worse psychological outcomes 
(Hagger & Orbell, 2003; Schiaffino & Revenson, 1992), however the opposite was found in relation to 
DMARD adherence in these RA patients. Part of this is likely to be related to the fact that illness 
perceptions are expected to differ depending on the aetiology of the illness (Hagger & Orbell, 2003) 
as a perception of a chronic, potentially serious illness with a number of symptoms that is not 
necessarily easily controlled through conventional DMARDs is a more accurate representation than a 
less serious, acute perception. This has also been shown in asthma as patients with a more chronic 
illness perception had better adherence to preventer medication when they were asymptomatic 
than patients who had an acute representation dictated solely by symptoms (Horne & Weinman, 
1998). Leventhal et al. (1980) propose that the symmetrical relationship between symptoms and 
disease labels are at the core of the regulation process, meaning that it would be expected that 
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patients would only be aware of their illness when they are experiencing symptoms. The presence of 
symptoms would therefore stimulate performance of the appropriate health behaviours; however, it 
is possible that this is maladaptive within a chronic, progressive illness such as RA where medication 
adherence during remission to prevent joint erosion is imperative. By accepting the reality of the 
illness, these patients may be more aware of the “benefit” part of the cost-benefit decision to take 
medications than others. This is also likely to be somewhat specific to medication taking as it has 
been shown that rates of depression are higher in patients with the more serious illness perceptions 
(Schiaffino & Revenson, 1992) which may be as a result of a realistic assessment of the likely 
outcomes through progressive disease activity (Young, 1992) and work disability (Barrett et al., 2000; 
Wolfe & Hawley, 1998; Young et al., 2002). 
The model that was found to be the best fit to the data in Chapter 9 (Figure 9.5) also included the 
Important Others and Perceived Behavioural Control factors of the Theory of Planned Behaviour, 
which have not been included in SEM analyses previously with regards to medication adherence. 
Given that Perceived Behavioural Control measured self-efficacy which is an important component of 
all models of health behaviour (Bandura, 1977; Azjen, 1988), the inclusion of this to explain 
adherence has strong face validity. As well as perceptions about the necessity of DMARDs and 
addressing any concerns patients may have, increasing patients’ efficacy at being able to take their 
DMARDs appropriately would also provide a succinct way of improving adherence not only to 
DMARDs but possibly also to other self-management behaviours.  
As well as differences in the social cognition models themselves, there were differences in adherence 
between the three treatment groups. Both cross-sectionally and longitudinally the new patients had 
the highest rates of forgetting but lowest rates of intentional non-adherence, despite the fact that 
they generally had the lowest sumscores on the psychological factors that were related to adherence 
such as BMQ necessity and SRM consequences and chronicity. This suggests that they are relatively 
happy with adhering to the regimen but struggle to fit it into their routine. This seems to be the most 
obvious time to target an intervention to prevent both types of non-adherence. Reminders to reduce 
rates of forgetting and psychological and behavioural training to maintain low levels of intentional 
non-adherence based on promoting adaptive illness perceptions could be beneficial. The longitudinal 
results suggest that focussing on illness and treatment perceptions, self-efficacy in taking the 
DMARDs in particular and engaging family, friends and co-workers could aid adherence as patients 
become more accustomed to their illness. However, more research is required to monitor adherence 
specifically by newly diagnosed patients as it is likely that their motivations would change over time.  
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It was found that there was variance in adherence over six months. Although there is very little 
previous research on which to base hypotheses because most do not measure adherence at more 
than one time point, de Thurah et al. (2010) found no variance in the proportion of low adherers to 
DMARDs over nine months. This was also true in the current dataset, but the intra-individual 
variability was quite high at 30% (Chapter 9). This was expected for the newly diagnosed patients as 
they become more accustomed to their treatment regimen but there were also changes in the other 
two treatment groups which were not expected. This may be due to the fact that treatment 
“holidays” are common (de Klerk et al., 2003; Kruse et al., 1992; Osterberg & Blaschke, 2005), that 
taking medications during remission is often difficult (Garcia-Gonzalez et al., 2008; Kane et al., 2001; 
Kane et al., 2003) and/or that a lack of treatment efficacy has caused patients to stop taking their 
DMARDs, however this was not measured in this study. There may also be some lack of validity for 
the adherence questionnaires, as test-retest was not carried out for the reduced Compliance 
Questionnaire for Rheumatology (Chapter 6). However, it is important that clinicians are aware of 
this potential variability and not to assume that a patient remains a good adherer over a long period 
of time. Regular measurement of adherence in the clinic would be preferred in order to address any 
problems, which would be more achievable with the reduced CQR produced in Chapter 6 as it is 
short and easily interpretable to give an indication to clinicians of potentially sub-optimal adherence.   
Although the social cognition models went some way to predicting and explaining adherence, none 
of the models were an ideal fit, indicating that there are other variables that are not currently 
included in the models and should be explored in the future. This could be related to the fact that 
patients who had a more “realistic” representation of RA (i.e. had higher consequences and 
chronicity scores) had better adherence but that other researchers have found that high scores on 
these factors are associated with higher levels of depression (Carlisle et al., 2005; Murphy et al., 
1999; Petrie et al., 2007; Treharne et al., 2005). Therefore although patients realise the need to take 
their DMARDs to mitigate the effects of future disability, this same realisation may be leading to a 
state of mind (depression) that makes effective adherence and self-management difficult (Bane, 
Hughes & McElnay, 2006; Hertzog et al., 2000). Adherence also appears to be a dynamic process that 
is reliant on disease-specific experience. Patients with more active disease seem to be more 
adherent, possibly in response to the increased symptomology (Leventhal et al., 1980). An 
interaction between age and disease activity and age and quality of life was found in relation to 
adherence where younger patients with lower disease activity had much lower adherence whereas 
those with high disease activity had high adherence. Similarly, younger patients with low adherence 
had better quality of life than those with high adherence. If adherence is reactive to disease activity, 
then it would be expected that those who are receiving little benefit or have a high treatment burden 
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would have worse quality of life. If increased symptomology, a realistic illness representation, 
depression and adherence are all associated, this could explain how the “rational” decisions (that are 
assumptions of models of illness) made by patients result in different outcomes, which may be 
contributing to the lack of fit of the structural equation models. Although this interaction 
demonstrates a limitation of this research in including patients in all stages of disease who have 
experienced different levels of disease activity, it also highlights an important point that adherence is 
dependent on context and experience and should not be treated in a prescriptive, inflexible way.  
12.5: The clinical importance of adequate adherence to DMARDs  
The results presented in this programme of research indicate that non-adherence to DMARDs is a 
substantial problem with 37.5% of patients demonstrating sub-optimal adherence. There is a 
possibility that this is an underestimate as patients who did not attend their appointment during the 
recruitment period may be more likely to be non-adherent and those who reported forgetting at 
baseline were more likely not to respond to the follow-up questionnaire. There was evidence that 
newly diagnosed patients were more susceptible to forgetting their DMARD doses which could 
lengthen the time it takes to establish an effective regimen to promote remission and may lead to 
irreversible joint damage during the first three years of illness (Young, 2008). 
It is well established that non-adherence to treatment leads to increased disease progression (Sharp, 
1999) and wasted resources through treatment escalation and increased healthcare contact (Brunzel 
& Laederach-Hofmann, 2000; DiMatteo, 1994; Steiner & Prochazka, 1997). This was evident to some 
extent in this study as patients who reported forgetting their DMARDs were more likely to be 
prescribed Leflunamide which is equally as efficacious as Methotrexate but much more expensive 
(Chapter 10). There were no significant differences in other costs that were collected prospectively 
over the six month follow-up period; however this may be because of the advanced disease duration 
of most patients and the short follow-up period. However, as the cost of non-adherence has not 
been calculated in rheumatoid arthritis before, this study highlights the importance of tracking the 
prescribing practices and NHS contacts of patients with sub-optimal adherence over the long term to 
establish the effects in a concrete way. Although this has been done retrospectively in other chronic 
illnesses (Balkrishnan et al., 2003; Balkrishnan et al., 2006), little is currently known about the impact 
to rheumatology clinics. 
Although these results refer mainly to consultant-run outpatient clinics, with more specialist nurses 
taking responsibility for long term care of patients, it is important for all healthcare practitioners to 
be aware of the impact of non-adherence and the possible reasons behind it, particularly the 
differences between intentional and unintentional non-adherence. Using peer support and small 
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nurse-led patient groups to advise and support patients, particularly after initial diagnosis could help 
to promote adaptive social cognition models that facilitate good adherence to DMARDs. In addition, 
the move towards more patients being responsible for self-administered anti-TNF α medication 
reiterates the need for more information about adherence to be known as these drugs are very 
expensive and have potentially harmful side effects if not administered properly. By being aware of 
the issues surrounding different types of adherence and the ways that patients in different stages of 
illness respond to medication and the information presented to them, healthcare practitioners can 
move towards an effective and suitable treatment plan for patients.   
12.6: Strengths and limitations of this programme of research 
The main strength of this programme of research was systematically measuring both intentional and 
unintentional non-adherence in patients at different stages of rheumatoid arthritis as well as 
establishing which of the most commonly used social cognition models of illness were predictive of 
medication adherence. In addition, the main study involved a large sample contributing to a 
prospective longitudinal study which is currently lacking in the literature. The inclusion of structural 
equation modelling also allows for more subtle analysis of the predictors of adherence which have 
identified a more coherent and informative model of medication non-adherence to DMARDs.  
There were some methodological limitations to these studies which should be discussed. Firstly, 
although the shortened Compliance Questionnaire for Rheumatology was subjected to confirmatory 
factor analysis in a sample different to the sample used to reduce the number of items, due to time 
constraints the CQR5 was not tested against an objective measure of adherence such as eMEMs. 
Although the fact that the hypothesis proposing that the social cognitive models would only be 
related to intentional non-adherence (measured by the CQR5) was supported which provides some 
assurance that the CQR5 was a valid measure, more robust psychometric testing is desirable.  
For the longitudinal study, patients were recruited mostly in the clinic with some additional patients 
being recruited by post. It may be that patients that were better at self-managing were recruited, 
however this potential bias would have underestimated non-adherence so the levels found in this 
study can be assumed to be at the lower end of what is apparent in the population. The recruitment 
rate shown in Chapter 7 was very high and the attrition rate shown in Chapter 8 was relatively low 
indicating that the sample is representative of the rheumatoid arthritis population so the results can 
be interpreted with some confidence. Although a very high percentage of available newly diagnosed 
patients were recruited, the sample size was too small to perform regression analyses for this group 
only. This would provide interesting and relevant results as they differed from the established 
patients both in their social cognitive models of illness and in adherence itself. The low number of 
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new diagnoses per year in the UK prohibited a larger sample. The difficulties in recruiting these 
patients means that the majority of previous research has not isolated them and so very little is 
known about changes in adherence and the effects that this may have on the disease course. 
However, based on the preliminary results for new patients presented here, it is clear that this 
should be a priority for research in the future in order to identify the best ways to develop 
interventions to aid self-management as the population ages and more patients are expected to 
suffer from auto-immune diseases. 
Although the Theory of Planned Behaviour was found to be predictive of adherence in the structural 
equation modelling, the high rate of missing responses for the Attitudes questions meant that this 
component could not be included in the analysis. This is a major limitation of the evaluation of this 
model as it has been shown that attitudes are strongly related to intentions to perform a behaviour 
(Armitage & Conner, 2001) and adherence behaviours themselves (Orbell et al., 2006). Although the 
questionnaire included clear instructions, the pattern of answering indicated that patients did not 
realise they were required to provide a preference for each attitude with most patients identifying 
only one out of the possible eight.  
Although this study provides some of the first longitudinal results for rheumatoid arthritis patients in 
respect to medication adherence, the follow-up of six months is relatively short and should be 
extended in order to provide more useful and relevant information in the relationship between social 
cognition models of illness, medication adherence and disease progression to inform clinical practice 
to improve prognosis and quality of life for rheumatoid arthritis patients in the future. 
12.7: Future work on adherence to DMARDs in rheumatoid arthritis 
Future research should focus specifically on the different types of non-adherence and the differing 
experience of newly diagnosed and established patients. By using a simple self-report screening 
measure such as the CQR5 and the RAM, adherence to medication should be routinely assessed in 
the clinic in order to identify patients for whom adhering to the regimen is difficult. This would allow 
for targeted interventions to address the likely problems around adherence and provide an 
opportunity for the clinician to address the topic in a non-threatening but open way. Disclosure of 
non-adherence by patients is often not apparent in a clinical setting (Belcher, Fried, Agostini & 
Tinetti, 2006; Maidment, Livingston & Katona, 2002; Treharne et al., 2006), but by being aware of 
intolerable side effects or other barriers to medication taking, a clinician could engage more in 
collaborative healthcare, as set out by NICE (2009).  
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As this longitudinal study has identified some of the predictors of non-adherence, future research 
should deliver a targeted intervention to address these issues. Two approaches should be 
considered. Firstly, it was shown that unintentional adherence primarily affects younger, newly 
diagnosed patients. An SMS message reminder tailored to the individual should be trialled as an 
attempt to prompt patients into taking their medications. Chapter 5 indicates that 90% of patients 
would be contactable via SMS message and other researchers have found that using this type of 
technology is suitable for delivering informative messages to patients (see systematic literature 
review in Chapter 4). This would provide a cheap and simple method of reminding patients about 
their medication doses and could also apply to other self-management behaviours such as 
attendance to outpatient appointments and regular blood tests. It is anticipated that these 
medication reminders would be required for 6-12 months to help patients to establish a habit of 
medication taking, after which these messages would no longer be required. Given the advanced 
technology available, this could be a simple automated service provided by the clinic which requires 
little maintenance after initial set-up. 
The longitudinal study found that perceptions of the illness chronicity, consequences and seriousness 
of symptoms, along with perceptions about the necessity and concerns of DMARDs were significantly 
related to adherence. After screening for patients that exhibit low levels of intentional adherence, an 
intervention that includes both psychological and behavioural training as well as education about the 
medication should be implemented in an attempt to establish suitable perceptions to aid adherence. 
Improving patients’ self-efficacy as well as including friends and family in a multifaceted design is 
likely to be the most successful (Kripalani et al., 2007; McDonald et al., 2002; Peterson et al., 2003). 
However, it is important for clinicians to be aware that adherence is not static and that experience 
with disease activity could lead to changes in adherence. Regular screening to address these changes 
is required and patient training may well need to be refreshed to address any illness perceptions that 
have changed within the individual. This would be particularly apparent after a significant change in 
treatment such as escalation to anti-TNF α therapy or orthopaedic surgery. 
In order to further inform these interventions, and to establish the impact of newer therapies on 
treatment adherence, it is also very important that adherence and social cognition models of illness 
are measured within individuals regularly over a long period of time to better understand the effects 
of disease activity and treatment on adherence to medication. This would be particularly beneficial 
for newly diagnosed patients who were shown in this research to be more reactive to acquired 
knowledge and experience over a relatively short period of time but whose adherence is particularly 
important as a large amount of joint damage often occurs in the three years from diagnosis 
(Conoghan et al., 2010). A cohort study that recruits patients at diagnosis and follows them up over a 
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number of years that measures adherence to medication, social cognition models of illness as well as 
related aspects such as treatment changes and contacts with the health service would provide 
invaluable evidence regarding which patients are most vulnerable to non-adherence, the possible 
causes and what affects non-adherence has in the long term, both for the patient and the health 
service. This kind of large, prospective longitudinal study is not currently available in rheumatoid 
arthritis looking specifically at adherence and the psychology of adjustment to chronic illness but 
would provide additional, related information to the cohort studies that are currently available such 
as the Early Rheumatoid Arthritis Network (ERAN), the Early Rheumatoid Arthritis Study (ERAS) and 
the Norfolk Arthritis Register (NOAR). 
12.8: Final conclusions 
This programme of research has demonstrated that adherence to medication is a complex, 
multifaceted process that involves both social cognition models of illness in a cost-benefit decision as 
well as relatively simple omissions that are unintentional. By measuring both intentional and 
unintentional non-adherence and testing each of the commonly used social cognition models, this 
study has provided evidence for some of the factors that influence adherence in different stages of 
rheumatoid arthritis, identifying potential areas for targeted intervention in the future. Few previous 
studies have systematically collected this information in RA or other chronic illnesses. These results 
should be carried forward to the clinical setting to address potential non-adherence in patients in a 
multifaceted way, focussing on the needs of the patient in relation to their knowledge, experience, 
perceptions of their illness and treatment and the ways in which they struggle to take their 
medications in an optimum fashion.    
 205 
 
References 
Abraham, C., Clift, S. & Grabowski, P. (1999) Cognitive predictors of adherence to malaria prophylaxis regimens 
on return from a malarious region: a prospective study. Social Science & Medicine, 48, 1641-1654. 
Abraham, C. & Sheeran, P. (1999) The Health Belief Model. Mark Conner & Paul Norman (Eds.) In Predicting 
Health Behaviour.  Open University Press. Buckingham, UK. 
Abraham, C., Sheeran, P. & Johnston, M. (1998) From health beliefs to self-regulation: theoretical advances in 
the psychology of action control. Psychology and Health 13, 569-591. 
Ajzen, I. (1988). Attitudes, personality, and behavior. Chicago: Dorsey Press. 
Ajzen, I. (1991) The Theory of Planned Behavior. Organizational Behavior and Human Decision Processes, 50, 
179-211. 
Ajzen, I. (2007) Attitudes, Personality and Behaviour. Open University Press, Maidenhead, UK. 
Albarracin, D., Johnson, B. T., Fishbein, M. & Muellerleile, P. A. (2001) Theories of reasoned action and planned 
behavior as models of condom use: a metaanalysis. Psychological Bulletin, 127, 142–61. 
Albers, J. M. C., Kuper, H. H., van Riel, P. L. C. M., Prevoo, M. L. L., van. Hof, M. A., van Gestel, A. M., et al. 
(1999). Socio-economic consequences of rheumatoid arthritis in the first years of the disease. 
Rheumatology, 38, 423-430. 
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O. et al. (2010) 2010 Rheumatoid 
Arthritis Classification Criteria. Arthritis & Rheumatism, 62 (9), 2569-2581.  
Allen LaPointe, N. M., Ou, F. S., Calvert, S. B., Melloni, C., Stafford, J. A., Harding, T. et al. (2010) Changes in 
beliefs about medications during long-term care for ischemic heart disease. American Heart Journal, 159(4), 
561-569. 
Anhoj, J. & Moldrup, C. (2004) Feasibiilty of collecting diary data from asthma patients through mobile phones 
and SMS (Short Message Service): Response rate analysis and focus group evaluation from a pilot study. 
Journal of Medical Internet Research, 6(4), e42. 
Armitage, C. J. & Conner, M. (2001) Efficacy of the theory of planned behaviour: a meta-analytic review. British 
Journal of Social Psychology, 40, 471–99. 
Atkins, L. & Fallowfield, L. (2006) Intentional and non-intentional non-adherence to medication amongst breast 
cancer patients. European Journal of Cancer, 42, 2271-2276. 
Ausburn L (1981). Patient compliance with medication regimens. In JL Sheppard (Ed.) Advances in Behavioural 
Medicine. Sydney: Cumberland College. 
Bachu, A. S., Hine, N. & Arnott, J. Technology devices for older adults to aid self management of chronic health 
conditions. Proceedings 10
th
 international ACM SIGACCESS conference 2008   
Bagozzi, R. P. & Yi, Y. (1988) On the evaluation of structural equation models. Journal of the Academy of 
Marketing Science, 16, 74-94. 
 206 
 
Bailey, W. C., Richards, J. M. Jr, Brooks, C. M., Soong, S. J., Windsor, R. A. & Manzella, B. A. (1990) A randomized 
trial to improve self-management practices of adults with asthma. Archives of Internal Medicine, 150, 1664-
1668. 
Baird, M. G., Bentley-Taylor, M. M., Carruthers, S. G. et al. (1984) A study of efficacy, tolerance and compliance 
of once-daily versus twice-daily metoprolol (Betaloc) in hypertension: Betaloc Compliance Canadian 
Cooperative Study Group. Clin Invest Med, 7, 95-102. 
Balkrishnan, R., Rajagopalan, R., Camacho, F., Huston, S. A., Murray, F. T. & Anderson, R. T. (2003) Predictors of 
medication adherence and associated health care costs in an older population with Type 2 Diabetes 
Mellitus: A longitudinal cohort study. Clinical Therapeutics, 25(11), 2958-2971. 
Balkrishnan, R., Bhosle, M. J., Camacho, F. T. & Anderson, R. T. (2006) Predictors of medication adherence and 
associated health care costs in an older population with Overactive Bladder Syndrome: A longitudinal 
cohort study. The Journal of Urology, 175, 1067-1072. 
Bandura, A. (1977) Self-efficacy: Toward a unifying theory of behavioural change. Psychological Review, 84(2), 
191-215. 
Bane, C., Hughes, C. M. & McElnay, J. C. (2006) Determinants of medication adherence in hypertensive 
patients: an application of self-efficacy and the theory of planned behaviour. Int J Pharm Pract, 14(3), 197-
204. 
Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L. et al. (2000) Adherence 
to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 
14, 357-366. 
Barber, N., Parsons, J., Clifford, S., Darracott, R. & Horne, R. (2004) Patients’ problems with new medication for 
chronic conditions. Quality and Safety in Health Care, 13(3), 172–5. 
Barrett, E. M., Scott, D. G., Wiles, N. J. & Symmons, D. P. (2000) The impact of rheumatoid arthritis on 
employment status in the early years of disease: a UK community-based study. Rheumatology, 39(12), 
1403-1409. 
Becker, M. H., Haefner, D. P. & Maiman, L. A. (1977b) The health belief model in the prediction of dietary 
compliance: a field experiment. Journal of Health and Social Behaviour, 18, 348–366. 
Beekman, A. T. F., Deeg, D. J. H., Geerlings, S. W., Schoevers, R. A., & Smit, J. H. (2001) Emergence and 
persistence of late life depression: A 3-year follow-up of the longitudinal aging study Amsterdam. Journal of 
Affective Disorders, 65, 131-138. 
Belcher, V. N., Fried, T. R., Agostini, J. V. & Tinetti, M. E. (2006) Views of older adults on patient participation in 
medication-related decision making. J. Gen Intern. Med., 21, 298-303. 
Belza, B. L. (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. Journal of 
Rheumatology, 22, 639-643. 
Belza, B. L., Henke, C. J., Yelin, E. H., Epstein, W. V., & Gilliss, C. L. (1993) Correlates of fatigue in older adults 
with rheumatoid arthritis. Nursing Research, 42, 93-99. 
Bennett, G. A., Cobb, S., Jacox, R., Jessar, R. A. & Ropes, M. W. (1956) Proposed diagnostic criteria for 
rheumatoid arthritis. Bulletin of the Rheumatic Diseases, 7(4), 121-124. 
 207 
 
Berrien, V. M., Salazar, J. C., Reynolds, E. & McKay, K. (2004) H.I.V. Medication Adherence Intervention Group. 
Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive 
nursing intervention. AIDS Patient Care STDS, 18, 355-363. 
Berry, D., Bradlow, A. & Bersellini, E. (2004) Perceptions of the risks and benefits of medicines in patients with 
rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology, 43, 901-905. 
Birnbaum, H. G., Barton, M., Greenberg, P. E., Sisitsky, T., Auerbach, R., Wanke, L. A. et al. (2000) Direct and 
indirect costs of Rheumatoid Arthritis to an employer. Journal of Occupational & Environmental Medicine, 
42(6), 588-596.  
Bishop, G. D. (1987) Lay conceptions of physical symptoms. Journal of Applied Social Psychology, 17, 127-146. 
Borah, B. J., Huang, X., Zarotsky, V. & Globe, D. (2009) Trends in RA patients’ adherence to subcutaneous anti-
TNF therapies and costs. Current Medical Research and Opinions, 25(6), 1365-1377. 
Bramley, D., Riddell, T., Whittaker, R., Corbett, T., Lin, R., Wills, M. et al. (2005) Smoking cessation using mobile 
phone text messaging is as effective in Maori as non-Maori. New Zealand Medical Journal, 118, U1494. 
Brawley, L. R. & Culos-Reed, S. N. (2000) Studying adherence to therapeutic regimens: Overview, theories and 
recommendations. Control Clin Trials, 21, 156S-163S. 
Brighton, S. W., de la Harpe, A. L., van Staden, D. J., Badenhorst, J. H. & Myers, O. L. (1988) The prevalence of 
rheumatoid arthritis in a rural African population. Journal of Rheumatology, 15, 405-408. 
Broadbent, E., Ellis, C. J., Thomas, J., Gamble, G. & Petrie, K. J. (2009) Further development of an illness 
perception intervention for myocardial infarction patients: A randomized controlled trial. Journal of 
Psychosomatic Research, 67, 17-23. 
Broadbent, E., Petrie, K. J., Main, J. & Weinman, J. (2006) The Brief Illness Perception Questionnaire. Journal of 
Psychosomatic Research, 60, 631-637. 
Brook, A. & Corbett, M. (1977) Radiographic changes in early rheumatoid disease. Ann Rheum Dis, 36, 71-73. 
Brooks, P. M. & Day, R. O. (1991) Nonsteroidal antiinflammatory drugs--differences and similarities. New 
England Journal of Medicine, 324(24), 1716-1725. 
Brown, G. K. (1990) A causal analysis of chronic pain and depression. Journal of Consulting and Clinical 
Psychology, 58, 127-137. 
Brown, T., A. (2006). Confirmatory Factor Analysis for Applied Research New York, Guildford Press. 
Brown, B. G., Bardsley, J., Poulin, D., Hillger, L. A., Dowdy, A., Maher, V. M. G. et al. (1997) Moderate dose, 
three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol 
_100mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 80, 111-115. 
Bruce, B. & Fries, J. F. (2003) The Stanford health assessment questionnaire (HAQ): a review of its history, 
issues, progress, and documentation. Journal of Rheumatology, 30 (1), 167-178. 
Brunzel, B. & Laederach-Hofmann, K. (2000) Solid organ transplantation: are there predictors for posttransplant 
noncompliance? A literature overview. Transplantation, 70, 711-716. 
 208 
 
Brus, H., van de Laar, M., Taal, E., Rasker, J. & Weigman, O. (1999) Determinants of compliance with 
medications in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient 
Education and Counseling, 36, 57-64. 
Butler, J. A., Peveler, R. C., Roderick, P. J., Horne, R, & Mason, J. C. (2004) Measuring compliance to drug 
regimes following renal transplantation: a comparison of self-report and clinician rating with electronic 
monitoring. Transplantation, 77, 786–789. 
Carlin, J. B., Galati, J. C. & Royston, P. (2008) A new framework for managing and analyzing multiply imputed 
data in Stata. Stata Journal, 8(1), 49-67. 
Carlisle, A. C. S., John, A. M. H., Fife-Shaw, C. & Lloyd, M. (2005) The self-regulatory model in women with 
rheumatoid arthritis: Relationships between illness representations, coping strategies and illness outcome. 
British Journal of Health Psychology, 10, 571-587. 
Casey, R. G., Quinlan, M. R., Flynn, R., Grainger, R., McDermott, T. E. D. & Thornhill, J. A. (2007) Urology out-
patient non-attenders: are we wasting our time? Irish Journal of Medical Science, 176(94), 305-308. 
Castren, J., Niemi, M. & Virjo, I. (2005) Use of email for patient communication in student health care: a cross-
sectional study. BMC Medical Informatics and Decision Making, 5(2),    NEED PAGES 
Champion, V.L. (1984) Instrument development for health belief model constructs. Advances in Nursing 
Science, 6, 73–85. 
Chan, E. S. L., Wilson, A. G. & Cronstein, B. N. (2010) Treatment of Rheumatoid Arthritis. In A. Adebajo (Ed.) 
ABC of Rheumatology (pp 71-75). Chichester, UK: John Wiley & Sons Ltd 
Chen, Z., Fang, L., Chen, L. & Dai, H. (2008) Comparison of an SMS text messaging and phone reminder to 
improve attendance at a health promotion center: A randomized controlled trial. Journal of Zhejiang 
University Science B, 9(1), 34-38. 
Chesney, M. A. (2000) Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 30(2), 
171-176. 
Chilcot. J., Wellsted. D. & Farrington. K. (2010) Illness Representations are associated with fluid non adherence 
among hemodialysis patients. Journal of Psychosomatic Research, 68, 203-212. 
Cioffi, D. (1990) Beyond attentional strategies: A cognitive-perceptual model of somatic interpretation. 
Psychological Bulletin, 109, 25-41. 
Clifford, S., Barber, N. & Horne, R. (2008) Understanding different beliefs held by adherers, unintentional 
nonadherers and intentional nonadherers: Application of the Necessity-Concerns Framework. Journal of 
Psychosomatic Research, 64(1), 41-46. 
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M. et al (2007) EULAR 
recommendations for the management of early arthritis: report of a task force of the European Standing 
Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of Rheumatic Disease, 
66, 34-45. 
Conaghan, P. G., Hensor, E. M. A., Keenan, A-M., Morgan, A. W., Emery, P. & the YEAR Consortium (2010) 
Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD 
therapy. Rheumatology, 49, 1894-1899. 
Cooper, N. J. (2000) Economic burden of Rheumatoid Arthritis: A systematic review. Rheumatology, 39, 28-33. 
 209 
 
Cooper, A., Lloyd, G., Weinman, J. & Jackson, G. (1999) Why patients do not attend cardiac rehabilitation: role 
of intentions and illness beliefs. Heart, 82, 234-236. 
Cooper, N. J., Mugford, M., Symmons, D. P., Barrett, E. M. & Scott, D. G. (2002) Total costs and predictors of 
costs in individuals with early inflammatory polyarthritis: a community-based prospective study. 
Rheumatology, 41(7), 767-774. 
Cramer, J. A. (1998) Consequences of intermittent treatment for hypertension: the case for medication 
compliance and persistence. American Journal of Managed Care, 4, 1563-1568. 
Dans, L. F., Tankeh-Torres, S., Amante, C. M. & Penserga, E. G. (1997) The prevalence of rheumatic diseases in a 
Filipino urban population: a WHO-ILAR COPCORD study. J Rheumatol, 24, 1814-1819. 
de Klerk, E., van der Heijde, D., Landewe, R., van der Tempel, H. & van der Linden, S. (2003) The Compliance 
Questionnaire – Rheumatology compared with electronic medication event monitoring: A validation study. J 
of Rheumatology, 30(11), 2469-2475.  
de Klerk, E., van der Heijde, D., Landewe, R., van der Tempel, H., Urquhart, J. & van der, Linden S. (2003) 
Patient compliance in rheumatoid arthritis, polymyalgia rheumatic and gout. J of Rheumatology, 30(1), 44-
54. 
de Klerk, E., van der Heijde, D., van der Tempel, H., van der Linden, S. (1999) Development of a questionnaire to 
investigate patient compliance with antirheumatic drug therapy. Journal of Rheumatology, 26, 2635-2641. 
de Ridder, D., Geenan, R., Kuijer, R. & van Middendorp, H. (2008) Psychological adjustment to chronic disease. 
The Lancet, 372, 246-255. 
de Thurah, A., Norgaard, M., Harder, I. & Stengaard-Petersen, K. (2010) Compliance with Methotrexate 
treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A 
prospective cohort study. Rheumatol Int, 30, 1441-1448. 
del Puente, A., Knowler, W. C., Pettit, D. J. & Bennett, P. H. (1989) High incidence and prevalence of rheumatoid 
arthritis in Pima Indians. Am J Epidemio, 129, 1170-1178. 
Devlin, N. & Parkin, D. (2004) Does NICE have a cost-effectiveness threshold and what other factors influence 
its decisions? A binary choice analysis. Health Economics, 5, 437-452. 
Dey, A., Reid, B., Godding, R. & Campbell, A. (2008) Perceptions and behaviour of access of the internet: A 
study of women attending a breast screening service in Sydney, Australia. International Journal of Medical 
Informatics, 77(1), 24-32. 
Diamantopoulos, A. S. J. A. (2000). Introducing Lisrel: a guide for the uninitated. London, SAGE. 
DiMatteo, M. R. (1994). Enhancing patient adherence to medical recommendations. Journal of the American 
Medical Association, 271, 79–83. 
DiMatteo, M R. (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health 
Psychology, 23(2), 207-218. 
DiMatteo, M. R., Haskard, K. B. & Williams, S. L. (2007) Health beliefs, disease severity and patients adherence. 
A meta-analysis. Medical Care, 45(6), 521-528. 
Ding, T., Ledingham, J., Luqmani, R., Westlake, S., Hyrich, K., Lunt, M. et al (2010) BSR and NHPR rheumatoid 
arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 49, 2217-2219. 
 210 
 
Dolan, P. (1997) Modeling valuations for EuroQoL health states. Medical Care, 35(11), 1095-1108. 
Dunbar-Jacob, J., & Schlenk, E. (2001). Patient adherence to treatment regimen. In A. Baum, T. A. Revenson, & 
J. E. Singler (Eds.), Handbook of health psychology (pp. 571–580). Mahwah, NJ: Erlbaum. 
Dunbar-Jacob, J., Erlen, J. A., Schlenk, E. A., Ryan, C. M., Sereika, S. M. & Doswell, W. (2000) Adherence in 
chronic disease. Annual Review of Nursing Research, 2000, 18, 48-90. 
Eberhardt, K. B. & Fex, E. (1995) Functional impairment and disability in early rheumatoid arthritis--
development over 5 years. J Rheumatol, 22(6), 1037-1042. 
Ediger, J. P., Walker, J. R., Graff, L., Lix, L., Clara, I., Rawsthorne, P. (2007) Predictors of medication adherence in 
inflammatory bowel disease. American Journal of Gastroenterology, 102, 1417-1426. 
Edwards, W. (1954) The theory of decision making. Psychological Bulletin, 51(4), 380-417. 
Elliott, R. A. (2008) Poor adherence to medication in adults with rheumatoid arthritis: Reasons and solutions. 
Disease Management and Health Outcomes, 16(1), 13-29. 
Elliott, R. A., Barber, N., Clifford, S., Horne, R. & Hartley, E. (2008) The cost effectiveness of a telephone-based 
pharmacy advisory service to improve adherence to newly prescribed medicines. Pharm World Sci, 30, 17-
23. 
Elliott, R. A., Ross-Degnan, D., Adams, A. S., Gelb Safran, D. & Soumerai, S. B. (2007) Strategies for coping in a 
complex world: Adherence behaviours among older adults with chronic illness. Journal of General Internal 
Medicine, 22, 805-810. 
Emery, P., Breedveld, F. C., Dougados, M., Kalden, J. R., Schiff, M. H. & Smolen, J. S. (2002) Early referral 
recommendations for newly diagnosed rheumatoid arthritis: evidence based development of a clinical 
guide. Annals of Rheumatic Disease, 61, 290-297. 
Erb, N., Duncan, R. C., Raza, K., Rowe, I. F., Kitas, G. D., & Situnayake, R. D. (2002). A regional audit of the 
prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the 
West Midlands. Rheumatology, 41, 1021-1024. 
Eysenbach, G. (2000) Consumer health informatics. British Medical Journal, 320(7251), 1713-1716. 
Faridi, Z., Liberti, L., Shuval, K., Northrup, V., Ali, A. & Katz, D. L. (2008) Evaluating the impact of mobile 
telephone technology on type 2 diabetic patients’ self management: the NICHE pilot study. Journal of 
Evaluation in Clinical Practice, 14(3), 465-469. 
Fautrel, B. & Guillemon, F. (2002) Cost of illness studies in rheumatic diseases. Current Opinion in 
Rheumatology, 14, 121-126. 
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. et al. (1993) The American 
College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical 
trials. Arthritis & Rheumatism, 36(6), 729-740. 
Fifield, J., McQuillan, J., Tennen, H., Sheehan, T. J., Reisine, S., Hesselbrock, V. & Rothfield, N. (2001) History of 
affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Annals of Behavioral 
Medicine, 23, 34-41. 
Fishbein, M. (1993) Introduction. In D.J. Terry, C. Gallois and M. McCamish (Eds.) The Theory of Reasoned 
Action: Its Application to AIDS-preventive Behaviour. Oxford: Pergamon  
 211 
 
Fogel, J., Albert, M. S., Schnabel, F., Ditkoff, A. B. & Neugut, I. A. (2002) Use of the internet by women with 
breast cancer. Journal of Medical Internet Research, 4, e9. 
Fogel, J., Albert, M. S., Schnabel, F., Ditkoff, A. B. & Neugut, I. A. (2003) Racial/ethnic differences and potential 
psychological benefits in use of the internet by women with breast cancer. Psycho-Oncology, 12, 107-117.  
Fornell, C. & Larcker, D. F. (1981) Evaluating structural equation models with unobservable variables and 
measurement error. Journal of marketing research, 18(3), 39-50. 
Fransen, J. & van Riel, P. L. C. M. (2005) The disease activity score and the EULAR response criteria. Clinical and 
Experimental Rheumatology, 23(Suppl 39), S93-S99. 
Fries, J. F., Spitz, P., Kraines, G. & Holman, H. (1980) Measurement of patient outcomes in arthritis. Arthritis and 
Rheumatism, 23, 137-145. 
Fries, J. F., Spitz, P. W. & Young, D. Y. (1982) The dimensions of health outcomes: the health assessment 
questionnaire, disability and pain scales. Journal of Rheumatology, 9 (5), 789-793. 
Fries, J. F., Williams, C. A., Morfeld, D., Singh, G. & Sibley, J. (1996) Reduction in long term disability in patients 
with rheumatoid arthritis by disease-modifying antirhumatic drug-based treatment strategies. Arthritis 
Rheum, 39, 616-622.  
Frostholm, L., Oernboel, E., Christensen, K. S., Toft, T., Olesen, F., Weinman, J. & Fink, P. (2007) Do illness 
perceptions predict health outcomes in primary care patients? A 2-year follow-up study. Journal of 
Psychosomatic Research, 62, 129-138. 
Gallefoss, F. & Bakke, P. S. (1999) How does patient education and self-management among asthmatics and 
patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med, 160, 
2000-2005. 
Garber, M. C., Nau, D. P., Erikson, S. R., Aikens, J. E. & Lawrence, J. B. (2004) The concordance of self report 
with other measures of medication adherence. A summary of the literature. Medical Care, 42(7), 649-652. 
Garcia-Gonzalez, A., Richardson, M., Garcia Popa-Lisseanu, M., Cox, V., Kallen, M. A., Janssen, N. et al. (2008) 
Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin 
Rheumatol, 27, 883-889. 
Garcia Popa-Lisseanu, M. G., Greisinger, A., Richardson, M., O’Malley, K. J., Janssen, N. M., Marcus, D. M. et al. 
(2005) Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients 
with rheumatic disease. Journal of Rheumatology, 32, 913-919. 
Girvin, B. McDermott, B. J. & Johnston, D. A. (1999) Comparison of enalapril 20mg once daily vs 10mg twice 
daily in terms of blood pressure lowering and patient compliance. J Hypertens. 17, 1627-1631. 
Goodacre, L. J. & Goodacre, J. A. (2004) Factors influencing the beliefs of patients with rheumatoid arthritis 
regarding disease-modifying medication. Rheumatology, 43, 583-586. 
Goodson, N. J., Wiles, N. J., Lunt, M., Barrett, E. M., Silman, A. J., & Symmons, D. P. M. (2002). Mortality in early 
inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis and 
Rheumatism, 48, 2010-2019. 
Gordon-Larsen, P., Nelson, M. C., Page, P. & Popkin, B. M. (2006) Inequality in the built environment underlies 
key health disparities in physical activity and obesity. Pediatrics, 117(2), 417-25. 
 212 
 
Grady, K. E., Kegeles, S. S., Lund, A. K., Wolk, C. H. & Farber, N. J. (1983) Who volunteers for a breast self-
examination program? Evaluating the bases for self selection. Health Education Quarterly, 10, 79–94. 
Grijalva, C. G., Chung, C. P., Arbogast, P. G., Stein, C. M., Mitchel, E. F. & Griffin, M. R. (2007) Assessment of 
adherence to and persistence on Disease Modifying Antirheumatic Drugs (DMARDs) in patients with 
Rheumatoid Arthritis. Medical Care, 45(10), S66-S76. 
Groarke, A., Curtis, R., Coughlan, R. & Gsel, A. (2004) The role of perceived and actual disease status in 
adjustment to rheumatoid arthritis. Rheumatology, 43(9), 1142-1149. 
Hagger, M. S. & Orbell, S. (2003) A meta-analytic review of the common sense model of illness representations. 
Psychology and Health, 18(2), 141-184. 
Hameed, K. & Akil, M. (2010) Rheumatoid Arthritis: Clinical Features and Diagnosis. In A. Adebajo (Ed.) ABC of 
Rheumatology (pp 71-75). Chichester, UK: John Wiley & Sons Ltd.   
Hamilton, W., Round, A. & Sharp, D. (2002) Patient, hospital and general practitioner characteristics associated 
with non-attendance: a cohort study. British Journal of General Practice, 52, 317-319. 
Hampson, S. E., Glasgow, R. E., & Ziess, A. (1994) Personal models of OA and their relation to self-management 
activities and quality of life. Journal of Behavioural Medicine, 17, 143-158. 
Harrison, J. A., Mullen, P. D. & Green, L. W. (1992) A meta-analysis of studies of the health belief model with 
adults, Health Education Research, 7, 107–116. 
Harvey, J., Lotze, M., Stevens, M. B., Lambert, G. & Jacobson, D. (1981) Rheumatoid arthritis in a Chippewa 
band. A Pilot screening study of disease prevalence. Arthritis Rheum, 24, 717-721. 
Hay, J. L., Ford, J. S., Klein, D., Primavera, L. H., Buckley, T. R., Stein, T. R. et al. (2003) Adherence to colorectal 
cancer screening in mammography-adherent older women. Journal of Behavioral Medicine, 26, 553–576. 
Haynes, R. B. (2001) Interventions for helping patients to follow prescriptions for medications. Cochrane 
Database of Systematic Reviews, Issue 1. 
Haynes, R. B., Montague, P., Oliver, T., McKibbon, K. A., Brouwers, M. C. & Kanani, R. (2000) Interventions for 
helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews. Issue 2. 
Haynes, R. B., Sackett, D. L., Gibson, E. S., Taylor, D. W., Hackett, B. C., Roberts, R. S. et al. (1976) Improvement 
of medication compliance in uncontrolled hypertension. Lancet. 1, 1265-1268. 
Hertzog, C., Park, D. C., Morrell, R. W. & Martin, M. (2000) Ask and ye shall receive: Behavioural specificity in 
the accuracy of subjective memory complaints. Applied Cognitive Psychology, 14, 257-275. 
Hill, J. (2005a) Adherence with drug therapy in the rheumatic diseases. Part one: A review of adherence rates. 
Musculoskeletal Care, 3(2), 61-73. 
Hill, J. (2005b) Adherence with drug therapy in the rheumatic diseases. Part two: Measuring and improving 
adherence. Musculoskeletal Care, 3(3), 143-156. 
Horne, R. & Weinman, J. (1998). Predicting treatment adherence: an overview of theorietical models. In: 
Myers, L. and Midence, K. (Eds.), Adherence to treatment in medical conditions, pp. 25–50. Harwood 
Academic, London. 
 213 
 
Horne, R., & Weinman, J. (2002) Self-regulation and self-management in asthma: exploring the role of illness 
perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health, 
17, 17–32. 
Horne, R., Weinman, J. & Hankins M. (1999) The beliefs about medicines questionnaire: the development and 
evaluation of a new method for assessing the cognitive representation of medication. Psychology & Health 
14(1), 1-24. 
Hospital Episodes Statistics (HESonline) 
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937. 
Hu, L. & Bentler, P. M. (1999) Cutoff criteria for fit indexes in covariance structure analysis: Conventional 
criteria versus new alternatives. Structural Equation Modeling, 6(1), 1-55. 
Hughes, D. A., Bagust, A., Haycox, A. & Walley, T. (2001) The impact of non-compliance on the cost-
effectiveness of pharmaceuticals: a review of the literature. Health Economics, 10, 601– 615. 
Hurkmans, E. J., Maes, S., de Gucht, V., Knittle, K., Peeters, A. J., Ronday, H. K. & Vliet Vlieland, T. P. M. (2010) 
Motivation as a determinant of physical activity in patients with Rheumatoid Arthritis. Arthritis Care & 
Research, 62(3), 371-377. 
Huyser, B. A., Parker, J. C., Thoreson, R., Smarr, K. L., Johnson, J. C., & Hoffman, R. (1998) Predictors of 
subjective fatigue amongst individuals with rheumatoid arthritis. Arthritis and Rheumatism, 41, 2230-2237. 
Irvine, J., Baker, B., Smith, J., et al. (1999) Poor adherence to placebo or amiodarone therapy predicts mortality: 
results from the CAMIAT study. Psychosom Med., 61, 566-575. 
Janz, N. & Becker, M. H. (1984) The Health belief model: A decade later. Health education quarterly, 11, 1-47. 
Jefferson T., DeMicheli V. & Mugford M. (2000) Elementary Economic Evaluation in Health Care: second edition. 
BMJ Publishing Group, J W Arrowsmith Ltd, Bristol, UK . 
Johnson, M. J., (2002) The medication model: a guide for assessing medication taking. Research and Theory for 
Nursing Practice: An International Journal, 16(3), 179–192. 
Johnson, M. J., Williams, M., Marshall, E. S. (1999) Adherent and nonadherent medication-taking in elderly 
hypertensive patients. Clinical Nursing Research, 8, 318-335. 
Joint Formulary Committee (2010) British National Formulary 60, Pharmaceutical Press, UK. 
Jones, M. A., Silman, A. J., Whiting, S., Barrett, E. M. & Symmons, D. P. M. (1996) Occurrence of rheumatoid 
arthritis is not increased in the first degree relatives of a population based inception cohort of inflammatory 
polyarthritis. Ann Rheum Dis, 55, 89-93. 
Jonsson, D. & Husberg, M. (2000) Socieoeconomic costs of rheumatic disease: Implications for technology 
assessment. International Journal of Technology Assessment in Health Care, 16, 1193-1200. 
Kane, S. V. (2006) Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol 
Ther, 23, 577-585. 
Kane, S. U., Cohen, R. D., Aikens, J. E. & Hanauer, S. B. (2001) Prevalence of nonadherence with maintenance 
Mesalamine in quiescent Ulcerative Colitis. The American Journal of Gastroenterology, 96(10), 2929-2933. 
 214 
 
Kane, S., Huo, D., Aikens, J., Hanauer, S. (2003) Medication nonadherence and the outcomes of patients with 
quiescent Ulcerative Colitis. The American Journal of Medicine, 114, 39-43. 
Katz, P. P., & Yelin, E. H. (1993). Prevalence and correlates of depressive symptoms among persons with 
rheumatoid arthritis. Journal of Rheumatology, 20, 790-796. 
Kippen, S., Fraser, M., & Ellis, J. (2005) As time goes by: issues for older people with their medication use. Aust. 
J. Ageing (24), 103–107. 
Kitas, G., Banks, M. J., & Bacon, P. A. (2001). Cardiac involvement in rheumatoid disease. Clinical Medicine, 1, 
18-21. 
Kitas, G. D., & Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology, 42, 607-
613. 
Kobelt, G., Jonsson, L., Lindgren, P., Young, A. & Eberhardt K. (2002) Modeling the progression of Rheumatoid 
Arthritis. Arthritis & Rheumatism, 46(9), 2310-2319. 
Kolenikov, S. (2009). "Confirmatory factor analysis using cfa." Stata Journal 9(3): 1-44. 
Koshy, E., Car, J. & Majeed, A. (2008) Effectiveness of mobile-phone short message service (SMS) reminders for 
ophthalmology outpatient appointments: Observational study. BMC Ophthalmology, 8, 9.  
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E. et al. (2002) Concomitant 
leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A 
randomized, double-blind, placebo-controlled trial. Ann Intern Med, 137, 726-733. 
Kripalani, S., Yao, X. & Haynes, R. B. (2007) Interventions to enhance medication adherence in chronic medical 
conditions. A systematic review. Arch Inter Med, 167, 540-550. 
Kruse, W., Koch-Gwinner, P., Nikolaus, T., Oster, P., Schlierf, G. & Weber, E. (1992) Measurement of drug 
compliance by continuous electronic monitoring: a pilot study in elderly patients discharged from hospital. J 
Am Geriatr Soc, 40, 1151-1155. 
Kubota, A., Fujita, M. & Hatano, Y. (2004) Development and effects of a health promotion program utilizing the 
mail function of mobile phones [Article in Japanese]. Nippon Koshu Eisei Zasshi, 51(10), 281-286. 
Kurniawan, S. (2006) An exploratory study of how older women use mobile phones. Ubiquitous Computing, 
4206, 105-122. 
Kurniawan, S. (2008) Older people and mobile phones: A multi-method investigation. International Journal of 
Human-Computer Studies, 66(12), 889-901. 
Kwon, H., Cho, J., Kim, H., Song, B., Oh, J., Han, J., Kim, H. et al. (2004) Development of web-based diabetic 
patient management system using short message service (SMS). Diabetes Research and Clinical Practice, 
66(suppl 1), S133-7. 
Lard, L. R., Huizinga, T. W. J., Hazes, J. M. W., & Vliet Vlieland, T. P. M. (2001). Delayed referral of female 
patients with rheumatoid arthritis. Journal of Rheumatology, 28, 2190-2192. 
Lazarus R. S. (1966) Psychological Stress and the coping process. New York: McGraw-Hill.      
 215 
 
Lazev, A., Vidrine, D., Arduino, R. & Gritz, E. (2004) Increasing access to smoking cessation treatment in a low-
income, HIV-positive population: the feasibility of using cellular telephones. Nicotine and Tobacco Research, 
6(2), 281-286. 
Lehane, E. & McCarthy, G., (2006) An examination of the intentional and unintentional aspects of medication 
nonadherence in patients diagnosed with hypertension. Journal of Clinical Nursing, 16(4), 689-706. 
Lehane, E. & McCarthy, G. (2007) Intentional and unintentional medication non-adherence: A comprehensive 
framework for clinical research and practice? A discussion paper. International Journal of Nursing Studies, 
44, 1468-1477. 
Leong, K. C., Chen, W. S., Leong, K. W., Mastura, I., Mimi, O., Sheikh, M. A. et al. (2006) The use of text 
messaging to improve attendance in primary care: a randomized controlled trial. Family Practice, 23(6), 
699-705. 
Leventhal, H., Brown, D., Schacham, S. & Engquist, G. (1979) Effects of preparatory information about 
sensations, threat of pain and attention on cold pressor distress. Journal of Personality and Social 
Psychology, 37, 688-714. 
Leventhal, H., Diefenbach, M. & Leventhal, E. A. (1992) Illness cognition: Using common sense to understand 
treatment adherence and affect cognition interactions. Cognitive Therapy and Research, 16(2), 143-163. 
Leventhal H., Meyer D. & Nerenz D. (1980) The Common Sense Representations of illness danger. In: S. 
Rachman (Ed). Medical Psychology, Volume 2, Pergamon Press.  
Leventhal H., Nerenz D. R. & Steele D. J. (1984) Illness representations and coping with health threats In: S. 
Rachman (Ed), Contributions to Medical Psychology, Vol 2. New York: Pergamon Press, 17-30.    
Liang, M. H., Larson, M., Thompson, M., Eaton, H., McNamara, E., Katz, R, et al. (1984) Costs and outcomes in 
rheumatoid arthritis and osteoarthritis. Arthritis Rheum, 27(5), 522-529. 
Linz, D., Penrod, S., Silverhus, S. & Leventhal, H. (1982) The cognitive organisation of disease and illness among 
lay persons. Unpublished manuscript, University of Wisconsin, Madison.  
Llewellyn, C. D., Miners, A. H., Lee, C. A., Harrington, C. & Weinman, J. (2003) The illness perceptions and 
treatment beliefs of individuals with severe haemophilia and their role in adherence to home treatment. 
Psychology and Health, 18(2), 185-200. 
Lowry, K. P., Dudley, T. K., Oddone, E. Z. & Bosworth, H. B. (2005) Intentional and unintentional non-adherence 
to antihypertensive medication. Annals of Pharmacotherapy, 39 (7), 1198–1203. 
Lumme-Sandt, K., Hervonen, A., Jylha, M. (2000) Interpretative repertoires of medication among the oldest old. 
Social Sci. Med. (50), 1843–1850. 
Luqmani, R., Hennell, S., Estrach, C., Basher, D., Birrell, F., Bosworth, A. et al on behalf of the British Society for 
Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working 
Group (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline 
for the management of rheumatoid arthritis (after the first 2 years). Rheumatology, 48(4), 436-439. 
MacGregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J., Aho, K. et al. (2000) Characterizing the 
quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum, 43, 30-37. 
Maidment, R., Livingston, G. & Katona, C. (2002) Just keep taking the tablets: adherence to antidepressant 
treatment in older people in primary care. Int. J. Ger Psych, 17(8), 752-757. 
 216 
 
Maini, R. (2001) Anti-TNF therapy of rheumatoid arthritis: from science to the pharmacopoeia. 
www.rheuma21st.com/archives/cutting_edge_tnf.html_20040915. 
Matteson, E. L. (2000). Current treatment strategies for rheumatoid arthritis. Mayo Clinic Proceedings, 75, 67-
74. 
Mattson, M. (1999) Towards a reconceptualization of communication cues to action in the health belief model: 
HIV test counselling. Communication Monographs, 66, 240–65. 
Matsui, D., Hermann, C., Klein, J., Berkovitch, M., Olivieri, N. & Koren, G. (1994) Critical comparison of novel 
and existing methods of compliance assessment during a clinical trial of an oral iron chelator. Journal of 
Clinical Pharmacology, 34, 944-949. 
McClure, R. J., Newell, S. J. & Edwards, S. (1996) Patient characteristics affecting attendance at general 
outpatient clinics. Archives of Disease in Childhood, 74, 121-125. 
McDonald, H. P., Garg, A. X. & Haynes, R. B. (2002) Interventions to enhance patient adherence to medication 
prescriptions; Scientific Review. JAMA 288(22), 2868-2879. 
Meenan, R. F., Yelin, E. H., Henke, C. J., Curtis, D. L. & Epstein, W. V. (1978) The costs of rheumatoid arthritis. A 
patient-oriented study of chronic disease costs. Arthritis Rheum, 21(7), 827-833. 
Menckeberg, T. T., Marcel, L. B., Bracke, M., Kaptein, A. A., Leufkens, H. G., Raaijmakers, J. A. M. & Horne, R. 
(2008) Beliefs about medicines predict refill adherence to inhaled corticosteroids. Journal of Psychosomatic 
Research, 64, 47-54. 
Milne, R. G., Horne, M. & Torsney, B. (2006) SMS reminder in the UK National Health Service: An evaluation of 
it’s impact on “No-shows” at hospital out patient clinics. Health Care Management Review, 31(2), 130-136. 
Mobile Data Association. The Q4 2008 UK Mobile Trends Report October 2008 – January 2009. 
http://www.themda.org/mda-press-releases/the-q4-2008-uk-mobile-trends-report.php 13th February 2009 
Morisky, D. E., Green, L. W. & Levine, D. M. (1986) Concurrent and predictive validity of a self-reported 
measure of medication adherence. Medical Care, 24(1), 67-74. 
Moss-Morris, R., Weinman, J., Petrie, K., Horne, R., Cameron, L. D. & Buick, D. (2002) The Revised Illness 
Perception Questionnaire (IPQ-R). Psychology and Health, 17(1), 1-16. 
Murphy, H., Dickens, C., Creed, F., & Bernstein, R. (1999). Depression, illness perception and coping in 
rheumatoid arthritis. Journal of Psychosomatic Research, 46, 155-164. 
National Audit Office (2009) Services for people with rheumatoid arthritis: Economic models of identification 
and treatment of early rheumatoid arthritis.  
National Institute for Health and Clinical Excellence (2008) Guide to the Methods of Technology Appraisal, NICE, 
London 1-76. 
National Rheumatoid Arthritis Society (2007) I want to work…. 
National Rheumatoid Arthritis Society (2010) The Economic Burden of Rheumatoid Arthritis.  
Neidel, J., Schulze, M. & Lindschau, J. (1995) Association between degree of bone-erosion and synovial fluid-
levels of tumor necrosis factor α in the knee joints of patients with rheumatoid arthritis. Inflammation 
Research, 44(5), 217-221. 
 217 
 
Nexoe, J., Kragstrup, J. & Sogaard, J. (1999) Decision on Influenza vaccination among the elderly. A 
questionnaire study based on the Health Belief Model and the Multidimensional Locus of Control Theory. 
Scandinavian Journal of Primary Healthcare, 17, 105-110.   
NICE (2009) Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE clinical guideline 79. 
National Collaborating Centre for Chronic Conditions 
NICE (2010) Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis.  
Nichol, M. B., Venturini, F. & Sung, J. C. (1999) A critical evaluation of the methodology literature on medication 
compliance. The Annals of Pharmacotherapy, 33, 531-540. 
Nicklas, L. B., Dunbar, M. & Wild, M. (2010) Adherence to pharmacological treatment of non-malignant chronic 
pain: The role of illness perceptions and medication beliefs. Psychology and Health, 25(5), 601-615. 
Nikiphorou, E. & Young, A. (2010) RA: overview of recommended diagnosis and drug treatment. Prescriber, 21, 
18-33. 
Nikolaus, S., Bode, C., Taal, E. & van de Laar. M. A. F. J. (2010) Four different patterns of fatigue in rheumatoid 
arthritis patients: results of a Q-sort study. Rheumatology, 49, 2191-2199. 
Norell, S. E. (1981) Accuracy of patient interviews and estimates by clinical staff in determining medication 
compliance. Social Science & Medicine - Part E, Medical Psychology, 15, 57-61. NICE technology appraisal 
guidance 130.  
NRAS (2010) The Economic Burden of RA. 
Nunnally, J. C.  (1978). Psychometric theory (2
nd
 ed.).  New York:  McGraw-Hill. 
Obermayer, J., Riley, W., Asif, O. & Jean-Mary, J. (2004) College smoking cessation using cell phone text 
messaging. Journal of American College Health 2004, 53(2), 71-78. 
Office for National Statistics. Internet Access Households and Individuals. 
http://www.statistics.gov.uk/pdfdir/iahi0809.pdf 28 August 2009  
Orbell, S., Hagger, M., Brown, V. & Tidy, J. (2006) Comparing two theories of health behaviour: A prospective 
study of noncompletion of treatment following cervical cancer screening. Health Psychology, 25(5), 604-
615. 
Osiri, M., Shea, B., Robinson, V., Suarez-Almazor, M., Strand, V., Tugwell, P. et al. (2003) Leflunomide for 
treating rheumatoid arthritis: a systematic review and meta-analysis. The Journal of Rheumatology, 30(6), 
1182-1190. 
Osterberg, L. & Blaschke, T. (2005) Adherence to Medication. New England Journal of Medicine, 353(5), 487-
497. 
Owen, S. G., Friesen, W. T., Roberts, M. S. & Flux, W. (1985) Determinants of compliance in rheumatoid 
arthritic patients assessed in their home environment. British Journal of Rheumatology, 24, 313-320. 
Park, D. C., Hertzog, C., Leventhal, H., Morrell, R. W., Leventhal, E., Birchmore, D. et al. (1999) Medication 
adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc, 47, 172–183. 
Personal Social Services Research Unit (2010) Unit Costs of Health and Social Care 2010. 
 218 
 
Patel, R. P. & Taylor, S. D. (2002) Factors affecting medication adherence in hypertensive patients. Annals of 
Pharmacotherapy 36, 40–45. 
Peterson, A. M., Takiya, L. & Finley, R. (2003) Meta-analysis of trials of interventions to improve medication 
adherence. Am J Health-Syst Pharm, 60, 657-665. 
Petrie, K. J., Cameron, L. D., Ellis, C. J., Buick, D. & Weinman, J. (2002) Changing illness perceptions following 
myocardial infarction for weight loss: randomized controlled trial. Psychosomatic Medicine, 64, 580-586. 
Petrie, K. J., Jago, L. A. & Devcich, D. A. (2007) The role of illness perceptions in patients with medical 
conditions. Current Opinion in Psychiatry, 20, 163-167. 
Petrie, K. J., Perry, K., Broadbent, E. & Weinman, J. (2011) A text message programme designed to modify 
patients’ illness and treatment beliefs improves self-reported adherence to asthma preventer medication. 
British Journal of Health Psychology, DOI: 10.1111/j.2044-8287.2011.02033.x 
Petrie, K. J. & Weinman, J. (2006) Why illness perceptions matter. Clinical Medicine, 6, 536-539. 
Pincus, T., Griffith, J., Pearce, S., & Isenberg, D. (1996). Prevalence of self-reported depression in patients with 
rheumatoid arthritis. British Journal of Rheumatology, 35, 879-883. 
Prevoo, M. L. L., van Gestel, A. M., van Hof, M. A., van Ruswuk, M. H., van de Putte, L. B. A. & van Riel, P. L. C. 
M. (1996) Remission in a prospective study of patients with rheumatoid arthritis. Br J Rheumatol, 35, 1101-
1105. 
Pugner, K. M. Scott, D. I., Holmes, J. W. & Hieke, K. (2000) The costs of Rheumatoid Arthritis: An international 
long-term view. Seminars in Arthritis & Rheumatism, 29(5), 305-320. 
Pullar, T (1991). Compliance with drug therapy. British Journal of Clinical Pharmacology, 32, 535–539. 
Ramey, D., Fries, J. & Singh, G. (1996) The Health Assessment Questionnaire 1995 — status and review. In: 
Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-
Raven; 1996:227-37. 
Rodgers, A., Corbett, T., Bramley, D., Riddell, T., Wills, M., Lin, R. et al. (2005) Do u smoke after txt? Results of a 
randomised trial of smoking cessation using mobile phone text messaging. Tobacco Control, 14(4), 255–261.  
Rogers, P. G., & Bullman, W. (1995) Prescription medicine compliance: review of the baseline of knowledge – 
report of the National Council on Patient Information and Education. Journal of Pharmacoepidemiology, 3, 
3-36. 
Rosenstock, I. M. (1966) Why people use health services. Milbank Memorial Fund Quarterly, 44, 94–124. 
Ross, S., Walker, A. & MacLeod, M. J. (2004) Patient compliance in hypertension: role of illness perceptions and 
treatment beliefs. Journal of Human Hypertension, 18(9), 607–613. 
Roter, D. L., Hall, J. A., Merisca, R., Nordstrom, B., Cretin, D. & Svarstad, B. (1998) Effectiveness of interventions 
to improve patient compliance: a meta-analysis. Med Care, 36, 1138-1161. 
Royston, P. (2004) Multiple imputation of missing values. Stata Journal, 4(3), 227-241. 
Rutter, C. L. & Rutter, D. R. (2007) Longitudinal analysis of the Illness Representation Model in patients with 
Irritable Bowel Syndrome (IBS). Journal of Health Psychology, 12(1), 141-148. 
Salzman, C. (1995) Medication compliance in the elderly. Journal of Clinical Psychiatry, 56(1), 18-22. 
 219 
 
Sarquis, L. M.,  Dellacqua, M. C., Gallani, M. C., Moreira, R. M., Bocchi, S. C., Tase, T. H. et al. (1998) 
[Compliance in antihypertensive therapy: analyses in scientific articles.] [Portuguese] Revista Da Escola de 
Enfermagem Da USP, 32, 335-353. 
Scharloo, M., Kaptein, A. A., Weinman, J., Bergman, Q., Vermeer, B. J. & Rooijmans, H. G. M. (2000) Patients’ 
illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. British 
Journal of Dermatology, 142, 899-907. 
Scharloo, M., Kaptein, A. A., Weinman, J., Hazes, J. M., Willems, L. N. A., Bergman, W. et al. (1998) Illness 
perceptions, coping and functioning in patients with rheumatoid arthritis, chronic obstructive pulmonary 
disease and psoriasis. Journal of Psychosomatic Research, 44(5), 573-585. 
Schiaffino, K. M. & Revenson, T. A. (1992) The role of perceived self-efficacy, perceived control and causal 
attributions in the adaptation to rheumatoid arthritis: distinguishing mediator from moderator effects. 
Personality and Social Psychology Bulletin, 18, 709-718. 
Schipper, L. G., Kievit, W., den Broeder, A. A., van der Laar, M. A., Adang, E. M. M., Fransen J. et al (2011) 
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with Methotrexate 
monotherapy is cost-effective. Rheumatology, 50, 1320-1330. 
Schuz, B., Marx, C., Wurm, S., Warner, L. M., Ziegelmann, J. P., Schwarzer, R. & Tesch-Romer, C. (2011) 
Medication beliefs predict medication adherence in older adults with multiple illnesses. Journal of 
Psychosomatic Research, 70, 179-187. 
Schwarzer, R. (1998) Optimism, goals and threats: How to conceptualise self regulatory processes in the 
adoption and maintenance of health behaviours. Psychology and Health, 13, 759-766. 
Schwarzer, R. & Fuchs, R. (1996) Self efficacy and health behaviour. In M. Conner and P. Norman (Eds) 
Predicting Health Behavior; Research and practice with social cognition models, (pp.23-61), Buckingham, 
UK: Open University Press 
Sharp, L. A. (1999). A medical anthropologist’s view on posttransplant compliance: the underground economy 
of medical survival. Transplantation Proceedings, 31, 315 – 335. 
Sheeran, P & Abraham, C. (1996) The health belief model. In M. Conner and P. Norman (Eds) Predicting Health 
Behavior; Research and practice with social cognition models, (pp.23-61), Buckingham, UK: Open University 
Press 
Shichikawa, K, Inoue, K, Hirota, S, Maeda, A, Ota, H, Kimura, M, Ushiyama, T, Tsujimoto, M (1999) Changes in 
the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996. Ann 
Rheum Dis, 58, 751-756. 
Silman, A. J., Ollier, W., Holligan, S., Birrell, F., Adebajo, A., Asuzu, M. C., Thomson, W., Pepper, L. (1993) 
Absence of rheumatoid arthritis in a rural Nigerian population. Journal of Rheumatology, 20, 618-622. 
Silman A. J. & Pearson J. E. (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Research, 
4(Suppl 3), S265-S272. 
Smolen, J. S., Landewe, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., et al. (2010) EULAR 
recommendations for the management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs. Annals of Rheumatic Disease doi:10.1136/ard.2009.126532  
Soliman, M. M., Ashcroft, D. M., Watson, K. D., Lunt, M., Symmons, D. P. M., & Hyrich, K. L. (2011) Impact of 
concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid 
 220 
 
arthritis: results from the British Society for Rheumatology Biologics Register. Annals of Rheumatic Diseases, 
70, 583-589. 
Stamuli, E. (2011) Health outcomes in economic evaluation: who should value health? British Medical Bulletin, 
97(1), 197-210. 
Staples, M. P., March, L., Lassere, M. Reid, C. & Buchbinder, R. (2011) Health-related quality of life and 
continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients 
from the Australian Rheumatology Association Database. Rheumatology, 50, 166-175. 
Steiner, J. F. & Prochazka, A. V. (1997) The assessment of refill compliance using pharmacy records: methods, 
validity, and applications. Journal of Clinical Epidemiology, 50(1), 105-116. 
Stevenson, F. A., Cox, K., Britten, N. & Dundar, Y. (2004) A systematic review of the research on communication 
between patients and health care professionals about medicines: the consequence for concordance. Health 
Expectations, 7(3), 235-245. 
Stone, C. E. (1984) The lifetime economic costs of rheumatoid arthritis. J Rheumatol, 11(6), 819-27. 
Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G. et al. (1999) Treatment of active 
rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid 
Arthritis Investigators Group. Arch Intern Med, 159, 2542-2550. 
Suarez-Almazor, M. E. & Conner-Spady, B. (2001) Rating of arthritis health states by patients, physicians and 
the general public: implications for cost-utility analyses. Journal of Rheumatology, 28, 648-656. 
Svensson, S., Kjellgren, K.I., Ahlner, J., Saljo¨, R. (2000) Reasons for adherence with antihypertensive 
medication. Int. J. Cardiol. (76), 157–163. 
Symmons, D. P. M. (2005) Looking back: Rheumatoid arthritis – aetiology, occurrence and mortality. 
Rheumatology, 44(suppl 4), iv14-iv17. 
Symmons, D. P., Jones, M. A., Scott, D. L., Prior, P. (1998) Longterm mortality outcome in patients with 
rheumatoid arthritis: early presenters continue to do well. J Rheumatol, 25, 1072–1077. 
Tabachnik, B. G. F., L. S. (1989). Using Multivariate Statistics. New York, Harper Collins. 
Tabachnick B. G. & Fidell L. S. (2007) Using Multivariate Statistics: Fifth Edition. Pearson, New York.  
Tak, S. H. & Hong, S. H. (2005) Use of the internet for health information by older adults with arthritis. 
Orthopaedic Nursing, 24(2), 134-138. 
ten Wolde, S., F. C. Breedveld,, Hermans, J., Vandenbroucke, J. P., van de Laar, M. A., Markusse H. M. et al. 
(1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet, 
347(8998), 347-352. 
The Euroqol Group (1990) Euroqol – a new facility for the measurement of health-related quality-of-life. Health 
Policy, 16, 199–208. 
Treharne, G. J., Kitas, G. D., Lyons, A. C. & Booth, D. A. (2005) Well-being in Rheumatoid Arthritis: The effects of 
disease duration and psychosocial factors. Journal of Health Psychology, 10(3), 457-474. 
Treharne, G. J., Lyons, A. C., Hale, E. D., Douglas, K. M. J. & Kitas, G. D. (2006) 'Compliance' is futile but is 
'concordance' between rheumatology patients and health professionals attainable? Rheumatology, 45, 1-5. 
 221 
 
Treharne, G. J., Lyons, A. C. & Kitas, G. D. (2004) Medication adherence in rheumatoid arthritis: effects of 
psychosocial factors. Psychology, Health & Medicine, 9(3), 337-349. 
Tsakonas, E., Fitzgerald, A. A., Fitzcharles, M. A., Cividino, A., Thorne, J. C., M’Seffar, A. et al (2000) 
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the 
Hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol, 27, 623-629. 
Tuldra, A., Fumaz, C. R., Ferrer, M. J., Bayes, R., Arno, A., Balague, M. et al (2000) Prospective randomized two-
arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to 
highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 25(3), 221-228. 
Urquart, J. (1999) The impact of compliance on drug development. Transplant Proc, 31(4A), 39S. 
van der Heide, A., Jacobs, J. W., Bijlsma, J. W., Heurkens, A. H., van Booma-Frankfort, C., van der Veen, M. J. et 
al. (1996) The effectiveness of early treatment with ‘second line’ antirheumatic drugs. A randomised, 
controlled trial. Ann Intern Med, 124, 699-707. 
van Gestel, A. M., Haagsma, C. J. & van Riel, P. L. C. M. (1998) Validation of rheumatoid arthritis improvement 
criteria that include simplified joint counts. Arthritis Rheum, 41, 1845-1850. 
van Hoogmoed, D., Fransen, J., Bleijenberg, G. & van Riel, P. (2010) Physical and psychosocial correlated of 
severe fatigue in rheumatoid arthritis. Rheumatology, 49, 1294-1302. 
van Lankveld, W. G. J. M., Derks, A. M. & van den, Hoogen, F. H. J. (2006) Disease related use of the internet in 
chronically ill adults: current and expected use. Annals of the Rheumatic Diseases, 65(1), 121-123. 
Van Riel, P. L. C. M. & Schumacher, H. R. (2001). How does one assess early rheumatoid arthritis in daily clinical 
practice? Best Practice & Research, Clinical Rheumatology, 15(1), 67-76. 
Vermeire, E., Hearnshaw, H., van Royen, P. & Denekens, J. (2001) Patient adherence to treatment: three 
decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics, 26, 331-342. 
Vidrine, D, Arduino, R, Lazev, A & Gritz, E. A. (2006) Randomized trial of a proactive cellular telephone 
intervention for smokers living with HIV/AIDS. AIDS, 20(2), 253–260. 
Vilella, A., Bayas, J., Diaz, M., Gulnovart, C., Diez, C., Simo, D. et al. (2004) The role of mobile phones in 
improving vaccination rates in travellers. Preventive Medicine, 38, 503-509. 
Viller, F., Guillemin, F., Briancon, S., Moum, T., Suurmeijer, T., van den Heuvel, W. (1999) Compliance to drug 
treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. Journal of Rheumatology, 
26(10), 2114–2122. 
Vitolins, M. Z., Rand, C. S., Rapp, S. R., Ribisl, P. M. & Sevick, M. A. (2000) Measuring adherence to behavioral 
and medical interventions. Controlled Clinical Trials, 21, 188S-194S. 
Volk, J. E. & Koopman, C. (2001) Factors associated with condom use in Kenya: a test of the health belief model, 
AIDS Education and Prevention, 13, 495–508. 
Waeber, B., Burnier, M. & Brunner, H. R. (2000) How to improve adherence with prescribed treatment in 
hypertensive patients? Journal of Cardiovascular Pharmacology, 35(Suppl 3), S23-S26. 
Wallston, K. A. (1993) Psychological control and its impact in the management of rheumatological disorders. 
Bailliere’s Clinical Rheumatology, 7, 281-295. 
 222 
 
Walsh, J. D., Blanchard, E. B., Kremer, J. M., & Blanchard, C. G. (1999). The psychosocial effects of rheumatoid 
arthritis on the patient and the well partner. Behaviour Research andTherapy, 37, 259-271. 
Wang, D., Kogashiwa, M. & Kira, S. (2006) Development of a new instrument for evaluating individuals’ dietary 
intakes. Journal of the American Dietetic Association, 106(10), 1588-1593. 
Watkins, K. W., Shifren, K., Park, D. C., & Morrell, R. W. (1999). Age, pain, and coping with rheumatoid arthritis. 
Pain, 82, 217-228. 
Weinman, J., Petrie, K. J., Moss-Morris, R. & Horne R. (1996) The Illness Perception Questionnaire: a new 
method for assessing the cognitive representation of illness. Psychology and Health, 11, 431-445. 
Weinstein, N. D. (1993) Testing four competing theories of health: Protective behaviour. Health Psychology, 12, 
324-333. 
Whitehead, S. J. & Ali, S. (2010) Health outcomes in economic evaluation: the QALY and utilities. British Medical 
Bulletin, 96, 5-21. 
World Health Organisation (2003) Adherence to long term therapies: Evidence for Action.       
Wilson, C., Flight, I., Hart, E., Turnbull, D., Cole, S. & Young, G. (2008) Internet access for delivery of health 
information to South Australians older than 50. Australian and New Zealand Journal of Public Health, 32(2), 
174-176. 
Wolfe, F. (1996) The natural history of rheumatoid arthritis. J Rheumatol Suppl, 44, 13-22. 
Wolfe, F. & Hawley, D. J. (1998) The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 
18 year study of 823 patients. J Rheumatol, (11), 2108-2117. 
Woods, S. P., Moran, L. M., Carey, C. L., Dawson, M. S., Iudicello, J. E., Gibson, S. et al. (2008) Prospective 
memory in HIV infection: Is “remembering to remember” a unique predictor of self reported medication 
management? Archives of Clinical Neuropsychology, 23, 257-270.  
Young, A. (2008) Current approached to drug treatment in rheumatoid arthritis. Prescriber, 19, 19-28. 
Young, L. D. (1992) Psychological factors in Rheumatoid Arthritis. Journal of Consulting and Clinical Psychology, 
60(4), 619-627. 
Young, A., Dixey, J., Cox, N., Davies, P., Devlin, J., Emery, P. et al. (2000) How does functional disability in early 
rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from 
the Early RA Study (ERAS). Rheumatology, 39(6), 603-601. 
Young, A., Dixey, J., Kulinskaya, E., Cox, N., Davies, P., Devline, J. et al. (2002) Which patients stop working 
because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study 
(ERAS). Annals of Rheumatic Disease, 61(4), 335-340. 
Zhu, T. Y., Tam, L. S. & Li, E. K. (2011) Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based 
cost-of-illness study. Rheumatology, 50, 1293-1301. 
  
 223 
 
Appendices 
Appendix 4.1: Full list of references retrieved for the ICT systematic literature review 
Text & email adherence (6) 
Anhøj, J., & Møldrup, C. (2004). Feasibility of collecting diary data from asthma patients through mobile phones and SMS 
(short message service): response rate analysis and focus group evaluation from a pilot study. Journal of Medical Internet 
Research, 6(4). 
Casey, R., G., Quinlan, M., R., Flynn, R., Grainger, R., McDermott, T., E., Thornhill, J., A. (2007) Urology out-patient non-
attenders: are we wasting out time? Irish Journal of Medical Science, 176(4), 305-308. 
Koshy, E., Car, J., & Majeed, A. (2008). Effectiveness of mobile-phone short message service (SMS) reminders for 
ophthalmology outpatient appointments: observational study. BMC Ophthalmology, 8(1), 9. 
Kwon, H. S., Cho, J. H., Kim, H. S., Lee, J. H., Song, B. R., Oh, J. A., et al. (2004). Development of web-based diabetic patient 
management system using short message service (SMS). Diabetes research and clinical practice, 66, 133-137. 
Milne, R., G., Horne, M. & Torsney, B. (2006) SMS reminders in the UK National Health Service: an evaluation of its impact 
on “no-shows" at hospital out-patient clinics. Health Care Management Review, 31(2), 130-136. 
wen Chen Li-zheng Fang Li-ying Chen Hong-lei Dai, Z. (2008). Comparison of an SMS text messaging and phone reminder to 
improve attendance at a health promotion center: A randomized controlled trial. ??????: B ????(001), 34-38. 
Text & email general (6) 
Brown, S. J., McCabe, C. S., Hewlett, S., McDowell, J. A., Cushnaghan, J., Breslin, A. M., et al. (2006). Rheumatology 
telephone helplines: Patient and health professionals' requirements. Musculoskeletal Care, 4(1). 
Castrén, J., Niemi, M., & Virjo, I. (2005). Use of email for patient communication in student health care: a cross-sectional 
study. BMC Medical Informatics and Decision Making, 5(1), 2. 
Haller, D., Sanci, L., Sawyer, S., Coffey, C., & Patton, G. (2006). RU OK 2 TXT 4 RESEARCH?--feasibility of text message 
communication in primary care research. Australian family physician, 35(3), 175. 
Huanga'c, F., Liu, S. C., Shihc, S. M., Taoc, Y. H., Wuc, J. Y., Jengc, S. Y., et al. (2006). A Web-based Short Messaging Service 
System to Enhance Family-centered Surgical Patient Care. Consumer-Centered Computer-Supported Care for Healthy 
People, 163. 
Neville, R., G., Reed, C., Boswell, B., Sergeant, P., Sullivan, T. & Sullivan, F., M. (2008) Early experience of the use of short 
message service (SMS) technology in routine clinical care. Informatics in Primary Care, 16(3), 203-211. 
Sullivan, K., W. (2002) See something you like? Patient surveys via the internet. Medical Group Management Association 
Connexion, 2(7), 52-53. 
Internet general arthritis (3) 
Beall Iii, M. P. S., Beall Jr, M. S., Greenfield, M., & Biermann, J. S. (2002). Patient Internet use in a community outpatient 
orthopaedic practice. The Iowa Orthopaedic Journal, 22, 103. 
Tak, S. H., & Hong, S. H. (2005). Use of the Internet for Health Information by Older Adults With Arthritis. Orthopaedic 
Nursing, 24(2), 134. 
van Lankveld, W., Derks, A. M., & van den Hoogen, F. H. J. (2006). Disease related use of the internet in chronically ill adults: 
current and expected use. Annals of the rheumatic diseases, 65(1), 121-123. 
Internet adherence (4) 
Carr, L. J., Bartee, R. T., Dorozynski, C., Broomfield, J. F., Smith, M. L., & Smith, D. T. (2008). Internet-delivered behavior 
change program increases physical activity and improves cardiometabolic disease risk factors in sedentary adults: results of 
a randomized controlled trial. Preventive Medicine, 46(5), 431-438. 
Cross, R. K., & Finkelstein, J. (2007). Feasibility and acceptance of a home telemanagement system in patients with 
inflammatory bowel disease: a 6-month pilot study. Digestive Diseases and Sciences, 52(2), 357-364. 
Gutteling, J. J., Busschbach, J. J. V., de Man, R. A., & Darlington, A. S. E. (2008). Logistic feasibility of health related quality of 
life measurement in clinical practice: results of a prospective study in a large population of chronic liver patients. Health and 
Quality of Life Outcomes, 6(1), 97. 
Wu, R. C., Delgado, D., Costigan, J., MacIver, J., & Ross, H. (2005). Pilot study of an Internet patient-physician 
communication tool for heart failure disease management. Journal of Medical Internet Research, 7(1). 
 224 
 
Internet general older adult (7) 
Campbell, R. J., & Nolfi, D. A. (2005). Teaching elderly adults to use the Internet to access health care information: before-
after study. Journal of Medical Internet Research, 7(2). 
Dey, A., Reid, B., Godding, R., & Campbell, A. (2008). Perceptions and behaviour of access of the Internet: A study of women 
attending a breast screening service in Sydney, Australia. International Journal of Medical Informatics, 77(1), 24-32. 
Flynn, K. E., Smith, M. A., & Freese, J. (2006). When do older adults turn to the Internet for health information? Findings 
from the Wisconsin Longitudinal Study. Journal of General Internal Medicine, 21(12), 1295-1301. 
Frosch, D. L., Bhatnagar, V., Tally, S., Hamori, C. J., & Kaplan, R. M. (2008). Internet Patient Decision Support: A Randomized 
Controlled Trial Comparing Alternative Approaches for Men Considering Prostate Cancer Screening. Archives of Internal 
Medicine, 168(4), 363. 
Leaffer, T. & Gonda, B. (2000) The internet: an underutilized tool in patient education. Computers in Nursing, 18(1), 47-52. 
Pautler, S. E., Tan, J. K., Dugas, G. R., Pus, N., Ferri, M., Hardie, W. R., et al. (2001). Use of the Internet for self-education by 
patients with prostate cancer. Urology, 57(2), 230. 
Wilson, C., Flight, I., Hart, E., Turnbull, D., Cole, S., & Young, G. (2008). Internet access for delivery of health information to 
South Australians older than 50. Australian and New Zealand Journal of Public Health, 32(2), 174-176. 
Internet general (27) 
Atack, L., Luk, R. & Chien, E. (2008) Evaluation of patient satisfaction with tailored online patient education information. 
Computers, Informatics, Nursing, 26(5), 258-264. 
Ayantunde, A. A., Welch, N. T., & Parsons, S. L. (2007). A survey of patient satisfaction and use of the internet for health 
information. International Journal of Clinical Practice, 61(3), 458-462. 
Ayers, S. L., & Kronenfeld, J. J. (2007). Chronic illness and health-seeking information on the Internet. Health, 11(3), 327. 
Bass, S. B., Ruzek, S. B., Gordon, T. F., Fleisher, L., McKeown-Conn, N., & Moore, D. (2006). Relationship of Internet health 
information use with patient behavior and self-efficacy: Experiences of newly diagnosed cancer patients who contact the 
National Cancer Institute's Cancer Information Service. Journal of health communication, 11(2), 219-236. 
Birchley, D., Pullan, R., & DeFriend, D. (2003). Patient attitudes to the Internet and analysis of the potential role of a 
dedicated colorectal website–a prospective study. Ann R Coll Surg Engl, 85, 398-401. 
Bussey-Smith, K., L. & Rossen, R., R. (2007) A systematic review of randomized control trials evaluating the effectiveness of 
interactive computerized asthma patient education programs. Annals of Allergy, Asthma and Immunology, 98(6), 507-516. 
Cima, R. R., Anderson, K. J., Larson, D. W., Dozois, E. J., Hassan, I., Sandborn, W. J., et al. (2007). Internet use by patients in 
an inflammatory bowel disease specialty clinic. Inflammatory Bowel Diseases, 13(10). 
Dart, J. (2008) The internet as a source of health information in three disparate communities. Australian Health Review, 
32(3), 559-569. 
Dickerson, S., Reinhart, A. M., Feeley, T. H., Bidani, R., Rich, E., Garg, V. K., et al. (2004). Patient Internet use for health 
information at three urban primary care clinics. Journal of the American Medical Informatics Association, 11(6), 499-504. 
Hart, A., Henwood, F., & Wyatt, S. (2004). The role of the Internet in patient-practitioner relationships: findings from a 
qualitative research study. Journal of Medical Internet Research, 6(3). 
Helft, P. R., Eckles, R. E., Johnson-Calley, C. S., & Daugherty, C. K. (2005). Use of the internet to obtain cancer information 
among cancer patients at an urban county hospital. Journal of Clinical Oncology, 23(22), 4954-4962. 
Hesse, B. W., Nelson, D. E., Kreps, G. L., Croyle, R. T., Arora, N. K., Rimer, B. K., et al. (2005). Trust and Sources of Health 
Information The Impact of the Internet and Its Implications for Health Care Providers: Findings From the First Health 
Information National Trends Survey (Vol. 165, pp. 2618-2624): Am Med Assoc. 
Jeannot, J. G., Froehlich, F., Wietlisbach, V., Burnand, B., Terraz, O., & Vader, J. P. (2004). Patient use of the Internet for 
health care information in Switzerland. Swiss Medical Weekly, 134(21-22), 307-312. 
Koivunen, M., Hätönen, H., & Välimäki, M. (2008). Barriers and facilitators influencing the implementation of an interactive 
Internet-portal application for patient education in psychiatric hospitals. Patient Education and Counseling, 70(3), 412-419. 
Marziali, E., & Donahue, P. (2006). Caring for others: Internet video-conferencing group intervention for family caregivers of 
older adults with neurodegenerative disease. The Gerontologist, 46(3), 398-403. 
Pandey, S. K., Hart, J. J., & Tiwary, S. (2003). Women's health and the internet: understanding emerging trends and 
implications. Social Science & Medicine, 56(1), 179-191. 
Pereira, J. L., Koski, S., Hanson, J., Bruera, E. D., & Mackey, J. R. (2000). Internet usage among women with breast cancer: an 
exploratory study. Clinical Breast Cancer, 1(2), 148-153. 
Peterson, M. W., & Fretz, P. C. (2003). Patient Use of the Internet for Information in a Lung Cancer Clinic* (Vol. 123, pp. 
452-457): Am Coll Chest Phys. 
 225 
 
Powell, J., & Clarke, A. (2006). Internet information-seeking in mental health. The British Journal of Psychiatry, 189(3), 273-
277. 
Salo, D., Perez, C., Lavery, R., Malankar, A., Borenstein, M., & Bernstein, S. (2004). Patient education and the internet: do 
patients want us to provide them with medical web sites to learn more about their medical problems? Journal of 
Emergency Medicine, 26(3), 293-300. 
Semere, W., Karamanoukian, H. L., Levitt, M., Edwards, T., Murero, M., D'Ancona, G., et al. (2003). A pediatric surgery 
study: parent usage of the Internet for medical information. Journal of pediatric surgery, 38(4), 560-564. 
Sharf, B. F. (1997). Communicating breast cancer on-line: support and empowerment on the Internet. Women & Health, 
26(1), 65-84. 
Tassone, P., Georgalas, C., Patel, N. N., Appleby, E., & Kotecha, B. (2006). Do otolaryngology out-patients use the internet 
prior to attending their appointment? The Journal of Laryngology and Otology, 118(01), 34-38. 
Theiler, R., Alon, E., Brugger, S., Ljutow, A., Mietzsch, T., Müller, D., et al. (2007). Evaluation of a Standardized Internet-
based and Telephone-based Patient Monitoring System for Pain Therapy With Transdermal Fentanyl. The Clinical Journal of 
Pain, 23(9), 804. 
Tse, M. M. Y., Lo, L. W. L., & Chan, M. F. (2007). The use of health technology and information: e-learning technological 
approach. CyberPsychology & Behavior, 10(6), 821-826. 
Välimäki, M., Nenonen, H., Koivunen, M., & Suhonen, R. (2007). Patients'perceptions of Internet usage and their 
opportunity to obtain health information. Medical informatics and the Internet in medicine, 32(4), 305. 
Vordermark, D., Kölbl, O., & Flentje, M. (2000). The Internet as a Source of Medical Information. Strahlentherapie und 
Onkologie, 176(11), 532-535. 
Internet communication older adult (1) 
Macias, W., & McMillan, S. The return of the house call: the role of internet-based interactivity in bringing health 
information home to older adults. Health communication, 23(1), 34. 
Internet communication (11) 
Allen, M., Iezzoni, L. I., Huang, A., Huang, L., & Leveille, S. G. (2008). Improving Patient-Clinician Communication About 
Chronic Conditions: Description of an Internet-Based Nurse E-Coach Intervention. Nursing Research, 57(2), 107. 
Bylund, C. L., Gueguen, J. A., Sabee, C. M., Imes, R. S., Li, Y., & Sanford, A. A. (2007). Provider–patient dialogue about 
internet health information: An exploration of strategies to improve the provider–patient relationship. Patient Education 
and Counseling, 66(3), 346-352. 
Goldberg, H. I., Ralston, J. D., Hirsch, I. B., Hoath, J. I., & Ahmed, K. I. (2003). Using an Internet comanagement module to 
improve the quality of chronic disease care. Joint Commission Journal on Quality and Patient Safety, 29(9), 443-451. 
Hong, T. (2008). Internet Health Information in the Patient-Provider Dialogue. CyberPsychology & Behavior, 11(5), 587-589. 
Iverson, S. A., Howard, K. B., & Penney, B. K. (2008). Impact of Internet Use on Health-Related Behaviors and the Patient-
Physician Relationship: A Survey-Based Study and Review. JAOA: Journal of the American Osteopathic Association, 108(12), 
699. 
Murray, E., Lo, B., Pollack, L., Donelan, K., Catania, J., White, M., et al. (2003). The Impact of Health Information on the 
Internet on the Physician-Patient Relationship Patient Perceptions (Vol. 163, pp. 1727-1734): Am Med Assoc. 
Sciamanna, C. N., Rogers, M. L., Shenassa, E. D., & Houston, T. K. (2007). Patient access to US physicians who conduct 
internet or e-mail consults. Journal of General Internal Medicine, 22(3), 378-381. 
Slakey, D. P., & Nowfar, S. Factors affecting patient-physician communication via the Internet. Journal of Healthcare 
Information Management—Vol, 18(1), 81. 
Stevenson, F. A., Kerr, C., Murray, E., & Nazareth, I. (2007). Information from the Internet and the doctor-patient 
relationship: the patient perspective–a qualitative study. BMC Family Practice, 8(1), 47. 
Swartz, S. H., Cowan, T. M., & Batista, I. A. (2004). Using claims data to examine patients using practice-based Internet 
communication: is there a clinical digital divide? Journal of Medical Internet Research, 6(1). 
Zickmund, S. L., Hess, R., Bryce, C. L., McTigue, K., Olshansky, E., Fitzgerald, K., et al. (2008). Interest in the Use of 
Computerized Patient Portals: Role of the Provider–Patient Relationship. Journal of General Internal Medicine, 23, 20-26. 
Internet behaviour change (13) 
Brennan, P. F., Moore, S. M., Bjornsdottir, G., Jones, J., Visovsky, C., & Rogers, M. (2001). HeartCare: an Internet-based 
information and support system for patient home recovery after coronary artery bypass graft (CABG) surgery. 
D'Alessandro, D. M., Kreiter, C. D., Kinzer, S. L., & Peterson, M. W. (2004). A randomized controlled trial of an information 
prescription for pediatric patient education on the Internet. Archives of Pediatrics and Adolescent Medicine, 158(9), 857-
862. 
 226 
 
Dickerson, S. S. (2005). Technology-patient interactions: Internet use for gaining a healthy context for living with an 
implantable cardioverter defibrillator. Heart & Lung-The Journal of Acute and Critical Care, 34(3), 157-168. 
Grant, R. W., Cagliero, E., Chueh, H. C., & Meigs, J. B. (2005). Internet use among primary care patients with type 2 diabetes. 
Journal of General Internal Medicine, 20(5), 470-473. 
Kerr, C., Murray, E., Stevenson, F., Gore, C., & Nazareth, I. (2006). Internet interventions for long-term conditions: patient 
and caregiver quality criteria. Journal of Medical Internet Research, 8(3). 
Lorig, K. R., Ritter, P. L., Laurent, D. D., & Plant, K. (2006). Internet-Based Chronic Disease Self-Management: A Randomized 
Trial. Medical Care, 44(11), 964. 
Masucci, M. M., Homko, C., Santamore, W. P., Berger, P., McConnell, T. R., Shirk, G., et al. (2006). Cardiovascular disease 
prevention for underserved patients using the Internet: bridging the digital divide. Telemedicine Journal & e-Health, 12(1), 
58-65. 
Monnier, J., Laken, M., & Carter, C. L. (2002). Patient and caregiver interest in internet-based cancer services. Cancer, 10(6), 
305-310. 
Nguyen, H. Q., Carrieri-Kohlman, V., Rankin, S. H., Slaughter, R., & Stulbarg, M. S. (2005). Is Internet-based support for 
dyspnea self-management in patients with chronic obstructive pulmonary disease possible? Results of a pilot study. Heart & 
Lung-The Journal of Acute and Critical Care, 34(1), 51-62. 
Nguyen, H. Q., Donesky-Cuenco, D. A., Wolpin, S., Reinke, L. F., Benditt, J. O., Paul, S. M., et al. (2008). Randomized 
Controlled Trial of an Internet-Based Versus Face-to-Face Dyspnea Self-Management Program for Patients With Chronic 
Obstructive Pulmonary Disease: Pilot Study. Journal of Medical Internet Research, 10(2). 
Oreilly, M. (1999). Is Internet-based disease management on the way? (Vol. 160, pp. 1039-1039): Can Med Assoc. 
Thomson, N. R., & Micevski, V. (2005). A descriptive project evaluation to determine Internet access and the feasibility of 
using the Internet for cardiac education. Heart & Lung-The Journal of Acute and Critical Care, 34(3), 194-200. 
Weingart, S. N., Rind, D., Tofias, Z., & Sands, D. Z. (2006). Who uses the patient internet portal? The PatientSite experience. 
Journal of the American Medical Informatics Association, 13(1), 91-95. 
  
 227 
 
Appendix 5.1: Using Information and Communication Technology in the Rheumatology 
clinic survey 
Where did you hear about this survey? (Please tick all that apply) 
In clinic  By post  At the University of Hertfordshire  
By an email  Via facebook  Via another website  
Friend/family member      
 
What is your gender (please circle)  Male   Female 
 
What is your current age (please circle) 
18 – 24  25 – 34   35 – 44  45 – 54  55 – 64  65+  75+ 
Please write down your postcode (this is to check the broadband connection in your area) 
.............................................................................................................................................. 
What is your highest level of education (please circle) 
No formal 
qualification 
Secondary school 
(GCSEs or equivalent) 
College  
(A levels or equivalent) 
University 
(Degree or 
equivalent) 
Postgraduate 
(Degree or equivalent) 
 
Please name your illness below and answer SECTIONS A & B 
...................................................................................................................................................................................
....... 
SECTION A 
Internet and Email 
Please answer the following question by ticking the boxes “yes”, “no” or “don’t know” boxes for both your 
home and place of work.  
1. If you do not currently work, please tick this box              
 At home           Don’t At work Don’t 
 Yes No know Yes No know 
Do you have access to a computer (including a laptop)       
Do you have internet access       
Do you have broadband internet access       
Do you have dial up internet access       
Do you use the internet        
 
2. When did you last use the internet? 
 
Within the last 3 months  More than 3 months 
ago 
 Never  
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3. How often, on average, do you access the internet 
 
Every day or almost every 
day 
 A couple of times a week  Once a week  
Once a month  Less than once a month  Never  
 
4. Do you have an email address? 
 
Yes   Go to Q4a No  Go to Q6 
4a.  Is this: 
Private/personal use  Work use  I have at least one of each  
 
5. How often do you access your emails? 
More than once a day  Once a day  Once a week  
Once a month or less  I don’t have an email 
address 
   
 
6. How often have you used the internet for the following activities (please tick) 
 Never Occasionally Frequently Very 
often 
Shopping     
Working     
Looking up general health information for yourself     
Looking up general health information for a friend or 
family member 
    
Looking up specific health information about your chronic 
illness  
    
MSN (instant messenger)     
Using these social networking sites: Facebook              
Bebo     
MySpace     
Friends 
Reunited 
    
Other     
 
7. Do you experience any of the following problems on a regular basis when using a computer (tick all that 
apply) 
Have difficulty seeing the screen  
Have difficulty seeing the keyboard  
Have difficulty in pressing the keys on the keyboard  
Have difficulty moving the mouse  
Have difficulty in setting up and maintaining an email account  
None of these  
 
SMS Text messaging 
 
8. Do you own a mobile phone? 
Yes  Go to Q9 No  Go to Section B. 
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9. How often do you have your mobile phone switched on? 
All the time  During the day only  If I forget to turn it off  
Only if I’m using it  Don’t know/Can’t remember    
 
10. How often do you take your mobile phone out with you when you leave the house? 
Always  Most of the time  Sometimes  
Never  Don’t know/can’t remember    
 
11. What do you use your mobile phone for most of the time? 
 
Text messaging   Phone calls  About the same for both  
 
12. How often, on average, do you receive text messages? 
 
More than once a day  Once a day  Once a week  
Once a month or less  Never    
 
13. How often, on average, do you send/reply to text messages? 
 
More than once a day  Once a day  Once a week  
Once a month or less  Never    
 
14. How confident would you say you are in reading text messages? 
 
Very confident  Quite confident  Not confident at all  
 
15. How confident would you say you are in sending text messages? 
 
Very confident  Quite confident  Not confident at all  
 
16. Do you experience any of the following problems on a regular basis when using your mobile phone (tick all 
that apply) 
Have difficulty seeing the screen  
Have difficulty seeing the buttons  
Have difficulty holding the phone  
Have difficulty pressing the buttons  
Have difficulty in using the text message features (e.g. predictive text)  
None of these  
 
 
Section B continues on the next page  
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SECTION B  
17. Does your arthritis hospital department or nurse have the facility for you to exchange emails with them? 
 
Yes  Go to Q17a No  Go to Q17b Don’t 
know 
 
 
17a.  Have you ever used this service if it is available? 
 
Yes  No  Don’t know/can’t remember  
 
17b.  If it were available, do you think you would use this service? 
 
Yes  No  Not sure  
 
18. Have you ever received an email or text message from a healthcare representative in the following 
situations 
 
 I have previously 
received a text 
message 
I would like to 
receive a text 
message 
I have previously 
received an 
email 
I would like to 
receive an 
email 
Appointment reminder     
Medication reminder     
Response to your question     
Inviting you to participate in 
research 
    
Telling you the results of some 
research 
    
None of these     
 
 
19. Have you ever visited any websites that are specifically aimed at people with arthritis? 
 
Yes  No  Don’t know/can’t remember  
 
20. Are there any health websites that you have visited and found particularly helpful? If yes, please state 
 
...................................................................................................................................................................................
.............. 
 
21. Would you use a forum dedicated to discussions about arthritis? 
 
Yes  No  Don’t know/not sure  
 
22. Would you be happy to provide your mobile phone number and/or email address for research using text 
messaging or emails to remind you about hospital appointments or to take your medication (this will not 
be taken at this point) 
 Text message Email 
Appointment reminder   
Medication reminder   
Neither   
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Appendix 7.1: Using social cognition models of illness to predict adherence questionnaire 
 
Demographic Information 
Please circle the answer to each question that applies to you 
1. Age: 18-29 30-39 40-49 50-59 60-69 70+ 
 
 
2. 
 
 
Gender: 
 
 
Male 
 
 
Female 
    
 
 
3. 
 
 
Highest level of education: 
 
 
Secondary school 
 
 
College 
 
 
University 
 
 
Post graduate 
 
 
4. 
 
 
Are you currently working: 
 
 
Yes 
 
 
No 
 
 
4a. 
 
 
If not currently working, is this due 
to your illness? 
 
 
Yes 
 
 
No 
 
 
5. 
 
 
Occupation 
 
 
................................................................................................................................... 
 
 
6. 
 
 
Previous occupation (if not 
currently working 
 
 
 
................................................................................................................................... 
 
 
7. 
 
 
How long have you had your 
illness? 
 
 
 
................................................................................................................................... 
 
 
8. 
 
 
Which medications are you 
currently taking? (please circle ALL 
that apply) 
 
 
Disease Modifying anti-rheumatic drugs 
 
(e.g. Methotrexate, Leflunamide, 
Sulfasalazine, Hydroxychloroquine) 
 
 
Biologic 
 
(e.g. Rituximab, Adalimumab, 
Etanercept, Infliximab) 
 
 
Other  
 
 
9. 
 
 
What is the current status of your 
illness? 
 
 
Active 
 
 
Remission 
 
 
12. How many times in the past 4 
weeks have you visited your GP for 
any reason? 
 
 
..................................................................................................................................... 
 
 
ID no: ............................................................ 
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By placing a tick in one box in each group below, please indicate which statements best describe your own health state 
today 
Mobility I have no problems in walking about   
 I have some problems in walking about   
 I am confined to bed   
    
Self Care I have no problems with self care   
 I have problems washing or dressing myself   
 I am unable to wash or dress myself   
    
Usual Activities (e.g. work,  I have no problems with performing my usual activities   
study, housework, family or I have some problems with performing my usual activities   
leisure activities) I am unable to perform my usual activities   
    
Pain/Discomfort I have no pain or discomfort   
 I have moderate pain or discomfort   
 I have extreme pain or discomfort   
    
Anxiety/Depression I am not anxious or depressed   
 I am moderately anxious or depressed   
 I am extremely anxious or depressed   
 
These items deal with ways you’ve been coping with the stress in your life since you were diagnosed with arthritis. 
Obviously, different people deal with things in different ways but I’m interested in how you’ve tried to deal with it. Each 
question says something about a particular way of coping. I want to know to what extent you’ve been doing what the item 
says. Don’t answer on the basis of whether it seems to be working or not – just if you’re doing it. Please read the 
statements and tick the box which best describes the way you have been coping. Try to rate each item separately in your 
mind from the others. Make your answers as true to you as you can 
 I haven’t been 
doing this at 
all 
I’ve been 
doing this a 
little bit 
I’ve been doing 
this a medium 
amount 
I’ve been doing 
this a lot 
I’ve been concentrating my efforts on doing 
something about the situation I’m in 
    
I’ve been saying to myself “this isn’t real”     
I’ve been taking action to try to make the situation 
better 
    
I’ve been refusing to believe it has happened     
I’ve been getting help and advice from other people     
I’ve been trying to come up with a strategy about 
what to do 
    
I’ve been accepting the reality of the fact that it has 
happened 
    
I’ve been trying to get advice or help from  other 
people about what to do 
    
I’ve been learning to live with it     
I’ve been thinking hard about what steps to take     
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The following questions are about how you take the medications for your arthritis. Please read the statements and tick the 
box which best describes the way you take your medications. Think about how you have taken your Disease Modifying 
Anti-Rheumatic Drugs (DMARDs) only (e.g. Methotrexate, Leflunamide, Sulfasazine, Hydroxychloroquine) in the past 
month.  
 Don’t agree 
at all 
Don’t agree Agree Agree very 
much 
I take my anti-rheumatic medicines because I then have fewer 
problems 
    
I definitely don’t dare to miss my anti-rheumatic medications     
My medicines are always stored in the same place and that’s 
why I don’t forget them 
    
I take my medications because I have complete confidence in 
my rheumatologist 
    
What the doctor tells me, I hang on to     
I sometimes forget to take my medicines     
I sometimes alter the dose of my medication to suit my own 
needs 
    
 
The following question is about the symptoms of your arthritis. Please read each symptom and tick the box to show 
whether: 
a) You have experienced this symptom in the past 2 months 
b) If you have experienced it, do you believe this symptom was caused by your arthritis 
Symptom a) Have you experienced 
this symptom is the past 
2 months? 
b) Do you believe this 
symptom was caused by 
your arthritis? 
Pain   
Sore throat   
Stiff joints   
Headache   
Blocked or runny nose   
Tiredness   
Fever   
Weight loss   
Poor sleep   
Loss of appetite   
Swelling of the joints   
Sickness: vomiting or nausea   
Breathlessness   
Abdominal cramps   
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The following questions are about what you think about your arthritis and how it affects you. Please read the statements 
carefully and tick the box which best describes how much you agree with the statement. 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
My arthritis will last a short time      
My arthritis is likely to be permanent rather than 
temporary 
     
My arthritis will last for a long time      
My arthritis will pass quickly      
I expect to have arthritis for the rest of my life      
The symptoms of my arthritis change a great deal from 
day to day 
     
My symptoms come and go in cycles      
My arthritis is very unpredictable      
I go through cycles in which my arthritis gets better and 
worse 
     
 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
My arthritis is a serious condition      
My arthritis has major consequences on my life      
My arthritis does not have much effect on my life      
My arthritis strongly effects the way others see me      
My arthritis has serious financial consequences      
My arthritis causes difficulties for those that are close to 
me 
     
 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
There is a lot that I can do to control my symptoms      
What I do can determine whether my arthritis gets better 
or worse 
     
The course of my arthritis depends on me      
Nothing I do will effect my arthritis      
I have the power to influence my arthritis      
My actions will have no effect on the outcome of my 
arthritis 
     
 
 Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly agree 
My arthritis will improve in time      
There is little that can be done to improve my 
arthritis 
     
My medicines will be effective in curing my arthritis      
The negative effects of my arthritis can be 
prevented (avoided) by my medicines 
     
My medicines can control my arthritis      
There is nothing which can help my arthritis      
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 Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly agree 
The symptoms of my arthritis are puzzling to me      
My arthritis is a mystery to me      
My arthritis doesn’t make any sense to me      
I have a clear picture or understanding of my 
arthritis 
     
I don’t understand my arthritis      
 
 Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly agree 
I get depressed when I think about my arthritis      
When I think about my arthritis, I get upset      
My arthritis makes me feel angry      
My arthritis does not worry me      
Having arthritis makes me feel anxious      
My arthritis makes me feel afraid      
 
The following questions are concerned with how you feel about taking your arthritis medications and your attitudes 
towards them. Read each statement carefully and circle the comment that you agree with most strongly. When reading 
these statements, please think about how you take all of your Disease Modifying Anti-Rheumatic Drugs only (e.g. 
Methotrexate, Leflunamide, Sulfasalazine, Hydroxychloroquine). 
For the next question, please circle one comment that you agree with most strongly for each numbered option. 
TPBA 
Taking all of the Disease modifying anti-rheumatic drugs for my arthritis would be: 
 
1. 
 
Wise 
 
Foolish 
 
2. 
 
Important 
 
Unimportant 
 
3. 
 
Satisfying 
 
Unsatisfying 
 
4. 
 
Pleasant 
 
Unpleasant 
 
5. 
 
Worthwhile 
 
Not worthwhile 
 
6. 
 
Necessary 
 
Unnecessary 
 
7. 
 
Good 
 
Bad 
 
8. 
  
Useful 
 
Of no use 
 
For the following questions, please read the statement and circle the answer that you agree with most 
Most people important to me think that I should 
take all of my tablets 
Extremely 
unlikely 
Unlikely Neither likely nor 
unlikely 
Likely Extremely 
likely 
Most people who have arthritis take all of their 
medications 
Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
People who are important to me think that I 
should/should not take all of my medicines 
Definitely 
shouldn’t 
Shouldn’t Neither should 
nor shouldn’t  
Should Definitely 
should 
Do you think it would be easy or difficult to take 
all of your medication 
Extremely 
difficult 
Difficult Neither easy nor 
difficult 
Easy Extremely 
easy 
How much personal control do you have over 
taking all of your medications 
Extremely 
low control 
Low control Neither high nor 
low control 
High 
control 
Extremely 
high control 
How confident are you that you will be able to 
take all of your medicines for the next month 
Very 
unconfident 
Unconfident Neither 
confident nor 
unconfident 
Confident Very 
confident 
How confident are you that over the next 
month, you could overcome obstacles that 
Very 
unconfident 
Unconfident Neither 
confident nor 
Confident Very 
confident 
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prevent you from taking all of your medicines? unconfident 
I believe that I have the ability to take all of my 
medicines 
Definitely 
don’t 
Don’t Neither do nor 
don’t 
Do Definitely 
do 
Whether or not I take all of my medicines is 
entirely up to me 
Strongly 
disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly 
agree 
How much do you feel that taking all of your 
medicines is beyond your control 
Very much Some Neither beyond 
nor not beyond 
my control 
A little Not at all 
 
Over the next month, my goal is to take my arthritis medicines: (please circle) 
 
Not at all Some of the time Most of the time All of the time 
 
 
a) According to the prescription from your doctor, how often should you take your disease modifying anti-
rheumatic medication? 
 
 
Once a week Once a day  More than once a day As needed Don’t know 
 
 
 
b) How often do you take your disease modifying anti-rheumatic medication? 
 
 
 Once a week Once a day More than once a day As needed Can’t remember 
  
 
c) If your answer to question (b) was different to question (a) please state why: 
 
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
.................................................................................................................................................................................. 
 
How often have you visited your GP in the last 4 weeks?  ...................................................................................................... 
 
The following questions are about how you feel about your medicines and your arthritis. Please read the statements 
carefully and then tick the box which most closely describes how much you agree or disagree with the statement. 
 Strongly 
disagree 
Disagre
e 
Neither 
agree nor 
disagree 
Agree Strongly 
agree 
I do not want to take medications      
My arthritis medications have unpleasant side effects      
In general I am opposed to medications      
It is too much trouble for me to get my prescriptions      
My arthritis medicines weaken my immune system      
My medications are too expensive      
My arthritis medications are effective in improving my 
symptoms 
     
I suffer more symptoms than other people with arthritis      
I am concerned about the risk of falling seriously ill      
I get sick more easily than other people with arthritis      
My arthritis may lead to serious health problems      
If I had a severe flare up of my arthritis, I would not be 
able to manage my daily activities 
     
I am afraid a flare up of my arthritis would make me very 
sick 
     
I am worried about having a flare up of my arthritis      
Whenever I get sick it seems to be serious      
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The following questions are about the way you feel about medications in general. Please read the statement and tick the 
box which best describes how much you agree or disagree with the statement 
 Strongly 
disagree 
Disagre
e 
Neither 
agree nor 
disagree 
Agree Strongly 
agree 
Most medicines are addictive      
People who take medicines should stop their treatment for 
a while every now and again 
     
Medicines do more harm than good      
All medicines are poisons      
Natural remedies are safer than medicines      
Doctors place too much trust in medicines      
If doctors had more time with patients they would prescribe 
fewer medicines 
     
Doctors use too many medicines      
 
The following questions are about the disease modifying anti-rheumatic drugs (e.g. Methotrexate, Leflunaminde, 
Sulfasazine, Hydroxychloroquine) that you take for your arthritis. When reading the statements, please think about these 
medicines only and tick the box which best describes how much you agree or disagree with the statement.  
 Strongly 
disagree 
Disagre
e 
Neither 
agree nor 
disagree 
Agree Strongly 
agree 
My medicines disrupt my life      
Having to take medicines worries me      
I sometimes worry about becoming too dependent on my 
medicines 
     
My medicines are a mystery to me      
I sometimes worry about the long term effects of my medicine      
My life would be impossible without my medicines      
My health in the future will depend on my medicines      
Without my medicines I would be very ill      
My medicines protect me from becoming worse      
My health, at present, depends on my medicines      
 
The following questions are about how you have been feeling in the last few weeks. Please read each statement and circle 
the number indicating how often you feel that way, where 1 is almost never and 5 is almost all the time. 
 Almost 
never 
   Almost all 
the time 
I feel like a failure 1 2 3 4 5 
I get a frightened feeling, as if something awful is about to 
happen 
1 2 3 4 5 
I feel guilty 1 2 3 4 5 
I can laugh and see the funny side of things 1 2 3 4 5 
I am disappointed in myself 1 2 3 4 5 
I get a frightened feeling, like butterflies in the stomach 1 2 3 4 5 
I feel cheerful 1 2 3 4 5 
I blame myself constantly 1 2 3 4 5 
I get a sudden feeling of panic 1 2 3 4 5 
I look forward with enjoyment to things 1 2 3 4 5 
I think about harming myself 1 2 3 4 5 
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 The following questions are about how you manage day to day activities with your arthritis. Please read the statements 
and tick the response which best describes your usual abilities over the past week 
 
 Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With 
MUCH 
difficulty 
UNABLE to 
do 
 
DRESSING and GROOMING 
 
    
Are you able to:     
Dress yourself, including tying shoelaces and doing buttons?     
Shampoo your hair?     
 
ARISING 
 
    
Are you able to:     
Stand up from an armless straight chair?     
Get in and out of bed?     
 
EATING 
 
    
Are you able to:     
Cut your meat?     
Lift a full cup or glass to your mouth?     
Open a new carton of milk (or soap powder)?     
 
WALKING 
 
    
Are you able to:     
Walk outdoors on flat ground?     
Climb up five steps?     
 
Please tick any aids or devices that you usually use for any of the above activities: 
 
Cane/walking stick    Walking frame  
Built-up or special utensils   Crutches  
Wheelchair   Special or built-
up chair 
 
Devices used for dressing (button hooks, zip pull, long-handled shoe horn)   
Other (please specify)   
 
Please tick any category for which you usually need help from another person: 
 
Dressing and grooming   Eating  
Arising   Walking  
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 Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With MUCH 
difficulty 
UNABLE 
to do 
HYGIENE 
 
    
Are you able to:     
Wash and dry your body?     
Take a bath?     
Get on and off the toilet?     
 
REACH 
 
    
Are you able to:     
Reach and get down a 5lb object (e.g. a bag of potatoes) from just 
above your head? 
    
Bend down to pick up clothing off the floor?     
 
GRIP 
 
    
Are you able to:     
Open car doors?     
Open jars which have been previously opened?     
Turn taps on and off?     
 
ACTIVITIES 
 
    
Are you able to:     
Run errands and shop?     
Get in and out of a car?     
Do chores such as vacuuming, housework or light gardening?     
 
Please tick any aids or devices that you usually use for these activities: 
 
Raised toilet seat   Bath seat  
Bath rail   Long-handled appliances for reach  
Long-handled appliances in the bathroom   Jar opener (for jars previously 
opened) 
 
Other (specify) 
 
Please tick any categories for which you usually need help from another person: 
 
Hygiene   Gripping and opening things  
Reach   Errands and housework  
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Appendix 7.2: Principle components analysis of the social cognition models questionnaires 
Factor loadings of the Theory of Planned Behaviour questionnaire 
  Factor   
  1 2 3 
  37.6% 12.2% 10.7% 
Item Question 
P
er
ce
iv
ed
 
b
eh
av
io
u
ra
l 
co
n
tr
o
l 
Im
p
o
rt
an
t 
o
th
er
s 
O
th
er
 R
A
 
TPBSN1 Important others  .901  
TPBSN2 Other RA patients   .844 
TPBSN3 Important others  .849  
TPBPC1 Easy to take meds .691   
TPBPBC2 Personal control taking meds .592   
TPBPBC3 Confident taking meds .829   
TPBPBC4 Overcome obstacles .720   
TPBPBC5 Ability to take meds .780   
TPBPBC6 Entirely up to me .373   
PTBPBC7 Beyond my control .588   
 
Subjective Norm Cronbach’s α = 0.526 
Perceived Behavioural Control Cronbach’s α = 0.782 
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Factor loadings of the Health Belief Model questionnaire 
  Factor   
  1 2 3 
  34.2% 11.1% 8.7% 
Item Question 
Se
ve
ri
ty
  
Lo
gi
st
ic
 
b
ar
ri
er
s 
G
en
er
al
ly
 
o
p
p
o
se
d
 t
o
 
m
ed
ic
at
io
n
 
HBMBar1 Don’t want to take   .799 
HBMBar2 Side effects .471   
HBMBar3 Generally opposed   .835 
HBMBar4 Too much trouble  .724  
HBMBar5 Weakens immunity .509   
HBMBar6 Too expensive  .614  
HBMBen1 Improve symptoms  -.630  
HBMBen2 More symptoms than others .504   
HBMBen3 Concerned seriously ill .738   
HBMBen4 Get sick more easily than others .625   
HBMSev1 Serious health problems .767   
HBMSev2 Daily activities if flare .763   
HBMSev3 Flare would make me very sick .833   
HBMSev4 Worried about flare .798   
HBMSev5 When I get sick it’s serious .652   
Barriers Cronbach’s α = 0.633 
Benefits Cronbach’s α = 0.632 
Severity Cronbach’s α = 0.853 
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Factor loadings of the revised illness perceptions questionnaire 
  Factor loadings 
  1 2 3 4 5 6 7 8 9 
  20% 12% 8.6% 6.7% 5.6% 4.3
% 
3.9% 3.2% 2.7
% 
Item Question 
C
o
h
es
io
n
 
Em
o
ti
o
n
 
C
h
ro
n
ic
  
P
er
so
n
al
 
co
n
tr
o
l 
C
o
n
se
q
u
e-
n
ce
s 
 f
o
r 
o
th
er
s 
C
yc
lic
al
 
P
er
so
n
al
 
co
n
se
q
u
e-
n
ce
s 
Tr
ea
tm
en
t 
co
n
tr
o
l 
N
o
th
in
g 
ca
n
 
h
el
p
 
SRMT1 Short    .618       
SRMT2 Permanent    .829       
SRMT3 Long    .869       
SRMT4 Quick   .809       
SRMT5 Rest of life   .738       
SRMC1 Symptoms change      .61
8 
   
SRMC2 Symptoms cycle      .77
5 
   
SRMC3 Unpredictable      .74
5 
   
SRMC4 Better & worse      .78
4 
   
SRMCon1 Serious       .717   
SRMCon2 Major consequences     .537  .585   
SRMCon3 Not much effect     .538     
SRMCon4 Others see me     .800     
SRMCon5 Financial consequences     .701     
SRMCon6 Difficulties for others     .780     
SRMPC1 I can control symptoms    .676      
SRMPC2 What I do    .776      
SRMPC3 Course depends on me    .631      
SRMPC4 Nothing will effect    .748      
SRMPC5 Power to influence    .484   -.501   
SRMPC6 Actions no outcome    .702      
SRMTC1 Improve in time   -.367    -.319  .32
4 
SRMTC2 Little can improve         .56
3 
SRMTC3 Meds cure        .512  
SRMTC4 Meds prevent negative effects        .795  
SRMTC5 Meds control        .687  
SRMTC6 Nothing can help         .49
4 
SRMCo1 Symptoms puzzling .869         
SRMCo2 RA mystery .884         
SRMCo3 RA makes no sense .871         
SRMCo4 Clear understanding of RA .729         
SRMCo5 Don’t understand RA .848         
SRME1 Depressed  .839        
SRME2 Upset   .858        
SRME3 Angry  .663        
SRME4 Does not worry me  .465       .47
8 
SRME5 Anxious  .794        
SRME6 Afraid  .712        
Bold = more than 1 loading,  underlined = unexpected factor loading 
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Appendix 7.3: Baseline mean sumscores for the new and established groups when new = 6 
months (A) and new = 2 years (B) 
 New A (6 months) New B (2 years) Established A Established B 
Total N 33 49 110 94 
Demographics 
Female (%) 23  (69.7) 32  (65.3) 77  (70) 68  (72.3) 
Age 55  (55, 22-81) 57  (55, 22-81) 61  (59, 33-89) 61  (62, 33-89) 
Disease duration 7.10  (1, 0.5-54) 6.48  (2, 0.5-54) 12.78  (10, 1.5-40) 13.99  (10, 0.5-40) 
Theory of Planned Behaviour 
Subjective norm 12.06  (12, 7-15) 12.00  (12, 7-15) 12.29  (12, 7-15) 12.36  (12, 7-15) 
Personal control 29.48  (33, 18-35) 29.96  (33, 18-35) 30.74  (31, 21-35) 30.72  (31, 19-35) 
Health Belief Model 
Barriers 16.48  (17, 6-24) 16.16  (17, 6-25) 15.56  (15, 6-27) 15.57  (14, 6-27) 
Benefits 11.83  (11, 4-16) 11.77  (12, 4-16) 11.96  (12, 6-17) 12.01  (17, 6-17) 
Severity 16.79  (18, 5-24) 16.30  (16, 5-24) 15.85  (17, 5-25) 15.93  (9, 4-16) 
Self Regulation Model 
Identity 3.58  (4, 0-5) 3.53  (4, 0-5) 3.43  (4, 0-5) 3.43  (4, 0-5) 
Chronicity 20.52  (24, 12-25) 20.11  (22, 5-25) 21.89  (23, 5-25) 22.33  (23, 9-25) 
Cyclical 13.42  (15, 6-20) 13.30 (14, 6-20) 13.48  (14, 4-20) 13.55  (14, 4-20) 
Consequences 20.97  (20, 12-28) 20.17  (20, 10-30) 20.29  (20, 10-30) 20.58  (21, 10-30) 
Personal control 19.39  (20, 11-30) 19.79  (20, 11-26) 18.86  (20, 6-28) 18.57  (20, 6-28) 
Treatment control 21.16  (21, 14-30) 20.89  (21, 14-30) 19.86  (20, 7-28) 19.77  (20, 6-28) 
Cohesion 13.96  (12, 5-20) 13.43  (12, 5-21) 12.75  (12, 5-25) 12.81  (11, 5-25) 
Emotional effect 18.87  (16, 7-30) 18.19  (16, 7-30) 17.29  (18, 7-30) 17.37  (14, 7-30) 
Beliefs about medications 
General Harm 9.13  (7, 4-16) 9.0  (8, 4-16) 9.10  (9, 4-16) 9.16  (11, 4-16) 
General Overuse 10.94  (11, 4-16) 10.66  (11, 4-16) 10.45  (11, 4-17) 10.52  (13, 4-17) 
Specific Concern 14.37  (16, 5-20) 13.98  (15, 5-20) 13.38  (13, 5-23) 13.41  (20, 5-23) 
Specific Necessity 16.47  (15, 5-23) 16.89  (17, 5-23) 19.26  (20, 5-25) 19.51  (20, 5-25) 
Depression, Anxiety & Positive Outlook 
Depression 9.19  (5, 5-23) 8.85  (6, 5-23) 8.19  (7, 5-21) 8.20  (6, 5-21) 
Anxiety 5.90  (3, 3-15) 5.72  (3, 3-15) 5.19  (4, 3-13) 5.17  (4, 3-13) 
Positive outlook 10.16  (10, 3-15) 10.17  (10, 3-15) 10.34  (11, 3-15) 10.36  (11, 3-15) 
Disease outcomes 
HAQ 1.00 (0.25, 0-2.75) 0.98  (0.38, 0-2.75) 1.21  (1.13, 0-2.88) 1.26  (1.13, 0-2.88) 
DAS28 3.98  (4.33, 0-5.4) 3.52  (3.59, 0-5.4) 3.06  (2.82, 0-6.87 3.07  (2.78, 0.5-6.87) 
EQ5D VAS 61.27  (73, 20-95) 63.04  (74, 20-95) 64.15  (70, 10-100) 63.76  (70, 10-100) 
EQ5D utility  0.52  (0.73, -0.18-1) 0.57  (0.69, -.018-1) 0.61 (0.69, -0.07-1) 0.60  (0.69, -0.07-1) 
Adherence 
Low intentional 6   (18.2%) 9  (18.4%) 32  (29.1%) 29  (30.9%) 
Forget 7  (21.2%) 10  (20.4%) 19  (17.3%) 16  (17.0%) 
Overall low 11 (33.3%) 16  (32.7%) 43  (39.1%) 38  (40.4%) 
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Appendix 8.1:  Internal consistency shown by Cronbach’s α for each of the model factors at 
six month follow-up  
Scale Cronbach’s α 
Theory of Planned Behaviour  
Social Norm 0.62 
Perceived Behavioural Control 0.77 
Important others 0.80 
Health Belief Model  
Barriers  0.64 
Benefits 0.52 
Severity 0.84 
Self Regulatory Model  
Identity 1 – general unwell SR identity – 0.75 
Identity 2 – RA symptoms  
Identity 3 – weight  
Chronic timeline 0.83 
Cyclical timeline 0.74 
Consequences 0.85 
Personal control 0.78 
Treatment control 0.55 
Cohesion 0.90 
Emotion 0.89 
Beliefs about Medications Questionnaire  
General harmful 0.71 
General overuse 0.81 
Specific concerns 0.75 
Specific necessity 0.91 
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Appendix 8.2: Mean model factor sumscores at six month follow-up for the 3 treatment 
groups 
 Whole sample Newly diagnosed Established Biologic 
Total N 171 42 68 61 
Theory of Planned Behaviour 
Subjective norm  12.17 (1.78) 12.34 (1.70) 11.92 (1.78) 12.33 (1.82) 
Important others 8.63 (1.43) 8.82 (1.31) 8.41 (1.59) 8.74 (1.32) 
Personal control  30.86 (3.54) 30.79 (3.68) 30.86 (3.36) 30.90 (3.69) 
Health Belief Model 
Barriers  16.46 (3.98) 16.59 (4.12) 16.08 (4.36) 16.77 (3.49) 
Benefits  12.38 (2.22) 12.30 (2.74) 11.92 (2.10) 12.88 (1.89) 
Severity  16.74 (3.82) 16.30 (4.34) 16.27 (3.81) 17.48 (3.41) 
Self Regulation Model 
Identity 3.89 (2.36) 3.70 (2.58) 3.62 (1.84) 4.30 (2.66) 
Chronic timeline  22.10 (3.52) 20.86 (4.92)* 22.22 (2.72) 22.69 (3.15)* 
Cyclical timeline  13.01 (3.15) 13.11 (2.73) 13.72 (2.83) 12.22 (3.54) 
Consequences  21.31 (4.81) 21.90 (4.08)* 19.52 (5.42)*+ 22.69 (4.08)+ 
Personal control 18.87 (4.19) 18.36 (4.43) 19.30 (3.30) 18.77 (3.91) 
Treatment control  19.62 (3.01) 19.18 (2.83) 19.67 (3.30) 19.84 (2.84) 
Cohesion 12.36 (4.22) 13.54 (4.56) 12.51 (4.09) 11.50 (3.99) 
Emotional effect  17.22 (5.30) 17.93 (5.40) 16.31 (5.58) 17.64 (4.90) 
Beliefs about medications 
General harm  9.05 (2.40) 9.33 (2.98) 9.32 (2.32) 8.61 (2.02) 
General overuse  10.82 (2.68) 11.15 (3.12) 10.71 (2.54) 10.72 (2.55) 
Specific concern  13.69 (3.43) 14.42 (4.04) 13.42 (3.43) 13.52 (3.00) 
Specific necessity 19.45 (3.46) 18.79 (3.99) 18.92 (3.17)* 20.41 (3.24)* 
Necessity-concerns 
differential 
5.76 (4.59) 4.37 (5.26)* 5.51 (4.22) 6.89 (4.30)* 
Depression, Anxiety and Positive Outlook 
Depression  8.45 (4.05) 9.35 (4.64) 7.65 (3.05) 8.70 (4.44) 
Anxiety  5.48 (2.93) 5.90 (3.13) 5.17 (2.77) 5.54 (2.96) 
Positive outlook 10.83 (3.09) 10.65 (3.17) 10.21 (3.44) 11.57 (2.51) 
Disease outcomes 
HAQ 1.26 (0.83) 1.05 (0.82)* 1.16 (0.84) 1.48 (0.79)* 
DAS 3.35 (1.03) 3.28 (0.98) 3.13 (1.16) 3.47 (1.01) 
EQ5D VAS  62.88 (19.64) 64.22 (20.35) 61.11 (20.48) 63.86 (18.40) 
EQ5D utility 0.59 (0.28) 0.56 (0.31) 0.63 (0.26) 0.56 (0.29) 
Adherence 
Low intentional  40 (23.4%) 7 (17.1%) 18 (27.3%) 15 (23.4%) 
Forget 37 (21.6%) 12 (29.3%) 11 (16.7%) 14 (21.9%) 
Overall low  62 (36.3%) 16 (39%) 23 (34.8%) 23 (35.9%) 
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Appendix 9.1: Mean model factor sumscores at six month follow-up for the different 
adherence groups 
 Intentional low Intentional high Forget Don’t forget Overall low Overall high 
Total N 40 125 37 126 62 103 
Theory of Planned Behaviour 
Subjective norm  8.18 (1.60) 8.78 (1.36) 8.53 (1.38) 8.66 (1.47) 8.34 (1.49 8.80 (1.38) 
Personal control  30.50 (3.66) 30.96 (3.51) 29.92 (3.94) 31.17 (3.38)* 30.49 (3.52) 31.06 (3.55) 
Health Belief Model 
Barriers  17.38 (4.19) 16.15 (3.95) 17.11 (4.33) 16.26 (3.96) 16.89 (4.20) 16.18 (3.92) 
Benefits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         11.98 (1.9) 12.61 (2.23) 12.41 (2.60) 12.48 (2.07) 12.13 (2.36) 12.65 (2.05)
Severity  15.73 (3.71) 17.19 (3.82)* 16.30 (4.19) 16.96 (3.76) 15.95 (3.86) 17.37 (2.05)* 
Self Regulation Model 
Identity  3.78 (2.35) 3.97 (2.40) 3.72 (2.13) 4.02 (2.46) 3.61 (2.82) 4.11 (2.43) 
Chronic timeline  22.10 (3.02) 22.18 (3.41) 21.85 (3.87) 22.26 (3.19) 21.81 (3.39) 22.36 (3.26) 
Cyclical timeline  13.40 (2.74) 12.93 (3.28) 13.51 (3.36) 12.93 (3.10) 13.30 (3.21) 12.90 (3.12) 
Consequences  20.60 (5.03) 21.54 (4.82) 21.72 (4.17) 21.20 (5.10) 20.90 (4.52) 21.55 (5.08) 
Personal control  18.73 (3.90) 18.96 (4.26) 19.08 (4.63) 18.90 (3.98) 19.10 (4.01) 18.78 (4.27) 
Treatment control  18.85 (3.56) 19.90 (2.80) 19.53 (3.57) 19.70 (2.86) 19.30 (3.28) 19.85 (2.86) 
Cohesion  12.20 (4.50) 12.53 (4.16) 12.75 (4.23) 12.35 (4.27) 12.23 (4.27) 12.58 (4.24) 
Emotional effect  16.30 (4.98) 17.72 (5.35) 17.65 (5.64) 17.22 (5.20) 16.53 (5.01) 17.89 (5.40) 
Beliefs about Medications Questionnaire 
General harm  8.90 (2.28) 9.14 (2.48) 9.32 (2.70) 9.02 (2.37) 9.11 (2.55) 9.06 (2.37) 
General overuse  10.78 (2.12) 10.81 (2.87) 11.84 (2.81) 10.47 (2.60) 11.34 (2.62) 10.47 (2.71) 
Specific concern  13.15 (2.70) 13.88 (3.65) 14.16 (3.51) 13.54 (3.44) 13.63 (3.19) 13.74 (3.61) 
Specific necessity  18.60 (3.36) 19.72 (3.48) 18.54 (4.17) 19.71 (3.44) 18.40 (3.56) 20.09 (3.27)* 
Necessity-concerns 
differential 
5.45 (4.42) 5.85 (4.67) 4.38 (5.17) 6.17 (4.37)* 4.77 (4.48) 6.35 (4.59)* 
Depression, Anxiety and Positive Outlook 
Depression  8.05 (3.41) 8.70 (4.27) 9.43 (4.39) 8.19 (3.91) 8.66 (4.10) 8.47 (4.07) 
Anxiety  4.75 (2.51) 5.80 (3.04) 6.24 (3.24) 5.27 (2.79) 5.29 (2.93) 5.70 (2.95) 
Positive outlook  11.23 (3.41) 10.63 (2.99) 10.64 (3.19) 10.85 (3.09) 11.05 (3.27) 10.61 (2.99) 
Disease outcomes 
HAQ 1.10 (0.81) 1.31 (0.84) 0.97 (0.77) 1.34 (0.84)* 1.02 (0.79) 1.40 (0.83)* 
DAS 3.27 (1.05) 3.38 (1.02) 3.59 (0.66) 3.25 (1.13) 3.42 (0.87) 3.28 (1.15) 
EQ5D VAS  70.95 (17.07) 60.07 (19.80)* 64.30 (19.21) 62.81 (19.70) 67.66 (18.67) 59.73 19.77)* 
EQ5D utility 0.67 (0.19) 0.56 (0.30)* 0.59 (0.29) 0.58 (0.28) 0.64 (0.25) 0.55 (0.30) 
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Appendix 9.2: Using baseline model factor sumscores to predict change in intentional adherence when baseline is high 
 Theory of Planned Behaviour Health Belief Model Self Regulatory Model Beliefs about Medications Clinical factors 
Variable Wald OR Wald OR Wald OR Wald OR Wald OR 
TPB important others 2.14 1.29         
TPB perceived control 0.73 0.92         
HBM barriers   1.61 0.90       
HBM benefits   3.73 1.44*       
HBM severity   1.10 0.89       
SRM Identity     0.03 1.06     
SRM chronicity     3.81 0.76*     
SRM cyclical     2.07 0.85     
SRM consequences     0.65 1.07     
SRM personal control     2.57 0.88     
SRM treatment control     3.08 1.22     
SRM coherence     0.001 0.997     
SRM emotion     0.19 1.03     
BMQ harmful       2.06 1.26   
BMQ overuse       0.13 1.04   
BMQ necessity        1.74 1.10   
BMQ concern       3.07 0.85   
HAQ         0.05 0.89 
DAS28         0.14 0.88 
EQ5D VAS         0.59 1.02 
EQ5D utility         2.59 0.03 
Model χ
2
 (2) = 2.33, p=0.313 χ
2
 (3) = 4.93, p=0.177 χ
2
 (8) = 12.79, p=0.119 χ
2
 (4) = 5.34, p=0.254 χ
2
 (4) = 3.88, p=0.423 
 Nagelkerke R
2
 = 0.037 Nagelkerke R
2
 = 0.077 Nagelkerke R
2
 = 0.188 Nagelkerke R
2
 = 0.082 Nagelkerke R
2
 = 0.082 
 85% correct                 (0% of 
changers) 
85.6% correct                       
(0% of changers) 
85.5% correct                                
(0% of changers) 
86.8% correct                                   
(6.3% of changers) 
87.4% correct                                                
(0% of changers) 
 
  
2
4
8
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Appendix 9.3: Using baseline model factor sumscores to predict change in intentional adherence when baseline is low 
 Theory of Planned Behaviour Health Belief Model Self Regulatory Model Beliefs about Medications Positive Outlook 
Variable Wald OR Wald OR Wald OR Wald OR Wald OR 
TPB important others 0.73 0.83         
TPB perceived control <0.001 1.00         
HBM barriers   0.08 0.97       
HBM benefits   1.21 1.27       
HBM severity   2.05 0.84       
SRM Identity     0.64 0.78     
SRM chronicity     0.67 0.88     
SRM cyclical     0.18 0.95     
SRM consequences     0.31 1.07     
SRM personal control     0.14 1.03     
SRM treatment control     0.58 1.14     
SRM coherence     0.02 0.98     
SRM emotion     1.78 0.89     
BMQ harmful       1.33 0.83   
BMQ overuse       0.001 1.00   
BMQ necessity        0.73 0.90   
BMQ concern       0.49 1.07   
Positive outlook         5.01 1.38* 
Model χ
2
 (2) = 0.84, p=0.66 χ
2
 (3) = 2.91, p=0.41 χ
2
 (8) = 5.27, p=0.73 χ
2
 (4) = 2.27, p=0.69 χ
2
 (1) = 5.77, p=0.016 
 Nagelkerke R
2
 = 0.026 Nagelkerke R
2
 = 0.089 Nagelkerke R
2
 = 0.157 Nagelkerke R
2
 = 0.072 Nagelkerke R
2
 = 0.171 
 50% correct                                   
(54.5% of changers) 
57.1% correct                          
(72.7%  of changers) 
59.5% correct                      
(63.6% of changers) 
70.7% correct                       
(86.4% of changers) 
66.7% correct                      
(63.6% of changers) 
 
 
  
2
4
9
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Appendix 9.4: Change in model factor sumscores to predict change in forgetting for patients who do not forget at baseline 
 Theory of Planned Behaviour Health Belief Model Self Regulatory Model Beliefs about Medications Combined model 
Variable Wald OR Wald OR Wald OR Wald OR Wald OR 
TPB important others 1.65 0.83       1.78 0.77 
TPB perceived control 1.42 1.09       0.91 1.10 
HBM barriers   2.01 1.12     1.19 1.12 
HBM benefits   0.06 1.04     0.01 1.02 
HBM severity   0.61 1.09     0.47 1.10 
SRM Identity     1.10 1.17   0.61 1.15 
SRM chronicity     0.36 0.96   0.02 0.99 
SRM cyclical     0.50 0.93   0.15 0.96 
SRM consequences     0.07 0.97   <0.001 1.00 
SRM personal control     0.93 1.08   0.44 1.06 
SRM treatment control     1.45 0.88   0.99 0.89 
SRM coherence     0.20 0.96   0.11 0.96 
SRM emotion     0.03 0.99   0.10 0.97 
BMQ harmful       0.47 1.10 0.06 0.96 
BMQ overuse       0.09 0.97 0.002 1.01 
BMQ necessity        0.03 0.99 0.10 1.04 
BMQ concern       0.40 0.94 0.79 0.91 
Model χ2 (2) = 2.72, p=0.26 χ2 (3) = 3.08, p=0.38 χ2 (8) = 4.77, p=0.78 χ2 (4) = 0.96, p=0.92 χ2 (17) = 10.20, p=0.90 
 Nagelkerke R2 = 0.037 Nagelkerke R2 = 0.043 Nagelkerke R2 = 0.071 Nagelkerke R2 = 0.013 Nagelkerke R2 = 0.158 
 85.2% correct                               
(0% of changers) 
85.8% correct                      
(0% of changers) 
87% correct                       
(0% of changers) 
86.4% correct                              
(0% of changers) 
86.8% correct                         
(6.7% of changers) 
2
5
0
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Appendix 9.5: Change in model factor sumscores to predict change in forgetting for patients 
who forget at baseline 
 Theory of Planned 
Behaviour 
Health Belief 
Model 
Self Regulatory Model Beliefs about 
Medications 
Variable Wald OR Wald OR Wald OR Wald OR 
TPB important 
others 
0.004 0.98       
TPB perceived 
control 
0.52 0.91       
HBM barriers   0.37 1.11     
HBM benefits   0.78 0.81     
HBM severity   0.08 1.05     
SRM Identity     1.00 0.68   
SRM chronicity     1.57 1.48   
SRM cyclical     0.48 0.71   
SRM consequences     3.32 0.66   
SRM personal 
control 
    2.36 1.55   
SRM treatment 
control 
    0.65 0.86   
SRM coherence     0.92 0.77   
SRM emotion         
BMQ harmful       0.18 0.90 
BMQ overuse       0.24 1.12 
BMQ necessity        0.06 1.06 
BMQ concern       <0.001 1.002 
Model χ
2
 (2) = 0.55, p=0.76 χ
2
 (3) = 1.17, 
p=0.76 
χ
2
 (8) = 4.77, p=0.78 χ
2
 (4) = 0.55, p=0.97 
 Nagelkerke R
2
 = 0.032 Nagelkerke 
R
2
=0.068 
Nagelkerke R
2
 = 0.071 Nagelkerke R
2
 = 
0.033 
 70.8% correct (                     
0% of changers) 
75% correct                     
(14.3% changers) 
87% correct                         
(0% of changers) 
69.6% correct                    
(0% of changers) 
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Appendix 10.1: Change in medication doses from baseline to six month follow-up for those prescribed these medications at baseline 
 MTX (mg) N (%) SSZ (mg) N (%) HCQ (mg) N (%) LFM (mg) N (%) >1 DMARD 
Intentional adherence          
Low 0 (0.48) 31 (73.8%) -576.92 (374.88) 14 (33.3%) -16.67 (16.67) 8 (19%) -11.67 (8.33) 2 (4.8%) 13 (31%) 
High -0.86 (0.50) 103 (85.1%) -421.05 (260.07) 25 (20.7%) -46.15 (40.22) 23 (19%) none  3 (2.5%) 38 (31.4%) 
Unintentional 
adherence 
         
Forgetful -0.78 (1.33) 17 (70.8%) -285.71 (473.80) 7 (29.2%) None 3 (12.5%) 2.50 (2.50) 2 (8.3%) 6 (25%) 
Not forgetful -0.64 (0.41) 118 (84.3%) -540.00 (243.10) 32 (22.9%) -41.18 (30.99) 28 (20%) -13.33 (6.67) 3 (2.1%) 45 (32.1%) 
Overall adherence          
Not adherent -0.32 (0.63) 42 (73.7%) -558.82 (290.42) 18 (31.6%) -14.29 (14.29) 9 (15.8%) -8.75 (6.57) 3 (5.3%) 16 (28.1%) 
Adherent -0.82 (0.51) 93 (86.9%) -400.00 (324.40) 21 (19.6%) -50.00 (43.52) 22 (20.6%) None  2 (1.9%) 35 (32.7%) 
 
Appendix 10.2: Percentage of patients whose DMARD prescription changed from baseline to six month follow-up 
 MTX change Baseline N (%) SASP  T1 N (%) HCQ  T1 N (%) LFM  T1 N (%) 
Intentional adherence         
Low Stop =  none 
Same = 39 (92.9%) 
Start = 3 (7.1%) 
37 (64.4) Stop = 4 (9.5%) 
Same = 33 (78.6%) 
Start = 5 (11.9%) 
18 (30.5) Stop = none 
Same = 40 (95.2%) 
Start = 2 (4.8%) 
7 (11.9) Stop = 2 (4.8%) 
Same = 39 (92.9%) 
Start = 1 (2.4%) 
4 (6.8)* 
High 
 
Stop = 3 (2.5%) 
Same = 102 (84.3%) 
Start = 16 (13.2%) 
114 (72.3) Stop = 5 (4.1%)  
Same = 105 (86.8%) 
Start = 11 (9.1%) 
38 (23.9) Stop = 2 (1.7%) 
Same = 107 (88.4%) 
Start = 12 (9.9%) 
19 (11.9) Stop = none 
Same = 120 (99.2%) 
Start = 1 (0.8%) 
3 (1.9) 
Unintentional adherence         
Forgetful Stop = 1 (4.2%) 
Same = 21 (87.5%) 
Start = 2 (8.3%) 
28 (65.9) Stop = 1 (4.2%) 
Same = 22 (91.7%) 
Start = 1 (4.2%) 
19 (43.2)* Stop = none 
Same = 23 (95.8%) 
Start = 1 (4.2%) 
3 (6.8) Stop = none 
Same = 24 (100%) 
Start = none 
4 (9.1)* 
Not forgetful 
 
Stop = 2 (1.4%) 
Same = 121 (86.4%) 
Start = 17 (12.1%) 
123 (71.6) Stop = 8 (5.7%) 
Same = 117 (83.6%) 
Start = 15 (10.7%) 
37 (21) Stop = 2 (1.4%) 
Same = 125 (89.3%) 
Start = 13 (9.3%) 
23 (13.1) Stop = 2 (1.4%) 
Same = 136 (97.1%) 
Start = 2 (1.4%) 
3 (1.7) 
Overall adherence         
Not adherent Stop = 1 (1.8%) 
Same = 52 (91.2%) 
Start = 4 (7.0%) 
56 (66.7) Stop = 4 (7.0%) 
Same = 48 (84.2% 
Start = 5 (8.8%) 
31 (35.6)* Stop = none 
Same = 55 (96.5%) 
Start = 2 (3.5%) 
9 (10.3) Stop = 2 (3.5%) 
Same = 54 (94.7%) 
Start = 1 (1.8%) 
6 (6.9)* 
Adherent Stop = 2 (1.9%) 
Same = 90 (84.1%) 
Start = 15 (14.0%) 
95 (72.7) Stop = 5 (4.7%) 
Same = 90 (84.1%) 
Start = 11 (10.3%) 
25(18.9) Stop = 2 (1.9%) 
Same = 93 (86.9%) 
Start = 12 (11.2%) 
17 (12.9) Stop = none 
Same = 106 (99.1%) 
Start = 1 (0.9%) 
1 (0.8) 
2
5
2
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